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Abstract 
Phospholipids (PLs) are found abundantly in mammalian cell membranes and support cellular 
health and function.  Their composition and shape promotes asymmetry within membrane 
bilayers and affects membrane physiological properties. PLs have the potential to facilitate 
cognitive function. A systematic review identified ten PL supplementation studies, including two 
acute and eight chronic (≥ 2 week) interventions.  Cognitive benefits, mainly memory 
enhancement, were reported for a single PL, phosphatidylserine, and a bovine milk-derived PL 
composite, which was used in the supplementation studies reported in this thesis. The quality 
of the empirical studies reviewed was compromised by poor study designs and/or analytical 
approach. Moreover, the review highlighted a lack of empirical studies considering PL 
supplementation in children and adolescents.  The focus of this thesis was to investigate the 
potential for bovine milk-derived PLs to promote cognitive function. Study 1 (n=70) was the first 
randomised placebo-controlled trial of the effects of PLs on cognitive performance in school-
aged children (6-8 years). This was a six week intervention trial during which the children were 
tested every 3 weeks on measures of memory, motor skills, executive function and processing 
speed.  Subjective evaluations of appetite, mood, motivation and mental alertness were also 
measured.  The impact of the supplement on cognitive performance was limited.  There was 
also no discernible effect on subjective state.  Study 2 (n=50) extended limited existing evidence 
to examine effects of PL supplementation in middle-aged/older adults with a subjective memory 
complaint.  This randomised placebo controlled trial investigated the acute and chronic effects 
of PL supplementation over 12 weeks on cognitive measures of memory and executive function 
and self-reports on the Cognitive Failures Questionnaire. Cognitive performance and the 
frequency of cognitive failures was measured at week 0 (acute), week 6 and week 12 (chronic). 
Few effects on cognitive performance following both acute and chronic supplement 
consumption were observed.  Cognitive failures were reduced in participants who received the 
active supplement and reported greater cognitive failures at baseline.  Across both studies, 
participants’ demographic characteristics and baseline performance had a greater impact on 
cognitive performance than the active supplement.  Overall, the findings from the PL 
intervention studies presented in this thesis add to the existing heterogeneous evidence of the 
potential for PLs to moderate cognitive performance.  Despite strong mechanistic data 
suggesting PLs could confer beneficial and/or protective effects on cognition, this thesis did not 
find clear evidence of a benefit of PLs for cognition.  Further examination of the potential 
benefits of PLs in other formulations for cognitive function in young and old samples is 
warranted. 
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Chapter 1 General Introduction and thesis aims 
1.1 Cognition and cognitive function across the lifespan 
Cognition is characterised by a complex set of higher mental functions (Nyaradi, Li, Hickling, 
Foster, & Oddy, 2013) that include memory, perception, attention, executive function and 
information processing, each of which represent cognitive domains (de Jager et al., 2014; Nouchi 
& Kawashima, 2014; Wesnes, 2010).  Notably, executive function encompasses multiple higher-
order cognitive processes, such as response inhibition, working memory, planning and cognitive 
flexibility (Lezak, Howieson, Bigler, & Tranel, 2012). Cognitive function develops from childhood 
through to young adulthood (Nouchi & Kawashima, 2014). Importantly, the development and 
maturation of the brain underlies this development.  For example, the development of the 
prefrontal cortex during adolescence corresponds to sophistication of executive function, 
including impulse control, behavioural inhibition and planning (Arain et al., 2013).  Cognitive 
development and decline follow different trajectories across the lifespan.  For instance, 
executive function components demonstrate separate developmental trajectories, such that 
attentional regulation develops from infancy (Berthelsen, Hayes, White, & Williams, 2017), 
whilst more complex executive skills enabling performance monitoring and relational reasoning 
begin to evolve during adolescence (Crone & Dahl, 2012).  Moreover, there is heterogeneity in 
when cognitive abilities peak and subsequently begin to deteriorate (Hartshorne & Germine, 
2015), with the earliest age-related cognitive decline evident in some domains from twenty 
years of age in healthy educated adults (Salthouse, 2009).  Frequently observed changes in 
cognitive function with age occur in processing speed, executive function (Murman, 2015) and 
memory for new information (Lezak et al., 2012). Currently, there is much interest in identifying 
factors that promote cognitive function during childhood/adolescence and/or prevent cognitive 
decline during ageing.  One such factor which is receiving much attention is the role of diet and 
the effects of specific nutrients on cognitive function.  
1.2 The effect of diet on cognitive function 
Diet has the potential to affect cognition and dietary factors are recognised to influence 
molecular systems and mechanisms that support cognitive functions (Gómez-Pinilla, 2008). 
Nutrition influences cognition such that improved nutrition is related to optimal brain function 
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(Nyaradi et al., 2013), with clear evidence of the deleterious effects of nutritional deficiencies 
and benefits of supplementation to correct these e.g. iron (Falkingham et al., 2010). A number 
of reviews of observational and interventional studies have reported certain dietary 
components as favourable for promoting cognitive function in both children (Lam & Lawlis, 
2017; Nyaradi et al., 2013; Spencer, Korosi, Layé, Shukitt-Hale, & Barrientos, 2017) and adult 
samples (Gómez-Pinilla, 2008; Spencer et al., 2017; Vauzour et al., 2017).  Hence, there is 
evidence that dietary manipulations offer an opportunity to enhance or maintain cognition in 
different age-groups and at different times across the lifespan.  
1.2.1 The potential for phospholipids to moderate cognitive performance 
There is increasing interest in the potential for milk dairy products and components, such as 
milk-derived phospholipids (PL), to impact upon cognitive function. PLs are amphiphilic lipids 
(having both hydrophilic and hydrophobic parts) present in all cell membranes of plants and 
animals and form lipid bilayers (Küllenberg, Taylor, Schneider, & Massing, 2012). The most 
common type in eukaryotic cells are glycerophospholipids (GPLs) (Nicolson & Ash, 2017). GLPLs 
as well as another lipid class, sphingolipids, present in milk are one of the main components of 
the milk fat globule membrane (MFGM) (Contarini & Povolo, 2013; Zhiqian Liu, Rochfort, & 
Cocks, 2018).  GPLs and sphingolipids are also available from other dietary sources, and 
soybeans and eggs are particularly good sources of both (Burling & Graverholt, 2008).  The 
composition of PLs is crucial to their potential to promote cognitive function and resolve 
inflammation associated with cognitive impairment and pathology.  Chapter 2, therefore, 
provides an important comprehensive introduction to cell membrane lipids and their potential 
facilitative and protective role in cognitive function.   
1.2.2 Phospholipid supplementation and cognitive performance  
Chapter 3 presents a systematic review of the extant literature exploring GPL supplementation 
across the lifespan.  Across the acute and chronic intervention studies reviewed, there is a 
preponderance of studies which supplement adults, particularly young healthy adults, with a 
complete absence of intervention studies in children and adolescents.  Overall, this review 
concluded that there was a lack of consistency with regard to intervention duration, dose of GPL 
administered and study eligibility criteria. A single GPL, phosphatidylserine (PS), and a composite 
PL supplement were observed to confer cognitive performance gains in cognitively healthy 
adults.  Methodological issues are discussed and inform recommendations for future GPL 
supplementation studies.  
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To address one of the main recommendations that came out of the systematic research review, 
Chapter 4 reports on a six week intervention study involving the supplementation of 6-8 year 
old children (n=70) with a bovine milk-derived PL-enriched protein concentrate drink (Study 1). 
The study conformed to a randomised, double-blind, placebo-controlled, parallel group study 
design.  Children consumed the experimental drinks (active/placebo) in school on weekdays.  
Cognitive performance and subjective evaluations of appetite, mood, motivation and mental 
alertness were measured every 3 weeks.   
Chapter 5 presents a second intervention study (Study 2) that builds on the limited empirical 
research concerning GPL supplementation in adults with a subjective memory complaint (SMC).  
Again, Study 2 conformed to a randomised, double-blind, placebo-controlled, parallel group 
study design.  This was a 12 week intervention in which participants (n=50) aged ≥50 years of 
age consumed either the bovine milk-derived PL-enriched protein concentrate drink or placebo 
at home.  The study included an acute assessment i.e. cognitive performance was assessed at 
baseline and again 90 minutes post-first dose, as well as chronic assessment every 6 weeks for 
12 weeks. Participants also completed a self-report questionnaire relating to the frequency with 
which they had experienced cognitive lapses and slips whilst completing everyday tasks 
(cognitive failures) over the intervening test visit period.   
Given the lack of extant empirical research considering the effect of GPL supplementation on 
cognitive performance in children, the introduction to Chapter 4 features a review of omega-3 
fatty acid (FA) interventions in school-aged children. Crucially, FAs are components of GPLs and 
contribute to the physiological properties of cell membranes.  The introduction to Chapter 4 also 
discusses developmental changes in the brain that take place across childhood and the 
relationship of these with cognitive development.  Similarly, Chapter 5 starts with an 
introduction to structural and functional brain changes with age and the association of these 
with cognitive decline.  Much of the research discussed in both sections is based upon brain 
imaging techniques. Such techniques provide insights into brain activity and network 
connectivity as well as more detailed information, such as fibre-density and myelination. In the 
context of cognitive development and decline, these techniques provide knowledge of brain 
alterations, which can be related back to cognitive function. However, these techniques are 
outside of the scope of this thesis and did not form part of the methodology for either 
intervention study.   
The final Chapter (Chapter 6) provides a summary of the findings from both intervention studies 
and makes recommendations in terms of potential GPL species and FA composition for future 
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supplementation studies.  Important limitations of the intervention studies and design 
recommendations are also discussed. 
1.3 Summary of thesis aims and hypotheses 
Taken together, this thesis aims to explore the impact of PLs (specifically GPLs and 
sphingomyelin (SM) in combination) on cognitive function to investigate whether 
supplementation translates to improved cognitive performance both acutely and chronically in 
children and middle-aged/older adults with a SMC.  The specific aims of this thesis are:  
 
1. To systematically review the effects of GPL acute and chronic supplementation on cognitive 
performance across the lifespan (Systematic research review, Chapter 3). 
2. To examine the effects of chronic dietary GPL (also containing SM) intervention on cognitive 
performance and subjective feelings (mood, alertness, motivation) in children aged 6 – 8 
years. It is hypothesised that supplementation with Lacprodan® PL-20 will promote 
cognitive function, in turn supporting better performance on a cognitive battery that 
measures memory, motor skills, executive function and processing speed relative to that 
shown by the control group (Study 1, Chapter 4).   
3. To examine the effects of acute dietary GPL (also containing SM) intervention on cognitive 
performance in adults aged 50 years and over with a SMC.  It is hypothesised that 
supplementation with Lacprodan® PL-20 will facilitate cognitive function and thereby 
promote better cognitive performance relative to the control group on cognitive measures 
assessing memory and executive function (Study 2, Chapter 5). 
4. To examine the effects of chronic dietary GPL (also containing SM) intervention on cognitive 
performance and self-reported cognitive failures in adults aged 50 years and over with a 
SMC.  It is hypothesised that supplementation with Lacprodan® PL-20 will enhance 
cognitive function and therefore augment cognitive performance on cognitive measures 
assessing memory and executive function and reduce self-reported cognitive failures 
compared to the control group (Study 2, Chapter 5). 
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Chapter 2 Introduction to cell membrane lipids and their potential 
facilitative role in cognitive function 
2.1  Glycerophospholipids 
Glycerophospholipids (GPLs) are glycerol-based phospholipids (PLs) and are the most prevalent 
class of lipids in mammalian cells (Blom, Somerharju, & Ikonen, 2011).  In addition to their 
glycerol backbone containing three hydroxyl groups (available in three positions: sn-1, sn-2 and 
sn-3), GPLs have two chains of fatty acids (FAs) and a phosphate head group (Cui & Decker, 
2015).  GPLs differ in the FAs attached at the sn-1 and sn-2 position of the glycerol backbone.  
Typically,  a saturated FA is esterified at the sn-1 location whilst a saturated, polyunsaturated, 
or monounsaturated FA occupies the sn-2 position (Fruhwirth, Loidl, & Hermetter, 2007; Manni 
et al., 2018; Yamashita et al., 2014). The biochemical structure of a GPL containing a saturated 
FA at the sn-1 position and a polyunsaturated FA at the sn-2 position is shown in Figure 2.1. 
 
Figure 2.1 Biochemical structure of a glycerophospholipid with a saturated fatty acid and a 
polyunsaturated fatty acid esterified at the sn-1 and sn-2 position respectively of the glycerol 
backbone.  Adapted from “Glycerophospholipid Supplementation as a Potential Intervention 
for Supporting Cerebral Structure in Older Adults,” by J. M. Reddan, D. J. White, H. 
Macpherson, A. Scholey and A. Pipingas, 2018, Frontiers in Aging Neuroscience, 10, p.49.  
Copyright 2018 by CC BY. Adapted with permission.  
 
6 
 
Stearic acid (saturated FA, 18:01)  or palmitic acid (saturated FA, 16:0) tends to found at the sn-
1 position, whilst at the sn-2 position, GPLs predominantly contain oleic (omega-9, 18:1), linoleic 
(LA; omega-6, 18:2) or alpha-linolenic acid (ALA; omega-3, 18:3), arachidonic acid (AA; omega-
6, 20:4), or eicosapentaenoic acid (EPA; omega-3, 20:5) and docosahexaenoic acid (DHA; omega-
3, 22:6) (Küllenberg et al., 2012; Layé, Nadjar, Joffre, & Bazinet, 2018).  The addition of different 
chemical moieties onto the sn-3 position modifies the head group and determines the type of 
phosphatidyl lipid (Coskun & Simons, 2011).  The chemical moieties include choline 
(phosphatidylcholine; PC), ethanolamine (phosphatidylethanolamine, PE), serine 
(phosphatidylserine, PS) and inositol (phosphatidylinositol, PI) (Hishikawa, Hashidate, Shimizu, 
& Shindou, 2014).  Importantly, GPLs can differ in their head group and acyl chains (promoting 
different chain length and saturation properties) (Fruhwirth et al., 2007).  GPLs are amphiphilic, 
the head group being water-loving (hydrophilic) whilst the FA tails are hydrophobic (Küllenberg 
et al., 2012).  This characteristic promotes self-assembly of different structures (e.g. lipid bilayer) 
when added into aqueous milieu, the assembly of which is governed by the GPL specific 
properties and conditions (Li et al., 2015). Figure 2.2 is a schematic representation of the lipid 
bilayer of a eukaryotic cell membrane. This illustrates other features of a cell membrane 
including proteins, glycolipids and cholesterol.  The bend or kink in the FAs attached to the PLs 
(boldface black lines) indicate double bonds.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Schematic representation of the lipid bilayer of a eukaryotic cell membrane.  
Reprinted from “Health effects of dietary phospholipids,” by D. Küllenberg, L. A. Taylor, M. 
Schneider and U. Massing, 2012, Lipids in Health and Disease, 11(3), p.2. Copyright 2012 by CC 
BY (Licensee BioMed Central Ltd.). Reprinted with permission. 
                                                          
1 18 represents the chain length (18 carbon atoms) and 0 represents the degree of saturation (0 
double-bonds), where 0 is saturated, 1 is monounsaturated and ≥ 2 is polyunsaturated (see 
Appendix 1 for nomenclature, chain length and degree of saturation of fatty acids referred 
to throughout the thesis). 
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Membrane lipids facilitate cellular health by providing a matrix allowing chemical and enzymatic 
reactions to take place in separate membrane compartments, opportunities for energy storage 
(caloric reserves), sites for localisation of peripheral functional molecules that interact with 
constituents of the membrane i.e. proteins (Janmey & Kinnunen, 2006; Nicolson & Ash, 2014) 
as well as bioactive molecules, such as phosphoinositides (PIs), enabling the recruitment of 
proteins present in the cytosol (intracellular fluid) that are involved in vesicle trafficking (Di Paolo 
& De Camilli, 2006). Cellular membranes are both complex and varied, and their composition is 
context-dependent (Sezgin, Levental, Mayor, & Eggeling, 2017).  Membrane lipid composition 
differs among cells, the compartments that exist within a cell and also between the two leaflets 
(bilayers) of a membrane (Fagone & Jackowski, 2009; Vance, 2015).  Transmembrane lipid 
transporter proteins, flippases and floppases, support membrane asymmetry (difference in the 
lipid composition of each monolayer of the membrane) by translocating certain lipids in both an 
ATP-dependent and independent manner, whilst scramblases (a further transmembrane 
protein) move lipids in a non-selective, energy-independent fashion, leading to disruption in 
asymmetry (Contreras, Sánchez-Magraner, Alonso, & Goñi, 2010; Kodigepalli, Bowers, Sharp, & 
Nanjundan, 2015; Williamson & Schlegel, 2002).  Differences in the lipid composition both across 
the leaflets and laterally within a monolayer are closely related to membrane curvature and 
shape (Yesylevskyy, Rivel, & Ramseyer, 2017) and promote distinct areas of surface charge 
across the membrane (Whited & Johs, 2015).   
2.2  Influence of glycerophospholipids on cell membrane characteristics 
2.2.1  Membrane curvature 
Remodelling of the lipid composition is one mechanism by which a membrane can alter its 
shape.  Membranes can form highly complex architectures and alterations in healthy cells are 
well-regulated (Jarsch, Daste, & Gallop, 2016).  Importantly, adjustments to a membranes 
architecture are required for the exchange of molecules and signals from the cytoplasm and 
extracellular areas (e.g. vesicle formation and  trafficking; Bohdanowicz & Grinstein, 2013; Jarsch 
et al., 2016; Settles, Loftus, McKeown, & Parthasarathy, 2010) and key cellular processes, such 
as division and differentiation (Yesylevskyy et al., 2017), as well as peripheral protein 
recruitment (Vanni, Hirose, Barelli, Antonny, & Gautier, 2014).  With cells being in a state of flux 
(Frolov, Shnyrova, & Zimmerberg, 2011), changes in membrane architecture occur on a variety 
of temporal and spatial scales (Yesylevskyy et al., 2017). GPLs can be grouped by shape due to 
their headgroup and fatty acyl chains.  Specifically, the length and saturation of GPL fatty acyl 
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chains and the size of the headgroup contribute to GPL shape (McMahon & Boucrot, 2015).  Both 
PC and PS are cylindrical in shape, forming flat monolayers, whereas PE and phosphatidic acid 
(PA: a PL and a precursor of GPLs) are roughly conical in shape, creating negative curvature 
(inverse) (McMahon & Boucrot, 2015).  Alternatively, PI creates positive curvature due to its 
inverted conical shape (Zimmerberg & Kozlov, 2006).  Crucially, when GPLs of a similar shape 
gather, the monolayer can spontaneously curve (McMahon & Boucrot, 2015).  This may result 
in the whole membrane altering its shape (i.e. bilayer coupling; McMahon & Gallop, 2005).   
2.2.2  Membrane fluidity 
The extent to which molecules can diffuse within the membrane (Vígh & Maresca, 2002) i.e. 
membrane fluidity, is essential for the proper functioning of cell membranes (Fan & Evans, 2015; 
García et al., 2014).   The presence of unsaturated FAs in membrane lipids promotes membrane 
fluidity (Los & Murata, 2004).  Indeed, an increase in the availability of unsaturated FAs leads to 
an increase in membrane fluidity (Schmitz & Ecker, 2008; Weijers, 2015), whereas damage to 
polyunsaturated fatty acids (PUFAs) can decrease membrane fluidity (García et al., 2014).  
Crucially, the acyl chain composition determines membrane fluidity, where saturated FAs, with 
their linear acyl chains, are able to pack together tightly (De Marothy & Elofsson, 2015).  
Alternatively, unsaturated FAs have double bonds, introducing a bend in their tails, resulting in 
less denser packing in the monolayer (McMahon & Boucrot, 2015).  The composition of the lipid 
membrane is continuously altered to modify membrane fluidity following changes in the 
physiochemical environment (Maulucci et al., 2016).  Optimal membrane functionality requires 
the maintenance of a narrow range of membrane physical properties (Levental, Malmberg, & 
Levental, 2018).  Importantly, incorporation of FAs into the membrane depends upon their 
availability and abundance, meaning membrane homeostasis (and therefore the preservation 
of membrane physical properties) relies upon a balanced pool of FAs (Maulucci et al., 2016).  
This highlights the relationship between diet and the FA profiles of GPLs, where dietary intake 
can influence GPL profiles (Saadatian-Elahi et al., 2009; Zheng et al., 2019).  
2.2.3  Membrane surface charge 
PE, PC are all zwitterionic (contain both positive and negative charged groups; net charge is 
neutral), whilst PS, PI and PA are negatively charged lipids (Ingólfsson et al., 2014). This results 
in ion concentration gradients being present at the membrane surface that are known to 
support electrostatic interactions between peripheral proteins and lipid headgroups (Whited & 
Johs, 2015).  With the abundance of PS present in the cytoplasmic side (inner-leaflet) of the 
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membrane, this confers a higher anionic charge relative to the exofacial side (outer-leaflet; 
Marquardt, Geier, & Pabst, 2015).  The presence of negative charges influence membrane 
characteristics (Tanguy, Kassas, & Vitale, 2018) by promoting separate membrane territories, 
supporting the localisation of peripheral proteins with cationic clusters (Bigay & Antonny, 2012). 
Importantly, the interaction between proteins and lipids depend on their respective charge, and 
attenuation of the charge due to membrane PL metabolism or redistribution can lead to 
peripheral proteins relocalising, resulting in different reactions (Yeung et al., 2008).   
Transmembrane helices enable transmembrane proteins to attach themselves to the plasma 
membrane (Baker, Wong, Eisenhaber, Warwicker, & Eisenhaber, 2017).  The positive inside rule 
denotes the enrichment of positively charged residues in cytoplasmic loops and at the 
cytoplasmic edge of transmembrane helices (Baker et al., 2017; De Marothy & Elofsson, 2015; 
von Heijne, 1989), which help proteins to orientate towards the inner-leaflet (De Marothy & 
Elofsson, 2015; Elazar, Weinstein, Prilusky, & Fleishman, 2016; Marquardt et al., 2015; van Geest 
& Lolkema, 2000). Membrane potential also influences the structure and function of 
transmembrane proteins (Bohdanowicz & Grinstein, 2013).  For example, the function of 
voltage-gated potassium channels (transmembrane channels) involved in physiological 
processes such as cell proliferation, neuronal excitability and neurotransmitter release 
exemplifies how the charge from lipid headgroups modulates their stability and operation 
(Escribá et al., 2008). 
2.2.4  Membrane rafts 
Lateral segregation of membrane constituents represented by membrane sub-
compartmentalisation illustrates the dynamic ability of membranes to form membrane rafts 
(Simons & Sampaio, 2011).  Membrane rafts are represented by a liquid-ordered phase, 
stabilised by the presence of cholesterol (Sonnino & Prinetti, 2013) and show tighter packing 
relative to non-raft phases of the membrane (Rajendran & Simons, 2005).  Membrane rafts serve 
many functions, such as cellular trafficking and signal transduction (Ariga, McDonald, & Yu, 2008; 
Hanzal-Bayer & Hancock, 2007).  Consistent with this, membrane rafts have been implicated as 
platforms for assembly and initiating signalling cascades (Staubach & Hanisch, 2011).   
Membrane rafts also act as sorting platforms for targeted protein traffic and are implicated in 
protein endocytosis (Staubach & Hanisch, 2011).  Additionally, they have also been found to 
support growth cone (neuronal growth) expansion as well as axon formation (Davare et al., 
2009; Grider, Park, Spencer, & Shine, 2009; Head, Patel, & Insel, 2014; Kamiguchi, 2006) and 
guidance (Kamiguchi, 2006).   
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The original composition of the membrane raft model reflects the close affinity between 
sphingolipids (see section 2.4) and cholesterol (Simons & Ikonen, 1997).  This association 
between sphingolipids and cholesterol is due, in part, to their strong hydrogen bonding (Slotte, 
2013; Sodt, Pastor, & Lyman, 2015).  The saturated hydrocarbon chains of sphingolipids 
contribute to their easy integration into areas of high acyl chain order (consistent with the 
presence of cholesterol in the membrane; Róg, Pasenkiewicz-Gierula, Vattulainen, & Karttunen, 
2009), unlike GPLs, which tend to have unsaturated FAs and therefore bends in their tails 
(Hanzal-Bayer & Hancock, 2007).  Both gangliosides (Simons & Toomre, 2000; Sandro Sonnino, 
Mauri, Chigorno, & Prinetti, 2007), which have mostly saturated FAs attached (Kolter, 2012) and 
relatively saturated PLs have also been associated with raft-like environments (Sezgin et al., 
2017).   
2.3 Types of glycerophospholipids 
2.3.1  Phosphatidylserine (PS) 
PS represents approximately 10% of the total lipids present in lipid membranes (Vance, 2003) 
and is unequally distributed across the cellular membrane (van Meer, Voelker, & Feigenson, 
2008).  The chemical strucure of PS is diplayed in Figure 2.3. 
 
Figure 2.3 Chemical structure of phosphatidylserine. Reprinted by permission from Springer 
Nature Customer Service Centre GmbH: Springer. Chromatographia.“Feasibility of 
Phospholipids Separation by Packed Column SFC with Mass Spectrometric and Light Scattering 
Detection,” by H. S. H. Yip, M. Ashraf-Khorassani and L. T. Taylor. Copyright 2007. Reprinted 
with permisson. 
PS is found mainly on the cytoplasmic side of the membrane in healthy eukaryotic cells, enabling 
various regulatory and structural membrane-bound enzymes to interact with it, where it acts as 
a co-factor (Zwaal, Comfurius, & Bevers, 2005).  However, during apoptosis, PL scrambling takes 
place leading to random distribution across the membrane (Williamson, 2015).  This disruption 
in asymmetry leads to the presence of PS on the outer leaflet, which is needed for effective 
ingestion (phagocytosis) of apoptotic cells by macrophages (Nagata, Suzuki, Segawa, & Fujii, 
2016; Segawa & Nagata, 2015).  Importantly, this programmed cell death is different to that 
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which is brought on by pathology, in that there is no risk of harmful intracellular enzymes and 
antigens being released (Leventis & Grinstein, 2010).   
As discussed in section 2.2.3, PS is a anionic GPL (Vance & Tasseva, 2013), which creates 
membrane electrostatics (Platre & Jaillais, 2017), such that an increase in the concentration of 
PS results in an increase in the negative electrostatic potential of the cellular membrane 
(Kooijman & Burger, 2009), making the membrane attractive to cationic proteins (Goldenberg 
& Steinberg, 2010).  PS is known to be a primary binding site (Lemmon, 2008) and there are a 
large number of proteins that bind PS, such as annexins and synaptotagmin.  This implicates PS 
in a number of cellular processes including signal transduction, membrane trafficking and 
neurotransmitter release (Stace & Ktistakis, 2006). PS also binds protein kinase C (PKC), 
a family of protein kinase enzymes, as discussed in section 2.7.3. 
2.3.2  Phosphatidylcholine (PC) 
PC is the most abundant PL present in plasma membranes, contributing approximately 40-50% 
of total cellular membrane lipids (Vance, 2015).  PC contributes to the synthesis of 
sphingomyelin (SM), in which the choline-phosphate head group is transferred to a ceramide 
lipid anchor (Gault, Obeid, & Hannun, 2010), the importance of which is discussed in section 
2.4.1.  The chemical strucure of PC is diplayed in Figure 2.4. 
 
Figure 2.4 Chemical structure of phosphatidylcholine. Reprinted by permission from Springer 
Nature Customer Service Centre GmbH: Springer. Chromatographia.“Feasibility of 
Phospholipids Separation by Packed Column SFC with Mass Spectrometric and Light Scattering 
Detection,” by H. S. H. Yip, M. Ashraf-Khorassani and L. T. Taylor. Copyright 2007. Reprinted 
with permisson. 
The breakdown of PC, by, for example, the enzyme phospholipase D (PLD), leads to the 
production of PA and free choline (Park et al., 2014).  Crucially, PA is a precursor of all membrane 
GPLs and is essential in the transmission, amplification and regulation of many intracellular 
signalling and cellular functions such as vesicle trafficking (Ammar, Kassas, Bader, & Vitale, 
2014).  Moreover, like PS, PA is negatively charged, thus supporting the binding of PA-binding 
protein domains with PA (Tanguy et al., 2018).  The importance of choline is discussed in section 
2.7.4. 
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2.3.3  Phosphatidylethanolamine (PE) 
PE along with PC form more than 50% of all PLs in eukaryotic cell membranes (Gibellini & Smith, 
2010).  PE makes up ~45% of brain total PLs (Vance & Tasseva, 2013) and is enriched in the 
internal layer of the cell membrane bilayer (Castro-Gómez, Garcia-Serrano, Visioli, & Fontecha, 
2015).  The chemical structure of PE is displayed in Figure 2.5. 
 
Figure 2.5 Chemical structure of phosphatidylethanolamine. Reprinted by permission from 
Springer Nature Customer Service Centre GmbH: Springer. Chromatographia.“Feasibility of 
Phospholipids Separation by Packed Column SFC with Mass Spectrometric and Light Scattering 
Detection,” by H. S. H. Yip, M. Ashraf-Khorassani and L. T. Taylor. Copyright 2007. Reprinted 
with permisson. 
The recruitment of PE to the plasma membrane enables cells to regulate their fluidity such that 
the increased presence of PE fosters rigidity of the bilayer (Dawaliby et al., 2016).  Further, PE is 
known to affect protein behaviour.  Due to its conical shape, PE causes membrane lateral 
pressure (stress), which has been coupled to transmembrane protein structure and function, 
such that alterations in pressure affect protein activation (Almeida, Preto, Koukos, Bonvin, & 
Moreira, 2017; van den Brink-van der Laan, Antoinette Killian, & de Kruijff, 2004).  Secondly, the 
conical shape induces packing defects randomly distributed across the outer-leaflet of various 
sizes, which act as binding sites for exposed hydrophobic residues of peripheral proteins 
(Vamparys et al., 2013; van den Brink-van der Laan et al., 2004; Vanni et al., 2013).  Moreover, 
PE is a precursor of the glycosylphosphatidylinositol (GPI) anchor (anchor for various 
transmembrane proteins; Kinoshita, 2016), enabling the anchorage of these to the outer-leaflet 
of the membrane (Paulick & Bertozzi, 2008).  PE also acts as a chaperone by facilitating the 
folding of proteins to enable their proper function (Bogdanov, Mileykovskaya, & Dowhan, 2008; 
Patel & Witt, 2017).  Also, evidence indicates that PE supports autophagy (cellular recycling) and 
therefore promotes the optimisation of cellular health and longevity (Madeo, Tavernarakis, & 
Kroemer, 2010).   
2.3.4  Phosphatidylinositol (PI) 
PI is located mainly in the inner-leaflet of the plasma membrane and represents less than 15% 
of all PLs and the smallest amount of any of the other main GPLs in the plasma membrane (Di 
Paolo & De Camilli, 2006; Fadeel & Xue, 2009; Yamaji-Hasegawa & Tsujimoto, 2006).  The 
chemical structure of PI is shown in Figure 2.6. 
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Figure 2.6 Chemical structure of phosphatidylinositol. Reprinted by permission from Springer 
Nature Customer Service Centre GmbH: Springer. Chromatographia.“Feasibility of 
Phospholipids Separation by Packed Column SFC with Mass Spectrometric and Light Scattering 
Detection,” by H. S. H. Yip, M. Ashraf-Khorassani and L. T. Taylor. Copyright 2007. Reprinted 
with permisson. 
Despite its low prevalence in the membrane, the phosphorylated derivatives of PI, 
phosphoinositides (PIs), influence most elements of a cells life, including being universal 
signalling entities, modulating vesicle trafficking and transmembrane proteins, such as ion 
channels, pumps and transporters, and importantly, regulating lipid distribution and metabolism 
via lipid transfer proteins (Balla, 2013; Clarke et al., 2015).  Crucially, each compartment within 
the membrane has a characteristic suite of PIs, which act as a specific lipid signature, attracting 
a specific complement of functionally significant, loosely bound peripheral proteins existing 
within the cytoplasm (Falkenburger, Jensen, Dickson, Suh, & Hille, 2010).    Membrane lipid 
remodelling is associated with a turnover of peripheral proteins, where a new unique set of 
peripheral proteins with their own enzymatic and signalling functions will associate with 
remodelled compartments (Di Paolo & De Camilli, 2006; Falkenburger et al., 2010).    
PI kinases can phosphorylate the 3, 4, and 5-hydroxyl groups of the inositol head group to 
produce 7 structurally related but distinct PIs, which include phosphatidylinositol-
monophosphate (PI3P, PI4P, and PI5P), phosphatidylinositol-bisphosphate (PI(3,4)P2, PI(3,5)P2, 
and PI(4,5)P2) and phosphatidylinositol-trisphosphate (PI(3,4,5)P3) (Antonietta De Matteis, Di 
Campli, & Godi, 2005).  PIs play an extensive number of roles, a number of which are known to 
support cognitive function.  These are discussed in section 2.7. 
2.4 Sphingolipids 
Sphingolipids are highly dynamic lipids that have a sphingoid base backbone (Merrill, 2011), this 
being sphingosine in mammals (Pralhada Rao et al., 2013).  FA acyl chains in sphingolipids vary 
in length between C16 and ≥ C28, and in most mammalian tissues, the most frequent types are 
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palmitic acid and lignoceric acid (saturated FA, 24:0) and nervonic acid (monounsaturated FA, 
24:1) (Sassa, Suto, Okayasu, & Kihara, 2012).  The addition of different headgroups forms 
complex sphingolipids, for example, the addition of phosphorylcholine creates SM (Young, Mina, 
Denny, & Smith, 2012).  The nervous system is particularly enriched in SM (Cutler & Mattson, 
2001) and the amount present within the brain changes throughout life (Posse de Chaves & 
Sipione, 2010). 
2.4.1  Sphingomyelin (SM) 
SM is a complex sphingolipid and the most abundant of the complex sphingolipids within 
mammalian cells (Castro-Gómez et al., 2015; Gault et al., 2010).  The chemical structure of SM 
is shown in Figure 2.7. 
 
Figure 2.7 Chemical structure of sphingomyelin. Adapted from “Sphingolipid and Ceramide 
Homeostasis: Potential Therapeutic Targets,” by S. A. Young, J. G. Mina, P. W. Denny and T. K. 
Smith, 2012, Biochemistry Research International, 2012, p.2. Copyright 2012 by CC BY. 
Adapted with permisson. 
Oligodendrocytes (myelinating cells of the central nervous system) and myelin 
(sheath surrounding axons) are particularly enriched with SM (Capodivento et al., 2017; Don et 
al., 2014).  SM is most frequently located within the outer layer of the bilayer membrane and in 
myelin sheaths, where it supports stability and preserves chemical resistance (Castro-Gómez et 
al., 2015).  The sphingolipid profile in humans features SM from axonal / dendritic branching and 
synaptogenesis through to adulthood (Olsen & Færgeman, 2017).  The presence of long-chain 
SM in the plasma membrane contributes to membrane thickness by conferring increased 
thickness.  This may support the integration of transmembrane proteins into the membrane 
owing to the length of their transmembrane domains (Slotte, 2013).  Various channels including 
voltage-gated potassium channels are modulated by SM (Combs, Shin, Xu, Ramu, & Lu, 2013; 
Milescu et al., 2009).  
2.5 Dietary sources of glycerophospholipids and sphingolipids, and 
their bioavailability 
In addition to de novo synthesis, GPLs and sphingolipids are available from diet and can be taken 
as supplements (Küllenberg et al., 2012).  The typical dietary daily intake of PLs is between 2 and 
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8 grams, with the body absorbing a greater amount of PC (>90%) (Cohn, Wat, Kamili, & Tandy, 
2008).  In respect of spingolipids, it has been suggested that a western diet provides 0.2-0.4 
grams per day, with most coming from animal sources (Vesper et al., 1999).  GPLs and 
sphingolipids are available in different concentrations in red and white meat, dairy products, 
egg yolk, fish, shellfish, roe, krill, vegetables, cereals and oils (Fong et al., 2016; Küllenberg et al., 
2012; Restuccia et al., 2012; Weihrauch & Son, 1983).  Particularly rich sources include soybeans, 
eggs and milk (Burling & Graverholt, 2008).  In respect of the relative concentration of GPLs 
present in these food items, soybeans are equally high in PC, PE and PI, whilst egg yolk is 
particularly high in PC, whereas milk is enriched in PC, PE and SM (Küllenberg et al., 2012).  Bile 
from the liver provides GPLs for intestinal absorption also; notably 10 – 15 grams per day, which 
is mostly PC (Wang, Liu, Portincasa, & Wang, 2013). Table 2.1 presents the total PL (g kg−1 total 
food) and respective PL (g kg−1 total phospholipids) content in common foods.  
Table 2.1 Total phospholipid and respective phospholipid content of common foodsa 
Food PL PC PE PS PI SM 
Chicken whole egg 34.9 770 166   24 
Bovine whole milk 0.2 327 285 141b  230 
Beef 7.0 493c 180 139d 46 64 
Pork 6.0 429 267 49 68 75 
Chicken breast 4.0 610 194 40 67 55 
Salmon (head) 5.4 547 140 104 25 83 
Tuna 6.0 379 210 54 85 40 
Soybean 20 450 263 50e 141  
Peanut 6.0 435 81 40e 242  
Soybean lecithin  386 164 06 192  
Egg lecithin  754 183   19 
Notes. Adapted from “Phospholipids in foods: prooxidants or antioxidants?” by L. Cui and E. A. 
Decker, 2015, Journal of the Science of Food and Agriculture, 96, p.22. Copyright 2015 by Society 
of Chemical Industry, Wiley Publishing. Adapted with permission. PL: total phospholipids, PC: 
phosphatidylcholine, PE, phosphatidylethanolamine, PS: phosphatidylserine, PI: 
phosphatidylinositol, SM: sphingomyelin. 
aThe values of total phospholipids are in g kg−1 total food. The values of individual phospholipids 
are in g kg−1 total phospholipids. bThe value includes PI. cThe value includes 
lysophosphatidylcholine. dThe value includes phosphatidic acid and cardiolipin. eThe values 
include phosphatidic acid. 
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GPLs have good bioavailability due to their amphiphilic nature (Li et al., 2015).  In the small 
intestine, GPLs along with cholesterol and other lipids form a fat-water emulsion, leading to the 
formation of micelles in the presence of bile salts, which are optimal for lipid intestinal 
absorption (Boyer, 2013; Fricker et al., 2010).  Digestion of SM has been observed as being more 
than 80% following supplementation with a 250 mg dose of milk SM (Ohlsson et al., 2010).  
2.6 Polyunsaturated fatty acid components of glycerophospholipids 
In the brain, which has a comparatively unique FA composition relative to other organs 
(Chouinard‐Watkins, Lacombe, Metherel, Masoodi, & Bazinet, 2019), PS and PE are particularly 
enriched with DHA and docosapentaenoic acid (DPA; omega-3, 22:5), whereas EPA is esterified 
to PI (Chen, Liu, Ouellet, Calon, & Bazinet, 2009).  GPLs in cell membranes within the brain have 
specific PUFA profiles (Layé et al., 2018). DHA and AA are prevalent in the brain, with DHA being 
reported to be the predominant omega-3 PUFA, contributing over 40% of total brain PUFA 
(Lacombe, Chouinard-Watkins, & Bazinet, 2018).  As already discussed, assimilation of FAs into 
PL membranes has consequences for cellular membrane composition, and the types of FAs 
present in cellular membranes influence membrane fluidity, membrane raft formation, 
membrane-generated signalling cascades (Raphael & Sordillo, 2013), vesicle budding and fusion, 
and protein function (Schmitz & Ecker, 2008).  Lipid remodelling (i.e. Lands’ cycle) depends, 
amongst other things, upon the availability of FAs, and so there needs to be a balanced pool of 
available FAs to serve the homeostatic requirements of membranes, especially to aid recovery 
following stress (Maulucci et al., 2016; Nicolson & Ash, 2017).  The notion of dietary fatty acids 
altering phospholipid composition is well supported and discussed in section 2.7.6.2. 
AA, EPA, DPA and DHA can be obtained directly from diet or synthesised from shorter-chain FAs.  
Specifically, omega-6 LA is required for the synthesis of AA, whereas omega-3 ALA is needed for 
the synthesis of EPA, DPA and DHA (Kaur, Chugh, & Gupta, 2014).  LA and ALA are classed as 
essential FA’s in that they cannot be produced in vivo by mammals and are therefore obtained 
exclusively from diet (Bazinet & Layé, 2014; Di Pasquale, 2009).  As the same metabolic pathways 
are used for the synthesis of long-chain PUFA from ALA and LA, this introduces competition (i.e. 
for desaturases and elongases) (Calder, 2016; Kaur et al., 2014).  Notably, the end products are, 
to a limited extent, proportional to their precursors (Layé et al., 2018).  As humans lack specific 
desaturase enzymes, they cannot synthesise omega-3 PUFA from omega-6 (Simopoulos, 2006).  
The omega-6:omega-3 ratio in tissue PLs directly reflects diet composition (Guillou, Zadravec, 
Martin, & Jacobsson, 2010).  Endogenous synthesis of EPA, DPA and DHA within the brain is poor 
relative to uptake from the plasma free (unesterified) FA pool (DeMar et al., 2006; DeMar, Ma, 
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Chang, Bell, & Rapoport, 2005), suggesting that the brain maintains levels of these FAs through 
uptake from dietary and/or liver sources available in plasma (Dyall, 2015).  The poor synthesis 
of EPA, DPA and DHA from ALA may partly be explained by the high proportion of ALA 
undergoing oxidisation (β‐oxidation) in the brain (Anderson & Ma, 2009; DeMar et al., 2005; 
Kaur et al., 2014).  The Western diet typically includes a low intake of EPA and DHA (Bradbury, 
2011; van Elst et al., 2014).  The ideal ratio of omega 6:omega 3 intake is 1-4:1 (Patterson, Wall, 
Fitzgerald, Ross, & Stanton, 2012), however, researchers suggest that the Western diet provides 
a ratio between 10-20:1 (Molendi-Coste, Legry, & Leclercq, 2011; Zárate, el Jaber-Vazdekis, 
Tejera, Pérez, & Rodríguez, 2017).  Importantly, a low intake of ALA with a high intake of LA 
results in omega-6 accumulation, including AA (Layé et al., 2018).  Whilst it is true that some 
omega-6 FAs are required for health, the Western diet provides an excessive quantity, which 
can lead to the displacement of DHA from membrane PLs (Bradbury, 2011). 
2.7 Potential role of glycerophospholipids in the protection and 
facilitation of cognitive function 
2.7.1  Relationship between glycerophospholipids and insulin resistance 
Insulin resistance (failure of cells to respond to insulin/to suppress hepatic gluconeogenesis and 
glucose release into the blood) and impaired glucose tolerance (IGT - where following a glucose 
load, cells are not able to clear glucose from the blood effectively) lead to disrupted glucose 
homeostasis (Ruud, Steculorum, & Brüning, 2017). Insulin resistance is a characteristic of 
metabolic syndrome (MetS) (Geragotou et al., 2016). Both insulin resistance and MetS are 
predictive of type 2 diabetes mellitus (T2DM) (Guo et al., 2018; Taylor, 2012) and all three 
increase the likelihood of experiencing cognitive decline and cognitive impairment, particularly 
dementia (DM) (Chang & Chieh Yen, 2018; Grover, 2018; Laws et al., 2017; Manschot et al., 
2006; Mayeda, Whitmer, & Yaffe, 2015; Neergaard et al., 2017; Umegaki, 2014; Yates, Sweat, 
Yau, Turchiano, & Convit, 2012; Zilliox, Chadrasekaran, Kwan, & Russell, 2016).  Previous 
research has observed a relationship between FA composition of skeletal muscle phospholipids 
and insulin sensitivity, such that reduced insulin sensitivity was found to be related to decreased 
PUFA concentrations (Borkman et al., 1993) and the proportion of palmitic acid (Vessby, 
Tengblad, & Lithell, 1994) present in skeletal muscle phospholipids.  More recently, a number of 
plasma PC species, namely 32:2, 34:1, 34:2, 34:3, 40:5, 42:4 and 42:5 as well as  SM 16:0 and 
24:1 were significantly associated with reduced odds of homeostatic model assessment insulin 
resistance (HOMA-IR) in older adults without diabetes (Semba et al., 2018). In a prospective 
study, serum PC 32:1, 36:1, 38:3, and 40:5 were all significantly positively associated with risk of 
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T2DM, whilst SM 16:1, lysophosphatidylcholine (lysoPC) - a product of PC hydrolysis by 
phospholipase A2 (PLA2) - 18:2 and PC 34:3, 40:6, 42:5, 44:4 and 44:5 were significantly inversely 
associated with risk of T2DM (Floegel et al., 2013). Similarly, lower concentrations of lysoPC 18:2 
was found to be predictive of both impaired glucose tolerance and T2DM in older adults (Wang-
Sattler et al., 2012).  Although research shows an association between PLs and insulin sensitivity, 
there is no evidence at this time to determine whether changes in in PLs lead to or are a result 
of insulin resistance (Chang, Hatch, Wang, Yu, & Wang, 2019).  
Impairment in the activation of atypical protein kinase C (aPKC) contributing to muscle insulin 
resistance in those with IGT and T2DM is related to reduced responsiveness of aPKC to 
PI(3,4,5)P3 (Beeson et al., 2003).  Indeed, PI(3,4,5)P3-mediated activation of protein kinase B 
(Akt) and aPKC in muscle promotes the translocation of the glucose transporter, GLUT4 (insulin-
regulated glucose transporter in adipose tissue and muscle cells essential for glucose uptake and 
are central to whole-body glucose homeostatis; Gao, Chen, Gao, Wang, & Xiong, 2017) from the 
cytoplasm to the plasma membrane, affording increased glucose uptake (Thong, Dugani, & Klip, 
2005).  In its basal state, GLUT4 is present in cytoplasmic vehicles, however, in response to 
insulin hormone, GLUT4 translocates to the plasma membrane to facilitate cellular glucose entry 
(van Dam, Govers, & James, 2005).  Alternatively, impaired PI(3,4,5)P3 signalling in muscle has 
been found to lead to lower levels of GLUT4 translocation and poorer glucose uptake resulting 
in diabetic pathophysiology (Tremblay, Lavigne, Jacques, & Marette, 2001). Moreover, in high 
glucose treated adipocytes, exogenous supplementation of PI(3,4,5)P3 was found to upregulate 
GLUT4 and increase glucose uptake and utilisation.  Furthermore, supplementation with 
PI(3,4,5)P3 and insulin was found to enhance glucose uptake and utilisation in adipocytes relative 
to PI(4,5)P2 and insulin or insulin alone; therefore, reduced cellular PI(3,4,5)P3 concentration 
may augment impaired insulin sensitivity in diabetes (Manna & Jain, 2013).   
2.7.2  Role of glycerophospholipids in synaptic plasticity and neuronal 
communication 
PI(4,5)P2 is the most abundant phosphorylated PI (Dickson & Hille, 2019) and the most dominant 
PI located in the plasma membrane (Sohn et al., 2018), specifically in the inner leaflet of the 
plasma membrane (Ye et al., 2018).  PI(4,5)P2 is known to control approximately 100 ion channels 
and transporters (Dickson, 2019) including voltage-gated potassium and calcium channels (Hille, 
Dickson, Kruse, Vivas, & Suh, 2015; Logothetis, Petrou, Adney, & Mahajan, 2010), therefore, 
changes in the availability and/or distribution of PI(4,5)P2 has consequences for neuron electrical 
activity (Dickson & Hille, 2019; Kruse, Vivas, Traynor-Kaplan, & Hille, 2016; Suh & Hille, 2005).  
PI(4,5)P2 interacts with hundreds of effector proteins and is implicated in a variety of cellular 
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functions, such as membrane fusion and exocytosis (Martin, 2015; Tan, Thapa, Choi, & 
Anderson, 2015).  Membrane fusion involves the coordinated merging of two bilayers (Martens 
& McMahon, 2008), whereas exocytosis concerns the regulated release of neurotransmitters or 
hormones that exist within secretory vesicles that promotes neuronal or hormonal 
communication (Wen et al., 2011).  PI(4,5)P2 has been observed to be involved in priming, a 
stage that follows vesicle docking and is prior to Ca2+-triggered fusion (Martin, 2012).  
Specifically, PI(4,5)P2 recruits and activates multifunctional PI(4,5)P2 binding proteins, such as 
synaptotagmin-1 and Munc13-1/2, to control SNARE protein function that mediates vesicle 
fusion (Ammar, Kassas, Chasserot-Golaz, Bader, & Vitale, 2013; Martin, 2012, 2015; Walter et 
al., 2017). Further, vesicle exocytosis has been observed at areas of high-concentration of 
PI(4,5)P2 (nanodomains) on the plasma membrane of neuroendocrine cells (Martin, 2015), and 
exocytosis and synaptic vehicle recycling at presynaptic sites are sensitive to PI(4,5)P2 availability 
(Cremona & De Camilli, 2001; Di Paolo & De Camilli, 2006). 
N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors are types of glutamate receptors that facilitate synaptic plasticity through 
their expression in pre- and post-synaptic membranes of the hippocampus (Voglis & 
Tavernarakis, 2006).  These receptors are crucial in evoking long-term potentiation (LTP) and 
long-term depression (LTD), both of which are thought to constitute the molecular mechanisms 
that form the basis of learning and memory  (Lüscher & Malenka, 2012).  Moreover, both are 
complementary in promoting the fine-tuning of neural circuitry (Bruel-Jungerman, Davis, & 
Laroche, 2007).  During NMDA receptor-dependent LTP and LTD, the synthesis of PI(3,4,5)P3 by 
phosphatidylinositol 3-kinases (PI3Ks) in dendritic spines from CA1 hippocampal cultured 
neurons was found to be upregulated. However, phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN) activity appears to prevent PI(3,4,5)P3 accumulation during LTD (Arendt 
et al., 2014).  This finding is consistent with the notion that synaptic potentiation tends to be 
associated with upregulation of the PI(3,4,5)P3 pathway whilst synaptic depression is related to 
downregulation of the pathway (Knafo & Esteban, 2012; Peineau et al., 2007).  Moreover, 
regular turnover of PI(3,4,5)P3 at postsynaptic terminals preserves AMPA receptor clustering 
and controls synaptic function in rat hippocampal neurons under basal conditions (Arendt et al., 
2010).  Similarly, PI(4,5)P2 availability and activity has been implicated in LTP in hippocampal 
membranes in old mice.  Improved LTP was found to be dependent upon the interaction 
between PI(4,5)P2 and myristoylated alanine-rich C kinase substrate (MARCKS), a PI(4,5)P2-
clustering molecule, such that increasing the levels of MARCKS resulted in improved LTP and 
memory retention (Trovò et al., 2013).  PI(4,5)P2 has also been found to be necessary for LTD 
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induction in the mouse hippocampal CA3-CA1 pathway (Kim et al., 2017).  Notably, the CA1 
subregion of the hippocampus has been implicated in pattern separation (i.e. differentiation of 
similar patterns of neural activity; Hanert, Pedersen, & Bartsch, 2019), whilst the CA3 subregion 
is crucial for the rapid encoding of new memories (Leutgeb & Leutgeb, 2007) and object 
recognition (Dillon et al., 2017). 
2.7.3 Role of glycerophospholipids in facilitating cognitive function via protein 
kinase C (PKC) activation  
PKC plays a key role in a variety of cellular signalling pathways that regulate cell differentiation, 
growth, transformation, apoptosis and tumorigenicity (Cosentino-Gomes, Rocco-Machado, & 
Meyer-Fernandes, 2012). There are different types of PKC which have different roles which 
merit some exploration in order to understand their potential to influence cognition.  PI(4,5)P2 
and PS have both been recognised as PKC activators.  Phospholipase C hydrolyzes PI(4,5)P2 to 
generate inositol triphosphate (IP3) and diacylglycerol (DAG); subsequent to this, Ca2+ is released 
following IP3 binding with intracellular receptors (Sun & Alkon, 2012).  Together, Ca2+ and DAG 
stimulate the conventional (also known as classical) PKC (cPKC) and PS mediates its activation 
(Dries & Newton, 2008).  In brief, cPKC has four isoenzymes (PKC-α, βI, βII, and γ), each 
containing four homologous domains (C1-C4), of which the tandem C1 domain mediates 
diacylglycerol (DAG) and PS binding in a Ca2+-dependent manner (Antal & Newton, 2014; 
Johnson, Giorgione, & Newton, 2000).  It has been reported that PS is a requirement for the 
activation of all PKC isozymes (Black & Black, 2013; Kanno et al., 2006; Loegering & Lennartz, 
2011) and PKC is known to have the greatest binding affinity with membranes containing PS 
when in the presence of activators (Alzamora, Brown, & Harvey, 2007; Newton, 1995).  PI(4,5)P2 
is also known to directly bind to PCK-Epsilon (PKC-ε) promoting neuron induction activity (Shirai, 
Murakami, Kuramasu, Iijima, & Saito, 2007).  Further, PKC-ε supports synaptogenesis and 
synaptic maturation by activating brain-derived neurotrophic factor (BDNF), nerve growth 
factor, and insulin-like growth factor (IGF) (Sen, Hongpaisan, Wang, Nelson, & Alkon, 2016).  PKC 
isoenzymes are particularly expressed in the hippocampus and have therefore been implicated 
in memory and learning (Sun & Alkon, 2009, 2014; Talman, Pascale, Jäntti, Amadio, & Tuominen, 
2016).  In preclinical studies, PKC activators have improved the availability and activity of PKC 
isoenzymes leading to the restoration of PKC signalling and downstream activity, such as 
synaptic remodelling and the stimulation of neurotrophic activity in areas including the 
hippocampus (Sun & Alkon, 2012).  Pharmacological activation of PKC has been shown to inhibit 
amyloid beta (Aβ)-induced toxicology of hippocampal neurons in vitro (Garrido, Godoy, Alvarez, 
Bronfman, & Inestrosa, 2002; Han, Zheng, Bastianetto, Chabot, & Quirion, 2004).  Furthermore, 
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PKC signalling activity has also decreased the accumulation of neurotoxic Aβ aggregates and tau 
protein hyperphosphorylation (Etcheberrigaray et al., 2004; Isagawa et al., 2000; Sun & Alkon, 
2006).  Indeed, activation of PKC-ε and PKC-α has been observed to prevent amyloid plaques 
and synaptic loss, and to maintain cognitive function in Alzheimer's disease (AD) transgenic mice 
(Hongpaisan, Sun, & Alkon, 2011). 
2.7.4  Contribution of glycerophospholipids to Choline availability 
Although choline, an essential nutrient (Blusztajn, Slack, & Mellott, 2017; Wallace et al., 2018), 
is obtained primarily though diet, PC contributes to choline availability via the methylation of PE 
to PC catalysed by PE N-methyltransferase (PEMT), followed by the action of phospholipases on 
PC (see also section 2.3.2) (Li & Vance, 2008; Zeisel & da Costa, 2009).  Choline is required for 
the synthesis of acetylcholine (ACh), the transportation of lipids and in cell-membrane signalling 
(da Costa, Gaffney, Fischer, & Zeisel, 2005; Penry & Manore, 2008).   The enzyme choline 
acetyltransferase (ChAT) is responsible for the synthesis of ACh from choline and acetyl-
coenzyme A (acetyl-CoA), the latter being supplied by mitochondria (Ferreira-Vieira, Guimaraes, 
Silva, & Ribeiro, 2016).  Importantly, in the brain, ACh mediates neuronal excitability as well as 
facilitates synaptic transmission and induces synaptic plasticity (Picciotto, Higley, & Mineur, 
2012).  ACh is used by cholinergic neurons, which innervate almost all regions of the brain (Woolf 
& Butcher, 2011).  Cholinergic signalling promotes anti-inflammatory properties, upregulation 
of BDNF, neurogenesis and LTP in the hippocampus, thereby having beneficial consequences for 
memory (Maurer & Williams, 2017). Notably, the modulation of memory by ACh may be specific 
to hippocampus-dependent memory, such as episodic and semantic memory rather than 
procedural memory (Haam & Yakel, 2017).  Moreover, ACh has also been proposed to regulate 
top-down control of attention in the prefrontal and parietal cortex (Klinkenberg, Sambeth, & 
Blokland, 2011).  At present, cholinesterase inhibitors (e.g. Donepezil and Rivastigmine; Gawel 
et al., 2016), which prevent acetylcholinesterase from breaking down ACh thereby increasing 
the levels of ACh at synapses, are used as standard care for the symptomatic treatment of AD 
(Hampel et al., 2019). The rationale for this is that cholinergic neurons of the basal forebrain 
(Gratwicke et al., 2013; Hampel et al., 2018; Liu, Chang, Pearce, & Gentleman, 2015) and 
cholinergic medial septum neurons (Hampel et al., 2019) are particularly vulnerable to 
neuropathology in AD.  
Choline is also irreversibly metabolised to betaine (Obeid, 2013; Sivanesan, Taylor, Zhang, & 
Bakovic, 2018) and betaine donates methyl groups to homocysteine, resulting in homocysteine 
being metabolised to methionine (McRae, 2013). Reducing levels of homocysteine is favourable 
for cognitive function with elevated levels of plasma total homocysteine concentrations 
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associated with reduced cognitive performance, independent of any structural brain alterations 
in non-demented older adults (Prins et al., 2002). Indeed, a review of 111 studies reported a 
positive association between increased plasma homocysteine levels and cognitive decline both 
in healthy and cognitively impaired patients, which was confirmed in meta-analyses (Setién-
Suero, Suárez-Pinilla, Suárez-Pinilla, Crespo-Facorro, & Ayesa-Arriola, 2016).   
2.7.5 Restoration of mitochondrial function by glycerophospholipid 
supplementation following oxidative stress 
PLs can be oxidised enzymatically (eOxPL) or non-enzymatically (OxPL). Lipoxygenases (LOXs) or 
cyclooxygenases (COXs) enzymes oxidise PLs in response to injury/infection in activated immune 
cells and platelets.  eOxPLs are formed acutely through the coupling of eicosanoid and 
prostaglandin pathways with enzymes involved in the Lands’ cycle (where a preformed oxidised 
FA is inserted into a lysophospholipid) or by direct oxidation (O’Donnell, Aldrovandi, Murphy, & 
Krönke, 2019). eOxPLs include a small number of specific molecular species and are formed via 
controlled processes in immune cells involving enzymes that are conserved among all 
mammalian species (O’Donnell & Murphy, 2012).  Enzymic-oxidation of omega 3 FAs exert anti-
inflammatory and inflammation resolving properties in addition to immunomodulatory effects 
as seen in model systems and most likely in humans also (Sottero et al., 2019).  Alternatively, 
OxPLs are created during chronic inflammation and atherosclerosis via uncontrolled processes 
leading to the generation of diverse species that tend to have damaging bioactivities (Aldrovandi 
& O’Donnell, 2013).  The non-enzymic oxidation is hard to control, as it is sustained by free-
radical chain reactions (Sottero et al., 2019).  Importantly, OxPLs tend to be related to later-
stage disease (O’Donnell & Murphy, 2012).  The generation of eOxPLs and OxPLs involves the 
removal of hydrogen from PL-bound PUFAs followed by the addition of oxygen to the acyl chain 
(O’Donnell et al., 2019; Smith & Murphy, 2008), which reflects the initiation phase of lipid 
peroxidation (Reis & Spickett, 2012).  In the case of eOxPLs, oxygen insertion is determined by 
the enzyme pathway (O’Donnell & Murphy, 2012).   
2.7.5.1  Reactive oxygen species, oxidative stress and lipid peroxidation 
Reactive oxygen species (ROS) can generate OxPLs (Smith & Murphy, 2008).  Cellular metabolism 
in living organisms generates ROS from molecular oxygen (Birben, Sahiner, Sackesen, Erzurum, 
& Kalayci, 2012).  Specifically, aerobic metabolism produces ROS as a by-product (Schieber & 
Chandel, 2014).  Complexes I and III of the mitochondrial electron transport chain (ETC) 
containing several redox centres are well known for generating ROS in living cells such as 
superoxide anion radical, a precursor of most ROS (Ademowo, Dias, Burton, & Griffiths, 2017; 
Pamplona, 2008).  In brief, oxidative phosphorylation in the synthesis of adenosine triphosphate 
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(ATP – energy for cells) involves electron flow between enzymes (Chaban, Boekema, & Dudkina, 
2014).  During oxidative phosphorylation, electrons removed from biological fuels including fatty 
acids and glucose go through the mitochondrial ETC to generate energy (Cheng et al., 2017).  
When electrons exit the chain before being reduced to water (electron leak), superoxide and 
hydrogen peroxide are produced (Treberg, Braun, Zacharias, & Kroeker, 2018), both of which 
are highly reactive species that cause nonspecific oxidative damage (Lobo, Patil, Phatak, & 
Chandra, 2010; Murphy, 2013).   
Importantly, as well as energy production for cells (e.g. ATP), mitochondria have a central role 
in intracellular Ca2+ signalling and cell growth (Kann & Kovács, 2007; Zhao et al., 2019).   As 
discussed, ROS are a by-product of normal mitochondrial metabolism and homeostasis (Zorov, 
Juhaszova, & Sollott, 2014).  ROS are involved in multiple cellular pathways (Dan Dunn, Alvarez, 
Zhang, & Soldati, 2015) and low levels of ROS are beneficial for the maintenance of physiological 
functions, such as signal transduction, gene expression, immunity and proliferation (Schieber & 
Chandel, 2014). To an extent, ROS metabolism is subtly regulated by enzymes (Zuo, Zhou, 
Pannell, Ziegler, & Best, 2015).  Cellular maintenance under conditions of low lipid peroxidation 
rates is performed via constitutive antioxidants defence systems that scavenge radicals.  
However, when lipid peroxidation rates are higher, the repair capacity is overwhelmed by the 
degree of oxidative damage.  In such cases, cells induce apoptosis or necrosis programmed cell 
death, which causes molecular damage and potentially increases the risk of pathology and 
accelerated ageing (Ayala, Muñoz, & Argüelles, 2014).  Dysregulation of the antioxidant systems 
or overproduction of oxidising molecules triggers oxidative stress (Angelova & Abramov, 2018; 
Gaschler & Stockwell, 2017; Scialò, Fernández-Ayala, & Sanz, 2017).  Oxidative stress (i.e. 
excessive amounts of ROS) represents an imbalance between production and metabolism of 
ROS and manifests an oxidative environment (Poljsak, Šuput, & Milisav, 2013). This imbalance is 
a universal condition in neurodegeneration (Niedzielska et al., 2016).  Excessive ROS disrupts 
redox homeostasis and results in damage to DNA, proteins and lipids (He et al., 2017), and 
injuries seen in diabetes (Figueroa-Romero, Sadidi, & Feldman, 2008; Kaneto, Katakami, 
Matsuhisa, & Matsuoka, 2010; Lee, Yu, Yang, Jiang, & Ha, 2003; Volpe, Villar-Delfino, Dos Anjos, 
& Nogueira-Machado, 2018), ageing (Davalli, Mitic, Caporali, Lauriola, & D’Arca, 2016; Santos, 
Sinha, & Lindner, 2018) and neurodegeneration (Angelova & Abramov, 2018; Liu, Zhou, Ziegler, 
Dimitrion, & Zuo, 2017; Wu, Du, Xue, Wu, & Zhou, 2012). ROS are able to penetrate 
mitochondrial membranes and propagate outside of cells to cause widespread tissue damage 
(Offen, Gilgun-Sherki, & Melamed, 2004).  Therefore, the extent to which the presence of ROS 
is beneficial or otherwise depends upon ROS levels (Cheng et al., 2018). 
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Lipids are extremely vulnerable to ROS (Niki, Yoshida, Saito, & Noguchi, 2005).  Oxygen-derived 
free radicals can oxidise membrane lipid components such as PLs causing lipid peroxidation, and 
this is particularly the case for PLs that contain PUFAs (Catalá & Díaz, 2016), such as LA, AA, and 
DHA (Gaschler & Stockwell, 2017).  Indeed, unsaturated FAs are major targets of free radicals 
leading to oxidative moderation, unlike SFAs, which are more resilient (Bochkov et al., 2017; Reis 
& Spickett, 2012). Specifically, lipids containing carbon-carbon double-bonds are particularly 
vulnerable (Ayala et al., 2014).  Lipid peroxidation impacts membrane physicochemical 
properties, fluidity and permeability, membrane-initiated signalling pathways, lipid-lipid and 
lipid-protein interaction dynamics, ion and nutrient transport and metabolic processes resulting 
in cell dysfunction and death (Adibhatla & Hatcher, 2010; Catalá, 2009; Volinsky & Kinnunen, 
2013).  Notably, the oxidant species, the type of linkage of the FA to the glycerol backbone and 
the fatty acyl chain present influence the OxPL profile (Reis & Spickett, 2012).  Exposure of 
biological membranes to ROS leads to a mixture of distinct OxPLs (Bretscher et al., 2015).  
Moreover, ROS are able to generate secondary oxidative products including aldehydes, which 
further promote and spread ROS-initiated damage (Hill & Bhatnagar, 2009). 4-hydroxy-2-
nonenal (4-HNE) and malondialdehyde (MDA) are the most studied species of aldehydes 
(Ademowo et al., 2017; Gaschler & Stockwell, 2017; Hauck & Bernlohr, 2016), with 4-HNE 
receiving attention due to the part it plays in the aetiology of neurodegeneration and 
cardiovascular disease (Barrera et al., 2015; Mali & Palaniyandi, 2014; Nègre-Salvayre et al., 
2017; Perluigi, Coccia, & Butterfield, 2012).  Oxidative stress and lipid peroxidative end-products 
are recognised as biomarkers of diabetes, inflammation and neurodegeneration (Adibhatla & 
Hatcher, 2010; Bigagli & Lodovici, 2019; Niedzielska et al., 2016). 
2.7.5.2  Mitochondrial dysfunction in the central nervous system 
Brain tissues consume approximately ten times more glucose and oxygen than other tissues 
(Angelova & Abramov, 2018).  The high levels of aerobic metabolism along with the large lipid 
content make the brain especially susceptible to oxidative damage (Adibhatla & Hatcher, 2010). 
Neurons require large amounts of ATP to maintain ionic gradients across cellular membranes 
and for communication (e.g. vesicle pool cycling; Kann & Kovács, 2007).  Neurons also transport 
mitochondria to distal synapses, therefore placing further demands on energy resources (Zhao 
et al., 2019).  As such, neuronal function and health are sensitive to mitochondrial dysfunction 
(Zhao et al., 2019).  High energy consumption levels within the brain places demand on 
mitochondria for energy production, with many mitochondrial mutations and toxins leading to 
tissue damage and pathology (Gandhi & Abramov, 2012).  Both mitochondrial dysfunction and 
mitochondrial ROS formation in the CNS are causative factors of acute brain insults and chronic 
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neurodegenerative states (Chinopoulos & Adam-Vizi, 2006; Johri & Beal, 2012; Kalogeris, Bao, 
& Korthuis, 2014).  Mitochondrial dysfunction with accompanying elevation in lipid peroxidation 
products has been observed in several age-related diseases (Ademowo et al., 2017).  All 
aggregated misfolded proteins including Aβ, tau, α‐synuclein and huntingtin that are 
characteristic of neurodegenerative disorders, inhibit mitochondrial function and cause further 
oxidative stress (Abramov, Berezhnov, Fedotova, Zinchenko, & Dolgacheva, 2017; Angelova & 
Abramov, 2017).  
Mitochondrial bioenergetics are largely conditional upon the physiology of the inner 
mitochondrial membrane, which is the location of redox complexes and phosphorylation 
apparatus involved in ATP production (Monteiro, Oliveira, & Jurado, 2013).  The integrity of the 
inner membrane is pivotal to mitochondrial function and depends on the provision of proteins 
and PLs (Schenkel & Bakovic, 2014).  The inner mitochondrial membrane is particularly rich in 
proteins (Aufschnaiter et al., 2017).  A significant proportion of these make up the oxidative 
phosphorylation system and their activity and stability is sensitive to their interactions with PLs 
(Schenkel & Bakovic, 2014).  As well as cardiolipin, a GPL found exclusively in mitochondrial inner 
membranes, mitochondrial membranes are characteristically enriched in PC and PE; however, 
PS, PI and PA are also present (Horvath & Daum, 2013).  Several lipid species including GPLs 
regulate mitochondrial shape and function through the recruitment of proteins, management 
of protein interactions and alterations of membrane structure and curvature (Frohman, 2015).  
As discussed, excess ROS can affect PL membrane biophysical properties by affecting their 
structure and interfering with intracellular functions (Ademowo et al., 2017).  This will likely 
disrupt mitochondrial function, which has been shown to be restored following consumption of 
membrane lipid replacement (MLR) supplements (Nicolson & Ash, 2017).  MLR supplements 
seek to replace damaged PLs (Nicolson et al., 2016).  Ageing and illness (acute and chronic) tend 
to be accompanied by oxidative damage to cellular membranes (Liguori et al., 2018; Uttara, 
Singh, Zamboni, & Mahajan, 2009) and lipid provision from diet often fails to provide the 
quantities required for preserving cellular membranes in an undamaged state in such cases 
(Nicolson, 2016).  In addition to GPLs, MLR supplements may provide antioxidants to protect the 
unsaturated FAs and GPLs from oxidation both during storage and ingestion, and 
fructooligosaccharides to protect the GPLs from the effects of temperature in the environment 
and enzymes and bile present in the gastrointestinal system (Nicolson & Ash, 2014).  Notably, 
there is some empirical evidence of MLR supplementation benefiting cognitive function, and 
reducing homocysteine levels and risk factors for MetS (reviewed in Nicolson & Ash, 2017). 
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2.7.6  Glycerophospholipids in the amelioration of inflammation  
Inflammation is part of the response against pathogenic organisms and toxic compounds, and is 
an essential component of the immune response following tissue injury (Raphael & Sordillo, 
2013).  Importantly, inflammation is typically self-limiting, with negative feedback systems such 
as secretion of pro-resolving lipid mediators and inhibition of pro-inflammatory signalling 
cascades resulting in its resolution (Calder, 2015).  Disruption or loss of these regulatory 
processes can lead to inappropriate, excessive or continued (chronic) inflammation that can 
cause irreversible tissue damage in the host, including in the brain (Leyrolle, Layé, & Nadjar, 
2016).  Chronic inflammation is typically low-grade and persistent (Franceschi & Campisi, 2014).  
Systemic inflammation results in elevated circulating pro-inflammatory cytokines including 
tumor necrosis factor alpha (TNF-α), C-reactive protein (CRP) and interleukin 6 (IL-6), which 
interact with the CNS (Lin et al., 2018).  Elevated levels of these pro-inflammatory cytokines are 
related to impairments in older adults in global cognition (Schram et al., 2007), executive 
function (Heringa et al., 2014; Schram et al., 2007), memory (Schram et al., 2007; Teunissen et 
al., 2003) and processing speed (Bettcher et al., 2014; Heringa et al., 2014). Chronic 
inflammation is a pervasive feature of ageing (referred to as inflammageing) (Franceschi & 
Campisi, 2014).  Indeed, increases in plasma/serum levels of several inflammatory mediators 
can be 2- to 4-fold in the elderly (Krabbe, Pedersen, & Bruunsgaard, 2004).  However, the 
association between elevated levels of pro-inflammatory cytokines and cognitive impairment 
has also been observed in young (Brydon, Harrison, Walker, Steptoe, & Critchley, 2008) and 
middle-aged adults (Marsland et al., 2015, 2006).  
In the CNS, the initial inflammatory response is coordinated by activated microglia, with chronic 
activation typically seen in neurodegenerative disease, which has the potential to cause 
neuronal injury due to continued production of cytokines and ROS (van Horssen, van Schaik, & 
Witte, 2017). In aged mice, microglia show an exacerbated inflammatory response and greater 
expression of cytokines.  Moreover, during ageing, increased DNA oxidative damage and greater 
intracellular ROS production have been observed; the latter activating nuclear factor kappa light 
chain enhancer of activated B cells (NF-κB), which serves to promote further neuroinflammation 
and cognitive impairment (von Bernhardi, Eugenín-von Bernhardi, & Eugenín, 2015). A sustained 
inflammatory response in the brain has been found to accelerate core AD pathologies (Kinney 
et al., 2018).  Notably, chronic inflammation has been associated with Aβ accumulation, tau 
pathology, and impairment of synaptic plasticity and neuronal loss (Newcombe et al., 2018).  
Recently, systemic inflammation in middle-age has been found to be related to cognitive decline 
over a 20-year period.  Participants (n=12,336) who had a midlife inflammation composite score 
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in the top quartile demonstrated steeper decline in their cognitive function than those in the 
lowest quartile.  This was also the case for those that had elevated inflammatory markers in 
midlife (which was found to be consistently related with memory decline) compared to those 
with lower levels, and both findings did not differ by Apolipoprotein E ε4 genotype (APOE ε4) 
i.e. risk of incident AD (higher for APOE ε4 carriers) did not influence the reported relationship 
(Walker et al., 2019).   
2.7.6.1 Potential of glycerophospholipid supplementation to reduce inflammation by 
restoring mitochondrial function  
Inflammasomes are multi-protein signalling complexes that activate inflammatory caspases, of 
which, nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) is well 
characterised (Jo, Kim, Shin, & Sasakawa, 2016).  NLPR3 inflammasome is known to regulate the 
maturation of pro-inflammatory interleukin (IL)-1 family cytokines interleukin-1 beta (IL-1β) and 
interleukin-18 (IL-18) via caspase-1 activation (Davis, Wen, & Ting, 2011; De Nardo & Latz, 2011).  
Both IL-1β and IL-18 drive inflammatory responses, which can result in neuronal damage (Song, 
Pei, Yao, Wu, & Shang, 2017).  The NLPR3 inflammasome signalling pathway largely contributes 
to neuroinflammation in the CNS and mitochondrial dysfunction has been observed as 
increasing the NLRP3 inflammasome-driven pro-inflammatory cascade in microglia (Sarkar et al., 
2017).  This may be due to the associated increase in ROS generation, which is known to activate 
the NLPR3 inflammasome (Heid et al., 2013; Zhou, Yazdi, Menu, & Tschopp, 2011).  Importantly, 
microglial NLRP3 inflammasome activation plays a critical role in dopaminergic neuronal loss 
(Lee et al., 2019) and contributes to pathogenesis following cerebral ischemia, traumatic brain 
injury (TBI) and haemorrhagic stroke (Song et al., 2017). In respect of AD, Aβ can promote the 
maturation of IL-1β by inducing augmented caspase-1 and NLRP3 activity via mitochondria ROS, 
causing an elevation in microglial neurotoxicity (Parajuli et al., 2013).   
Another route by which mitochondrial dysfunction induces an inflammatory response is via 
danger-associated molecular patterns (DAMPs).  DAMPS are released following cellular 
(including neuronal) stress or death (Bajwa, Pointer, & Klegeris, 2019) and interact with pattern 
recognition receptors (PRRs) to activate the host’s immune system (Roh & Sohn, 2018).  Oxidised 
mitochondrial DNA (mtDNA), a consequence of excessive ROS generation (Bhatti, Bhatti, & 
Reddy, 2017), is acknowledged as being subtype of the DAMP family (Mathew et al., 2012).  
Oxidised mtDNA is released from mitochondria into the cytoplasm following the opening of the 
mitochondrial transition pore (ROS induced) and under conditions of cellular stress or necrosis, 
are further released into extracellular fluid (Boyapati, Tamborska, Dorward, & Ho, 2017; 
Nakayama & Otsu, 2018). Once in the cytoplasm or extracellular space, mtDNA is able to evoke 
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a pro-inflammatory response (West & Shadel, 2017). Specifically, mtDNA activates several 
innate immune pathways involving NLRP3, Toll-like receptor 9 (TLR9) and stimulator of 
interferon genes (STING) signalling (Fang, Wei, & Wei, 2016).  This in turn leads to the 
enhancement of the transcriptional activity of inflammatory cytokines and interferons 
(Nakayama & Otsu, 2018).  
Restoration of mitochondrial function though MLR supplementation discussed in section 2.7.5 
may be an important therapeutic strategy against the role of mitochondrial dysfunction in 
inflammation.  MLR supplementation of GPLs can restore the structure and function of various 
cellular membranes (Nicolson & Ash, 2014). In doing so, MLR has the potential to improve 
mitochondrial function and reduce levels of ROS. This in turn would result in better management 
of inflammation and therefore may contribute to the management of inflammation-driven 
diseases (Cruz & Kang, 2018). 
2.7.6.2 Fatty acid composition of phospholipids and the consequences for 
inflammation 
Overall, it is thought that the effect of FAs on inflammatory cell responses involves their 
incorporation into PLs within the cell membrane (Calder, 2008b). Crucially, dietary intake 
impacts the FA profiles of PLs (Saadatian-Elahi et al., 2009; Zheng et al., 2019) and increased 
intake of marine omega-3 FAs has been observed to augment EPA and DHA concentrations in 
membrane PLs of blood cells that engage in inflammatory processes  (Browning et al., 2012; 
Faber et al., 2011; Kew et al., 2004; Rees et al., 2006).  Further, incorporation of marine omega-
3 FAs into membrane PLs of cells that participate in inflammation is both time- and dose-
dependent (Browning et al., 2012; Rees et al., 2006). Moreover, increased incorporation of DHA 
and EPA from diet or following supplementation results in the displacement of omega-6 PUFAs, 
particularly AA, from cell membrane PLs (Calder, 2013; Walker et al., 2015; Wood et al., 2010), 
which is favourable for attenuating the pro-inflammatory response in the context of 
inflammation (Innes & Calder, 2018).  Specific examples of how the FA content of cell membrane 
PLs influence inflammation concern their impact on lipid raft formation and by being precursors 
of various bioactive lipids following being released from the lipid membrane by, for example, 
the action of phospholipases (Calder, 2012, 2013; Raphael & Sordillo, 2013).   
2.7.6.2.1 Lipid raft formation 
Lipid rafts in the plasma membrane that concentrate membrane proteins and lipids such as 
cholesterol, SM and saturated FAs, serving as signalling platforms, can be affected by the 
saturation and length of FAs in cell membrane PLs (Endo & Arita, 2016).  As discussed, lipid rafts 
are found in a highly structured liquid-ordered states (Stillwell, 2006).  However, omega-3 PUFA 
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acyl chains are highly disordered (Shaikh, Kinnun, Leng, Williams, & Wassall, 2015) and indicate 
conformational flexibility, thereby are able to affect lipid raft organisation by disturbing 
molecular order and acyl chain packing (Shaikh, 2012).  Indeed, omega-3 PUFA have a low 
affinity for cholesterol (Kučerka et al., 2010; Shaikh, 2012).  Alternatively, studies using 
quantitative imaging with polarity sensitive probes suggest omega-3 PUFA enhance the 
molecular order of rafts. For example, using mouse models, omega-3 PUFA promoted the 
formation of ordered lipid microdomains and enhanced the molecular order of the 
immunological synapse on the T cell side, a cholesterol-dependent interface. Importantly, these 
alterations in the molecular order influence the recruitment of select proteins into the synapse, 
resulting in suppression of downstream activation and proliferation of T cells (Kim, Barhoumi, 
McMurray, & Chapkin, 2014; Kim et al., 2008).   
DHA and/or EPA have been observed to incorporate directly into membrane fractions crudely 
corresponding to rafts in a variety of cell types (Briolay, Jaafar, Nemoz, & Bessueille, 2013; Li et 
al., 2005; Schley, Brindley, & Field, 2007; Shaikh, Rockett, Salameh, & Carraway, 2009).  
Consistent with this, earlier in vivo studies that supplemented mice with an omega-3 PUFA 
enriched fish-corn oil mixture (Fan, McMurray, Ly, & Chapkin, 2003) or enriched fish-corn oil 
mixture or DHA ethyl ester (Fan, Ly, Barhoumi, McMurray, & Chapkin, 2004) (compared to corn 
oil as placebo) reported incorporation of omega-3 PUFA in lipid raft and soluble membrane PLs 
in murine splenic T-cells, which resulted in reduced raft SM content.  Moreover, omega-3 PUFA 
were observed to suppress the partitioning of PKC theta (PKC-θ) into lipid rafts, which was 
related to reduced activation of transcription factors Activating protein-1 (AP-1) and NF-κB and 
suppression of IL-2 production, a T cell growth factor (Fan et al., 2004).  Activation of AP-1 and 
NF-κB promotes pro-inflammatory cytokine production and elevates pro-inflammatory 
signalling (Luo & Zheng, 2016; Pugazhenthi, Zhang, Bouchard, & Mahaffey, 2013; Turner, Nedjai, 
Hurst, & Pennington, 2014). 
Further evidence of how omega-3 PUFA incorporation can impact the function of membrane 
proteins includes the observation that DHA is able to inhibit the dimerization and recruitment 
of Toll-Like receptor 4 (TLR4) into membrane lipid raft fractions (Ciesielska & Kwiatkowska, 2015; 
Hwang, Kim, & Lee, 2016; Rogero & Calder, 2018; Wong et al., 2009).  TLR4 plays a pivotal role 
in the escalation of the inflammatory response (Molteni, Gemma, & Rossetti, 2016) and 
mediates both infection-induced inflammation as well as sterile inflammation caused by 
endogenous molecules (Wong et al., 2009).  Importantly, TLR4 is known to trigger pro-
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inflammatory transcription via adaptor proteins, in turn inducing transcription factors AP-1 and 
NF-κB (Loegering & Lennartz, 2011; Troutman, Bazan, & Pasare, 2012).  
2.7.6.2.2 Pro-inflammatory, pro-resolving and anti-inflammatory lipid mediators 
PUFA within cell membrane PLs are selectively released from their sn-2 position leading to 
unesterified PUFA (and a lysophospholipid), which are precursors of metabolically active lipid 
mediators (Lacombe et al., 2018).  AA is a major substrate for the biosynthesis of eicosanoids, 
which are highly bioactive lipid mediators (Raphael & Sordillo, 2013). AA is frequently found in 
membrane PLs of macrophages, neutrophils and lymphocytes, making AA a typical eicosanoid 
precursor (Calder, 2013).  Eicosanoid mediators including numerous leukotrienes (LTs), 
prostaglandins (PGs) and thromboxanes (TXs), can be created following the oxidation of AA by 
LOX, COX and cytochrome P450 (CYP) enzymes or through non-enzymatic free radical 
mechanisms (Calder, 2015; Dennis & Norris, 2015).  Notably, COX-1 is thought to support cellular 
housekeeping functions (Calder, 2015), whilst COX-2 is recognised as a significant mediator of 
inflammatory pathways (Gandhi, Khera, Gaur, Paul, & Kaul, 2017).  PGs, TXs and LTs tend to be 
pro-inflammatory (Das, 2018). For example, prostaglandin E2 (PGE2) is able to induce IL-6, whilst 
leukotriene B4 (LTB4) produced by macrophages and neutrophils supports inflammatory 
mediator synthesis including superoxide and inflammatory cytokines leukotrienes C4 (LTC4), D4 
(LTD4) and E4 (LTE4) (Innes & Calder, 2018).  The metabolism of AA takes place following 
esterified AA being cleaved from membrane PLs, which is carried out by three main 
phospholipases families, such as PLA2, resulting in increased free AA (Hanna & Hafez, 2018).  
PLA2 can be activated by inflammatory stimuli (Sun et al., 2010).  Although typically associated 
with inflammation, eicosanoids do have homeostatic functions (Dennis & Norris, 2015). 
However, excessive or inappropriate production of AA-derived eicosanoids is related to disease 
(Calder, 2006; Chiurchiù, Leuti, & Maccarrone, 2018).  
2.7.6.2.2.1  Pro-resolving lipid mediators 
Contrary to pro-inflammatory lipid mediators, specialised pro-resolving mediators (SPMs) act as 
immunoresolvents and include AA-derived lipoxins (LXs: LXA4 and LXB4), resolvins (E-series 
synthesised from EPA: RvE1–3 and D-series synthesised from DHA: RvD1–6), 
protectins/neuroprotectins (protectins generated in neural tissue) (PD1/NPD1 and PDX), 
maresins from DHA (MaR1 and MaR2) and DPA-derived 13-series resolvins (RvT1–4) (Dalli, Chiang, 
& Serhan, 2015; Serhan, 2014; Serhan & Chiang, 2013; Serhan, Chiang, & Dalli, 2018).  Following 
acute inflammation, SPMs support various pro-resolving processes including the termination of 
further leukocyte infiltration, inhibition of pro-inflammatory cytokines and promotion of anti-
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inflammatory mediator production, activation of endogenous resolution programs and aiding 
tissue regeneration (Buckley, Gilroy, & Serhan, 2014; Serhan, 2014). In view of chronic 
inflammation, SPMs have been observed to directly regulate adaptive immune cells, such as B 
and T lymphocytes, both of which are heavily involved in chronic inflammation (Ariel, Chiang, 
Arita, Petasis, & Serhan, 2003; Ariel et al., 2005; Chiurchiù et al., 2016; Kim et al., 2016; Ramon, 
Gao, Serhan, & Phipps, 2012).  
Interestingly, several neurodegenerative diseases, such as AD and multiple sclerosis (MS) that 
are typically characterised by chronic inflammation, also appear to be related to failure of 
activating pro-resolving mechanisms (Chiurchiù et al., 2018). Evidence for dysfunction of 
inflammation resolution comes from post-mortem hippocampal tissue and cerebrospinal fluid 
(CSF) of AD patients and healthy controls.  Dysfunction was evidenced by reduced LXA4 in the 
CSF and the hippocampus and elevations of two SPM receptors in AD brains. Moreover, levels 
of LXA4 and RvD1 in the CSF associated with scores on the Mini-Mental State Examination 
(MMSE) (Wang et al., 2015).  In another study that involved AD patients and age-matched 
controls, MaR1, PD1 and RvD5 were found to be lower in the entorhinal cortex of AD patients 
(one of the first regions to show neurodegeneration in AD; Howett et al., 2019), however, levels 
of prostaglandin D2 (PGD2), a pro-inflammatory lipid mediator, were higher in AD. Furthermore, 
it was also reported that certain lipids were associated with specific characteristics; LXA4, MaR1, 
RvD1 and PDX induced neuroprotective activity, MaR1 and RvD1 down-regulated Aβ42-generated 
inflammation in microglia and MaR1 stimulated Aβ42 uptake by microglia (Zhu et al., 2016).  
Additionally, treatment of primary neuronal and glial cultures with another DHA derived SPM, 
namely NPD1, has been identified to both decrease amyloidogenic and upregulate non-
amyloidogenic processing of amyloid precursor protein (Zhao et al., 2011).  Further evidence of 
the pro-resolving characteristics of SPMs, particularly SPMs supporting neuronal survival and Aβ 
uptake by microglia has been reported by in vitro studies (Fiala, Halder, et al., 2015; Fiala, 
Terrando, & Dalli, 2015; Mizwicki et al., 2013).   
2.7.6.2.2.2  Anti-inflammatory characteristics of omega-3 polyunsaturated fatty acids 
Omega-3 PUFAs DHA and EPA also demonstrate anti-inflammatory properties.  This is 
exemplified by DHA and EPA competing with AA for metabolism by PLA2 (Wada et al., 2007) and 
COX-2, and as consequence, limiting the production of AA-derived pro-inflammatory lipid 
mediators (Endo & Arita, 2016; Ye & Ghosh, 2018). Crucially, the extent of the competition is 
dependent upon the concentration of the competing lipids (Wada et al., 2007).  Notably, EPA is 
also a precursor for eicosanoids, however, those derived from EPA are structurally distinct from 
AA-derived eicosanoids rendering those produced from EPA less potent pro-inflammatory 
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mediators (Das, 2018).  Therefore, EPA availability promotes decreased generation of potent 
AA-derived eicosanoids whilst increasing the production of weak eicosanoids (Calder, 2015). 
Additionally, given that increased content of DHA and EPA in cell membranes is associated with 
reduced content of AA, the increased incorporation means there will be less AA available to act 
as a substrate of pro-inflammatory eicosanoids (Calder, 2013; Rees et al., 2006).  
Crucially, the incorporation of DHA and EPA into inflammatory cell membranes also enables the 
modulation of inflammatory gene expression via interaction with numerous nuclear receptors 
and transcription factors (Calder, 2008a). Previous evidence in support of this reported DHA and 
EPA reduced the production of pro-inflammatory cytokines (Baumann et al., 1999), whilst more 
recently, an in vitro study revealed DHA and EPA treated macrophages showed decreased 
expression of IL-6, TNF-α and monocyte chemoattractant protein-1 (MCP-1) (Wang et al., 2009).  
Importantly, MCP-1, a chemokine, is integral in regulating migration and infiltration of 
macrophages (Deshmane, Kremlev, Amini, & Sawaya, 2009). Moreover, basal effects of DHA, 
EPA and EPA + DHA on the expression of ten genes associated with inflammation in unstimulated 
cultured THP-1-derived macrophages have been explored.  Collectively, DHA or EPA or both in 
combination (at different doses) reduced the expression of genes concerned with the NF-κB 
pathway, cytokine production including TNF-α expression and reduced nitric oxide synthase 2 
(NOS2) expression, a pro-oxidative gene, and enhanced microsomal glutathione S-transferase 1 
(MGST1) expression, an anti-oxidative gene (Allam-Ndoul, Guénard, Barbier, & Vohl, 2016).  A 
similar study reported DHA and EPA affecting the inflammatory nature of activated THP-1-
derived macrophages across a range of lipopolysaccharide (LPS) concentrations (responsible for 
inducing inflammation).  Both DHA and EPA down-regulated the generation of pro-inflammatory 
cytokines related to the NF-κB pathway, however, individually DHA was found to be more potent 
compared to EPA in attenuating IL-1β and IL-6 secretion, whereas EPA modulated TNF-α to a 
greater extent than DHA (Mullen, Loscher, & Roche, 2010).   
2.8 Summary 
GPLs are major constituents of cell membranes and include PS, PC, PE and PI, with the latter 
being the precursor of 7 structurally related but distinct PIs (see section 2.3.4).  SM, a 
sphingolipid (PL species), is also found in cell membranes. Cells can have different organisations 
of GPLs in their membranes (and bilayers), for example, mitochondria are particularly enriched 
with PC, PE and cardiolipin.  The composition of GPLs vary in respect of the phosphate head 
group and FA chains.  This promotes asymmetry within and across membrane bilayers.  Such 
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diversity has implications for membrane electrostatics, lipid-protein interactions, membrane 
shape and curvature, membrane fluidity and lateral segregation of membrane constituents 
illustrated by lipid rafts.  Importantly, cell membrane lipids support cellular health and function. 
Empirical evidence suggests numerous key properties of GPLs (and SM) that facilitate cellular 
function.  These include (not exhaustive) PS acting as a primary binding site for peripheral 
proteins and PE affecting transmembrane protein structure and function by causing membrane 
lateral pressure.  Further, PC hydrolysis promotes increased PA availability in turn likely 
facilitating vesicle trafficking, whereas SM supports lipid raft formation as well as myelin stability 
and transmembrane channels, such as voltage-gated potassium channels.  
There are various potential mechanisms by which GPLs may support cognitive function.  Insulin 
resistance, a feature of MetS, is associated with cognitive impairment.  The PI PI(3,4,5)P3 is 
reported to support GLUT4 translocation to the plasma membrane by activation of aPKC and 
Akt in muscle leading to increased glucose uptake. The same result was found when high glucose 
treated adipocytes were supplemented with PI(3,4,5)P3.  PI(3,4,5)P3 has also been observed to 
be upregulated during LTP and LTD.  For example, regular turnover of PI(3,4,5)P3 at postsynaptic 
terminals preserves AMPA receptor clustering, a glutamate receptor that facilitates synaptic 
plasticity in the hippocampus. Another PI, PI(4,5)P2, has also been identified as supporting LTP 
via its interaction with a protein localised to the plasma membrane. This same PI has been 
implicated in neuron function through its regulation of voltage-gated potassium and calcium 
channels and its involvement in the preparation of synaptic vesicles following vesicle docking 
and prior to vesicle fusion. Moreover, PI(4,5)P2 and PS are recognised for their role in PKC 
activation and therefore have the potential to promote synaptic remodelling, stimulate 
neurotrophic activity in the hippocampus and inhibit Aβ-induced toxicology.  Another GPL, PC, 
indirectly supports neuronal excitability, synaptic transmission and plasticity by contributing to 
ACh synthesis from choline.  Membrane lipid replacement supplementation featuring GPLs aims 
to restore mitochondrial function, which may offer therapeutic benefits following lipid 
peroxidation by oxidative stress.  Restoration of mitochondrial function may also serve as a 
strategy for reducing systemic inflammation, which has been associated with cognitive 
impairment in young, middle-aged and older adults. The FA profile of GPLs has also been studied 
in the context of inflammation.  Incorporation of omega-3 PUFA into lipid rafts has been related 
to reduced activation of transcription factors, activation of which is known to promote pro-
inflammatory cytokine production and pro-inflammatory signalling.  Also, DHA and EPA released 
from the cell membranes act as precursors of SPMs that support various pro-resolving 
processes. Crucially, lower levels of SPMs have been associated with AD. 
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Chapter 3 Systematic review of glycerophospholipid supplementation 
studies across the life span and their cognitive outcomes 
3.1  Introduction 
This chapter reports on a systematic review of the effects of GPL supplementation on cognitive 
outcomes across the lifespan, including both acute and chronic supplementation studies.  To 
date, no review has reviewed these studies systematically. The aim of the systematic review was 
to address the following questions: 
a) Is there evidence that specific GPLs or a GPL composite can confer a benefit for cognitive 
performance? 
b) Is acute GPL supplementation sufficient to enhance cognitive performance? 
c) Does the literature suggest a dose-response effect and/or an ideal duration of 
supplementation (chronic)? 
d) Does supplementation support a particular cognitive domain or are benefits seen across 
multiple domains? 
3.2 Methods 
This systematic review followed the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) 2009 checklist and is registered in PROSPERO. The registration number is 
CRD42019148939.  
3.2.1 Search strategy and search terms 
The following electronic databases were searched, CINAHL 1 January 1960 – 3 January 2020, 
Embase Classic + Embase 1947 – 3 January 2020, Ovid MEDLINE(R) 1946 – 3 January 2020, and 
PubMed on 3 January 2020. Details of the cognitive search terms, limits and tags are located in 
Appendix 2. For each search conducted, the relationship was: (cognitive terms combined with 
OR) AND (PL terms combined with OR). The reference lists of identified articles were examined 
individually to supplement the electronic search. Further, an inventory of existing references 
obtained from on-going citation alerts was also examined.  
3.2.2 Inclusion and exclusion criteria 
This review was limited to articles published in peer-reviewed journals in English. Case reports, 
abstracts and conference proceedings were not included. Articles were included or excluded in 
this review using the criteria in Table 3.1. 
35 
 
Table 3.1 Inclusion and exclusion criteria used for the assessment of study eligibility  
 Inclusion criteria Exclusion criteria 
Population 
 Cognitively healthy participants or 
participants expressing subjective 
complaints concerning their memory 
or cognition or classed as having age-
associated memory impairment/age-
associated cognitive impairment, of 
any age.  
 Human samples. 
 Minimum reporting requirements 
included sample size and composition. 
× Studies including participants 
with a psychiatric or medical 
disorder that could interfere 
with cognitive function, 
including a neurological 
disorder, such as dementia, 
Parkinson's disease, stroke, 
focal brain lesions, multiple 
sclerosis or epilepsy. 
× Non-human samples. 
× No detail of sample. 
Intervention 
 Single or multiple GPL(s) – composite - 
as the active supplement.  Where 
another ingredient is present in the 
active supplement, this must also be 
present in the placebo to the same 
quantity. 
 Interventions can be either acute or 
chronic and can be delivered in any 
form e.g. liquid, gel capsule, powder 
etc. In the case of cross-over studies, 
there is no restriction on the length of 
wash-out period.   
 Both researchers and their sample are 
blinded to the treatment condition(s) 
(double-blind). 
 Minimum reporting requirements 
included GPL dose and duration of 
intervention. 
× Non-GPL ingredient present 
in the active or placebo 
supplement not given in 
equal quantity in the 
comparator. 
× Open label or single-blind 
study. 
× No detail concerning GPL 
dose nor the duration of 
intervention. 
Comparison 
 A placebo condition.  Where a placebo 
contains an active ingredient (for 
example, a GPL or a vitamin), this same 
ingredient must be administered to 
the same quantity within the active 
supplement.  Other experimental 
conditions are acceptable in addition 
to the placebo condition. 
× No placebo condition. 
× Use of a non-inert substance 
as the placebo or the addition 
of an active ingredient not 
matched in active 
supplement. 
Outcome 
 Studies including at least one objective 
measure of cognitive performance will 
be considered. Paper or computerised 
measures are acceptable. 
× No objective measure of 
cognitive performance. 
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3.2.3 Study selection process 
The literature search yielded a total of 7242 citations. Following removal of 439 duplicates, a 
total of 6803 citations were retrieved for possible inclusion in the review. The titles and abstracts 
of these citations were screened by one reviewer (CC) to remove obviously irrelevant reports 
(such as animal studies, review papers, case studies, abstracts/posters/chapters, n=742), 
resulting in retention of 6061 papers. Another reviewer (DH) independently screened, at 
random, 5% of the titles and abstracts to establish agreement about the inclusion and exclusion 
of studies. The inter-rater agreement was 95%.  Any disagreements during this process were 
resolved by discussion and a consensus decision was reached. The full-text versions of 103 
articles plus citations identified through other sources (n=4) were retrieved and examined for 
eligibility based on the inclusion and exclusion criteria, and authors were contacted to clarify 
any missing information. Inter-rater agreement was 100%. As a result of this second screening 
process, a further 100 articles were excluded leaving a total of 7 articles included in the review.  
A flow diagram (Figure 3.1) presents the study selection process.  
In addition to the 7 included articles, three further articles based on intervention studies that 
supplemented Lacprodan® PL-20 (Boyle et al., 2019; Hellhammer, Waladkhani, Hero, & Buss, 
2010; Schubert, Contreras, Franz, & Hellhammer, 2011) were also included in the review.  These 
studies did not meet the inclusion and exclusion criteria, as sphingomyelin (a sphingolipid, see 
section 2.4.1), a constituent of the active supplement, was not incorporated in the placebo.  
However, as the intervention studies reported in this thesis supplemented Lacprodan® PL-20, it 
is important to consider these.   
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Figure 3.1 Study selection flow diagram  
 
3.2.4 Data extraction  
The Cochrane data extraction form was modified for the purposes of this review.  Data were 
extracted by one researcher (CC), and authors were contacted when insufficient information 
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extracted by another researcher (DH). Any disagreements were resolved by discussion, and a 
consensus decision was reached. 
The following information was extracted from the reviewed studies: Ingredient: Details the 
specific GPL(s) provided and the source, where this was available. Sample characteristics: The 
sample size and composition (sex, age). All reviewed studies included cognitively healthy 
samples. Five of the studies recruited samples based upon specific inclusion criteria, such as 
meeting the criteria for age-associated memory impairment.  Design and intervention: Study 
design and details of the active and placebo supplements as well as any other ingredients 
provided as part of the intervention. Specifics include supplement composition, form, dose and 
frequency of administration and intervention length (acute or chronic).  The cognitive testing 
schedule and/or any specific details concerning the design of the study that are noteworthy can 
also be found here. Cognitive measures: A summary of the objective cognitive measure(s) used 
including a brief description where the nature of the measure is not obvious from the title 
and/or where there are multiple parts (test battery). Where any Clinical Rating Scales were 
administered or biological samples taken to explore the effects of supplementation (e.g. 
changes in GPL levels in plasma), details of these have also been included for completeness.  
Reported findings: A summary of any significant differences by condition as well as marginally 
significant differences (≥ .05 - .07) and/or trends (> .07 - < .10) in favour of GPL supplementation 
or otherwise. Subgroup / further analysis: A summary of any findings indicating significant 
differences, marginally significant differences and/or trends following any further analyses or 
subgroup analyses.  Effect summary: The reported effects of GPL supplementation were 
summarised as positive (+), no effect (x), negative effect (-) and (?) where there was any doubt 
regarding the reported outcome.  
3.3  Key characteristics of the studies reviewed 
A summary of the ten reviewed studies is provided in Table 3.A (Appendix 3). The experimental 
design of the studies included in this review conformed to a randomised, double-blind, placebo-
controlled design.  Of the ten studies reviewed, one study recruited healthy pregnant women 
and tested their infants at 10 and 12 months of age (Cheatham et al., 2012), seven studies 
recruited young adults (18-44 years) (Baumeister et al., 2008; Boyle et al., 2019; Harris, Dysken, 
Fovall, & Davis, 1983; Hellhammer et al., 2010; Parker et al., 2011; Rosadini, Sannita, Nobili, & 
Cenacchi, 1990; Schubert et al., 2011), two of which followed an acute supplementation strategy 
(Harris et al., 1983; Rosadini et al., 1990),  whilst one study recruited middle-aged adults (45-64 
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years) (Crook, Tinklenberg, Yesavage, Petrie, Nunzi, Massari, et al., 1991) and one included 
older-adult samples (65 years +) (Vakhapova, Cohen, Richter, Herzog, & Korczyn, 2010).  Where 
sample age ranges were across two periods, such as 50 – 90 years of age, as in the case of 
Vakhapova et al. (2010), average age (within each condition where sample average age was not 
given) was used to determine which age category the study was assigned to. 
PS was supplemented most frequently, being administered in five of the ten studies (Baumeister 
et al., 2008; Crook et al., 1991; Parker et al., 2011; Rosadini et al., 1990; Vakhapova et al., 2010).  
Supplements were supplied as an oral dose in five studies (Cheatham et al., 2012; Crook et al., 
1991; Harris et al., 1983; Parker et al., 2011; Vakhapova et al., 2010), intravenously in one study 
(Rosadini et al., 1990), in food form in another study (nutritional bar; Baumeister et al., 2008) or 
as a drink in three studies (milk; Boyle et al., 2019; Hellhammer et al., 2010; Schubert et al., 
2011).  
Of the studies that assessed the benefit(s) of chronic administration, the longest intervention 
duration was from 18 weeks gestation to 90 days postpartum (approx. 8 months; Cheatham et 
al., 2012) whereas the shortest was 2 weeks (Parker et al., 2011). Finally, four of the ten 
reviewed studies used neuropsychological tests2 (or a component of these) to identify an effect 
of treatment (Cheatham et al., 2012; Crook et al., 1991; Harris et al., 1983; Vakhapova et al., 
2010). 
Within Table 3.A (Appendix 3), the cognitive outcomes are reported as per the original 
publication, however, these have been re-categorised according to their domain in line with the 
work of Galioto and Spitznagel (2016) presented in Table 3.2 ‘Overview of study findings by 
cognitive domain’ and in the remainder of this Chapter.  The framework used by Galioto and 
Spitznagel (2016) is adapted from Lezak, Howieson, Bigler and Tranel (2012); widely accepted as 
the standard reference that provides comprehensive coverage on the measurement of cognitive 
domains.  Importantly, Galioto and Spitznagel (2016) set out descriptions of cognitive domains 
and subdomains, as well as examples of tasks associated with each domain that are relevant for 
studies reported in this review.  One exception concerns verbal fluency, which Galioto and 
Spitznagel (2016) categorise as a function of language.  However, this review considers verbal 
                                                          
2 Digit symbol substitution of the Wechsler Adult Intelligence Scale was used by Harris et al. 
(1983); Mullen Scales of Early Learning was used by Cheatham et al. (2012); NexAde™ 
cognitive battery was used by Vakhapova et al. 2010; Benton Visual Retention Test, 
Wechsler Memory Scale Logical Memory Subtest (Form A) and Wechsler Memory Scale 
Associative Learning Subtest (Form A) was used by Crook et al. (1991). 
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fluency to represent executive function, as per Lezak et al. (2012). The following section provides 
an overview of the cognitive outcomes and the effects of GLPs reported in the reviewed studies.   
3.3.1 Risk of bias assessment  
Each study was assessed for risk of bias using the Cochrane Collaboration’s tool for assessing 
risk of bias in randomised trials (Higgins et al., 2011). This assessment tool covers 6 domains of 
bias, where a judgement is taken of high, low or unclear risk of bias (Jørgensen et al., 2016): 
Selection bias (random sequence generation and allocation concealment), performance bias 
(blinding of participants and personnel), detection bias (blinding of outcome assessment), 
attrition bias (incomplete outcome data), reporting bias (selective reporting) and other sources 
of bias.  Two reviewers (CC and DH) independently assessed each study against each of the 6 
domains based on the predetermined criteria.  Any disagreements during this process were 
resolved by discussion, and a consensus decision was reached.  Risk of bias assessments for each 
of the ten studies are provided in Figure 3.2.  
Details on the randomisation technique was not elaborated in six of the ten studies and 
therefore a judgement of unclear risk of bias was awarded. Allocation concealment was 
described in four of the studies. Specifics as to any measures undertaken to blind study 
participants and personnel from knowledge of which treatment a participant had received were 
also lacking in 5 of the studies.  Further, blinding of outcome assessment was unclear in most 
studies.  Insufficient information was provided regarding risk for incomplete outcome data to 
permit a judgement of low or high risk in five of the studies.  Although two of the ten studies 
(Boyle et al., 2019; Cheatham et al., 2012) have been registered on the clinical trials database, 
there was insufficient detail to make an informed decision regarding selective reporting.  Due to 
this and the absence of a published study protocol for each of the respective studies meant a 
judgement of unclear risk of bias was taken for the domain of reporting bias.  A small sample 
size (Baumeister et al., 2008; Harris et al., 1983; Rosadini et al., 1990) and the absence of a 
measure of compliance to monitor supplement intake from experimental procedures 
(Baumeister et al., 2008; Crook et al., 1991; Hellhammer et al., 2010; Parker et al., 2011; 
Schubert et al., 2011) were typically recorded under the domain of other sources of bias. 
Fundamentally, a judgment of low risk of bias was taken against the latter only when no other 
source(s) of bias could be listed otherwise a judgement of high risk of bias was taken. 
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Figure 3.2 Risk of bias assessments for each of the ten studies 
3.4  Cognitive outcomes of acute and chronic supplementation: 
Overview of reported results 
3.4.1  Gestation and infancy (n=1) 
One study considered the effects of supplementing pregnant women with six Nutrasal PhosChol 
gel capsules per day, each containing 833 mg PC, from 18 week gestation until 90 days 
postpartum on neurodevelopment (Cheatham et al., 2012). Only women who intended to 
breastfeed until 90 days postpartum were recruited to the study (only mothers were 
supplemented postpartum).  Infants were tested at 10 and 12 months of age, with all infants 
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demonstrating developmental age effects (better performance with age).  No treatment effects 
were reported other than marginal significance for better performance on a measure of delayed 
recall (deferred action imitation) by those in the placebo condition at 12 months (p = .056).  
However, this finding did not persist when dietary betaine intake (measured by food diary) at 
30-week gestation was added to the analysis as a covariate, found to be significantly higher in 
the PhosChol condition (p < .05). In a separate stepwise regression analysis using backward 
elimination, betaine intake at 30-week gestation was a negative predictor of immediate 
visuospatial recall at 10 months when the task was novel (p = .061), whereas betaine intake at 
45 days postpartum was a significant positive predictor of immediate visuospatial recall when 
the task was novel (p = .058), language development (p = .017) and global development 
(composite measure) (p = .026) at 12 months.  Analysis of choline intake at 45 days postpartum 
revealed the same patterns of prediction.  
3.4.2  Young adults (n=7) 
3.4.2.1  Acute administration (n=2) 
Two acute cross-over studies administered a single dose of 20 g of lecithin3 (PC) or placebo orally 
to healthy adults five hours before cognitive testing (Harris et al., 1983) or 25 mg, 50 mg, 75 mg 
of PS or matching placebo intravenously to healthy male adults following EEG recordings at 10, 
30, 90, 180 and 360 minutes post PS or placebo administration (Rosadini et al., 1990).  Despite 
plasma choline levels being raised in the lecithin condition to nearly double that of the placebo 
condition during the test session (+ 5 hours post lecithin consumption), this did not confer any 
cognitive benefit (Harris et al., 1983). Similarly, there was no significant difference in cognitive 
performance following the administration of PS at 25 mg, 50 mg or 75 mg, or placebo (Rosadini 
et al., 1990). 
3.4.2.2  Chronic administration (n=5) 
Five of the studies reviewed recruited young adults to explore whether supplementation 
provides stress-buffering effects to attenuate stress-induced cognitive performance 
impairments (Baumeister et al., 2008; Boyle et al., 2019; Hellhammer et al., 2010; Parker et al., 
2011; Schubert et al., 2011).  Acute stress is known to have divergent effects on cognitive 
performance, which can be, amongst other things, dependent upon the cognitive domain (Boyle 
et al., 2019).  For instance, post-acute stress induction, cortisol responders have been found to 
                                                          
3 The GPL and FA profiles depend upon the raw material sources. Typically consists of PC, PE, PS 
and PI. Originally assigned to pure PC (van Hoogevest & Wendel, 2014).   
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demonstrate better performance on a measure of attention (Plieger et al., 2017) and pattern 
separation relative to non-responders when stress was induced during memory consolidation 
(Jiang, Tran, Madison, & Bakker, 2019).  
Baumeister et al. (2008) gave healthy males one IQ PLUS brain bar containing 200 mg soy-based 
PS or a placebo bar for 6 weeks. Both bars were equivalent in energy and macronutrient (protein, 
carbohydrate, fat) and vitamin content. After 6 weeks of supplementation (with participants 
tested at baseline and endpoint), no benefit of PS was found on a measure of inhibitory control 
nor on a measure of vigilance / focus following acute stress. However, both conditions 
demonstrated practice effects. 
Parker at al. (2011) recruited healthy men meeting the criterion of being physically active for a 
cross-over trial and gave participants IQPLUS Foods LLC containing 200 mg soy-based PS (per 
serving; 400 mg per day) or a matching placebo for 2 weeks.  Each cognitive testing session took 
place after each 2-week intervention period in which a measure of working memory was 
assessed pre-acute exercise bout, then again +5 and +60 minutes post-acute exercise bout. A 
beneficial trend for PS supplementation was found for average time per correct calculation 
relative to placebo at pre-acute exercise bout only (treatment x time interaction, p = .007).  
When cognitive performance was assessed at pre-acute exercise bout only, a significant benefit 
of PS was found for average time per correct calculation (p = .001) and marginal significance was 
found for accuracy (number of correct calculations; p = .07).  No significant differences were 
found for serum cortisol, total testosterone, or cortisol to testosterone ratio by condition or 
condition and time.  
Three included studies that also induced acute stress as part of their experimental procedure 
supplemented their sample with either Lacprodan® PL-20 milk drink containing PC, PE, PS, PI 
and the sphingolipid SM or a placebo milk drink. In all cases, the drinks were prepared from 
bovine milk. Boyle et al. (2019) gave healthy males who rated themselves as high on 
perfectionism (and are therefore likely to be high stress vulnerable) either the PL milk drink (2.7 
g of PLs per day) or placebo for 6 weeks.  Testing was carried out at baseline and following the 
intervention, and a benefit of the PL milk drink was found for reaction time on a measure of 
vigilance / focus post-acute stress (p = .01).  Interestingly, the PL milk drink was not found to 
attenuate the cortisol response but there was a marginally significant difference between those 
that had consumed the PL milk drink for 6 weeks who showed reduced anticipatory subjective 
stress ratings post-intervention vs. the placebo (p = .06).  Conversely, those in the PL milk 
condition also reported significantly increased subjective arousal during peak stress exposure 
following 6 weeks of intervention (p = .03).  
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Similarly, the PL milk drink enriched with either 1.0% (300 mg) or 0.5% (150 mg) PLs or placebo 
was given to chronically stressed healthy men for 6 weeks (Schubert et al., 2011).  However, 
unlike the study by Boyle et al. (2019), testing was conducted post-intervention only, prior to 
and following acute stress exposure.  No effect of treatment was detected.  After exploratory 
data analysis, the sample was split by age using a median split at 41 years. It was found that the 
older participants (41-51 years) who had received 1.0% PL milk drink demonstrated superior 
performance on a measure of immediate visual recall relative to older participants who had 
received either 0.5% PL or placebo post-acute stress exposure (p = .042).  Moreover, participants 
in the 1.0% PL milk drink condition demonstrated higher cortisol levels, whereas the placebo had 
the lowest levels, before and after acute stress exposure, but this was not significant. 
A similar experimental procedure was conducted by Hellhammer et al. (2010) who 
supplemented healthy male adults matched on age and socio-economic status with either the 
PL milk drink (13.5 g of PLs per day) or placebo for 3 weeks, and again exposed participants to 
acute stress exposure, with cognitive testing sessions taking place 20 minutes before and 10 
minutes after this (post-intervention).  A trend was found towards a difference in the 
performance of participants in both conditions on a measure of verbal recognition memory, with 
those in the PL composite milk condition demonstrating faster reaction times compared to the 
placebo condition (p = .09).  After controlling for inter-individual variation in cortisol 
concentration, this difference became marginally significant (p = .06) in the same direction.  
Further subgroup analysis determined that the PL milk drink also dampened endocrine and 
psychological stress response but only in highly stressed individuals.
45 
 
Table 3.2 Overview of study findings by cognitive domain 
Cognitive domains and 
subcomponents 
Task 
Number of reported 
findings in favour of 
supplement 
Supplement 
Supplement 
duration 
Age of sample Condition of sample 
Attention and processing 
speed 
           
Attentional capacity Forward digit span 0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Attentional capacity Divided attention 0/1b BC-PS 12 weeks Middle aged AAMI 
  0/2     
Vigilance / focus D2 concentration test 0/1c PS from soy 6 weeks Young adults Healthy 
Vigilance / focus Attention switch task 1/1d PL-20 6 weeks Young adults Healthy (high stress) 
Vigilance / focus 
Symbol spotting of the 
NexAde™ 
0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
  
1/3 
    
Processing speed Digit-symbol substitution 0/2e,a,f 
1. PS-
DHA/EPAa; 
2. Lecithin 
(PC)f 
1. 15 weeksa; 
2. Acutef 
1. Older adultsa; 
2. Young adultsf 
1. Memory 
complaintsa; 
2. Healthyf 
  0/2     
Executive function       
Reasoning 
Pattern identification of the 
NexAde™ 
0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Inhibitory control 
Stroop word-colour 
interference 
0/1c PS from soy 6 weeks Young adults Healthy 
Working memory N-back (memory load: 2) 0/1d PL-20 6 weeks Young adults Healthy (high stress) 
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Cognitive domains and 
subcomponents 
Task 
Number of reported 
findings in favour of 
supplement 
Supplement 
Supplement 
duration 
Age of sample Condition of sample 
Working memory Serial subtraction task 1/1g PS from soy 2 weeks Young adults 
Healthy (physically 
active) 
Working memory Backward Digit Span 0/2h,a,i 
1. PS-
DHA/EPAa; 2. 
PSi 
1. 15 weeksa; 
2. Acutei 
1. Older adultsa; 
2. Young adultsi 
1. Memory 
complaintsa; 
2. Healthyi 
Verbal fluency Category noun generation 0/1f Lecithin (PC) Acute Young adults Healthy 
 
 1/7     
Language       
Language development 
MacArthur-Bates Short Form 
Vocabulary Checklist 
0/1j 
Nutrasal 
PhosChol 
18-week 
gestation - 90 
days 
postpartum 
Infants Healthy 
Receptive and expressive Mullen Scales of Early Learning 0/1j 
Nutrasal 
PhosChol 
18-week 
gestation - 90 
days 
postpartum 
Infants Healthy 
  0/2     
Psychomotor       
Fine and gross Mullen Scales of Early Learning 0/1j 
Nutrasal 
PhosChol 
18-week 
gestation - 90 
days 
postpartum 
Infants Healthy 
  0/1     
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Cognitive domains and 
subcomponents 
Task 
Number of reported 
findings in favour of 
supplement 
Supplement 
Supplement 
duration 
Age of sample Condition of sample 
Visual ability       
Visual reception Mullen Scales of Early Learning 0/1j 
Nutrasal 
PhosChol 
18-week 
gestation - 90 
days 
postpartum 
Infants Healthy 
 
 0/1     
Visuospatial ability       
Visuospatial ability 
Rey Complex Figure Test (copy 
time) 
1/1k,a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Visuospatial ability 
Rey Complex Figure Test (copy 
quality) 
0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
 
 1/2     
Memory and learning       
Immediate recall: verbal / 
visual 
Short-term visual spatial 
memory delayed response task 
0/1j 
Nutrasal 
PhosChol 
18-week 
gestation - 90 
days 
postpartum 
Infants Healthy 
Immediate recall: verbal / 
visual 
Name Face Association 1/1k,b BC-PS 12 weeks Middle aged AAMI 
Immediate recall: verbal / 
visual 
Telephone number recall 1/1l,b BC-PS 12 weeks Middle aged AAMI 
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Cognitive domains and 
subcomponents 
Task 
Number of reported 
findings in favour of 
supplement 
Supplement 
Supplement 
duration 
Age of sample Condition of sample 
Immediate recall: verbal / 
visual 
Selective reminding 0/1b BC-PS 12 weeks Middle aged AAMI 
Immediate recall: verbal / 
visual 
First-Last Names 0/1b BC-PS 12 weeks Middle aged AAMI 
Immediate recall: verbal / 
visual 
Categorised serial learning task 0/1f Lecithin (PC) Acute Young adults Healthy 
Immediate recall: verbal / 
visual 
Paired-associates learning task 0/1f Lecithin (PC) Acute Young adults Healthy 
Immediate recall: verbal / 
visual 
Short-Term Retention Test for 
sequences of letters 
0/1i PS Acute Young adults Healthy 
Immediate recall: verbal / 
visual 
Immediate Retention Test for 
sequences of colours 
0/1i PS Acute Young adults Healthy 
Immediate recall: verbal / 
visual 
VISGED Visual Memory Test 1/1n PL-20 6 weeks Young adults 
Healthy (chronically 
stressed) 
Immediate recall: verbal / 
visual 
Rey Auditory Verbal Learning 
Test (trial 1) 
1/1m,a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Immediate recall: verbal / 
visual 
Rey Auditory Verbal Learning 
Test- verbal total learning (sum 
of scores of trials 1-5) 
1/1l,a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Immediate recall: verbal / 
visual 
Rey Complex Figure Test 0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Immediate recall: verbal / 
visual 
Recall a pattern of the 
NexAde™ 
0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
 
 5/14     
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Cognitive domains and 
subcomponents 
Task 
Number of reported 
findings in favour of 
supplement 
Supplement 
Supplement 
duration 
Age of sample Condition of sample 
Delayed recall: verbal / visual Deferred imitation 0/1j 
Nutrasal 
PhosChol 
18-week 
gestation - 90 
days 
postpartum 
Infants Healthy 
Delayed recall: verbal / visual Name Face Association 1/1k,b BC-PS 12 weeks Middle aged AAMI 
Delayed recall: verbal / visual Misplaced objects recall 1/1l,b BC-PS 12 weeks Middle aged AAMI 
Delayed recall: verbal / visual Selective reminding 0/1b BC-PS 12 weeks Middle aged AAMI 
Delayed recall: verbal / visual Categorised serial learning task 0/1f Lecithin (PC) Acute Young adults Healthy 
Delayed recall: verbal / visual 
Rey Auditory Verbal Learning 
Test  
1/1l,a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Delayed recall: verbal / visual Rey Complex Figure Test 0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
Delayed recall: verbal / visual 
Delayed pattern recall of the 
NexAde™ 
0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
  3/8     
Recognition: verbal / visual Facial Recognition 1/1k,b BC-PS 12 weeks Middle aged AAMI 
Recognition: verbal / visual 
Uncategorised word 
recognition task 
0/1f Lecithin (PC) Acute Young adults Healthy 
Recognition: verbal / visual Uppercase letter recognition 1/1o PL-20 3 weeks Young adults Healthy 
Recognition: verbal / visual 
Rey Auditory Verbal Learning 
Test  
0/1a PS-DHA/EPA 15 weeks Older adults Memory complaints 
 
 2/4     
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Cognitive domains and 
subcomponents 
Task 
Number of reported 
findings in favour of 
supplement 
Supplement 
Supplement 
duration 
Age of sample Condition of sample 
Neuropsychological tests not 
otherwise categorised 
      
Benton Visual Retention Test - 0/1b BC-PS 12 weeks Middle aged AAMI 
Wechsler Memory Scale Logical 
Memory Subtest (Form A) 
- 1/1l,b BC-PS 12 weeks Middle aged AAMI 
Wechsler Memory Scale 
Associative Learning Subtest 
(Form A) 
- 0/1b BC-PS 12 weeks Middle aged AAMI 
 
 1/3     
aVakhapova et al. (2010); bCrook et al. (1991); cBaumesiter et al. (2008); dBoyle et al. (2019); e0/1 component of NexAde™ / 0/1 subtask of WAIS; fHarris 
et al. (1983); gParker et al. (2011); h0/1 component of NexAde™; iRosadini et al. (1990); jCheatham et al. (2012); kSignificant treatment effect also found 
following analysis of subgroup data; lSignificant treatment effect found following analysis of subgroup data only; mSignificant treatment effect also found 
following analysis of subgroup data and a trend following intention to treat analysis (of whole sample); nSchubert et al. (2011); oHellhammer et al. 
(2010). AAMI: Age-associated memory impairment; BC-PS: bovine cortex phosphatidylserine; PC: Phosphatidylcholine; PS: Phosphatidylserine, PS-
DHA/EPA: Phosphatidylserine-Docosahexaenoic acid/Eicosapentaenoic acid. 
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3.4.3  Middle aged adults (n=1) 
Adults (n=149) who met the criteria for age-associated memory impairment (AAMI) were given 
300 mg of bovine cortex PS per day or a matched placebo for 12 weeks (Crook et al., 1991). 
Paper based neuropsychological tests were administered at baseline and endpoint; also, a 
computerised psychometric battery was undertaken at baseline, then again at weeks 3, 6, 9, 12 
and 16 (the latter being 4 weeks post-endpoint). Also, a Clinical Global Rating Scale was 
undertaken by a study psychologist/registered nurse during an interview with participants at 
weeks 12 and 16 to explore improvements since treatment initiation.  Condition related 
performance differences were found in favour of PS supplementation. Specifically, those in the 
PS condition demonstrated significantly better performance than those in the placebo condition 
on immediate visual and verbal associative recall at weeks 3 and 6 (p < .001), delayed visual and 
verbal associative recall at weeks 3 (p = .04) and 6 (p = .03), and on recognition of visual items 
at week 12 (p = .01), however, at week 3, this was marginally significant (p = .05).  In addition, 
cluster analysis of baseline data was performed, which identified two subgroups differentiated 
by memory function at baseline i.e. good vs. poor.  Those identified as having poor memory 
function at baseline consistently showed treatment effects, so a separate analysis was 
conducted on the data from these participants alone (n=57). Again, those in the PS condition 
performed significantly better than those in the placebo condition on immediate visual and 
verbal associative recall at weeks 3 (p = .01), 6 (p = .04) and 12 (p = .01), delayed visual and verbal 
associative recall at week 12 (p = .04), with marginal significance at week 3 (p = .05), on 
recognition of visual items at weeks 3 (p = .03), 6 (p = .02), 12 (p = .02)  and 16 (p = .01), on 
immediate verbal recall at week 16 (p < .001) and delayed visual recall at weeks 6 (p < .001) and 
16 (p = .03). Moreover, these same participants scored significantly higher on immediate and 
delayed verbal recall on the Logical Memory Subtest of the Wechsler Memory Scale (WMS) at 
week 12 (p < .03).  Lastly, those in the PS condition scored significantly higher on the Clinical 
Global Rating Scale at week 12 for memory for names of persons after introductions (p = .02), 
ability to maintain concentration when reading, conversing or performing tasks (p = .02), 
whereas marginally significant improvements were found at week 12 for overall global change 
in cognitive status (p = .05) and visual analogue scale of global improvement (p = .05) in favour 
of PS supplementation, however, these benefits did not persist after ceasing supplementation 
for 4 weeks (i.e. at week 16). 
3.4.4  Older adults (n=1) 
Vakhapova et al. (2010) supplemented adults with memory complaints with PS conjugated to 
omega-3 LC PUFA (PS-DHA/EPA: 300 mg PS, 79 mg DHA+EPA, DHA/EPA ratio 3:1) or placebo for 
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15 weeks and tested participants using two separate cognitive measures and a cognitive battery 
at baseline and endpoint. In addition, participants were interviewed using the Clinical Global 
Impression of Change (CGI-C) at week 7 and endpoint. Performance by participants in the PS-
DHA/EPA condition was found to be superior to that of the placebo condition for immediate 
verbal recall (trial 1; PP analysis: p = .041; ITT analysis: p = .069), and there was a trend for 
visuospatial ability, such that copy time was faster for the PS-DHA/EPA condition (PP: p = .079). 
Overall, on both measures, those in the PS-DHA/EPA condition tended to improve more than 
those in the placebo condition.  Responder analysis based upon better performance in 
immediate verbal recall (trial 1) and overall improvement in the CGI-C was significantly 
associated with condition (PP analysis: p = .034; ITT analysis: p = .035), with the ratio of 
percentage of responders in the PS-DHA/EPA:placebo conditions being 22:8 (PP analysis) and 
23:9 (ITT analysis), respectively.  As with the study carried out by Crook and colleagues (1991), 
a subgroup of the sample (n=78) was identified as responding differentially to treatment. 
However, unlike Crook et al. (1991), the subgroup included participants with relatively good 
cognitive performance at baseline. The analysis of differences by condition within this subgroup 
revealed a benefit of PS-DHA/EPA over the placebo condition for immediate verbal recall trial 1 
(p = .006), verbal total learning: sum of scores of trial 1-5 (p = .002) and delayed verbal recall (p 
= .045).  Marginal significance was found for visuospatial ability, such that copy time was faster 
for the PS-DHA/EPA condition relative to the placebo condition (p = .055). In respect of the 
responder analysis, again a significant correlation was found (PP analysis: p = .016), with 
responders comprising 25% of the PS-DHA/EPA condition and 5% of the placebo condition. 
Although there were no significant differences reported for the CGI-C between the conditions 
both for the whole sample and the subgroup, in both cases, more participants in the PS-
DHA/EPA condition were classified as clinically improved. 
3.5 Discussion 
A systematic review of GPL supplementation studies and their reported cognitive outcomes was 
conducted. Ten quantitative studies were eligible for inclusion in this review. 
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3.5.1  Summary of findings 
Six of the reviewed studies reported benefits4 in cognitive performance following 
supplementation compared to placebo (Boyle et al., 2019; Crook et al., 1991; Hellhammer et al., 
2010; Parker et al., 2011; Schubert et al., 2011; Vakhapova et al., 2010).  Across the six studies, 
cognitive performance enhancement was reported following PS and PS-DHA/EPA 
supplementation (Crook et al., 1991; Parker et al., 2011; Vakhapova et al., 2010). A composite 
GPL mixture included PL-20 bovine milk concentrate (Boyle et al., 2019; Hellhammer et al., 2010; 
Schubert et al., 2011) also resulted in improved cognitive performance.  Moreover, benefits of 
supplementation to cognition were seen across the adult lifespan in individuals with and without 
memory complaints: young (Boyle et al., 2019; Hellhammer et al., 2010; Parker et al., 2011; 
Schubert et al., 2011), middle-aged (Crook et al., 1991) and older adults (Vakhapova et al., 2010).  
As infants were assessed in only one study, it is difficult to conclude that GPL supplementation 
does not have the potential to facilitate cognitive performance in this age group. Also, not all 
infants were breastfed for the expected 90 days (Cheatham et al., 2012), which may have 
affected the study findings.  Memory (immediate, delayed, recognition and performance on 
neuropsychological measures sensitive to memory function) appeared to benefit more than any 
other cognitive domain (Crook et al., 1991; Hellhammer et al., 2010; Schubert et al., 2011; 
Vakhapova et al., 2010).  However, of all cognitive domains, memory was predominantly 
assessed across the ten studies, therefore, this benefit for memory performance may reflect the 
extent to which memory measures were utilised, especially in two studies that recruited 
participants with memory complaints (Crook et al., 1991; Vakhapova et al., 2010). In addition to 
memory outcomes, PS and PS-DHA/EPA were also found to be beneficial for executive function 
(working memory; Parker et al., 2011) and visuospatial performance (Vakhapova et al., 2010) 
respectively, while PL-20 bovine milk concentrate facilitated performance on a measure 
assessing vigilance/focus (Boyle et al., 2019).  Two studies that reported a main effect of 
treatment conducted post hoc subgroup analyses following identification of subsets within the 
sample that responded differentially to treatment (Crook et al., 1991; Vakhapova et al., 2010).  
Notably, Crook et al. (1991) identified a subgroup who demonstrated poor memory function at 
baseline, whilst conversely, Vakhapova et al. (2010) determined a subgroup who showed 
relatively good cognitive performance at baseline.  Despite the differences in baseline 
performance, those who received the active supplement showed significantly or marginally 
                                                          
4 Includes significant differences, marginally significant differences and trends. 
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significantly better performance vs. placebo, in line with the performance of the whole sample.  
In addition, Crook et al. (1991) also reported those who received PS scored significantly higher 
on a neuropsychological measure that assessed immediate and delayed verbal recall and were 
rated significantly or marginally significantly higher on a clinical global rating scale at endpoint; 
findings that were not evident from the analysis of the whole sample.  
One acute study that supplemented PS at different doses (25 mg, 50 mg and 75 mg; Rosadini et 
al., 1990) and one chronic study that supplemented 200 mg soy-based PS as part of a nutritional 
bar for 6 weeks (Baumeister et al., 2008) did not find a benefit of PS. Importantly, both studies 
recruited small samples (n=8 and n=16, respectively).  Studies with small samples have low 
statistical power (Suresh & Chandrashekara, 2012), contributing to a reduced likelihood of 
detecting true effects (Button et al., 2013).  The notion that the small sample size contributed 
to the null findings reported by Baumeister and colleagues (2008) is further supported by the 
positive treatment effect observed following a 2 week intervention of equivalent quantity (200 
mg) of soy-derived PS seen in healthy young males (crossover n=18; Parker et al., 2011); 
although as different outcome measures were employed by both studies, it may be that the 
measure used by Parker at al. (2011) was more sensitive to detect alterations in cognitive 
performance afforded by PS supplementation.  
Of the two studies that used PC as the active supplement, neither study reported an advantage 
of supplementation for cognitive performance following acute (Harris et al., 1983) or chronic 
(Cheatham et al., 2012) administration.  Notably, Harris et al. (1983) did observe that mean 
plasma choline levels were nearly double post-lecithin supplementation compared to placebo 
levels, however, this did not facilitate any improvement in cognitive performance. Cheatham et 
al. (2012) attributed the lack of a favourable influence of PC supplementation on cognitive 
performance to the use of a low dose and the location of the study, this being the United States, 
where most diets contain good sources of choline.   
The benefit of PS supplementation for cognitive performance is likely to be the result of the 
many roles PS plays in facilitating cognitive function. PS readily crosses the blood-brain barrier 
(BBB) and is concentrated in the brain (Mozzi, Buratta, & Goracci, 2003; Starks, Starks, Kingsley, 
Purpura, & Jäger, 2008).  In addition to its role in PKC activation, which can potentially promote 
synaptic remodelling and support neurotrophic activity in the hippocampus (see section 2.7.3), 
PS is also considered critical for the functioning of neuronal membranes, including secretory 
vesicle release, signal transduction, and cellular communication and growth (Vance & 
Steenbergen, 2005).  In aged rats, PS supplementation led to an increase in the levels of PS in 
55 
 
the hippocampus, which was accompanied by the normalisation of cognitive function (Babenko 
& Semenova, 2011).   
PS conjugated to omega-3 LC PUFA (DHA/EPA) was also found to confer a cognitive performance 
advantage following supplementation (Vakhapova et al., 2010).  It is noteworthy that PS sourced 
from bovine cortex also has a high DHA content (Vakhapova et al., 2010), as supplemented by 
Crook and colleagues (1991).  Sufficient quantities of DHA-enriched PS are necessary for fusion 
of intra-neuronal secretory granules with the pre-synaptic membrane, the subsequent release 
of neurotransmitter molecules into the synaptic cleft and postsynaptic neurotransmitter-
receptor interactions (Kim, Akbar, & Kim, 2010; Tanaka, Farooqui, Siddiqi, Alhomida, & Ong, 
2012).  PS from squid has been reported to reduce choline acetyltransferase (AchE; the enzyme 
that synthesises ACh) reactive neuron loss in the hippocampal CA3 region and to raise glucose 
uptake in both the frontal lobe and hippocampus in rats with trimethyltin-induced memory 
deficits (Park et al., 2012).  Similar findings have been reported by Lee et al. (2015) who noted 
oral squid derived PS supplementation restored AchE-reactive neurons in hippocampus CA1 and 
CA3 areas, hippocampal choline transporter mRNA and muscarinic acetylcholine receptor type 
1 mRNA expression, enhanced hippocampal DHA concentration and improved memory ability 
in aged rats with age-related memory impairment.  Importantly, PS can be converted to 
lysophosphatidylserine (lysoPS) by phospholipases (i.e. phospholipase A1 (PLA1) and PLA2) 
(Frasch & Bratton, 2012) and DHA-bound lysoPS has been suggested to be an effective substrate 
for foetal brain DHA accumulation (Tsushima, Ohkubo, Onoyama, Linder, & Takahashi, 2014).  
Additionally, the major facilitator superfamily domain-containing protein 2a (Mfsd2a) has been 
proposed as the major route of DHA uptake into the brain in the form of lysophospholipids 
including lysoPS but not unesterified FA (Nguyen et al., 2014).  Therefore, DHA-bound lysoPS 
may have the potential to elevate levels of DHA availability in the brain, which in turn has 
consequences for neuronal membrane PS levels.  That is, DHA in neural tissues is positively 
correlated with the accumulation of PS in neuronal membranes (Hamilton, Greiner, Salem, & 
Kim, 2000; Kim et al., 2010; Kim, Akbar, Lau, & Edsall, 2000).  Moreover, there is some evidence 
that DHA by itself can facilitate cognition function across the lifespan (Ghasemi Fard, Wang, 
Sinclair, Elliott, & Turchini, 2019; Weiser, Butt, & Mohajeri, 2016), however, particular 
subpopulations may be more likely to benefit, such as those with low basal levels (Derbyshire, 
2018; Ostermann & Schebb, 2017). 
PL-20 bovine milk concentrate was also found to be favourable in supporting superior cognitive 
performance as reported in all three of the studies in which it was administered. Collectively, an 
advantage of PL-20 bovine milk concentrate was seen on an attention switch task assessing 
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vigilance/focus (Boyle et al., 2019), on a visual memory test that targeted immediate visual recall 
in a subgroup of the sample (Schubert et al., 2011) and on a measure of verbal recognition 
(Hellhammer et al., 2010).  The milk concentrate used comprises PC, PE, PS, PI and SM 
(Hellhammer et al., 2010; Küllenberg et al., 2012; Schubert et al., 2011).  In view of the 
physiological properties of GPLs, which may potentially protect and promote cognitive function 
(see section 2.7), there are a number of mechanisms that could underpin the performance 
advantages seen in these studies. That said, overall, the findings were not consistent. Boyle et 
al. (2019) did not find a significant effect of treatment on a measure of working memory, a 
marginal significant difference was found between the PL milk drink and placebo conditions 
after inter-individual variation in cortisol concentration had been controlled for (Hellhammer et 
al., 2010), and the benefit of treatment as reported by Schubert et al. (2011) was observed only 
after post-hoc analysis split by age. 
3.5.2  Methodological issues 
There are a number of methodological flaws in the studies reviewed that merit careful 
consideration.  The first issue concerns the use of covariates. Entering a covariate into an 
analysis allows for the variance in performance associated with that covariate to be removed, 
thus enabling a more accurate estimate of the effects of the main factor (usually 
condition/treatment) of interest (Schneider, Avivi-Reich, & Mozuraitis, 2015). Age (Deary et al., 
2009a; Murman, 2015; Nouchi & Kawashima, 2014; Pangelinan et al., 2011) and IQ (Diaz-Asper, 
Schretlen, & Pearlson, 2004; Mohn, Sundet, & Rund, 2014) have been found to significantly 
predict cognitive function. It is therefore desirable to enter these as covariates into any analysis 
of cognitive performance. Baseline performance, usually the biggest predictor of subsequent 
performance, can also be controlled for in intervention studies. There is some variation in the 
literature concerning the approach to take towards baseline performance, whether to include 
this as a covariate or to assess change from baseline. However, including baseline performance 
as a covariate reduces the extent to which experimental findings are affected by baseline 
performance differences (Vickers & Altman, 2001), which were evident in two studies in 
particular (Crook et al., 1991; Vakhapova et al., 2010).  A comparison of ANOVA and ANCOVA 
(i.e. adjustment for baseline performance), with both change score and post-intervention score 
as the response variable, and linear mixed modelling for the estimation and testing of treatment 
effects found each approach provided unbiased estimates of treatment effects, however, 
ANCOVA was determined to be most effective based upon precision of estimates, 95% coverage 
probability and power (O’ Connell et al., 2017).  Out of the ten studies reviewed, eight studies 
included a baseline measure (all except Cheatham et al., 2012; Harris et al., 1983), three of which 
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were post-intervention but prior to acute stress exposure (Hellhammer et al., 2010; Parker et 
al., 2011; Schubert et al., 2011).  Of these, baseline performance was entered into the analysis 
performed by Boyle et al. (2019), in the analysis of the neuropsychological tests and 
computerised psychometric battery undertaken by Crook and colleagues (1991), and in the 
analysis of the Rey Auditory Verbal Learning Test (RAVLT) and Rey Complex Figure Test (RCFT) 
by Vakhapova et al. (2010), although this was dichotimised (1 SD ± mean).  In addition, age was 
also controlled for by Boyle et al. (2019), although this was subsequently removed, as it was not 
found to be a significant covariate. Vakhapova et al. (2010) also entered and removed 
participants’ demographics, as these too were found to be nonsignificant.  Of note, participants 
in the intervention study conducted by Hellhammer et al. (2010) were matched on age in order 
to reduce error variance.  In addition, MMSE score (26/>26) at baseline was found to be a 
significant covariate and was therefore retained in the analysis of the RAVLT and RCFT by 
Vakhapova and colleagues (2010), whereas the inclusion of baseline performance in the analysis 
of the neuropsychological tests by Crook et al. (1991) controlled for baseline memory function.  
A second methodological issue concerns the matching of study products and monitoring 
participant compliance in respect of supplementation consumption.  Matching active and 
placebo supplements ensures allocation concealment and therefore researchers and 
participants remain blind, which reduces bias (Bhide, Shah, & Acharya, 2018).  Keeping a record 
of compliance informs decisions taken on the inclusion of data in per protocol or intention-to-
treat analysis, or even the removal of data collected from the analysis, depending upon how 
participant supplement consumption aligns with study requirements. Of the ten studies 
reviewed, seven studies reported the active and placebo supplements matched (Boyle et al., 
2019; Cheatham et al., 2012; Crook et al., 1991; Harris et al., 1983; Parker et al., 2011; Rosadini 
et al., 1990; Vakhapova et al., 2010) and of the eight chronic interventions, three studies 
reported monitoring participant supplement consumption (Boyle et al., 2019; Cheatham et al., 
2012; Vakhapova et al., 2010). 
Other methodological issues that compromise the quality of the reviewed studies include the 
possible presence of practice effects and small sample sizes.  Baumeister et al. (2008) observed 
cognitive performance improvements in both the PS and placebo conditions following the 
supplementation period, which they reason may have been due to familiarisation with the 
experimental situation and cognitive measures.  Practice effects have been reported on 
measures assessing immediate and delayed recall of word lists and serial subtraction following 
repeated testing (Bell, Lamport, Field, Butler, & Williams, 2018).  As such, it is possible that 
practice effects may have been a confounding variable in other studies reviewed, such as the 
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study by Vakhapova et al. (2010) who used the RAVLT or the study by Parker et al. (2011) who 
used a serial subtraction task (serial 7’s). To minimise the influence of practice effects on 
participant performance, Boyle et al. (2019) had participants complete two practise versions of 
the cognitive measures during familiarisation.  Sample sizes were particularly small in three 
studies in particular (Baumeister et al., 2008; Harris et al., 1983; Rosadini et al., 1990), which 
minimises the power of a study to detect any treatment effects.  More generally, there was a 
lack of reported power calculations across the studies, however, as Boyle et al. (2019) report, 
this may be due to the lack of appropriate extant evidence concerning the protective effects of 
PL intake on cognitive performance. 
A further methodological limitation concerns the selection of cognitive measures. Cognitive 
measures differ in their sensitivity to detect a benefit to cognitive function following nutritional 
intervention.  A lack of treatment effect may represent a real absence of a nutrient-induced 
change to cognitive performance in a particular domain or it may be the result of a lack of 
sensitivity of a cognitive measure to detect that change (Lieberman, 2003).  As such, the 
evaluation of cognitive measures as to their sensitivity to detect nutrient-induced change(s) to 
cognitive performance is critically important (Hoyland, Lawton, & Dye, 2008). None of the 
reviewed studies justified their utilisation of the cognitive measures employed in respect of their 
sensitivity to identify nutrient-induced changes in cognition. However, the selection of specific 
cognitive measures was justified in the context of them being sensitive to stress (Boyle et al., 
2019) and in another study, selection of primary measures was based upon variables that 
showed the clearest pattern of decline in AAMI from normative data (Crook et al., 1991).  On a 
somewhat related point, three of the ten studies used a cognitive test battery (Cheatham et al., 
2012; Crook et al., 1991; Vakhapova et al., 2010), the use of which can substantially increase the 
number of measures used on a sample and therefore increase the risk of false positives i.e. Type 
1 error rate.  
3.5.3  Recommendations for future GPL supplementation studies 
To address the above limitations and gaps in the research area, several recommendations can 
be made to support future research undertaken to explore the effects of GPL supplementation 
on cognitive performance. Importantly, there is a lack of studies to evaluate the effects of GPL 
supplementation in children and adolescents. Childhood and adolescence are characterised as 
periods of cognitive development (Bidzan-Bluma & Lipowska, 2018; Casey, Getz, & Galvan, 2008; 
Paus, 2005) and may therefore be particularly sensitive to GPL supplementation.  Future 
research studies that supplement children and/or adolescents with GPLs would therefore 
address this gap in knowledge.  Care should be taken in such circumstances to use age-
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appropriate cognitive measures, for example, executive function is known to develop 
throughout childhood and adolescence (Best & Miller, 2010).  Literature on omega-3 
supplementation in children and adolescents, where there are numerous intervention studies, 
could be used as a basis for sample size estimates and in the selection of sensitive cognitive 
measures.  Further, additional GPL intervention studies should be conducted using infants to 
build on the existing findings (Cheatham et al., 2012).  To date, no longitudinal studies have been 
undertaken to examine the effects of GPL supplementation over an extended amount of time. 
In the context of cognitive ageing (adulthood), it has been recommended that intervention trials 
have long intervention periods of at least 18 months (Vauzour et al., 2017).  However, long 
intervention periods will be expensive to run and potentially vulnerable to considerable 
attrition.  Any supplementation studies that follow aged participants over a substantial period 
should plan for attrition bias and use cognitive measures that are sensitive to changes in 
cognitive function over time.  Conversely, further research to investigate acute effects of GPL 
supplementation are also welcome to add to the current findings (Harris et al., 1983; Rosadini 
et al., 1990).  Supplementing PS at higher doses in future acute supplementation studies may 
translate to improvements in cognitive performance not previously seen (Rosadini et al., 1990). 
This could inform understanding of the dose-response relationship, which is another avenue 
that should be further explored.  Acute measurements can be built into chronic 
supplementation studies to minimise burden to participants and the resources required by 
research teams.  Other methodological considerations for future work include assessing 
participants’ cognitive performance prior to the commencement of supplementation (true 
baseline) to derive a clearer picture of whether supplementation aids cognitive function. By 
using an inert substance as the placebo and not combining this with other ingredients as part of 
the GPL supplement, a more accurate picture of treatment effects, which can confidently be 
attributed to GPLs might be obtained. Data analysis strategies should be stated prior to data 
collection (a priori) and the use of median splits should be avoided, as this may exaggerate or 
even produce effects that reflect artefacts of the reduction of continuous variables to categorical 
groups (Hamer et al., 2016). Moreover, analyses should include suitable covariates to control 
for confounding influences including baseline performance.  This is especially important when 
there is recruitment bias, such as when the sample is highly educated, since education is known 
to correlate highly with cognitive performance.  Studies should be sufficiently powered to detect 
statistical significance and therefore an a priori sample size calculation should be performed 
(Suresh & Chandrashekara, 2012).  Lastly, the FA composition of the GPLs that comprise the 
supplement should be specified wherever possible. Vakhapova et al. (2010) was the only study 
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to detail the FA profile attached to the glycerol backbone of the GPL used, however, it is 
appreciated that lipidomics is a newly emerged discipline meaning that older studies were 
limited in the ability to provide such detail.  Soy based GPL products are likely to have FAs that 
are derived from plants, whereas GPL products can now be formulated with marine derived FAs 
(as in the case of Vakhapova et al., 2010). 
3.5.4  Conclusion 
From the ten studies reviewed, it is difficult to draw any firm conclusions regarding the efficacy 
of GPLs on cognitive performance due to the lack of a consistent effect. However, there is some 
indication that PS may be particularly advantageous in facilitating cognitive performance.  
Memory was the most frequently assessed of all cognitive domains across the ten studies and 
GPL supplementation was observed to confer superior performance when immediate, delayed 
and recognition memory was tested.  Given that GPLs and FAs have characteristics that promote 
and protect cognitive function, it is likely to be difficult to unpick the contribution that either 
one makes to improved cognitive performance, especially if they have synergistic effects, which 
has been suggested for PS-DHA (Zhang, Xu, Wang, & Xue, 2019).  A risk of bias assessment was 
undertaken against each of the ten studies included within the review.  An unclear risk of bias 
judgement was made most often against the 6 domains due to an insufficient provision of 
information within the corresponding research papers.  A high risk of bias judgement was 
recorded against seven of the studies for the domain of other sources of bias.  A small sample 
and a lack of supplement intake monitoring were most commonly identified across these studies 
and contributed to this judgement.  
The aim of this systematic review was to address four key questions concerning GPL 
supplementation.  Using the evidence based on the findings of the reviewed studies, it can be 
suggested that PS as a single supplement and PL-20 as a composite supplement may be 
promising in conferring a cognitive performance advantage, however, the advantage gained by 
PL-20 may be limited to individuals who are more vulnerable to experience stress (Boyle et al., 
2019). Currently, there is no evidence to suggest a dose-response effect or the ideal duration 
over which supplementation should take place to promote cognitive performance. Both acute 
supplementation studies reviewed reported null findings (Harris et al., 1983; Rosadini et al., 
1990), which may suggest that acute supplementation of GPLs does not offer any benefit.  
However, both studies used small samples, one study supplemented PC (Harris et al., 1983), 
which was not found to offer an advantage to cognitive performance in the only other study in 
which it was administered (Cheatham et al., 2012), and the dose of PS was potentially too low 
in the second study (Rosadini et al., 1990).  Finally, as discussed, memory seems to benefit most 
61 
 
from GPL supplementation, however, evidence from other domains is suggestive of benefits, 
including vigilance/focus, working memory and visuospatial ability. The greater number of 
favourable effects reported for memory performance needs to be considered in context.  
Memory was tested most frequently of all cognitive domains across the ten studies; two studies 
that utilised multiple memory measures recruited samples with subjective memory decline and 
used a GPL supplement with a high concentration of DHA, both of which may increase the 
likelihood of finding a positive result of supplementation. Future research that heeds the above 
recommendations will further elucidate the potential of GPL supplementation to promote 
cognitive function. 
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Chapter 4 A randomised placebo-controlled trial examining the 
effects of chronic (six week) phospholipid intake on cognitive 
performance in children aged 6 – 8 years of age (Study 1). 
4.1 Introduction 
One of the recommendations that came out of the systematic review (Chapter 3) was for future 
GPL intervention studies to explore the potential benefit(s) of supplementing children, an area 
that has not received attention previously. To address this gap in the extant literature, this 
chapter reports on a 6 week intervention study that supplemented Lacprodan® PL-20 to a 
sample of children aged 6 – 8 years.  As discussed in Chapter 1, the development of cognitive 
function is a protracted process that continues throughout childhood and adolescence through 
to young adulthood (Catherine Lebel, Treit, & Beaulieu, 2019; Nouchi & Kawashima, 2014).  
Childhood is therefore an optimal time in which to study the potential cognitive function 
enhancing properties of Lacprodan® PL-20. 
4.2 Continuation of brain development during childhood  
The frontal lobe has a prolonged developmental trajectory, however, there are developmental 
stages during which there is greater development from birth-2 years, 7-9 years and during the 
mid-teenage years (Bryan et al., 2004).  The prefrontal cortex continues to mature through 
childhood and adolescence (Giedd, 2004), demonstrated by a reduction of neuronal and 
synaptic density and dendrite growth, but also gains in white matter volume, promoting the 
formation of distributed neural networks suitable for complex cognitive processing (Tsujimoto, 
2008).  This area of the frontal lobe facilitates higher cognitive functions by supporting memory 
consolidation and expression (Preston & Eichenbaum, 2013) and mediating social cognition 
(Bicks, Koike, Akbarian, & Morishita, 2015) and executive functions, such as planning, decision 
making and judgement (Funahashi & Andreau, 2013), working memory (Lara & Wallis, 2015) and 
attention, specifically attentional control (Rossi, Pessoa, Desimone, & Ungerleider, 2009).  
Development of subcortical structures, including the basal ganglia, amygdala, and 
hippocampus that are also involved in memory, executive function and emotion continues 
through to late adolescence (Nyaradi et al., 2013).   
4.2.1 Region specific changes during development 
The maturation of the brain is a complex process that reflects interactions between genetic, 
environmental and epigenetic factors (Kolb & Gibb, 2011; Lenroot & Giedd, 2008; Peterson, 
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2003; van Loo & Martens, 2007).  By the age of 6, 95% of total cerebral volume has been 
achieved (Lenroot & Giedd, 2006); however, maximal growth is not reached until approximately 
age 14 years in males and 11 in females (Giedd et al., 1999).  Importantly, individual subregions 
follow temporally unique developmental trajectories in which lower-order sensorimotor regions 
mature before higher-order association areas (Gogtay et al., 2004; Taki et al., 2011).  The notion 
of regional specific development is supported by the findings that the prefrontal cortex is one 
of the last to mature (Casey, Giedd, & Thomas, 2000), and the development of areas with fronto-
temporal connections are slower relative to other regions (Lebel, Walker, Leemans, Phillips, & 
Beaulieu, 2008).  Fractional anisotropy, an indicator of white matter microstructural properties 
(Bathelt, Gathercole, Johnson, & Astle, 2017), is sensitive to white matter coherence, 
myelination and axonal organization (Alkonyi et al., 2011; Grieve, Williams, Paul, Clark, & 
Gordon, 2007), and has highlighted different white matter fibre tracts demonstrating different 
developmental patterns, possibly due to age-related reprogramming and myelination (Lebel et 
al., 2008).   
4.2.2 Alterations in cortical thickness in development and associations with 
cognitive performance 
 
A reduction in cortical thickness and an increase in white matter fractional anisotropy (a 
measure of white matter integrity) occurs during childhood and adolsecence (Moura et al., 
2017).  Cortical thickening takes place prior to cortical thinning (Kharitonova, Martin, Gabrieli, 
& Sheridan, 2013).  Grey matter reduction is thought to reflect axonal myelination (Gogtay et 
al., 2004; Gogtay & Thompson, 2010; Paus, 2005; Sowell, Thompson, Leonard, et al., 2004), 
synaptic pruning (Gogtay et al., 2004; Sowell, Thompson, & Toga, 2004) and trophic glial and 
vascular changes (Morrison & Hof, 1997).  Axonal myelination and synaptic proliferation and 
pruning are critical mechanisms that influence cognitive development (Luna et al., 2001; 
McGivern, Andersen, Byrd, Mutter, & Reilly, 2002).  Widespread white matter anisotropy 
developmental changes have been reported in cognitively healthy children from age 6.  
Specifically, age-related increases have been found in prefrontal regions, in the pathways 
between the basal ganglia and the thalamus and those extending within the basal ganglia, in the 
internal capsule, in ventral visual streams and in the corpus callosum, as well as in intra-
hemispheric tracts and areas corresponding to cortico-thalamic and cortico-spinal tracts 
extending from sensory-motor regions (Barnea-Goraly et al., 2005).  Recent research using 
neurite orientation dispersion and density imaging  (NODDI) has characterised increases in 
fractional anisotropy as being the result of increased myelination and/or axonal packing rather 
than alterations in axon coherence and geometry (Mah, Geeraert, & Lebel, 2017).  
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Cortical thinning has been related to cognitive performance in childhood and adolescence. For 
example, in a sample of 12-14 year olds, thinner parietal cortices were associated with better 
performance on measures of visuospatial planning abilities, problem solving, verbal learning and 
memory (Squeglia, Jacobus, Sorg, Jernigan, & Tapert, 2013).  Frontal lobe grey matter thinning 
was predictive of better verbal memory retrieval independent of age (not mediated by) in 
children aged 7-16 years (Sowell, Delis, Stiles, & Jernigan, 2001).  Moreover, frontal grey matter 
thinning in the left lateral dorsal frontal and the left lateral parietal regions related to improved 
vocabulary subtest scores, whereas grey matter thickening in the left medial occipital region was 
associated with improved block design subtest performance in a longitudinal study that assessed 
children on average 2.2 years apart between 5-11 years of age (Sowell, Thompson, Leonard, et 
al., 2004). The relationship between executive function and cortical thickness, independent of 
the effects of age, has been explored in children between 8-19 years of age.  Thinner cortices in 
bilateral parietal and frontal regions were related to improved working memory updating; 
whereas for inhibition, better performance was associated with thinner cortices in bilateral 
occipital and parietal regions (Tamnes et al., 2010).  Alternatively, better shifting performance 
was related to thinning in the central lateral region in the left hemisphere but also thicker cortex 
in the right occipital lobe (Tamnes et al., 2010).  Mediation analysis has been used to consider 
whether cortical thinning can explain the relationship between age and cognitive performance 
on a context monitoring and inhibitory task in children aged 5-10 years. Cortical thinning of the 
right inferior frontal gyrus was found to mediate the relationship between age and faster 
reaction times on congruent and incongruent trials, whilst cortical thinning of the anterior 
cingulate cortex was found to mediate the relationship between age and reaction times on 
incongruent trials only (Kharitonova et al., 2013).   
 
4.2.3 Increased activation and specialisation of connectivity between brain 
regions in development, and associations with cognitive performance 
In addition to cortical thinning, other changes take place during development, which also have 
implications for cognition.  Cortical activation patterns become more focal, with less reliance on 
regions uncorrelated with task performance, leading to improved efficiency (Durston et al., 
2006). There is also evidence of increased neural activation with age being favourable for 
cognitive capacity (Klingberg, Forssberg, & Westerberg, 2002).  Selective inhibitory control 
(Bedard et al., 2002; Luna et al., 2001) and visuo-spatial working memory (Kwon, Reiss, & 
Menon, 2002) are enhanced with age.  Such behavioural improvements have been accompanied 
by increased brain activation in the prefrontal cortex and parietal cortex (Kwon et al., 2002; Luna 
et al., 2001) as well as the striatal and thalamic regions (Luna et al., 2001).   
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Functional magnetic resonance imaging (fMRI) during associative encoding of object face 
pairings shows a linear increase in the recruitment of visual processing regions with age, and 
activation within these regions mediated the relationship between age and memory 
performance to a greater extent than the mediating effect of hippocampal activation in 6-19 
year olds.  Moreover, greater activation during encoding in the bilateral fusiform gyrus and 
lateral occipital cortex was related to increased performance on a delayed recognition test 
(Rosen et al., 2018).  On a task of verbal working memory, where executive function demands 
remained the same across task difficulty, children (9-15 years of age) demonstrated significantly 
less accurate and slower responses at greater difficulty levels (increased cognitive load) relative 
to young adults. Furthermore, children were also found to exhibit less of an increase in working 
memory load-dependent activation in multiple frontal and parietal cortical regions but also 
showed less of a decrease of activation in the default mode network (DMN) as a function of 
difficulty compared to young adults (20-25 years of age).  Therefore, although the same neural 
networks were employed, clear differences were seen between the two age groups in terms of 
activation during increased cognitive demand (Vogan, Morgan, Powell, Smith, & Taylor, 2016).   
A meta-analysis of functional neuroimaging data which examined activation associated with 
updating, switching and inhibition tasks reported that children aged 6-12 years were found to 
demonstrate no unique activation for updating tasks.  Importantly, one of the conclusions drawn 
from the meta-analysis suggests that in the context of neural activation, updating and switching 
processes may be indistinguishable in children unlike in adolescence (McKenna, Rushe, & 
Woodcock, 2017).  Indeed, executive function processes do follow different developmental 
trajectories and this notion of unity (indistinguishable) and diversity (distinguishable) is 
supported by the varying degree to which executive function unites or separates as a function 
of age (Best & Miller, 2010). 
Improvements in episodic memory performance have been linked to different hippocampal 
connectivity patterns in 4 and 6 year olds, with 6 year olds having greater connectivity within 
the anterior/posterior hippocampal memory networks, which has been related to better 
episodic memory performance.  In contrast, 4 year olds recruit more regions outside of the 
hippocampal memory network. Together, these findings suggest specialisation of hippocampal 
connectivity in which there is functional integration (Riggins, Geng, Blankenship, & Redcay, 
2016).  In another study considering developmental differences in white matter connectivity and 
episodic memory in children of the same age range, immediate recall and delayed recognition 
performance was predicted by white matter connectivity between the left hippocampus and the 
inferior parietal lobule.  However, recall of contextual details was predicted by white matter 
66 
 
connectivity between the right hippocampus and the inferior parietal lobule (Ngo et al., 2017). 
Moreover, in a sample of 6 - 14 year olds and young adults, hippocampus maturity was related 
to better orthogonalization of highly similar representations on a Mnemonic Similarity Task 
(Keresztes et al., 2017).   
4.2.4. Interim summary: Continuation of brain development during childhood  
Brain imaging techniques and measures of brain activity have shown ongoing developmental 
changes throughout childhood.  Specific regions of the brain show different developmental 
patterns, in which those associated with lower-order cognitive functions develop first.  A 
reduction in grey matter reflects an increase in white matter connectivity enabling more focal 
cortical activation.  Alongside these developmental changes, there is a sophistication of 
cognitive function demonstrated by improvements in performance on measures assessing 
visuospatial skills, executive functions and memory. 
4.3 Nutrition and cognition in childhood 
 
Nutrition plays a crucial role in brain development (van de Rest et al., 2012), learning and 
cognitive function of children (Frensham, Bryan, & Parletta, 2012).  Optimal nutrition is crucial 
for the brain both in respect of healthy development and function (Bourre, 2006; Dani, Burrill, 
& Demmig‐Adams, 2005; Singh, 2004).  Indeed, prospective longitudinal studies have proposed 
that poor nutrition influences cognition and neurodevelopment (Liu, Raine, Venables, Dalais, & 
Mednick, 2003; Martins et al., 2011).  Nutrients are available from bioactive natural compounds 
found in foods but also from fortified foods and dietary supplements that serve to enhance 
nutrient intake (Elliott & Ong, 2002).  There is an extensive body of literature documenting 
micronutrient supplementation studies in children that consider the effects on cognitive 
performance of a range of micronutrients in healthy and unhealthy samples, and of different 
micronutrient doses and durations of administration (reviewed in Bellisle, 2004; Benton, 2010; 
Eilander et al., 2010; Lam & Lawlis, 2017; Spencer, Korosi, Layé, Shukitt-Hale, & Barrientos, 
2017).   
Omega-3 FAs are bioactive lipids, the benefits of which on cognitive function following 
supplementation has been studied and reviewed widely across the life span, particularly from 
marine sources.  As discussed in Chapter 2, FAs are attached to GPLs at the sn-1 and sn-2 position 
of the glycerol backbone and the assimilation of DHA and EPA into membrane PLs affects cellular 
membrane composition, membrane fluidity and membrane raft formation (see Chapter 2).    
Moreover, the incorporation of DHA and EPA into the lipid membrane promotes pro-resolving 
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and anti-inflammatory properties (see sections 2.7.6.2.2.1 and 2.7.6.2.2.2).  DHA is a principal 
omega-3 PUFA in the brain, contributing over 40% of total brain PUFA (Lacombe et al., 2018). 
High concentrations of DHA in neural tissues are associated with high levels of PS (Kim, 2011).  
Enrichment of DHA in neurons can promote efficient biosynthesis and accumulation of PS (Guo, 
Stockert, Akbar, & Kim, 2007). There is also evidence that PS and DHA have a synergistic effect 
in the promotion of cognitive function (Zhang et al., 2019).  Although, as stated previously (see 
sections 2.7.6.2 and 3.5.1), DHA and EPA are known to support cognitive function separately 
also, for example, DHA regulates intracellular signalling, gene expression, myelination, 
neurogenesis, neurotransmission, synaptic plasticity, membrane receptor function (Calder, 
2012; Kuratko, Barrett, Nelson, & Salem, 2013; Prado & Dewey, 2014; Weiser et al., 2016) and 
acts on ion channels (Elinder & Liin, 2017).  Moreover, sufficient levels of DHA in neural 
membranes have been found to be critical for cortical glucose uptake (Pifferi et al., 2005; 
Ximenes da Silva et al., 2002).  In the absence of GPL supplementation studies investigating the 
effects of GPL supplementation on cognitive performance in children, this next section will 
consider DHA and EPA supplementation studies that have been conducted in school-aged 
children, which are of interest. 
4.3.1 Effects of nutritional intervention on cognitive performance in school-
aged children: DHA and EPA 
 
Numerous studies have considered the effect of omega-3 FAs, particularly DHA and EPA, on 
cognition in school-aged children; supplementing diet with varying doses, over different periods 
of time, in different populations (reviewed in Huffman, Harika, Eilander, & Osendarp, 2011; Kirby 
& Derbyshire, 2018; Kuratko, Barrett, Nelson, & Salem, 2013; Osendarp, 2011; Rangel-Huerta & 
Gil, 2018; Ryan et al., 2010; van de Rest et al., 2012).  This interest arises from the known effects 
of omega-3 FAs in the brain, their prevalence in the brain, and the inadequacy of intake 
particularly in those consuming a western style diet.  As discussed, DHA is quantitatively the 
most important omega-3 FA in the brain (Dyall, 2015).  Dietary intake tends to be inadequate 
for children and adults (Nyaradi et al., 2013).  A review of dietary intake of PUFAs in European 
countries reported intake to be inadequate when considered against the European Food Safety 
Authority (EFSA) recommendations.  This was particularly pronounced for EPA and DHA in 
children aged 4 - 9 years, although there was large heterogeneity in intake assessment methods 
and data presentation across the included studies (Sioen et al., 2017).  Earlier evidence suggests 
that this is a common finding. A systematic analysis of 226 country-specific nutrition surveys 
addressing consumption levels of dietary fats and oils between 1990 and 2010 reported 
increases in marine omega-3 were seen in countries that already demonstrated relatively high 
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consumption (e.g. Southeast Asia), and higher amounts tended to be consumed by older ages 
(Micha et al., 2014).  Importantly, dietary intake data from local and national surveys has led to 
the suggestion that children who do not live close to a marine environment have diets low in 
DHA and EPA (Ryan et al., 2010).  This is particularly problematic given that DHA and EPA are not 
efficiently synthesised in humans, rather they are more effectively obtained directly from diet 
(marine sources) or supplements (van de Rest et al., 2012).   
Table 4.1 presents a summary of RCTs that have supplemented diet with marine-omega-3 FAs 
(DHA and EPA) in school-aged children to explore whether there is any benefit for cognitive 
performance.   Only studies that recruited and supplemented the diet of school-aged children 
(4-12 years; Cooper, Tye, Kuntsi, Vassos, & Asherson, 2015) without cognitive impairment, and 
assessed cognitive performance objectively were included.  Studies that supplemented marine-
omega-3 FAs in combination with micronutrients (where there was no separate omega-3 
condition) were excluded.  Follow-up studies of prenatal or infant interventions were also not 
considered.  All studies meeting these eligibility criteria were RCTs.  All children that participated 
in the trials were cognitively healthy, however, the DOLAB studies (I and II) recruited children 
underperforming in reading – DOLAB I: ≤ 33rd centile (Richardson, Burton, Sewell, Spreckelsen, 
& Montgomery, 2012); DOLAB II: < 20th centile (Montgomery, Spreckelsen, Burton, Burton, & 
Richardson, 2018); these being the target populations. Measures other than those that assessed 
cognitive performance, for example, behavioural questionnaires (Montgomery et al., 2018; 
Richardson et al., 2012), are not reported.  Notably, one study assessed changes in functional 
activation whilst also measuring performance on a continuous performance task (McNamara et 
al., 2010), whilst another included a measure of academic performance, reflecting the average 
score in six subjects (Portillo-Reyes, Pérez-García, Loya-Méndez, & Puente, 2014).  Where not 
obvious, a statement concerning the cognitive domain assessed by each measure listed within 
Table 4.1 is provided according to the classification made by the original paper.   
The shortest duration of supplementation was 8 weeks (Kennedy et al., 2009; McNamara et al., 
2010) and the longest was 12 months in the NEMO study (Osendarp et al., 2007).  All trials 
supplemented DHA, although 4/9 studies supplemented EPA in addition to DHA.  However, one 
of these used a negligible dose (~4mg; Kennedy et al., 2009).  The smallest amount supplied was 
88mg DHA per day (Osendarp et al., 2007) and the largest was 1200mg DHA per day in a dose-
ranging study (McNamara et al., 2010).  Children recruited to the trials included healthy 
(Kennedy et al., 2009; McNamara et al., 2010; Montgomery et al., 2018; Osendarp et al., 2007; 
Richardson et al., 2012; Ryan & Nelson, 2008), marginally nourished (Osendarp et al., 2007), 
mild-moderately malnourished (Portillo-Reyes et al., 2014) and children with poor omega-3 
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intake and iron deficiency (Baumgartner et al., 2012) or poor omega-3 intake, of which 26% were 
stunted and ~30% were iron deficient (Dalton et al., 2009). The youngest children that 
participated were 4 years of age (Ryan & Nelson, 2008), whilst the oldest were 12 years of age 
(Kennedy et al., 2009; Portillo-Reyes et al., 2014).  All studies recruited both boys and girls, 
except one that included boys only (McNamara et al., 2010); and seven out of the nine trials 
used tablets or capsules to deliver either the active or placebo ingredients, whilst one used a 
powder dissolved in a fruit-flavoured drink (Osendarp et al., 2007) and another used a spread 
that was provided on two slices of bread (Dalton et al., 2009). 
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Table 4.1 Summary of Randomised Control Trials of marine-omega-3 FA supplementation on outcomes of cognitive performance in school-aged 
children. 
Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
Baumgartner 
et al. (2012) 
South Africa – 4 
primary schools 
serving low-
income rural 
villages. 
Randomised, placebo-controlled, 
double-blind study. 
8.5 month duration - 2-by-2 
factorial design. 
1. 1 x Iron tablet 50 mg + non-iron 
placebo tablet per day; 
2. 2 x 420 mg DHA + 80 mg EPA 
oral gelatin-coated fish-oil 
capsules + non-DHA/EPA 
placebo capsules (containing 
medium-chain triglycerides) per 
day; 
3. 1 x Iron (50 mg) tablet + 2 x 420 
mg DHA + 80 mg EPA capsules 
per day; 
4. Placebo + placebo per day. 
 
Supplemented 4 d/wk during 
school days. 
Iron or non-iron placebo tablets 
were given before 08.00 and 
swallowed with a 200ml fruit-
flavoured beverage containing 
~10mg vitamin C per serving.  DHA 
+ EPA or non-DHA/EPA placebo 
capsules were given between 
10.30 – 11.00 during midmorning 
break. 
n=321 iron deficient children aged 6 – 
11 years of age with a poor iron and ω-
3 FA intake – dietary assessment 
indicated ω-6:ω-3 ratio of ~60:1 
randomly allocated. 
1. n=81 of which N=70 completed 
cognitive assessment follow-up. 
Male:female ratio % - 48:52; age 
(average ± SD): 8.9 ± 1.4 years. 
2. n=81 of which 72 completed 
cognitive assessment follow-up. 
Male:female ratio % - 57:43; age:  
8.9 ± 1.3 years. 
3. n=79 of which N=73 completed 
cognitive assessment follow-up. 
Male:female ratio % - 53:47; age: 8.8 
± 1.3 years. 
4. n=80 of which N=73 completed 
cognitive assessment follow-up. 
Male:female ratio % - 45:55; age: 9.1 
± 1.4 years. 
 
No difference in the prevalence of 
anaemia between boys and girls 
(nearly 1 in 5 children were anaemic). 
DHA + EPA supplementation 
significantly increased relative 
composition of each in total 
phospholipid fraction of erythrocyte 
membranes and reduced AA and ω-
6:ω-3 ratio in membranes (p < .05). 
Tested and baseline and 
endpoint. 
a) Kaufman Assessment 
Battery for children (KABC-
II) x 4 subtests - working 
memory, short-term 
memory, long-term 
(delayed) memory and 
visuospatial copy task; 
 
b) Hopkins Verbal Learning 
Test (HVLT). Measures 
short-term and recognition 
memory. 
 
 
 
No significant main treatment 
effects. 
Subgroup analysis:  
- Anaemic children (at baseline) 
given DHA + EPA performed 
significantly worse in the working 
memory subtest of KABC-II (p < 
.05).  
- Girls with iron deficiency 
performed significantly worse 
following consuming DHA + EPA 
in the long-term memory subtest 
of KABC-II (p < .05), whereas 
boys with iron deficiency tended 
to demonstrate better 
performance following DHA + 
EPA (p = .09). 
- Girls recalled significantly more 
words on HVLT recall 2 after 
receiving DHA + EPA (or iron 
alone) relative to those 
supplemented with iron + DHA + 
EPA or placebo + placebo (p > 
.05). 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
Dalton et al. 
(2009) 
South Africa – 
single primary 
school serving a 
community with 
low 
socioeconomic 
status and of 
mixed ancestry 
(African–
European– 
Malay). 
Randomised, placebo-controlled, 
single-blind study. 
6 month duration (104 days). 
Intervention group: 25 g specially 
formulated bread spread 
containing ω-3 PUFA-rich fish flour 
p/school day. Contained fish flour 
(42.0% wt/wt), red palm oil fat 
(41.6% wt/wt), canola oil, lecithin, 
flavourings, sugar syrup, citric 
acid, and ascorbic acid per school-
day. 
Control group: 25 g analogous 
spread with no fish flour 
(commercial superfine rusk (94% 
wt/wt) bread flour) p/school-day. 
Both types of spread were given 
on two slices of bread. 
Spread containing ω-3 PUFA-rich 
fish flour was equivalent to 
~892mg of DHA per week. 
n=183 7 - 9 year old children randomly 
allocated.  Dietary assessment 
determined the children had virtually 
no intake of fatty fish and a very low 
intake of lean fish.  
Intervention group: N=91 of which 
n=77 completed cognitive assessment 
follow-up. Male:female ratio % - 48:52; 
age (average ± SD):  8.2 ± 0.7 years. 
Control group: 
n=92 of which N=78 completed 
cognitive assessment follow-up. 
Male:female ratio % - 45:55; age:  8.1 ± 
0.6 years. 
26% of sample were stunted and ~30% 
were iron deficient.  Very few were 
anaemic.  
Significant increase of DHA and EPA 
concentrations in plasma PC (p < .001), 
RBC membrane PC (p < .001) and RBC 
membrane PE (p < 0.005) fractions in 
those in the intervention group but not 
placebo group. 
 
 
Tested and baseline and 
endpoint in local language. 
a) Hopkins Verbal Learning Test 
(HVLT); 
b) Reading test- naming / 
association test; 
c) Spelling test; 
Reading and spelling test scores 
were converted to a 
standardized score (T-score). 
PP analysis 
- Marginally significant effect of 
treatment for HVLT recall 1 (p = 
.063) and a trend for recall 3 (p = 
.075). A significant treatment 
effect for HVLT recognition (p = 
.019) and discrimination index 
scores (p = .008). 
- Marginally significant effect of 
treatment for the reading test (p 
= .065). 
- Performance by the intervention 
group remained the same at pre- 
and post-intervention on the 
spelling test, however, 
performance significantly 
declined in the control group (p = 
.013).  
 
ITT analysis  
- Significant treatment effects for 
HVLT recognition (p = .015) and 
HVLT discrimination index scores 
(p = .005). 
- A significant treatment effect was 
also found for the spelling test (p 
= .016) (see above). 
 
RBC PE membrane FA composition:  
- Associations found between DHA,  
total ω-3, and ω-6:ω-3 ratio 
respectively with HVLT total score 
(p = .042; .058; .013), HVLT 
recognition (p = .013; .035; .085) 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
and HVLT discrimination index 
scores (p = .015; .027; .007).  
- Marginal inverse correlation 
between total ω-6 and spelling 
test score (p = .055).  
  
Neither iron deficiency nor stunting 
confounded the findings. 
Kennedy et al. 
(2009) 
UK, Newcastle-
upon-Tyne area 
– home-based 
intervention.  
Randomised, double-blind, 
placebo-controlled, dose-ranging 
pilot study. 
8 week duration. 
1. 1000 mg DHA per day; 
2. 400 mg DHA per day; 
3. Placebo. 
Parents of the children received 2 
x bottles, each containing 100 
soft-gel capsules for consumption 
in the morning and 2 x bottles, 
each containing 100 soft-gel 
capsules for consumption in the 
evening. Capsules in each bottle 
contained either 500 mg DHASCO-
S containing 200 mg DHA + ~4 mg 
EPA and vegetable oil as the 
remainder or placebo capsules – 
500 mg commercially available 
vegetable oil + ~15 mg ALA + 250 
mg LA. 
Capsule consumption was under 
parental supervision where 2 x 
capsules were consumed in the 
morning and 3 x capsules were 
consumed in the evening.  
n=90 10 – 12 year old children (healthy 
as per self- and parental-ratings) 
randomly allocated. 
1. n=30 (male: 15); age (average ± SD):  
10.70 ± 0.79 years; 
2. n=28 (male: 17); age:  11.11 ± 0.79 
years; 
3. n=30 (male: 12); age:  10.87 ± 1.01 
years. 
Tested and baseline and 
endpoint. 
Assessed pre and post-8-week 
period intervention: pre-
breakfast (08.00), +1 hr (09.45) 
and +3 hrs (11.45) after a 
standard breakfast.  
a) Internet battery comprising 
word presentation, picture 
presentation, arrow reaction 
time test, arrow flanker test, 
paired associate learning, 
sentence verification, 
delayed word recognition, 
delayed picture recognition.  
This was administered +1 hr 
post the standard breakfast. 
b) Cognitive Drug Research 
(CDR) battery comprising 
picture presentation; word 
presentation/immediate 
word recall; simple reaction 
time; digit vigilance task: 
choice reaction time; spatial 
working memory; numeric 
working memory; delayed 
word recall; delayed word 
Data capture errors meant n=86 
provided a full set of data for 
inclusion in the analysis of the 
Internet Battery assessments +1 hr 
following breakfast pre and post-
intervention. 
a) No significant main treatment 
effects. 
b) Significant effect of treatment on 
the speed of performing the 
delayed word recognition task (p 
< .05), whereby, in comparison 
to placebo, the 400 mg DHA 
group were significantly faster 
prior to breakfast (p < .05) and 
+3 hrs after breakfast (p < .01).  
The 1000 mg DHA group 
performed significantly slower 
prior to breakfast (p < .05). 
 
Overall, the pattern of results 
strongly suggests that this effect 
was due to chance fluctuations in 
performance and that the 
treatments had no consistent or 
interpretable effect on 
performance. 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
recognition; delayed picture 
recognition. This was 
administered pre- and +3 hrs 
post the standard breakfast.   
McNamara et 
al. (2010) 
USA Randomised, placebo-controlled, 
double-blind, dose-ranging 
functional magnetic resonance 
imaging study. 
8 week duration. 
1. 1200 mg DHA (algal triglyceride 
DHASCO) per day; 
2. 400 mg DHA (algal triglyceride 
DHASCO)  per day; 
3. Placebo (corn oil). 
 
All children took 6 x 500 mg 
capsules daily – 3 with breakfast 
and 3 with dinner.  Each DHA 
capsule contained ~200 mg DHA 
and no EPA.  
Children in the 1200 mg DHA 
condition received 600 mg twice 
per day, whilst those in the 400 
mg DHA condition received 200 
mg twice per day. 
All children were asked to 
maintain their normal diet 
throughout.  
Mean erythrocyte DHA 
composition at baseline did not 
differ significantly between the 
treatment and placebo groups. 
n=38 8 – 10 year old boys (healthy) 
randomly allocated. 
1. n=14 of which n=13 completed; age 
(average ± SD):  9.5 ± 0.7 years; 
2. n=12 of which n=10 completed; age: 
9.2 ± 1.0 years; 
3. n=12 or which n=10 completed; age 
8.8 ± 0.8 years. 
 
Erythrocyte DHA composition 
increased significantly following 8 
weeks in 400 mg DHA condition (p < 
.001), and in 1200 mg DHA condition (p 
< .001). This was not seen in the 
placebo condition. 
 
Tested and baseline and 
endpoint. 
Assessed functional activation 
of the dorsolateral prefrontal 
cortex during a sustained 
attention task: - Identical-pairs 
continuous performance task – 
series of 1-digit numbers 
presented.  Respondents 
required to press a button with 
their right index finger for all 
instances where the same 
number is presented twice 
sequentially.  Outcomes 
included: 
- Percentage of correct 
selections; 
- Errors of commission; 
- Discriminability; 
- Reaction time. 
The task was alternated with a 
control task to control for 
finger movement.  
No significant main treatment 
effect for Identical-pairs 
continuous performance task. 
DHA supplementation dose-
dependently raised erythrocyte 
DHA composition, which was 
positively correlated with 
functional cortical activation and 
inversely correlated with reaction 
time at baseline (p = .01) and 
endpoint (p = .02) during 
performance of the task.  
fMRI summary of findings (all p < 
.05): 
- Supplementation either with 
1200 mg or 400 mg of DHA for 8 
weeks significantly increased 
functional activation in the 
dorsolateral prefrontal cortex  
during performance of an 
attention task relative to placebo, 
which could not be attributed to 
performance differences on the 
task. 
- Lower activation was seen in the 
occipital cortex in the 400mg 
DHA group and cerebellar cortex 
in the 1200 mg DHA group 
relative to placebo. 
- Greater decrease in activation of 
the bilateral cerebellum was seen 
in the 1200 mg DHA group 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
relative to the 400 mg DHA 
group. 
Montgomery 
et al. (2018) 
DOLAB II 
UK, across 5 
counties 
proximate to 
Oxfordshire – 84 
x primary 
schools and 
academies. 
 
Fixed-dose, randomized 
(minimization, 30% random 
element), double-blind, placebo-
controlled trial. 
16 week duration. 
Intervention group: 3 x 200 mg 
DHA (from algal oil) in 500 mg 
capsules = 600 mg DHA per day. 
Control group: 3 x 500 mg 
capsules containing corn/soybean 
oil per day. 
Schools received 16 week supply 
of capsules (labelled with 
participant’s name) and were 
required to give 3 x capsules once 
a day at lunchtime.  Parents also 
received 16 week supply and were 
required to provide these to their 
children at weekends, during 
school holidays and any other 
times when their child was not in 
school.  
 
n=376 7 - 9 year old children (healthy) 
randomly allocated. 
A recalibrated version of the British 
Ability Scales (New BAS II) and the new 
BAS 3 (for comparison) were used to 
assess children’s reading ability.  
Recruited those who were 
underperforming in reading (< 20th 
centile) on either measure. 
Baseline data indicated mean reading 
performance of the children was 1.3 
SD below normal, equating to a 
reading performance around 27 
months below chronological age. 
Baseline working memory scores 
indicated children were around 0.8 SD 
(digits forwards) and 0.7 SD (digits 
backwards) below population norms.   
Intervention group: N=187 of which 
n=185 completed the follow-up. 
Male:female ratio % - 64.2:35.8; age 
(average ± SD): 105.6 ± 10.2 months. 
Control group: n=189 of which N=187 
completed the follow-up.  Male:female 
ratio % - 63.2:40.7; age: 105.3 ± 10.1 
months. 
~20% eligible for free-school meals in 
each group. 
Blood DHA levels significantly 
increased across the 16 weeks in the 
intervention group relative to the 
Tested and baseline and 
endpoint. 
Measures of reading ability: 
a) Word Reading Achievement 
sub-tests from the New BAS 
II and BAS 3 – single word 
reading tests. 
 
Measures working memory: 
a) Digits forward; 
b) Digits backwards.  
 
Measures were age-
standardised and measures of 
working memory and reading 
ability use T‐scores (working 
memory: x ̄50, SD 10; reading 
ability x ̄100, SD 15). 
 
Group comparisons carried out for 
the whole sample, with subgroup 
analysis on those children whose 
baseline reading scores ≤ 10th 
centile (n=231). 
No significant main effect of 
treatment for all measures.  
Post-hoc multivariate regressions 
reached the same conclusion. 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
control group, where there was no 
change (p < .001). 
Osendarp et 
al. (2007) – 
NEMO study 
South Australia - 
home-based 
intervention and 
Indonesia - 6 x 
primary schools  
Randomised, placebo-controlled, 
double-blind studies. 
12 month duration - 2-by-2 
factorial design. 
1. Micronutrient mix – 10 mg iron, 
5 mg zinc, and vitamins – 150 
µg folate, 400 µg A, 1 mg B-6, 
1.5 µg B-12, and 45 mg C per 
day; 
2. 88 mg DHA + 22 mg EPA per 
day; 
3. Micronutrient mix + 88 mg DHA 
+ 22 mg EPA per day; 
4. Placebo. 
 
4 x supplement products were in 
powder form that were added to 
a base powder containing 8 g 
protein, 12 g sugar, 4 g 
maltodextrin.  The supplement 
powders were dissolved in a 100 
ml fruit-flavoured drink (soy 
0.6%).  Powders and the fruit-
flavoured drink were mixed using 
a plastic shaker with a screw top, 
which were shaken for ≥ 20 
seconds.  
In Indonesia only, in addition to 
the drinks, children received 3 x 
biscuits at the same time 
providing ~100 kcal as a protein-
energy supplement.  
6 – 10 year old children either well-
nourished (Australia) or marginally 
nourished (Indonesia) school-aged 
children.   
Australian sample (n=396 randomly 
allocated): 
1. n=106 of which n=67 completed 
cognitive assessment follow-up 
(male: 36); age (average ± SD): 8.5 ± 
1.0 years. 
2. n=96 of which n=67 completed 
cognitive assessment follow-up 
(male: 37); age: 8.8 ± 1.0 years. 
3. n=92 of which n=71 completed 
cognitive assessment follow-up 
(male: 43); age:  8.8 ± 0.9 years. 
4. n=102 of which n=71 completed 
cognitive assessment follow-up 
(male: 43); age: 8.8 ± 0.9 years. 
Effect of treatment of DHA + EPA on 
change in plasma EPA, plasma DHA, and 
total plasma ω-3 FAs (p < .05). 
Indonesian sample (n=384 randomly 
allocated): 
1. n=94 of which n=92 completed 
cognitive assessment follow-up 
(male: 52); age: 8.2 ± 0.9 years. 
2. n=97 of which n=94 completed 
cognitive assessment follow-up 
(male: 45); age: 8.1 ± 1.1 years. 
Tested and baseline, midpoint 
(+6 months) and endpoint. 
Indonesian sample - English 
language assessment battery 
was translated and back-
translated into the local 
language, Bahasa Indonesia, for 
verification. Some items were 
changed according to cultural 
sensitivity. 
Both samples: 
a) Digits backwards; 
b) Visual attention 2 –Measures 
visual selective attention; 
c) Coding. Measures visual-
motor processing speed and 
coordination, short-term 
memory, visual perception, 
visual scanning, cognitive 
flexibility, attention; 
d) Block design. Measures 
visuospatial problem solving, 
visual nonverbal reasoning, 
visual perception and 
organization; 
e) Fluency structured and 
random. Measures executive 
function; 
f) Rey Auditory Verbal Learning 
Test (RAVLT). Measures 
immediate and long-term 
verbal memory; 
69/384 Indonesian children 
performed at floor on the RAVLT.  
The scores of these children were 
removed from the analysis 
performed using the data from this 
measure. 
To reduce the chances of obtaining 
a false positive when analysing 
multiple outcomes, the analysis of 
the effect of the treatment was 
conducted on clusters of the 
individual cognitive tests by means 
of a factor analysis using oblique 
rotation – 3 factors emerged for 
each country: 
Australian sample:- 
1. Fluid intelligence - coding, fluency 
structured and random, 
vocabulary, digits backwards, 
mathematical reasoning and block 
design. 
2. Verbal learning and memory - 
RAVLT-A3, RAVLT-slope and 
RAVLT delayed recall. 
3. Attention - visual attention 2. 
 
Following 6 and 12 months of the 
intervention, no significant 
treatment effects were found. 
Indonesian sample:- 
1. Fluid intelligence - design fluency 
and block design. 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
Given the lack of detail concerning 
the placebo, assumed this 
included the base powder and 
fruit-flavoured drink only. 
Supplemented 6 days per week – 
powdered based drinks 
consumed. 
 
 
 
 
 
3. n=98 of which n=94 completed 
cognitive assessment follow-up 
(male: 49); age:  8.2 ± 1.1 years. 
4. n=95 of which n=88 completed 
cognitive assessment follow-up 
(male: 44); age:  8.1 ± 1.1 years. 
Effect of treatment of DHA + EPA on 
change in plasma DHA, and total plasma 
ω-3 FAs (p < .05). 
Children from Southern Australia were 
in schools of higher socioeconomic 
status, whilst those from Indonesia 
were in schools of middle to low 
socioeconomic status in an urban poor 
area. 
No child was severely malnourished or 
severely anaemic.  
g) Vocabulary. Measures 
acquired knowledge and 
verbal concept formation; 
h) Mathematical reasoning. 
2. Verbal learning and memory - 
RAVLT-A3, RAVLT-slope, delayed 
recall, and vocabulary. 
3. Attention and concentration - 
visual attention, coding, digits 
backwards, and mathematical 
reasoning. 
Following 12 months of the 
intervention, no significant 
treatment effects were found. 
 
 
Portillo-Reyes 
et al. (2014) 
Mexico - 2 
schools of low 
socioeconomic 
status. 
Randomised, placebo-controlled, 
double-blind study. 
3 month duration. 
Intervention group: 3 x oral 
gelatin-coated ω-3 capsules (each 
containing 60 mg of DHA and 90 
mg of EPA) per day. 
Control group: 3 x soybean oil 
capsules per day. 
Capsules given by teachers in the 
early morning and at lunchtime. 
Capsules given in the afternoon, 
at weekends and during school 
holidays were provided by 
parents.  
n=55 8 – 12 year old, mild to 
moderately malnourished children 
randomly allocated. Dietary 
assessment revealed: 8% of the 
children consumed one portion of fish 
two or more times a week, 39% one 
ration a week, 19% a ration every two 
weeks, and 34% a ration of once a 
month. 
Intervention group: n=30 - all 
completed cognitive assessment 
follow-up (male: 26); age (average ± 
SD):  9.37 ± 1.17 years. 
Control group: n=25 of which N=20 
completed cognitive assessment 
Tested and baseline and 
endpoint. 
Measure of processing speed:  
a) Symbol search; 
 
Measures of visuoperceptual 
integration: 
a)Embedding figures test; 
b) Visual closure; 
Measures of visuoconstructive 
integration: 
a) Block design; 
b) TMT A; 
 
Measure of attention:  
a) Letter cancellation; 
 
Effect of treatment for symbol 
search (p = .006), embedded 
figures (p = .020), visual closure (p 
= .035). block design (p = .001), 
Stroop colour (p = .007), Stroop 
colour-word (p = .039) and matrix 
reasoning (p = .045).  
No significant effect of treatment 
for academic performance 
outcomes. 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
Supplemented 7 days a week. follow-up (male: 16); age: 9.08 ± .99 
years. 
 
 
 
Measures of memory: 
a) Rey complex figure; 
b) Word list – immediate free 
recall and delayed recall; 
 
Measures of language: 
a) Semantic fluency; 
b) Comprehension instruction; 
 
Measures of executive function 
(EF): 
a) Matrix reasoning; 
b) Letter-number sequencing; 
c) Stroop colour and word test; 
d) TMT-B. 
 
Also assessed academic 
performance – average score 
achieved by children in Spanish, 
Mathematics, History, 
Geography, Science and Civic 
Education. 
Richardson et 
al. (2012) – 
DOLAB I study 
UK, Oxfordshire 
– 74 x primary 
schools 
Randomised, placebo-controlled, 
double-blind study. 
16 week duration. 
Intervention group: 3 x 200 mg 
DHA (from algal oil) in 500 mg 
capsules = 600 mg DHA per day. 
Control group: 3 x 500 mg 
capsules containing corn/soybean 
oil per day. 
Schools received 16 week supply 
of capsules (labelled with 
participant’s name) and were 
required to give 3 x capsules once 
n=362, 7 - 9 year old children (healthy) 
randomly allocated. 
Underperforming in reading (≤ 33rd 
centile - equivalent to reading at 
around 18 months behind 
chronological age). Baseline data 
indicated mean reading performance 
of the children was 1.5 SD below 
normal, equating to a reading 
performance around 18 months below 
chronological age. 
Intervention group: n=180 of which 
n=179 completed the follow-up (male: 
Tested and baseline and 
endpoint. 
Measure of reading ability: 
a) Word Reading Achievement 
sub-tests of the British Ability 
Scales (BAS II) – single word 
test of reading ability; 
 
Measures working memory: 
a) Digits forwards; 
b) Digits backwards. 
 
Measures of working memory 
and reading ability use T-scores 
Additional planned group 
comparisons were conducted as 
follows: 
- Children whose baseline reading 
scores ≤ 20th centile (n=224). 
- Children whose baseline reading 
scores ≤ 10th centile (n=105). 
 
No significant main effect of 
treatment for reading ability.  
 
Subgroup analysis:  
- Significant treatment effect for   
children whose baseline reading 
scores ≤ 20th centile (p = .041) 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
a day at lunchtime.  Parents also 
received 16 week supply and were 
required to provide these to their 
children at weekends, during 
school holidays and any other 
times when their child was not in 
school.  
 
 
96); age (average ± SD): 103.7 ± 10.0 
months. 
Control group: n=182 of which n=180 
completed the follow-up (male: 96); 
age: 104.8 ± 10.1 months. 
 
 
(working memory: x ̄50, SD 10; 
reading ability x ̄100, SD 15). 
 
and for children whose baseline 
reading scores ≤ 10th centile (p = 
.011).  
 
No significant main effect of 
treatment for measures of working 
memory.  
Subgroup analysis:  
- Marginal significance for better 
performance by those in the 
intervention group for digits 
forward out of those children 
whose baseline reading scores ≤ 
20th centile (p = .069). 
 
Based on the gains in reading 
ability, in children with an initial 
reading performance ≤ 20th centile, 
active treatment was associated 
with an additional 0.8 months 
mean increase in reading age 
change scores vs. placebo, while 
those whose baseline reading 
scores ≤ 10th centile, the additional 
reading age gain from treatment 
was 1.9 months. 
Ryan and 
Nelson 
(2008) 
Multicentre (11 
sites) across USA 
Randomised, placebo-controlled, 
double-blind study. 
4 month duration. 
Intervention group: 400 mg DHA 
(DHASCO-S) as a triglyceride 
supplied as 2 x 200 mg bubble 
gum-flavoured softgel chewable 
capsules per day. 
n=202 4.0 – 4.8 year old children 
(healthy) randomly allocated. 
PP analysis 
Intervention group: n=77 (male: 39), 
age (average ± SD): 52.0 ± 2.3 months. 
Control group: n=86 (male: 43); age: 
51.4 ± 2.4 months. 
 
Tested and baseline and 
endpoint. 
a) Leiter-R Test of Sustained 
Attention; 
b) Peabody Picture Vocabulary 
Test (PPVT)- listening 
comprehension and 
receptive vocabulary; 
No significant treatment effects 
(for either PP or ITT analysis).  
Regression analysis revealed a 
statistically significant positive 
association between level of DHA 
in capillary whole blood and better 
performance on PPVT for the ITT 
group (p = .018). Removal of 
Hispanic/Latino participants from 
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Author 
(year) 
Country, 
setting 
Intervention  Sample demographics Measures Findings 
Control group: high-oleic 
sunflower oil supplied as 2 x 
softgel capsules per day. 
 
ITT analysis  
Intervention group: n=85 (male: 45); 
age: 51.9 ± 2.3 months. 
Control group: n=90 (male: 47); age: 
51.6 ± 2.4 months. 
DHA blood analysis 
Intervention group: n=46 (male: 28); 
age: 51.7 ± 2.4 months.  
Control group: n=47 (male: 25); age: 
51.3 ± 2.4 months. 
 
Mean capillary whole blood content of 
DHA in those in the intervention group 
increased by more than 300% (p < 
.001) post supplementation. This 
remained low in the control group. 
c) Day-Night Stroop Test. 
Measures executive function;  
d) Conners’ Kiddie Continuous 
Performance Test (kCPT). 
Measures attention deficits. 
the analysis meant this finding 
increased in magnitude (ITT 
analysis, p = .008 / PP analysis, p = 
.04). 
 
 
Notes. AA: Arachidonic acid (C20:4); ALA: Alpha-Linolenic acid (C18:3); BAS II: British Ability Scales (BAS II); CDR: Cognitive Drug Research; CPRS-L / CTRS-
L: Conners’ Rating Scales; DHA: Docosahexaenoic acid (C22:6); EPA: Eicosapentaenoic acid (C20:5); FA: Fatty acid; fMRI: Functional Magnetic Resonance 
Imaging; HVLT: Hopkins Verbal Learning Test; ITT: intention to treat; KABC-II: Kaufman Assessment Battery for children; kCPT: Conners’ Kiddie 
Continuous Performance Test; LA: Linoleic acid (C18:2); LC-PUFA: Long-chain polyunsaturated fatty acid; ω‐3: omega‐3 fatty acids; ω‐6: omega‐6 fatty 
acids; x:̄ mean; PC: phosphatidylcholine; PE: Phosphatidylethanolamine; PP: Per protocol; PPVT: Peabody Picture Vocabulary Test; PUFA: 
Polyunsaturated fatty acid; RAVLT: Rey Auditory Verbal Learning Test; RBC: Red blood cell. 
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Collectively, the findings of the studies are inconsistent making it difficult to reliably draw a 
conclusion regarding the effects of marine-omega-3 FA supplementation on cognitive 
performance in school-aged children.  Comparing the studies is made difficult by the 
heterogeneity that exists across the nine studies in terms of the populations assessed (including 
differences in inclusion criteria), dosage, treatment types and combinations, sample size, routes 
of omega-3 administration, assessment of cognitive performance, study duration, method of 
assessment of nutrient intake and the presence of confounding variables (Rangel-Huerta & Gil, 
2018; van de Rest et al., 2012).  Of those to report a benefit (5/9), two studies included healthy 
children (McNamara et al., 2010; Richardson et al., 2012), whilst three studies recruited children 
with poor omega-3 intake and iron deficiency (Baumgartner et al., 2012), children who were 
classed as mild-moderately malnourished (Portillo-Reyes et al., 2014) or children with poor 
omega-3 intake, a quarter of these being stunted and approximately a third being iron deficient 
(Dalton et al., 2009).  The effect of treatment was most clearly seen across a range of cognitive 
domains following 3 months of treatment (Portillo-Reyes et al., 2014), yet the quality of this 
study was poor.   
Importantly, as the focus of this Chapter concerns whether cognitive performance of healthy 
school-aged children can be improved following GPL plus SM supplementation, trials that 
recruited healthy children are of central interest.  In trials with suboptimal nutrient status, there 
is likely to be a more readily detectable impact following supplementation.  However, 
conversely, the effects of supplementation may not be evident when there is inadequate intake 
of other nutrients (other than those  supplemented, which may be likely to be the case in 
undernourished samples, since only one deficiency is addressed) (Stonehouse, 2014; van de Rest 
et al., 2012).  In the two studies that recruited healthy children and reported an effect of 
treatment, participants received 600 mg DHA per day over 16 weeks (DOLAB I; Richardson et al., 
2012), or 400 mg (low-dose) or 1200 mg (high-dose) of DHA per day over 8 weeks (McNamara 
et al., 2010).  Reading scores were found to improve significantly in those with a  baseline 
reading score of ≤ 20th centile and separately, ≤ 10th centile, and marginally better performance 
was seen on a measure of working memory in those whose baseline reading score was ≤ 20th 
centile (Richardson et al., 2012).  Therefore, the significant benefit of treatment on reading 
ability was only evident in those whose reading performance fell within the lowest 20 per cent 
of the normal distribution (Richardson et al., 2012).  However, in an RCT (DOLAB II) that 
replicated the original DOLAB I study (same eligibility criteria, dosage and intervention period), 
no benefit of supplementation was found (Montgomery et al., 2018).  It was reasoned that 
several differences may have contributed to this disparity, including the use of a recalibrated 
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version of the British Ability Scales II (BAS II) due to the change in the UK National Curriculum, 
which may be less sensitive to detect change, multiple recruitment issues, and lower omega-3 
uptake in blood DHA levels.  However, the authors note that there is a lack of clear relationship 
between blood DHA levels and changes in performance (Montgomery et al., 2018).   In the 
second study, supplementation of DHA (at 400 mg or 1200 mg doses) for 8 weeks did not lead 
to an improvement on a task of sustained attention, yet functional activation in the prefrontal 
cortex increased significantly relative to placebo in the absence of differences in performance 
(McNamara et al., 2010).  In addition, lower activation was identified in the occipital cortex 
following 400 mg DHA supplementation and in the cerebellar cortex after 1200 mg DHA 
supplementation for 8 weeks (McNamara et al., 2010).  It was concluded that DHA regulates 
functional activity in cortical attention networks, which may be mediated by augmented 
dopamine receptor-mediated activity, amplification of astrocyte-mediated neurovascular 
metabolic coupling, neurotrophic effects and/or decreases in central inflammatory signalling 
cascades (McNamara et al., 2010).  Consistent with the lack of improvement in cognitive 
performance after 8 weeks of taking 400 mg DHA per day, Kennedy and colleagues (2009) 
concluded that their findings were due to chance (type 1 error), and that DHA supplementation 
had no significant effect.  The remaining trials that recruited healthy children found no 
treatment effect after receiving 88 mg DHA and 22 mg EPA per day, for 6 days per week over 12 
months in a well-nourished Australian sample (Osendarp et al., 2007) or of 400 mg DHA per day 
over 4 months in an American sample (A. S. Ryan & Nelson, 2008).  In spite of the lack of 
consistent evidence to support an effect of DHA supplementation on cognitive performance, 
DHA supplementation raised erythrocyte DHA composition in a dose-dependent manner and 
was positively associated with functional cortical activation.  DHA was, however negatively 
correlated with reaction time on a sustained attention task both at baseline and endpoint 
(McNamara et al., 2010). 
4.3.2 Interim summary: Nutrition and cognition in childhood 
Dietary intake data suggests suboptimal intake of omega-3 FAs from marine sources in children.  
Studies that have considered the role played by these FAs have reported their involvement in 
signal transduction and intracellular signalling and the facilitative effects they have on 
neurotransmitter communication and the amelioration of inflammation. Nine RCTs have 
explored supplementing the diet of school-aged children with preformed DHA; four of these 
administered DHA in combination with EPA.  Of those that recruited healthy children, no 
consistent benefit of supplementation was found.  Across the nine studies, there were a number 
of methodological limitations including small sample sizes, inappropriate intervention lengths 
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and doses administered, use of control products with bioactive constituents and multiple 
measurement issues.  Such limitations are likely to compromise the possibility of finding an 
effect of treatment.   
4.4 Aims of Study 1 and related hypothesis 
The primary aim of the study presented in this Chapter was to examine whether supplementing 
the diet of 6 – 8 year old school-children over a period of 6 weeks with a GPL and SM supplement 
(Lacprodan® PL-20) would improve cognitive performance on measures assessing memory, 
motor skills, working memory and processing speed (cognitive battery).  Based upon the 
empirical evidence presented in Chapter 2, it was hypothesised that supplementation with 
Lacprodan® PL-20 would facilitate cognitive function, in turn promoting better performance on 
the cognitive battery relative to that shown by the control group.  It was further hypothesised 
that age (see section 4.2 for a discussion on brain maturation, this being correlated with 
sophistication of cognitive function) and IQ (Checa & Fernández-Berrocal, 2015; Haier, 2014) 
would be positively associated with performance on the cognitive battery.  Moreover, females 
were expected to demonstrate an advantage on a verbal memory measure (Andreano & Cahill, 
2009; Asperholm, Nagar, Dekhytar & Herlitz, 2019; Pauls, Petermann & Lepach, 2013) relative 
to males, whilst males were expected to perform faster on the processing speed measures 
compared to females (Roivainen, 2011).  No further hypotheses could be proposed regarding 
gender performance differences, either because such differences have not been identified in 
the previous literature or there are inconsistent findings.  Data from the Choice Reaction Time 
measure of the Cambridge Neuropsychological Test Automated Battery (CANTAB) obtained 
following an acute study on the effects of breakfast compared with no breakfast in 11 – 13 year 
olds was used to calculate the sample size (Adolphus et al., under review).  A secondary aim was 
to explore whether Lacprodan® PL-20 supplementation had any effect on subjective evaluations 
of appetite, mood, motivation and mental alertness, as measured by a Likert scale.   
  
83 
 
4.5 Methods 
4.5.1 Participants 
The study sample comprised healthy males and females, aged 6-8 years, from two primary 
schools in Leeds (UK).  Both schools are geographically close (within the same village) and 
comparable in size and type.  Study participants were recruited from a pool of children (n=193) 
in two academic years across the two schools.  Ages 6-8 years correspond to compulsory primary 
school Years 2 and 3 in the British School System.  Year 2 corresponds to Key Stage 1 and Year 3 
corresponds to Key Stage 2 in the education system.  Following screening, a total of 133 children 
met the inclusion criteria.   This was reduced to 132 due to one child being absent from baseline 
testing.  Of these, 108 (80%) children completed the intervention.  A CONSORT diagram showing 
the flow of participants through each phase of the trial is provided in Figure 4.1.  
 
 
  
84 
 
 
Figure 4.1 CONSORT diagram showing the flow of participants through each phase of the trial 
(pre-screening, screening, randomisation and intervention). 
n=193 healthy children aged 6–8 years. 
n=38 excluded prior to screening 
-36 opt-out letters returned; 
-1 planned to change school 
following the school holiday; 
-1 child had Down’s syndrome. 
 
n=155 children were invited to screening 
n=22 not randomised 
- 1 dairy intolerant; 
- 12 rated the experimental 
drinks <5; 
- 1 poor attention – failed to 
engage in screening 
exercises; 
- 3 additional opt-out letters 
received; 
- 3 changed school following 
the school holiday; 
- 1 suspected of having 
Autistic Spectrum Disorder 
and behaviour was difficult 
to manage; 
- 1 poor verbal skills and 
failed to engage with 
researcher.  
 
n=133 eligible and randomised 
n=1 was absent for 
baseline testing. 
 
n=132 enrolled on to the intervention 
n=66 allocated to the active 
condition, of which 55 completed  
Discontinued intervention (n=11) 
n=66 allocated to the placebo 
condition, of which 53 completed 
Discontinued intervention (n=13)              
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4.5.1.1 Eligibility criteria 
A full list of the study inclusion and exclusion criteria is presented in Table 4.2. A child was 
enrolled into the study if they met these criteria and if their parent/guardian had provided 
written consent. 
Table 4.2 Inclusion and exclusion criteria for study sample 
Inclusion criteria Exclusion criteria 
- Aged 6-8 years; - Poor general health; 
- Rated the experimental drinks >5 on a Likert 
scale for at least one flavour (out of three). 
A score of >5 indicated the child found the 
drink palatable and expressed they were 
happy to consume it over the intervention 
period; 
- Inability to perform or impaired 
performance on the cognitive measures 
due to red-green colour vision deficiency. 
Deficiency tested using a colour 
perception test (Ishihara, 1951) during 
screening; 
- Willingness to consume the experimental  
drinks and participate in all test sessions 
across the intervention period (6 weeks); 
- Behavioural difficulties or attention 
disorders (e.g. Attention Deficit 
Hyperactivity Disorder); 
- Able to follow verbal and simple written 
instructions in English; 
- A learning disability that interferes with 
the ability to understand written or verbal 
communication; 
- Normal vision, with appropriate corrective 
lenses, if required; 
- Inability to understand the objective(s) of 
the cognitive measures or carry out the 
measures; 
- Able to understand cognitive testing 
instructions and responding requirements. 
- Any food allergies or intolerances (e.g. 
lactose intolerance); 
- Acute illness within the week prior to 
testing; 
 - Current administration of any psychotropic 
medication or supplementation in the 
month prior to testing, or during testing. 
 
4.5.1.2 Recruitment 
Opt-out permission letters (Appendix 4) were sent by the participating schools to 
parents/guardians to gain permission for their child/children to participate. Children were not 
enrolled into the study in all cases where parents/guardians did not give their permission.  Prior 
to each study cohort commencing the study, open sessions were held at the schools to which all 
parents/guardians were invited to attend should they want to find out more about the study.  
Staff at the schools were provided with an information sheet detailing the study requirements 
and a study timetable.  
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4.5.2 Experimental design 
The study conformed to a randomised, double-blind, placebo-controlled, parallel groups study 
design.  A breakdown of the allocation by condition is provided in the CONSORT diagram (Figure 
4.1).   
4.5.2.1 Experimental procedure  
Allocation to condition using a pre-prepared randomisation list took place prior to screening.  
This avoided the risk of unblinding a child during screening in the case of any minor differences 
between the active and placebo drink supplements (colour/taste) when they sampled them.  
Participants were seen in school, Monday-Friday, 25 minutes before breaktime during their 
usual school day for supplement consumption.  Participants were also seen for screening and 
cognitive testing sessions in school, which took place alongside participants’ usual school routine 
(between 09.00 – 15.00). Cognitive performance was assessed on three occasions: at baseline 
(week 0) prior to starting the intervention, mid-intervention (+ 3 weeks/21 days; midpoint) and 
after consuming the experimental drinks for 6 weeks (+ 6 weeks/42 days; endpoint), as shown 
in Figure 4.2. 
 
 
 
 
 
Figure 4.2 Study test schedule 
4.5.2.2 Sample size calculation 
To estimate the number of participants required to detect a statistically significant difference 
between conditions, power was calculated based upon the effect observed in Adolphus et al. 
(under review) for the CANTAB Choice Reaction Time (movement time) outcome measure. The 
calculation was undertaken by an independent statistician (Quadt Consultancy BV) using SAS 
(SAS Institute Inc, NC, USA) and indicated that a sample of 58 participants per arm (n=116) would 
be sufficient to detect a difference of means (mean difference) of 0.05 with an alpha of 0.05 and 
80% power.  
Occasion 1: 
Screening 
Occasion 2: 
Baseline 
Occasion 3: 
Midpoint 
Occasion 4: 
Endpoint 
Week -1 Week 3 
(Day 21) 
Week 0 Week 6 
(Day 42) 
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4.5.2.3 Ethical approval 
This study received ethical approval from the Institute of Psychological Sciences Research Ethics 
Committee (Ref 14-0101) on 17/05/2014.  Parents/guardians of the participants were informed 
as to the nature and aims of the study via opt-out permission letters. Return of opt-out letter 
slips were collected by the schools and provided to the research team.  In all cases where letter 
slips were not returned, it was assumed that informed consent had been given by the 
parents/guardians. Ongoing oral assent was obtained from the participants throughout the trial.  
4.5.3 Intervention  
4.5.3.1 Supplements 
Either an active or placebo supplement (isovolumetric drinks) was consumed by participants 
over 6 weeks: 
a) Active: Containing Lacprodan®PL-20 (22.5 g PL-20 within a 250 ml drink); 
b) Placebo: Matched for taste and appearance against the active supplement (250 ml). 
 
The ingredients within the active and placebo supplements (%) are provided in Table 4.3 by 
flavour and a breakdown of the PL constituents of Lacprodan® PL-20 is listed in Table 4.4. 
Table 4.3 Composition of active and placebo supplements by flavour (%). 
 Ingredient 
Strawberry 
active 
Raspberry 
active 
Banana 
active 
Strawberry 
placebo 
Raspberry 
placebo 
Banana 
placebo 
Lacprodan® PL-20 9 9 9 0 0 0 
Skim Milk Powder 0 0 0 13,2 13,2 13,2 
Butter oil 0 0 0 2,4 2,4 2,4 
Lactose 6,1 6,1 6,1 0 0 0 
Sucrose 1,1 1,1 1,1 1,1 1,1 1,1 
Sucralose 0,02 0,02 0,02 0,02 0,02 0,02 
Stabilizer 0,25 0,25 0,25 0,25 0,25 0,25 
Potassium 
chloride 
0,17 0 0 0,17 0,17 0,17 
Flavour - 
Strawberry 
0,25 0 0 0,25 0 0 
Flavour - Vanilla 0,1 0,1 0 0,1 0,1 0 
Flavour- 
Raspberry 
0 0,22 0 0 0,22 0 
Flavour- 
BananaCream 
0 0 0,2 0 0 0,2 
Water 83 83 83,1 82,5 82,5 82,7 
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Table 4.4 Composition of molecular PL species in Lacprodan® PL-20 (Sokol et al., 2015) 
Lipid classes Molar abundance (mol%) 
Phosphatidylethanolamine 35 
Phosphatidylcholine 18 
Phosphatidylserine 9 
Phosphatidylinositol 5 
Sphingomyelin 8 
 
Experimental drinks were available in three flavours - banana, strawberry or raspberry - and 
contained in TetraBrik® cartons.  Only the colour and fruit character appearing on the front of 
each carton (to identify flavour) and a condition code differed between cartons.  Experimental 
drinks were stored in a refrigerator onsite.  Experimental drinks were consumed in a controlled 
manner in the classroom under the supervision of the research team and teachers.   
4.5.3.2 Assessment of compliance 
The weight of each experimental drink carton was recorded prior to and following consumption 
to determine how much of the supplement had been consumed on each occasion.  Names of 
the intended recipients were written on each carton prior to weighing and drink dissemination 
was monitored to ensure the correct participant received the correct drink.  Experimental drinks 
were not consumed at weekends or during holidays.   
The inclusion of a participant in the PP analyses was determined by their consumption of the 
experimental drinks across the intervention period.  Consumption across this period had to meet 
a recommended threshold (~85% of the prescribed dose and taking into account the regularity 
of consumption). Consumption by each participant was plotted and subsequently inspected by 
the research team and Arla Food Ingredients P/S, Denmark, in order to decide which participants 
could be included in the PP analysis (n=70) based on the amount consumed and pattern of 
intake.  
4.5.3.3 Known drug reactions and interaction with other therapies 
An expert panel approved Lacprodan®PL-20 as part of nutrition bars and milk-based nutritional 
beverages as safe, suitable and GRAS in July 2014. A copy of this is provided in Appendix 5.  As 
both supplements contain ingredients available from / used in regular food products only, it is 
not anticipated that the supplements will interact with other therapies or lead to a drug 
reaction.  
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4.5.3.4 Study restrictions  
Participants were asked to maintain their usual diet throughout the 6 week study period.  
4.5.3.5 Adverse events 
Participants were asked to inform a teacher or any member of the research team if they felt 
unwell at the time of or following consuming experimental drinks. On such occasions, an adverse 
event form was required to be completed.  Any adverse event was to be discussed with Arla 
Food Ingredients P/S, Denmark, enabling a decision to be made as to whether the situation 
should be monitored or whether the participant should be withdrawn from the study.   
4.5.3.6 Blinding  
Parents, teachers, participants and researchers were blind to condition allocation 
(active/placebo) throughout the study and data analysis.  Both experimental drinks were 
matched for appearance and taste as far as possible. 
4.5.4 Screening 
Each screening session lasted ~45 minutes and took place in a quiet environment (school 
library).  During screening, children tried a sample of the experimental drink in each flavour 
(either the active or placebo supplement pre-determined by condition allocation), rated each 
one for palatability (out of 10), and undertook screening measures (see section 4.5.4.1). 
Following completing the screening measures, children competed a 10-point Likert scale to 
measure subjective evaluation of appetite, mood, motivation and mental alertness (Appendix 
6), cognitive measures (practice version; see Table 4.5), followed by a 10-point Likert scale asking 
recipients to provide cognitive measure evaluation ratings (Appendix 7). Completing a practice 
version of the cognitive measures allowed each child to become familiar with all test 
requirements and provided an opportunity to identify any child who failed to comprehend 
these.  All children demonstrated that they were able to understand all test instructions and 
requirements.   
4.5.4.1 Screening measures 
4.5.4.1.1 Wechsler Abbreviated Scale of Intelligence (WASI) 
Administering the WASI (Wechsler, 1999) enabled the statistical analysis to be adjusted for 
individual differences in current levels of intellectual functioning in the analyses.  This measure 
covers the age range of 6-89 years and has four subtests, however, two can be used to establish 
a measure of intellectual functioning, specifically, the vocabulary and matrix reasoning subtests 
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(Wechsler, 1999).  Split-half reliabilities for the subtest are between 0.8-0.9 (Axelrod, 2002).  The 
abbreviated form of WASI has a high reliability coefficient of 0.93 for children (Wechsler, 1999). 
Factor analysis has corroborated the two-factor model specified in the WASI manual (The 
Psychological Corporation, 1999) of Verbal Comprehension and Perceptual Organisation, 
thereby evidencing construct validity (Ryan et al., 2003).  
4.5.4.1.2 Ishihara colour perception test 
This test screens for 90-95% of congenital red-green colour deficiency.  Single and double digits 
are shown on plates, 1 plate per page.  Plates 1-25 were administered. For scoring, ≥ 6 errors on 
plates 2-17 suggest a colour deficiency (HSE, 2005).  
4.5.4.1.3 Socio-demographic information 
In addition to age, gender, and ethnicity, it was anticipated that eligibility for free school meals 
would be obtained as a proxy for socioeconomic status.  However, school meal status records 
kept by the schools were inaccurate and therefore not recorded. 
4.5.5 Testing procedure 
4.5.5.1 Test session 
Each experimenter referred to a test schedule on each test occasion.  Consequently, as far as 
possible, participants were tested at roughly the same time of day at baseline, midpoint and 
endpoint.  Any participant absent from school (and therefore not consuming supplement drinks) 
was tested on return to school providing this was within 3 days of the date of the original 
planned test session.  Participants were tested in a quiet environment (school library).  At the 
start of each test session, participants completed the 10-point Likert scale assessing subjective 
state (Appendix 6), then the cognitive measures (see Table 4.5), followed by the 10-point Likert 
scale concerning cognitive measure evaluation (Appendix 7). Four participants were tested at 
any one time and test sessions took ~25 minutes.  Test session duration varied owing to response 
latencies and the number of attempts participants took at a set number of trials (by stage) for 
one of the measures.  All teaching staff were aware of when test sessions were taking place and 
school timetables were altered, as far as possible, to accommodate where necessary, however, 
few disruptions were caused.  All researchers followed a standardised instruction sheet, 
ensuring consistency in the administration of the measures. Figure 4.3 provides a flow diagram 
of the study procedure from screening to endpoint. 
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Figure 4.3 Study protocol flow diagram 
  
SCREENING (week -1) 
Experimental drink palatability assessment; 
Screening measures; 
Likert scale of subjective state; 
Practice cognitive measures; 
Likert scale of cognitive measure evaluation. 
 
BASELINE (week 0) 
Likert scale of subjective state; 
Cognitive measures; 
Likert scale of cognitive measure evaluation; 
Experimental drink consumption (day 1). 
 
MIDPOINT (week 3; post dose 21) 
Likert scale of subjective state; 
Cognitive measures; 
Likert scale of cognitive measure evaluation. 
 
1 week 
3 weeks 
ENDPOINT (week 6; post dose 42) 
Likert scale of subjective state; 
Cognitive measures; 
Likert scale of cognitive measure evaluation. 
 
3 weeks 
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4.5.5.1.1 Self-report measures completed during test sessions 
4.5.5.1.1.1 Self-report measure of subjective state 
Prior to the administration of the cognitive measures, participants completed a 10-point Likert 
scale to assess subjective evaluation of appetite, mood, motivation and mental alertness. Eight 
subjective states were measured including hunger, cheerfulness, bad temperedness, energy 
levels, keenness to try hard (on the cognitive measures), ease of distraction, ease of focusing 
and wakefulness. 
Originally it was planned to utilise a visual analogue scale (VAS) i.e. a 10 cm line anchored at 
both ends with opposing descriptors defining the bounds of each subjective state being 
measured e.g. hunger.  Respondents were required to place a vertical line against each scale to 
indicate the level of intensity they felt.  However, after trialling this in a pilot study with similarly 
aged children (6-8 years), it was determined that the children had trouble in deciding where to 
place the line against each scale according to how they felt.  Following this, 10-star shapes, as 
an alternative to a horizontal line were trialled, requiring recipients to colour in the appropriate 
number of stars to represent how they felt according to the scale.  This alteration in 
measurement ensured that respondents had no difficulty in completing the scales.  
4.5.5.1.1.2 Cognitive measure evaluation 
Following the administration of the cognitive measures, a 10-point Likert scale was administered 
to obtain ratings evaluating the cognitive tests. Participants were asked about their perceptions 
concerning test battery difficulty, how much they had concentrated during the test battery, how 
they felt they had performed and how frustrated they had felt whilst completing the cognitive 
measures. 
4.5.5.1.2 Assessment of cognitive performance 
The order and nature of the cognitive measures that were administered along with respective 
completion times, the cognitive domains assessed, and outcome variables generated are listed 
in Table 4.5. 
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Table 4.5 Cognitive measures presentation during test sessions 
Cognitive measure Measure duration 
(minutes) 
Cognitive domain(s) 
assessed 
Outcome variables 
Rivermead 
Behavioural Memory 
Test for Children: story 
subtest (RBMT-C) 
3 Immediate verbal 
memory 
Number of details 
correctly recalled out 
of 31. 
CANTAB: Motor 
Screening (MOT) 
2a Motor skills 
Distance from the 
cross; reaction time. 
CANTAB: Spatial 
Recognition Memory 
(SRM) 
5a Visuospatial 
recognition memory 
Number of correct 
trials; reaction time. 
CANTAB: Spatial Span 
(SSP) 
5a 
Working memory 
capacity (executive 
function) 
Highest span 
achieved; number of 
correct trials; 
reaction time 
(correct trials). 
CANTAB: Simple and 
Choice Reaction Time 
(SRT/CRT) 
3a Processing speed 
Number of correct 
trials; reaction time 
and movement time 
(correct trials). 
Rivermead 
Behavioural Memory 
Test for Children: story 
subtest 
1 Delayed verbal 
memory 
Number of correctly 
answered story-
based questions out 
of 10. 
Note. CANTAB: Cambridge Neuropsychological Test Automated Battery. 
aReported by Cambridge Cognition (2006).  
4.5.5.1.2.1 Rivermead Behavioural Memory Test for children (RBMT-C) 
The Rivermead Behavioural Memory Test for Children (RBMT-C; Wilson, Adrich, & Ivani-Chalian, 
1991) assesses memory capacity (in children) by attempting to simulate everyday situations 
(Anderson, Catroppa, Morse, & Haritou, 1999).  The measure is suitable for use with children 
aged 5-10 years and includes 12 separate subtests that can be combined to give an overall 
numeric memory score or administered and scored individually.  This study used the story 
subtest to assess immediate and delayed verbal memory. Parallel versions were used for each 
test occasion and version allocation followed a Latin square design. Performance on this 
measure is not affected by previous experience of the test (no learning effect) and the 
correlation coefficients between test and retest have been reported as r=0.44 - 0.73 (Spearman's 
rank correlation coefficient) across the age groups 5 – 9 year olds, all p < .05 (Aldrich & Wilson, 
1991). 
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The story subtest comprises an immediate recall stage and a delayed recall stage.  Prior to the 
administration of this measure, each participant was asked if they were willing to be recorded 
using audio recording equipment.   No participant refused the request.  Story cards are available 
as part of the measure, which depict specific scenes from each story (1 story card per parallel 
version).  A story card was presented to participants during the immediate recall stage, shortly 
before a story was read aloud by a researcher.   
To assess immediate verbal memory, respondents are read a story aloud, which they are asked 
to listen carefully to.  Each story communicates 31 separate details.  Immediately following story 
presentation, respondents are asked to recall the story they have just heard in as much detail as 
possible.  Responses are scored out of a total of 31 using a marking schedule, representing the 
total number of unique story details recalled.  To assess delayed verbal memory, respondents 
are asked 10 story-based questions successively. Responses for this section are scored out of a 
total of 10.  Any corrections made by participants either during story recall or when answering 
the 10 questions were accepted. 
4.5.5.1.2.2 Cambridge Neuropsychological Test Automated Battery (CANTAB) 
CANTAB is a  neuropsychological test battery that has been used in numerous research studies 
in school-aged children without impairment (Evans, 2006; Luciana & Nelson, 1998; Sheppard 
and & Cheatham, 2013), as well as in those with Down Syndrome (Edgin et al., 2010; Pennington, 
Moon, Edgin, Stedron, & Nadel, 2003; Visu-Petra, Benga, Ţincaş, & Miclea, 2007), attention 
deficit hyperactivity disorder (Coghill, Banaschewski, Bliss, Robertson, & Zuddas, 2018; Fried, 
Hirshfeld-Becker, Petty, Batchelder, & Biederman, 2015), autism spectrum disorder (Corbett, 
Constantine, Hendren, Rocke, & Ozonoff, 2009) and epilepsy (Palade & Benga, 2007).  CANTAB 
is validated and standardised based on a normative database from healthy populations aged 4-
90 years (Cambridge Cognition, 2006) and comprises a suite of neuropsychological tests that 
assess executive function, memory, attention and social cognition (Cacciamani et al., 2018; 
Teixeira, Zachi, Roque, Taub, & Ventura, 2011).  It is ideal for use with children, as responses are 
made via touchscreen and there are minimal instructions, so language ability does not confound 
results (Sheppard and & Cheatham, 2013).  Moreover, with many of the measures being error-
based, this reduces the risk of floor effects and the availability of parallel versions helps to 
minimise practice effects (Edgin et al., 2010).  
Parallel versions of each measure were employed on each test occasion and version allocation 
was carried out using a Latin square design.  Four nonverbal cognitive measures available from 
the CANTAB suite were administered using a touch-screen portable computer, which was 
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acceptable to all participants given their experience with touch-screen items available at home.  
All responses were automatically recorded during performance.  Participants were asked to 
respond as quickly and as accurately as they could and were able to use their preferred hand for 
responding.  
4.5.5.1.2.2.1 Motor Screening Task (MOT) 
Principally, this measure assesses whether sensorimotor or other difficulties of the respondent 
will impair data collection (Soares et al., 2015).  Respondents are required to press a coloured 
cross following its presentation on screen.  There are 10 trials (1 cross per trial).  The location of 
each cross is random. The maximum number of attempts taken to press the cross by some 
participants in this study was 3.  Crosses were not missed consistently on trials by any 
participant, meaning where multiple attempts to press the cross were taken, this was not due 
to movement or dexterity problems.  
4.5.5.1.2.2.2 Spatial Recognition Memory (SRM) 
Five boxes appear on the screen in succession, the location of each is to be remembered.  
Following five separate box presentations, two boxes appear simultaneously.  Of these, one is 
positioned in a novel location (distractor) and the other is positioned in the same location that 
was occupied previously by one of five boxes (target). Respondents are required to press the 
target box. There are 20 trials in four blocks of five.  The location of the target boxes is tested in 
the reverse order to their original presentation order.  A review of the neuropsychological, 
behavioural, and neuroimaging studies concluded that spatial memory is supported by the 
hippocampus (Burgess, Maguire, & O’Keefe, 2002).  This has also been reported in hippocampal 
lesion studies using rats (Barker & Warburton, 2011; Broadbent, Squire, & Clark, 2004). 
4.5.5.1.2.2.3 Spatial Span (SSP) 
Nine randomly positioned white boxes are presented on screen and change colour in a sequence 
that alters for each trial.  The position of the nine boxes remain the same throughout the trials.  
Respondents are required to recall the same sequence by pressing the same boxes that changed 
colour in the same order. Trials start with 2 boxes changing colour and increase to 9 boxes in a 
sequence (spans 2-9) depending on performance i.e. better performance results in a higher span 
being reached.  Respondents are allowed three attempts at each span; if all three attempts are 
failed, the test ends automatically.  The sequences presented for the three trials within each 
span are always different.  Essentially this measure assesses the ability to recall a series of 
discrete stimuli immediately following their presentation and is considered to be a nonverbal 
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analogue of the Digit Span Test (Teixeira et al., 2011).  The measure is based upon the Corsi Block 
Tapping Test (Cambridge Cognition, 2012), which taps visuospatial working memory (Brunetti, 
Del Gatto, & Delogu, 2014), requiring a respondent to keep a visuospatial pattern and a 
movement sequence in mind (Guariglia, 2007).  The prefrontal lobe has been implicated in 
Spatial Span performance in both cognitively healthy participants and patients with frontal lobe 
damage (Bor, Duncan, Lee, Parr, & Owen, 2006).  
4.5.5.1.2.2.4 Simple and Choice Reaction Time (SRT/CRT) 
This measure was presented in two parts.  Firstly, Simple Reaction Time involves a yellow flash 
presented inside a circle located in the centre of the screen. Respondents are required to press 
within the circle as quickly as possible post-onset of the flash.  For the final part, Choice Reaction 
Time, a yellow flash is presented in one of five smaller circles and respondents are required to 
press within the same circle that the flash was presented in as quickly as possible post-onset.  A 
press-pad is used for this measure and respondents are required to hold a button down (on the 
press-pad) at all times unless they are responding. The same hand is used to hold the button 
down and respond with.  Each part comprises 15 trials.  Reaction time is measured as the time 
between stimulus onset and release of the button, whilst movement time is the time between 
release of the button and contact with the screen.  Simple and Choice Reaction Time measures 
are sensitive to processing speed, with the former engaging stimulus detection and response 
production states and the latter involving additional processing stages concerning stimulus 
discrimination and response selection (Woods, Wyma, Yund, Herron, & Reed, 2015a, 2015b).   
4.6 Statistical approaches common across both studies  
Cognitive measure data were extracted and entered in Excel and checked for accuracy.  
Participant responses from the RBMT-C measure were audio recorded, transcribed using a 
template and scored according to the marking scheme.  Subjective data was also scored.  Scores 
were tallied by participant and week, entered and checked for accuracy in Excel.  
The analytical approach for this study and the study of middle-aged and older adults with a 
subjective memory complaint (SMC) presented in Chapter 5 was reviewed by an independent 
statistician (Quadt Consultancy BV, personal communication).  In the present study, Choice 
Reaction Time was the primary outcome variable, whilst other cognitive outcomes and 
subjective measures were secondary outcome variables.  A p-value of <.05 was considered 
statistically significant, between .05 and .07 marginally significant, and between >.07 and <.10 
as a trend.  For all analyses, the significance level was set at α = 5%.  All data were analysed using 
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SAS 9.4 (SAS Institute Inc, NC, USA).  Plotted data represent individual observations and means 
(± standard error; SE) unless otherwise stated.   
Baseline participant characteristics were plotted and checked for outliers and skewness and 
compared using independent groups t-tests or the Mann-Whitney U test for continuous 
variables and Pearson’s Chi-Squared test or Fisher’s Exact test (when the expected cell counts 
were below 5) for frequency data. The assumptions of each test were checked as appropriate.  
Cognitive and subjective data were analysed using the SAS® mixed procedure (PROC MIXED).  
The mixed procedure fits linear mixed models to data to model means, variance and covariance 
and permits data to show nonconstant variability (SAS Institute Inc. 2008).  By computing 
Restricted Maximum Likelihood (REML) to estimate covariance parameters, the mixed 
procedure can accommodate data that is missing at random (Rubin, 1976).  This method of 
estimation is preferred especially with unbalanced data (Yang, 2010).  Within the model, 
condition (active or placebo) was a fixed between-subjects factor and week (midpoint and 
endpoint) was a fixed within-subjects factor. As age (Deary et al., 2009a; Murman, 2015; Nouchi 
& Kawashima, 2014; Pangelinan et al., 2011), gender (Maitland, Intrieri, Schaie, & Willis, 2000; 
Palejwala & Fine, 2015; Pangelinan et al., 2011; Upadhayay & Guragain, 2014; Weiss, Kemmler, 
Deisenhammer, Fleischhacker, & Delazer, 2003) and IQ (Diaz-Asper et al., 2004; Mohn et al., 
2014) all correlate with cognitive function, these were controlled for in the analysis of the 
cognitive data.  Baseline cognitive performance was also included as a covariate within the same 
analyses.  For tests where the number of correct trials achieved exceeded performance at 
baseline, a corresponding baseline was not available to use as a varying covariate. Therefore, 
the average of the available baseline trials (i.e. RT) was used.  Adjusting for baseline performance 
is preferred to analysis of change from baseline (Senn, 2014; Vickers & Altman, 2001).  
Importantly, even when there is no significant difference between experimental groups (due to 
randomisation), adjusting the analysis by including baseline as a covariate can reduce the within-
group variance thereby improving the accuracy of the estimates and the power of the statistical 
test (Tabachnick & Fidell, 2013).  Importantly, variance explained by the component being 
controlled for is removed from the error variance when estimating the difference in the outcome 
between treatment conditions (Fleiss, 1999).  Trial also featured as a covariate in analyses where 
time (reaction time / movement time) or distance was the outcome of interest following 
independent statistical advice (Quadt Consultancy BV, personal communication).  The total 
number of attempts at each span to the highest span achieved and the highest span achieved 
(both inclusive) on each test occasion for the SSP measure was also entered into the model as a 
covariate for all outcome measures of SSP where this led to an improvement in model fit. 
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All cognitive and subjective data were plotted, and skewness and kurtosis were checked. 
Extreme negative skew was corrected by reflecting the data. Transformations (logarithmic or 
square root) were applied to normalise the distribution of residuals.  Data was modelled with 
and without outliers to explore whether exclusion resulted in a better model.  Data were 
considered outliers where studentized residuals exceeded ± 3.0.  On all occasions, removal of 
outliers led to an improvement in model fit.  Specifically, an improvement in model fit was 
determined by the corrected Akaike Information Criterion (AICC; Hurvich & Tsai, 1989), which 
indicates the amount of remaining unexplained variance after a model has been fitted.  Model 
fitting is an iterative process, with a smaller AICC value indicating an improvement in the fit of a 
model (smaller-is-better; SAS Institute Inc. 2008). The AICC protects against overfitting (Quadt 
Consultancy BV, personal communication). For the initial model for each outcome, all main 
effects, covariates and interactions were requested, following which, terms with a p value ≥.10 
were removed one at a time, starting with the higher order interactions to improve model fit.  
On each occasion of model generation, the AICC, F values and corresponding significance of the 
main effects, covariates and interactions were inspected.  After all higher order interactions that 
did not contribute to the variance explained by the model had been removed, two-way 
interactions were then examined and removed accordingly and so on.  The order of removal of 
each term was determined by its F and significance value: the term with the smallest F value and 
therefore the highest p value was removed first.  If the removal of a term led to a poorer fit 
(higher AICC value), it was added back into the model.  For each model, the AICC, table of fixed 
effects and residual plots were inspected (to identify deviations from normality), and final 
models were chosen based on ‘best fit’ i.e. the model that explained the greatest proportion of 
variance.   
F values and corresponding significance values for main effects, covariates and interactions that 
were retained in the final model and therefore contributed to the variance explained by that 
model for each outcome variable are presented in the respective Chapters or corresponding 
appendices 8-28.  Significant covariates were plotted to determine direction of relationship with 
the dependent variable.  The main effect of condition and interactions featuring condition where 
p <.10 are plotted. Bar charts present main effects of condition and trial, or condition*week 
interactions, whilst line charts represent gender*condition*week interactions and scatter plots 
show all other higher order interactions.  All p values are rounded to three decimal places unless 
p <.001 (reported as p<.001).  All differences between nominal variables (gender, condition and 
week) where p <.10 are reported by reference to least squares means (± SE).  Least squares 
means (LS-means) are adjusted means for unbalanced data and covariates (SAS Institute Inc. 
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2014). Trial was also included in a model as a nominal variable for outcomes where this led to 
an improvement in the model (Quadt Consultancy BV, personal communication). The Tukey 
method was employed for multiple comparison adjustment of LS-means differences.  
Heterogeneity of regression slopes was identified by the presence of significant 
baseline*condition, baseline*week and baseline*condition*week interactions. In such cases, 
adjusted (Tukey method) LS-means differences were reported (at different levels of the 
corresponding covariate for higher order interactions), as these give the most appropriate test 
of the effect in question for the entire sample (Quadt Consultancy BV, personal communication). 
Only meaningful comparisons between main effects and a covariate i.e. differences within a 
condition at midpoint and endpoint or differences between conditions at either midpoint or 
endpoint are reported.   
4.7 Results 
4.7.1 Participant characteristics 
The characteristics of the 70 school-aged children that met the experimental drink consumption 
threshold (per protocol analysis) across the 6 weeks are presented in Table 4.6. 
Table 4.6 Participant characteristics of those included in the analyses from both conditions 
 Active 
 (n=31) 
Median (Range) / 
Mean ± SE 
Placebo 
 (n=39) 
Median (Range) /  
Mean ± SE 
Active vs. placebo 
condition 
Age (months) 89.0 (76, 104) 89.0 (78, 104) U = 598, p = .939 
IQ 89.0 (75, 102) 90.0 (79, 114) U = 441.5, p = .054 
WASI vocabulary 15.71 ± 0.83 19.08 ± 0.95 t(68) = 2.59, p = .012a 
WASI matrix reasoning 13.16 ± 1.05 14.67 ± 0.91 t(68) = 1.09, p = .281a 
Gender                                
M                    15 (48%) 21 (54%) Χ2(1, N = 70) =.21, p = 
.650 
F 16 (52%) 18 (46%)  
Ethnicity   Χ2(2, N = 70) = 1.92, p 
= .693b 
WB 30 (97%) 38 (97%)  
Mixed W&BC 1 (3%)   
AOMB  1 (3%)  
Colour deficiency 2 (6%) 1 (3%) Χ2(1, N = 70) =.64, p = 
.580b 
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 Active 
 (n=31) 
Median (Range) / 
Mean ± SE 
Placebo 
 (n=39) 
Median (Range) /  
Mean ± SE 
Active vs. placebo 
condition 
Status 
  
Χ2(1, N = 70) =.00, p = 
.961 
None 24 (77%) 30 (77%)  
High functioning autism 1 (3%)   
Gifted and Talented - 
reading and maths 
 1 (3%)  
Special Educational Need -  
motor skill impairment 
 1 (3%)  
Special Educational Need – 
behaviour 
 1 (3%)  
On a behaviour plan 1 (3%)   
Intermittent hearing loss  1 (3%)  
Poor gross/fine motor skills 
1 (3%)   
Behavioural characteristics 
identified during testingc 
4 (13%) 5 (13%)  
Notes. Values in order of appearance: Median (range), Mean ± SE and number of participants 
(percentages rounded to nearest whole number).  AOMB: Any other mixed background, F: 
Female, M: Male, Mixed W&BC: Mixed White and Black Caribbean, WASI: Wechsler 
Abbreviated Scale of Intelligence, WB: White British.  
aEqual variances assumed. bExact test. cApathetic, distractible, reserved, unmotivated. 
There were no significant differences between conditions for age or gender.  There was a 
marginally significant difference between the IQ of participants, with those in the placebo 
condition having a higher IQ score (Median = 90) compared to those in the active condition 
(Median = 89), U = 441.5, p = .054 (Table 4.6). It is also noteworthy that the range of IQ scores 
is greater in the placebo condition relative to the active condition.  Figure 4.4 presents the 
distribution of IQ by condition and gender and indicates that females in the placebo condition 
tended to score more highly in respect of current levels of intellectual functioning compared to 
females in the active condition and males per se.   
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Figure 4.4 WASI IQ score of each participant included in the per protocol analysis by gender 
and condition.  
Further exploration of this difference indicated that this is driven by a significant difference in 
WASI vocabulary subcomponent scores (Wechsler, 1999), with those in the placebo condition 
(M = 19.08) scoring significantly higher than those in the active condition (M = 15.71), t(68) = 
2.59, p = .012 (Table 4.6). This difference is shown in Figure 4.5, where both males and females 
in the placebo condition tended to score more highly comparatively to males and females in the 
active condition.  
 
 
 
 
 
 
 
Figure 4.5 WASI vocabulary score of each participant included in the per protocol analysis by 
gender and condition.  
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4.7.2 Effect of intervention on cognitive performance on the RBMT-C and 
CANTAB measures 
4.7.2.1 Measures of processing speed 
Table 4.7 provides a summary of the means (± SE) across measures of processing speed for each 
condition.   
Table 4.7 Mean (± SE) on measures of processing speed (Simple and Choice Reaction Time) by 
condition and week 
Outcome 
Baseline 
Week 0 
Mean ± SE 
Midpoint 
Week 3 
Mean ± SE 
Endpoint 
Week 6 
Mean ± SE 
Active vs. 
placebo 
CANTAB CRT 
movement time for 
correct trials (ms) 
   
 
Active  416.84 ± 9.64 429.12 ± 
10.05 
420.88 ± 
11.99 F(1,65) = 0.54, 
p = .467 Placebo 400.86 ± 7.95 425.91 ± 
12.66 
421.23 ± 9.70 
CANTAB CRT number 
of correct trials (n) 
   
 
Active  14.03 ± 0.20 14.13 ± 0.16 13.97 ± 0.25 F(1,67) = 0.61, 
p = .437 Placebo 14.18 ± 0.15 14.00 ± 0.20 13.72 ± 0.21 
CANTAB CRT reaction 
time for correct trials 
(ms) 
   
 
Active  494.54 ± 
10.49 
505.13 ± 
10.01 
506.65 ± 
11.91 
F(1,65) = 7.25, 
p = .009 
Placebo 478.71 ± 8.00 502.28 ± 8.50 491.83 ± 9.29 
CANTAB SRT number 
of correct trials (n) 
   
 
Active  13.52 ± 0.26 13.61 ± 0.27 13.45 ± 0.27 F(1,65) = 2.37, 
p = .129 Placebo 13.26 ± 0.24 13.74 ± 0.26 13.41 ± 0.25 
CANTAB SRT reaction 
time for correct trials 
(ms) 
   
 
Active  485.70 ± 
13.98 
458.59 ± 8.99 496.18 ± 
17.71 F(1,65) = 2.20, 
p = .143 Placebo 458.35 ± 
10.09 
478.71 ± 
11.92 
478.40 ± 
10.04 
CANTAB SRT 
movement time for 
correct trials (ms) 
   
 
Active  460.67 ± 
14.50 
476.32 ± 
14.49 
465.77 ± 
16.73 F(1,64) = 2.45, 
p = .122 Placebo 496.43 ± 
18.58 
447.49 ± 
16.49 
470.03 ± 
15.21 
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4.7.2.1.1 Choice Reaction Time (CRT) 
4.7.2.1.1.1 Movement time for correct trials 
In the final model, 46 outlying observations were removed to normalise residuals.  Baseline 
movement time was a significant covariate, F(1,65) = 82.72, p = <.001, with baseline 
performance being positively correlated with movement time at midpoint and endpoint.  Trial 
was marginally significant, F(14,922) = 1.70, p = .050, performance over which fluctuated across 
the 15 trials. Gender was also marginally significant, F(1,65) = 4.00, p = .050, with females 
demonstrating slower movement times (2.59 ± 0.01) than males (2.56 ± 0.01).  IQ was not a 
significant covariate, F(1,65) = 2.40, p = .126.  Age was also not significant and removed from 
the final model.  There was no significant main effect of condition, F(1,65) = 0.54, p = .467, and 
baseline*condition interaction was found not to be significant and was removed from the final 
model.  There was a significant baseline*condition*week interaction, F(3,1768) = 2.79, p = .039, 
however, inspection of post hoc comparisons did not reveal a significant difference.  One other 
higher order interaction was found to be significant, gender*condition*week, F(3,65) = 8.55, p 
<.001 (Figure 4.6). 
The significant interaction between gender*condition*week is shown in Figure 4.6(A) and 
4.6(B).  Figure 4.6(A) shows females in the active condition illustrated faster movement times at 
endpoint compared to midpoint, whereas males performed similarly across both weeks in the 
same condition.  Figure 4.6(B) indicates that females in the placebo condition performed better 
at midpoint relative to endpoint, but the opposite was shown by males in the same condition.  
In line with this, inspection of post hoc analysis revealed females in the active condition were 
significantly slower at midpoint (2.61 ± 0.01) than at endpoint (2.58 ± 0.01; t(65) = 3.69, p = 
.010).  In addition, females in the placebo condition were significantly faster at midpoint (2.57 ± 
0.01) than at endpoint (2.61 ± 0.01; t(65) = -4.58, p <.001).   
A significant interaction between condition*week was also found, F(1,65) = 9.67, p = .003, shown 
in Figure 4.6(C).  At midpoint, the placebo condition demonstrated superior performance to the 
active condition, however, this was not maintained at endpoint, as the active condition 
illustrated faster movement speeds on this test occasion.  Inspection of post hoc comparisons 
revealed those in the active condition at midpoint (2.58 ± 0.01) performed significantly slower 
than at endpoint (2.56 ± 0.01; t(65) = 3.07, p = .016). 
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Figure 4.6 Movement time for correct trials on the Choice Reaction Time (CRT).  (A-B) The x 
axis represents week and the y axis is movement time (ms) over midpoint and endpoint. Lines 
denote the mean. Error bars denote the SE of the mean. (C) The x axis is week and the y axis is 
movement time (ms) over midpoint and endpoint. Columns denote the mean. Error bars denote 
the SE of the mean. * p <.05.  (A) Is the active condition, (B) is the placebo condition. 
4.7.2.1.1.2 Number of correct trials 
No outlying observations were removed from the final model.  Baseline performance was a 
significant covariate, F(1,67) = 8.05, p = .006, with baseline performance positively associated 
with the number of correct trials at midpoint and endpoint.  Age, IQ and gender were not 
significant covariates and were removed from the final model.  There was no significant main 
effect of condition, F(1,67) = 0.61, p = .437.  Moreover, baseline*condition interaction was not 
significant and was removed from the final model.  Of the higher order interactions, only 
gender*condition*week was significant, F(4,63) = 3.16, p = .020.   
Interaction between gender*condition*week on Choice Reaction Time (CRT): Movement 
time for correct trials 
  
Interaction between condition*week on Choice Reaction Time (CRT): Movement time for 
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The significant interaction between gender*condition*week is presented in Figure 4.7(A) and 
4.7(B).  Figure 4.7(A) indicates that both females and males tended to be more accurate at 
midpoint relative to endpoint in the active condition. Figure 4.7(B) shows that females 
performed similarly across both weeks, however, males illustrated superior performance at 
endpoint compared to midpoint in the placebo condition.  Inspection of post hoc comparisons 
revealed a marginally significant difference between females in the placebo condition at 
midpoint (0.62 ± 0.05) performing more accurately than males in the same condition at endpoint 
(0.40 ± 0.05; t(63) = 3.09, p = .0.57).  Also, there was a trend towards males in the placebo 
condition (0.40 ± 0.05) completing less trials correctly compared to males in the active condition 
at endpoint (0.63 ± 0.06; t(63) = -2.97, p = .076).   
 
Figure 4.7 Number of correct trials on the Choice Reaction Time (CRT).  The x axis represents 
week and the y axis is the number of correct trials (n) over midpoint and endpoint. Lines denote 
the mean. Error bars denote the SE of the mean. (A) Is the active condition, (B) is the placebo 
condition. 
4.7.2.1.1.3 Reaction time for correct trials 
In the final model, 29 outlying observations were removed to normalise residuals.  Baseline 
reaction time was a significant covariate, F(1,65) = 89.32, p <.001, with reaction time at baseline 
positively correlating with performance at subsequent test points. Trial was also found to be a 
significant covariate F(14,923) = 6.44, p <.001, performance over which fluctuated across the 15 
trials. IQ was not a significant covariate, F(1,65) = 0.30, p = .584.  Age and gender were also not 
significant covariates and were removed from the final model.  Of the higher order interactions, 
IQ*condition*week and gender*condition*week interactions were found to be significant.  
The significant interaction between IQ*condition*week, F(3,1830) = 4.12, p = .006, is shown in 
Figure 4.8(A) and 4.8(B).  Inspection of post hoc comparisons revealed a marginally significant 
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difference at an IQ score of 100 between reaction time shown by those in the placebo condition 
at midpoint (2.67 ± 0.01) relative to their performance at endpoint (2.65 ± 0.01; t(64) = 2.63, p 
= .052), with better performance demonstrated at endpoint.  This became significant at an IQ 
score of 110 (2.66 ± 0.02 vs. 2.62 ± 0.02; t(64) = 3.23, p = .010).   
Figure 4.8(C) and 4.8(D) depict the significant gender*condition*week interaction, F(4,64) = 
7.08, p <.001. In both conditions, females demonstrated faster reaction speeds at midpoint 
compared to endpoint, whereas males responded more quickly at endpoint relative to midpoint.  
Post hoc comparisons revealed a marginally significant difference between females in the 
placebo condition (2.70 ± 0.01) demonstrating slower reaction time to that of males in the same 
condition at endpoint (2.64 ± 0.01; t(64) = 3.02, p = .067).  Further, there was a marginally 
significant difference between the performance of males in the placebo condition at midpoint 
(2.67 ± 0.01) compared to endpoint (2.64 ± 0.01; t(64) = 3.07, p = .059).  
A significant baseline*condition interaction was also found, F(1,65) = 5.94, p = .018, shown in 
Figure 4.8(E).  Inspection of post hoc comparisons revealed that at a log baseline reaction time 
of 2.55, those in the placebo condition (2.62 ± 0.01) were significantly slower than those in the 
active condition (2.58 ± 0.01; t(65) = 2.03, p = .046).  There was a marginally significant difference 
in performance between the conditions at a log baseline reaction time of 2.80, such that those 
in the placebo condition (2.73 ± 0.01) performed more quickly than those in the active condition 
(2.77 ± 0.02; t(65) = -1.95, p = .055).  This became significant at a log baseline reaction time of 
2.85 (2.76 ± 0.02 vs. 2.82 ± 0.02; t(65) = -2.13, p = .037) and greater (slower reaction time).   
A significant main effect of condition and a significant condition*week interaction were also 
found, F(1,65) = 7.25, p = .009 and F(2,64) = 4.42, p = .016, respectively.    In respect of the main 
effect of condition, those in the active condition (2.667 ± 0.01) demonstrated better 
performance compared to those in the placebo condition (2.670 ± 0.01), however, post hoc 
comparisons did not reveal a significant difference.  The condition*week interaction indicated 
that performance was similar across both conditions over time.  Specifically, those in the active 
condition performed similarly to those in the placebo condition at midpoint (2.67 ± 0.01 vs. 2.67 
± 0.01) and at endpoint (2.66 ± 0.01 vs. 2.67 ± 0.01).  Inspection of post hoc comparisons did not 
reveal a significant difference. 
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Figure 4.8 Reaction time for correct trials on the Choice Reaction Time (CRT). (A-B) the x axis 
represents IQ score and the y axis is reaction time (ms) over midpoint and endpoint. Regression 
lines show relationship between x and y by week. (C-D) the x axis represents week and the y axis 
is reaction time (ms) over midpoint and endpoint. Lines denote the mean. Error bars denote the 
SE of the mean. (E) The x axis is the log baseline reaction time (ms) and the y axis is log reaction 
Interaction between IQ*condition*week on Choice Reaction Time (CRT): Reaction time 
for correct trials 
     
Interaction between gender*condition*week on Choice Reaction Time (CRT): Reaction 
time for correct trials 
  
Interaction between baseline*condition on Choice Reaction Time (CRT): Reaction time 
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time (ms) over subsequent test points. Regression lines show relationship between x and y by 
condition. (A & C) Is the active condition, (B & D) is the placebo condition.  
4.7.2.1.2 Simple Reaction Time (SRT) 
4.7.2.1.2.1 Number of correct trials 
In the final model, 3 outlying observations were removed to normalise residuals.  Number of 
correct trials at baseline was a significant covariate, F(1,65) = 9.61, p = .003, with this being 
positively related to number of correct trials at subsequent test points.  There was a trend 
towards gender as a significant covariate, F(1,65) = 3.09, p = .084, with females (13.95 ± 0.18) 
being more accurate than males (13.49 ± 0.19).  IQ was not a significant covariate, F(1,65) = 0.23, 
p = .632.  Age as a covariate and baseline*condition, baseline*week and 
baseline*condition*week interactions were also nonsignificant and were removed from the 
final model.  There was no significant main effect of condition, F(1,65) = 2.37, p = .129. 
A significant interaction between gender*condition*week was found, F(3,59) = 5.95, p = .001.  
Figure 4.9(A) indicates females in the active condition illustrated superior performance at 
endpoint, however, males in the same condition were more accurate at midpoint compared to 
endpoint.  In the placebo condition, Figure 4.9(B), females performed similarly over both weeks, 
whereas males again performed better at midpoint. Inspection of post hoc comparisons 
revealed that males in the active condition were significantly more accurate at midpoint (14.32 
± 0.37) than at endpoint (12.78 ± 0.36; t(59) = 3.58, p = .015).  Furthermore, males in the placebo 
condition at midpoint (13.96 ± 0.29) were marginally significantly more accurate relative to their 
performance at endpoint (12.92 ± 0.28; F(59) = 3.14, p = .050).   
There was also a marginally significant IQ*condition*week interaction, F(3,59) = 2.57, p = .063, 
and a significant condition*week interaction, F(1,59) = 5.81, p = .019. Inspection of post hoc 
comparisons revealed a marginally significant difference between the performance of those in 
the placebo condition at midpoint (14.16 ± 0.22) compared to endpoint (13.51 ± 0.21; t(59) = 
2.62, p = .053). No other post hoc comparisons were significant. 
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Figure 4.9 Number of correct trials on the Simple Reaction Time (SRT). The x axis represents 
week and the y axis is the number of correct trials (n) over midpoint and endpoint. Lines denote 
the mean. Error bars denote the SE of the mean. (A) Is the active condition, (B) is the placebo 
condition.  
4.7.2.1.2.2 Reaction time for correct trials 
In the final model, 33 outlying observations were removed to normalise residuals.  Baseline 
reaction time was a significant covariate, F(1,65) = 108.03, p <.001, with baseline reaction time 
showing a positive relationship with reaction time at midpoint and endpoint.  Trial and gender 
were also found to be significant covariates, F(14,900) = 2.49, p = .002 and F(1,65) = 4.87, p = 
.031, respectively.  Performance fluctuated across trial. Females demonstrated poorer 
performance (2.65 ± 0.01) compared to that of males (2.62 ± 0.01).  IQ was not a significant 
covariate, F(1,65) = 0.95, p = .334, and age was also not significant and removed from the final 
model. There was no significant main effect of condition, F(1,65) = 2.20, p = .143. 
Baseline*condition*week and baseline*condition were also found not to be significant and were 
removed from the final model.  There was a significant baseline*week interaction, F(1,1775) = 
5.32, p = .021, and a significant main effect of week, F(1,65) = 5.25, p = .025, however, post hoc 
comparisons did not reveal a significant difference 
A significant interaction between gender*condition*week was also found, F(3,65) = 5.67, p = 
.002, shown in Figure 4.10.  Irrespective of condition, females performed better at midpoint 
whilst males performed better at endpoint.  Inspection of post hoc comparisons revealed that 
females in the placebo condition reacted significantly faster at midpoint (2.63 ± 0.01) than at 
endpoint (2.66 ± 0.01; t(65) = -3.18, p = .044). Also, females in the placebo condition (2.66 ± 
0.01) reacted significantly slower than males in the active condition at endpoint (2.59 ± 0.01; 
t(65) = 3.57, p = .015).  There was a marginally significant difference between females in the 
Interaction between gender*condition*week on Simple Reaction Time (SRT):  Number 
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active condition (2.65 ± 0.01) responding more slowly than males in the same condition at 
endpoint (2.59 ± 0.01; t(65) = 3.06, p = .060).   
 
Figure 4.10 Reaction time for correct trials on the Simple Reaction Time (SRT). The x axis 
represents week and the y axis is reaction time (ms) over midpoint and endpoint. Lines denote 
the mean. Error bars denote the SE of the mean. (A) Is the active condition, (B) is the placebo 
condition. 
4.7.2.1.2.3 Movement time for correct trials 
In the final model, 29 outlying observations were removed to normalise residuals. Baseline 
movement time was a significant covariate, F(1,64) = 54.69, p <.001, which showed a positive 
association with movement time at later test points.  Age was marginally significant, F(1,64) = 
3.74, p = .058.  IQ was not a significant covariate, F(1,64) = 0.31, p = .582, and gender and trial 
were also not significant and removed from the final model.  Performance by week was 
marginally significant, F(1,64) = 3.54, p = .064, such that movement times were slower at 
midpoint (2.61 ± 0.01) compared to endpoint (2.59 ± 0.01). There was no significant main effect 
of condition, F(1,64) = 2.45, p = .122 and no significant interaction between 
baseline*condition*week and this was removed from the final model.  Of the higher order 
interactions, the following were found to be significant; trial*condition*week, F(56,1673) = 1.37, 
p = .038, IQ*condition*week, F(3,1731) = 5.19, p = .001, age*condition*week, F(3,1731) = 3.80, 
p = .010, and gender*condition*week, F(4,64) = 2.98, p = .025.  Two way interactions including 
baseline*condition and condition*week were also significant, F(1,64) = 4.83, p = .032, and 
F(1,64) = 8.37, p = .005, respectively.  
Although performance by trial, condition and week appeared to be similar, post hoc 
comparisons revealed a marginally significant difference between those in the placebo condition 
Interaction between gender*condition*week on Simple Reaction Time (SRT):  Reaction 
time for correct trials 
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at midpoint moving slower for trial 13 (2.67 ± 0.03) than at endpoint for trial 10 (2.52 ± 0.03; 
t(1673) = 4.03, p = .062). No other post hoc comparisons were significant. 
Figure 4.11(A) and 4.11(B) show the significant interaction between IQ*condition*week, 
F(3,1731) = 5.19, p = .001. Figure 4.11(A) indicates that at lower IQ scores, those in the active 
condition demonstrated faster movement time at midpoint, but at higher IQ scores, faster 
movement time was displayed at endpoint. Participants in the placebo condition, Figure 4.11(B), 
demonstrated the opposite pattern of performance by week. Inspection of post hoc 
comparisons revealed at an IQ score of 90 and greater, there was a marginally significant 
difference at midpoint between those in the placebo condition (2.58 ± 0.01) and those in the 
active condition (2.63 ± 0.02; t(64) = -2.52, p = .067), with faster movement time for those in the 
placebo condition.  This became significant at an IQ score of 100 (2.55 ± 0.02 vs. 2.68 ± 0.03; 
t(64) = -3.50, p = .005) and 110 (2.53 ± 0.03 vs. 2.72 ± 0.05; t(64) = -3.29, p = .009).  Within 
condition, at an IQ score of 90 and greater, those in the active condition were significantly slower 
at midpoint (2.63 ± 0.02) than at endpoint (2.60 ± 0.02; t(64) = 2.98, p = .021).  Whilst, those in 
the placebo condition were significantly faster at midpoint (2.55 ± 0.02) compared to their 
performance at endpoint (2.59 ± 0.02; t(64) = -3.33, p = .008) at an IQ score of 100 and greater. 
The significant interaction between age*condition*week, F(3,1731) = 3.80, p = .010, is shown in 
Figure 4.11(C) and 4.11(D).  Irrespective of condition, younger participants demonstrated slower 
movement time at midpoint, whereas older participants showed slower movement time at 
endpoint.  Inspection of post hoc comparisons revealed at 90 months of age, participants in the 
placebo condition (2.58 ± 0.01) were significantly faster than those in the active condition at 
midpoint (2.64 ± 0.02; t(64) = -2.83, p = .030).  Within condition, those in the active condition 
were significantly slower at midpoint (2.63 ± 0.03) than at endpoint (2.57 ± 0.03; t(64) = 3.13, p 
= .014) at 80 and 90 months of age (2.64 ± 0.02 vs. 2.60 ± 0.02; t(64) = 3.19, p = .012).  Whereas, 
at 100 months of age, those in the placebo condition were significantly faster at midpoint (2.59 
± 0.02) than at endpoint (2.65 ± 0.02; t(64) = -3.38, p = .007).  
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Figure 4.11 Movement time for correct trials on the Simple Reaction Time (SRT). 
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Figure 4.11 continued. (A-B) The x axis represents IQ score and the y axis is movement time (ms) 
over midpoint and endpoint. (C-D) The x axis is age (months) and the y axis is movement time 
(ms) over midpoint and endpoint. (A-D) Regression lines show relationship between x and y by 
week. (E-F) The x axis represents week and the y axis is movement time (ms) over midpoint and 
endpoint. Lines denote the mean. Error bars denote the SE of the mean. (G) The x axis is the log 
baseline movement time (ms) and the y axis is the log movement time (ms) over subsequent 
test points. Regression lines show relationship between x and y by condition. (H) The x axis is 
week and the y axis is movement time (ms) over midpoint and endpoint. Columns denote the 
mean. Error bars denote the SE of the mean. * p <.05. (A, C & E) Is the active condition, (B, D & 
F) is the placebo condition.  
Figure 4.11(E) and 4.11(F) present the significant gender*condition*week interaction, F(4,64) = 
2.98, p = .025. Figure 4.11(E) indicates females in the active condition moved more slowly at 
endpoint relative to midpoint, however, males tended to perform similarly across both test 
occasions in the same condition.  Figure 4.11(F) on the other hand shows females in the placebo 
condition demonstrated greater movement latencies at midpoint relative to endpoint, whilst 
males tended to perform better at midpoint. In general, females tended to move more slowly 
compared to males irrespective of condition. Inspection of post hoc comparisons revealed a 
marginally significant difference between females in the placebo condition moving more quickly 
at midpoint (2.58 ± 0.02) than at endpoint (2.62 ± 0.02; t(64) = -3.02, p = .067).  Further, males 
in the placebo condition (2.57 ± 0.02) demonstrated marginally significantly faster movement 
time relative to females in the active condition at midpoint (2.66 ± 0.02; t(64) = -3.03, p = .065).  
Also, females in the active condition were marginally significantly slower at midpoint (2.66 ± 
0.02) than at endpoint (2.61 ± 0.02; t(64) = 3.06, p = .061).   
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on Simple Reaction Time (SRT): Movement 
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The significant baseline*condition interaction, F(1,64) = 4.83, p = .032, is shown in Figure 
4.11(G).  Inspection of post hoc comparisons revealed that at a log baseline movement time of 
2.7 and greater (slower movement time), those in the placebo condition illustrated significantly 
faster movement time (2.62 ± 0.02) relative to participants in the active condition (2.69 ± 0.02; 
t(64) = -2.51, p = .015). 
Lastly, the significant condition*week interaction, F(1,64) = 8.37, p = .005, is shown in Figure 
4.11(H).  This indicates that at midpoint, those in the placebo condition illustrated faster 
movement time relative to participants in the active condition, however, at endpoint, 
performance was similar across both conditions. Inspection of post hoc comparisons revealed 
at midpoint, those in the placebo condition (2.58 ± 0.01) were significantly faster than those the 
active condition (2.64 ± 0.02; t(64) = -2.83, p = .031).  Further, those in the active condition were 
significantly slower at midpoint (2.64 ± 0.02) than at endpoint (2.60 ± 0.02; t(64) = 3.19, p = 
.012).   
4.7.2.2 Measures of memory performance 
Table 4.8 provides a summary of the means (± SE) across measures of memory performance for 
each condition.   
Table 4.8 Mean (± SE) on measures of memory performance (Rivermead Behavioural Memory 
Test for Children and Spatial Recognition Memory) by condition and week 
Outcome 
Baseline 
Week 0 
Mean ± SE 
Midpoint 
Week 3 
Mean ± SE 
Endpoint 
Week 6 
Mean ± SE 
Active vs. 
placebo 
RBMT-C immediate 
verbal recall (n) 
    
Active  13.02 ± 1.23 11.94 ± 1.33 13.60 ± .98 F(1,65) = 2.06, 
p = .156 Placebo 15.91 ± .99 16.66 ± .88 17.21 ± .89a 
RBMT-C delayed 
verbal recall (n) 
   
 
Active  5.32 ± .36 5.15 ± .32 5.24 ± .24 F(1,64) = 3.82, 
p = .055 Placebo 5.67 ± .23 5.88 ± .24 5.90 ± .26a 
CANTAB SRM 
number of correct 
trials (n) 
   
 
Active  10.63 ± 0.39b 11.77 ± 0.40b 12.03 ± 0.59b F(1,66) = 0.11, 
p = .739 Placebo 11.72 ± 0.37 12.44 ± 0.34 12.41 ± 0.39 
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Outcome 
Baseline 
Week 0 
Mean ± SE 
Midpoint 
Week 3 
Mean ± SE 
Endpoint 
Week 6 
Mean ± SE 
Active vs. 
placebo 
CANTAB SRM 
reaction time for 
correct trials (ms) 
   
 
Active  2491.38 ± 
98.14b 
2660.73 ± 
110.64b 
2785.46 ± 
138.81b F(1,64) = 4.10, 
p = .047 Placebo 2591.59 ± 
89.12 
2428.96 ± 
92.07 
2357.50 ± 
84.64 
Note: an=38 bn=30 
4.7.2.2.1 Rivermead Behavioural Memory Test for Children (RBMT-C) 
4.7.2.2.1.1 Immediate recall 
No outlying observations were removed from the final model (see section 4.6). Baseline 
performance was a significant covariate, F(1,65) = 47.77, p <.001, such that this showed a 
positive relationship with the number of items recalled at midpoint and endpoint.   Gender was 
also a significant covariate, F(1,65) = 4.10, p = .047, with females (15.87 ± 0.63) recalling 
significantly more items correctly than males (14.08 ± 0.62).  Age showed a trend when included 
as a covariate, F(1,65) = 3.31, p = .073, with more items being recalled by older participants. IQ 
was not a significant covariate and was removed from the final model.  There was no significant 
main effect of condition, F(1,65) = 2.06, p = .156. No higher order interactions nor 
baseline*condition and baseline*week interactions were found to be significant.  There was a 
marginally significant condition*week interaction, F(1,61) = 3.54, p = .065, and this interaction 
is driven by the performance by those in the active condition (12.76 ± 0.86), which is significantly 
poorer to that of participants in the placebo condition at midpoint (16.14 ± 0.76; t(61) = 2.93, p 
= .024). 
4.7.2.2.1.2 Delayed recall 
No outlying observations were removed from the final model.  Age was marginally significant, 
and IQ showed a trend when included as covariates, F(1,64) = 3.52, p = .065 and F(1,64) = 3.23, 
p = .077, respectively. Both were positively associated with midpoint and endpoint i.e. those 
who were older or who had a higher IQ performed better on subsequent test occasions.  Gender 
was not a significant covariate, F(1,64) = 0.03, p = .859.  Baseline was not a significant covariate 
also and was removed from the final model.  No higher order interactions nor 
baseline*condition and baseline*week interactions were found to be significant.  Condition was 
marginally significant, F(1,64) = 3.82, p = .055, such that those in the placebo condition (5.80 ± 
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0.19) recalled more items correctly following a delay compared to those in the active condition 
(5.33 ± 0.21). 
4.7.2.2.2 Spatial Recognition Memory (SRM) 
4.7.2.2.2.1 Number of correct trials 
No outlying observations were removed from the final model. There was a trend towards 
baseline being a significant covariate, F(1,66) = 3.31, p = .074, such that the total number of 
correct trials at baseline was positively correlated with the total number achieved at midpoint 
and endpoint. Age, IQ and gender were not significant covariates and were removed from the 
final model. There was no significant main effect of condition, F(1,66) = 0.11, p = .739.  No higher 
order interactions nor baseline*condition and baseline*week interactions were found to be 
significant.  There was a significant main effect of week, F(1,60) = 4.12, p = .047, such that 
performance was better at endpoint (1.58 ± 0.07) relative to midpoint (1.53 ± 0.07). 
4.7.2.2.2.2 Reaction time for correct trials 
In the final model, 13 outlying observations were removed to normalise the residuals.  Baseline 
reaction time was a significant covariate, F(1,64) = 77.07, p <.001, being positively correlated 
with reaction time at subsequent test points.  Trial was also significant covariate, F(16,851) = 
3.63, p <.001, such that reaction time varied by trial. IQ was marginally significant, F(1,64) = 3.96, 
p = .051 and was positively associated with reaction time at midpoint and endpoint.  Age and 
gender were not significant covariates and were removed from the final model.  There were 
significant baseline*condition*week and baseline*condition interactions, F(1,1570) = 4.74, p = 
.030 and F(1,64) = 4.17, p = .045, respectively (Figure 4.12).   
 
 
 
117 
 
 
 
 
Figure 4.12 Reaction time for correct trials on the Spatial Recognition Memory (SRM). (A-C) 
The x axis is log baseline reaction time (ms) and the y axis is log reaction time (ms) over 
subsequent test points (A-B) Regression lines show relationship between x and y by week. (C) 
Regression lines show relationship between x and y by condition. (A) Is the active condition, (B) 
is the placebo condition. 
The significant interaction between baseline*condition*week is presented in Figure 4.12(A) and 
4.12(B).  Inspection of post hoc comparisons indicated that those in the placebo condition (3.30 
± 0.02) were significantly faster compared to participants in the active condition at endpoint 
(3.40 ± 0.02; t(63) = -3.57, p = .004) at a log baseline reaction time of 3.4 and greater (slower 
baseline reaction time). Within condition, those in the placebo condition were significantly 
slower at midpoint (3.34 ± 0.02) compared to endpoint (3.30 ± 0.02; t(63) = 3.18, p = .012) at a 
log baseline reaction time of 3.4 and greater.   
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Figure 4.12(C) represents how performance by condition differed as a function of baseline 
performance.  Inspection of post hoc comparisons revealed that those in the placebo condition 
(3.27 ± 0.02) responded significantly faster than those in the active condition (3.32 ± 0.02; t(64) 
= -2.22, p = .030) at a log baseline reaction time of 3.3 and above (slower baseline performance).  
A significant main effect of condition was found, F(1,64) = 4.10, p = .047, such that participants 
in the active condition performed more slowly (3.35 ± 0.02) relative to their counterparts in the 
placebo condition (3.28 ± 0.02), however, post hoc comparisons did not reveal a significant 
difference.  There was a trend towards a main effect of week, F(1,63) = 3.37, p = .071, with 
midpoint performance being slower (3.33 ± 0.02) than endpoint (3.31 ± 0.02).  The analysis also 
revealed a marginally significant interaction between baseline*week, F(1,1570) = 3.49, p = .062. 
4.7.2.3 Measure of motor skills 
Table 4.9 provides a summary of the means (± SE) for each condition.   
Table 4.9 Mean (± SE) on Motor Screening Task (MOT) outcomes by condition and week 
Outcome 
Baseline 
Week 0 
Mean ± SE 
Midpoint 
Week 3 
Mean ± SE 
Endpoint 
Week 6 
Mean ± SE 
Active vs. 
placebo 
CANTAB Motor 
reaction time 
(ms) 
    
Active  844.36 ± 17.42 834.05 ± 19.78 865.70 ± 28.23 F(1,66) = 0.91, 
p = .344 Placebo 775.86 ± 14.86 778.18 ± 17.47 751.90 ± 19.01 
CANTAB Motor 
distance (mm) 
   
 
Active  31.51 ± 1.09 32.73 ± 1.01 30.88 ± 1.03 F(1,68) = 0.00, 
p = .995 Placebo 32.66 ± .95 30.47 ± .89 33.42 ± .88 
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4.7.2.3.1 Motor Screening Task (MOT) 
4.7.2.3.1.1 Reaction time 
In the final model, 22 outlying observations were removed to normalise the residuals. Baseline 
reaction time was a significant covariate, F(1,1260) = 6.28, p = .012, with baseline performance 
positively correlated with reaction time at midpoint and endpoint. Trial was also found to be a 
significant covariate, F(9,621) = 7.32, p <.001, with performance fluctuating across the ten trials. 
Age and IQ were not significant covariates, F(1,66) = 0.16, p = .692 and F(1,66) = 0.11, p = .739, 
respectively.  Gender was also not a significant covariate and was removed from the final model. 
There was no significant main effect of condition, F(1,66) = 0.91, p = .344.  There were significant 
baseline*condition*week and IQ*condition*week interactions, F(2,1260) = 9.64, p <.001 and 
F(3,1260) = 3.70, p = .011, respectively (Figure 4.13).   
 
Figure 4.13 Reaction time on the Motor Screening Task (MOT). (A-B) The x axis is the log 
baseline reaction time (ms), and the y axis is the log reaction time (ms) over subsequent test 
points. (C-D) The x axis represents IQ scores, and the y axis is reaction time (ms) over midpoint 
and endpoint. Regression lines show relationship between x and y by week. (A & C) Is the active 
condition, (B & D) is the placebo condition. 
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Figure 4.13(A) and 4.13(B) illustrate how performance differed by week and condition as a 
function of baseline performance.  Inspection of post hoc comparisons revealed at a log baseline 
reaction time between 2.6 to 2.8 (inclusive), those in the placebo condition were significantly 
faster (2.81 ± 0.02) than those in the active condition at endpoint (2.91 ± 0.02; t(68) = -3.16, p = 
.012).  Whereas, at a log baseline reaction time of 3.0, there was a marginally significant 
difference, such that particiapants in the placebo condition (2.86 ± 0.02) demonstrated faster 
reaction time relative to those in the active condition at midpoint (2.92 ± 0.02; t(68) = -2.56, p = 
.060).  This became significant at a log baseline reaction time of 3.1 and greater (slower baseline 
reaction time: 2.86 ± 0.02 vs. 2.94 ± 0.02; t(68) = -3.13, p = .014).  Within condition, at a log 
baseline reaction time of 2.6 to 2.8 (inclusive), those in the active condition were significantly 
faster at midpoint (2.81 ± 0.02) than at endpoint (2.91 ± 0.02; t(68) = -3.87, p = .001).  Further, 
there was also a trend towards those in the placebo condition responding more slowly at 
midpoint (2.86 ± 0.02) relative to their performance at endpoint (2.81 ± 0.02; t(68) = 2.43, p = 
.082) at a log baseline reaction time of 2.6; this became marginally significant at a log baseline 
reaction time of 2.7 (2.86 ± 0.02 vs. 2.82 ± 0.02; t(68) = 2.55, p = .061).  At a log baseline reaction 
time of 3.1 and greater (slower baseline reaction time), participants in the active condition were 
significantly slower at midpoint (2.94 ± 0.02) compared with endpoint (2.88 ± 0.02, t(68) = 3.35, 
p = .007).  
The significant IQ*condition*week interaction is shown in Figure 4.13(C) and 4.13(D).  At a lower 
IQ score, those in the active condition (Figure 4.13(C)) showed poorer performance (slower 
reaction time) at midpoint, this being the opposite to that shown by those with lower IQ scores 
in the placebo condition (Figure 4.13(D)). Conversely, at higher IQ scores, those in the active 
condition showed faster reaction speeds at midpoint, whilst those in the placebo condition 
performed better at endpoint. Inspection of post hoc comparisons revealed at an IQ score of 
100, participants in the placebo condition (2.83 ± 0.02) were significantly faster than the active 
condition at endpoint (2.91 ± 0.03; t(68) = -2.77, p = .036).  Within condition, at an IQ score of 
100 and above (higher IQ), those in the placebo condition were significantly slower at midpoint 
(2.86 ± 0.02) than at endpoint (2.83 ± 0.02; t(68) = 3.38, p = .006).  
There was also a marginally significant age*condition*week interaction, F(3,1260) = 2.47, p = 
.060, a significant condition*week interaction F(1,68) = 7.01, p = .010, and a significant 
baseline*week interaction, F(1,1260) = 4.21, p = .041.  Inspection of post hoc comparisons in 
respect to the significant condition*week interaction revealed a trend towards faster reaction 
times at endpoint shown by those in the placebo condition (2.84 ± 0.01) compared to those in 
the active condition (2.89 ± 0.02; t(68) = -2.38, p = .092). 
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4.7.2.3.1.2 Distance 
In the final model, 2 outlying observations were removed to normalise the residuals. Baseline 
performance was a significant covariate, F(1,1282) = 4.52, p = .034, such that baseline 
performance was positively correlated with performance at midpoint and endpoint. Gender was 
also a significant covariate, F(1,68) = 9.09, p = .004, with females (5.22 ± 0.09) making responses 
significantly closer to the location of the stimulus than males (5.60 ± 0.09).  A trend for trial was 
also revealed F(9,621) = 1.67, p = .094, where again, performance varied across the 10 trials.  
Age and IQ were not significant covariates and were removed from the final model. There was 
no significant main effect of condition, F(1,68) = 0.00, p = .995.  No higher order interactions nor 
baseline*condition and baseline*week interactions were found to be significant.  There was a 
significant main effect of week, F(1,69) = 5.57, p = .021, such that responses were closer to the 
stimulus at midpoint (5.38 ± 0.07) than at endpoint (5.44 ± 0.07). 
4.7.2.4 Measure of executive function performance (working memory) 
Table 4.10 provides a summary of the means (± SE) for each condition.   
Table 4.10 Mean (± SE) on Spatial Span outcomes by condition and week 
Outcome 
Baseline 
Week 0 
Mean ± SE 
Midpoint 
Week 3 
Mean ± SE 
Endpoint 
Week 6 
Mean ± SE 
Active vs. 
placebo 
CANTAB SSP reaction 
time for correct trials 
(ms) 
    
Active  4149.09 ± 
81.24a 
4144.87 ± 
73.76a 
4254.14 ± 
81.35a F(1,62) = 2.39, 
p = .127 Placebo 4241.16 ± 
73.48b 
4319.63 ± 
79.46b 
4014.94 ± 
60.95b 
CANTAB SSP number 
of correct trials (n) 
   
 
Active  11.97 ± 0.95a 13.63 ± 0.99a 14.60 ± 1.04a F(1,61) = 3.04, 
p = .086 Placebo 13.19 ± 0.96b 13.95 ± 0.90b 13.65 ± 0.90b 
CANTAB SSP highest 
span achieved (n) 
   
 
Active  4.50 ± 0.20a  4.83 ±0.19a 5.00 ± 0.20a F(1,63) = 3.33, 
p = .073 Placebo 4.73 ± 0.19b 4.89 ± 0.17b 4.84 ± 0.17b 
Note: an=30 bn=37 
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4.7.2.4.1 Spatial Span (SSP)  
4.7.2.4.1.1 Number of correct trials 
In the final model, 3 outlying observations were removed to normalise residuals.  Baseline was 
not a significant covariate, F(1,61) = 1.85, p = .179.   Age and IQ were significant covariates, 
F(1,61) = 6.42, p = .014 and F(1,61) = 7.95, p = .007 respectively, with both being positively 
associated with performance at midpoint and endpoint i.e. those who were older or had higher 
IQ performed better on subsequent test sessions.  Gender was also a significant covariate, 
F(1,61) = 7.71, p = .007, with males (15.01 ± 0.05) responding correctly on significantly more 
trials than females (14.89 ± 0.05).  The total number of attempts made to the highest span 
achieved and the highest span achieved both by week were also significant covariates, F(10,38) 
= 84.85, p <.001 and F(1,45) = 14646.3, p <.001, respectively.  Both were positively associated 
with improvement at midpoint and endpoint.  No higher order interactions nor 
baseline*condition and baseline*week interactions were found to be significant.  There was a 
trend for condition (Figure 4.14), F(1,61) = 3.04, p = .086, with those in the active condition 
(14.96 ± 0.05) correctly responding to marginally more trials compared to participants in the 
placebo condition (14.93 ± 0.05). 
Figure 4.14 Number of correct trials on the Spatial Span (SSP). The x axis is condition and the y 
axis is the number of correct trials (n) over midpoint and endpoint. Columns denote the least 
squares means. Error bars denote the SE of the least squares means. 
4.7.2.4.1.2 Reaction time for correct trials 
In the final model, 23 outlying observations were removed to normalise residuals. Baseline 
reaction time was a significant covariate, F(1,62) = 21.82, p <.001, with baseline reaction time 
showing a positive relationship with reaction time demonstrated at midpoint and endpoint.  
Trial and the total number of attempts at each span to the highest span achieved were also 
significant covariates, F(26,983) = 240.90,  p <.001 and F(10,41) = 3.31, p = .003, respectively.  
Both of which were positively correlated with performance at midpoint and endpoint.  IQ and 
Main effect of condition on Spatial Span (SSP): Number of correct trials 
 
 
10
11
12
13
14
15
16
Active Placebo
Condition 
N
u
m
b
er
 o
f 
co
rr
ec
t 
tr
ia
ls
 (
n
) 
p =.086 
123 
 
gender were not significant covariates, F(1,62) = 0.20, p = .653, and F(1,62) = 0.75, p = .391, 
respectively.  Age was also not a significant covariate and was removed from the final model. 
There was no significant main effect of condition, F(1,62) = 2.39, p = .127.   There were significant 
higher order interactions as follows, baseline*condition*week interaction, F(3,1727) = 4.86, p = 
.002, gender*condition*week interaction, F(3,62) = 6.14, p = .001, age*condition*week, 
F(4,1727) = 4.59, p = .001, and IQ*condition*week, F(3,1727) = 4.37, p = .005. 
The significant baseline*condition*week interaction, F(3,1727) = 4.86, p = .002, is displayed in 
Figure 4.15(A) and 4.15(B). Inspection of post hoc comparisons revealed at a log baseline 
reaction time of 3.65 and slower (poorer baseline performance), those in the placebo condition 
(3.64 ± 0.01) were significantly faster compared to participants in the active condition at 
endpoint (3.68 ± 0.01; t(62) = -2.68, p = .045).  Within condition, those in the placebo condition 
were significantly slower at midpoint (3.66 ± 0.01) compared to endpoint (3.64 ± 0.01; t(62) = 
4.85, p <.001) at a log baseline reaction time of 3.60 and slower.   
The significant gender*condition*week interaction, F(3,62) = 6.14, p = .001, is displayed in Figure 
4.15(C) and 4.15(D).  Figure 4.15(C) represents performance within the active condition and 
shows that females within this condition demonstrated faster reaction time at midpoint relative 
to endpoint. However, males in the active condition performed similarly across both weeks. In 
the placebo condition (Figure 4.15(D)), both females and males performed better at endpoint 
relative to midpoint.  Inspection of post hoc comparisons revealed that only the females in the 
placebo condition were significantly slower at midpoint (3.66 ± 0.01) than at endpoint (3.63 ± 
0.01; t(62) = 5.72, p <.001).  
The presence of significant interactions between age*condition*week, F(4,1727) = 4.59, p = .001 
and IQ*condition*week, F(3,1727) = 4.37, p = .005 also indicate that performance also varied 
across condition and week depending upon the age and IQ of the participants.  The interaction 
between condition, week and age is shown by Figure 4.15(E) and 4.15(F).  Both indicate that 
younger participants performed better at endpoint, whilst older participants illustrated faster 
reaction time at midpoint, irrespective of condition.  Inspection of post hoc comparisons 
revealed that those in the placebo condition demonstrated significantly slower reaction times 
at midpoint (3.66 ± 0.01) relative to endpoint (3.62 ± 0.01; t(62) = 5.83, p <.001) at 80 and 90 
months of age.   
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Figure 4.15 Reaction time for correct trials on the Spatial Span (SSP). 
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Figure 4.15 continued. (A-B) The x axis is the log baseline reaction time (ms) and the y axis is the 
log reaction time (ms) over subsequent test points.  (C-D) The x axis represents week and the y 
axis is reaction time (ms) over midpoint and endpoint. Lines denote the mean. Error bars denote 
the SE of the mean. (E-F) The x axis is age (months) and the y axis is the reaction time (ms) over 
midpoint and endpoint. (G-H) The x axis represents IQ score and the y axis is reaction time (ms) 
over midpoint and endpoint. (I) the x axis is week and the y axis is the reaction time (ms) over 
midpoint and endpoint. Columns denote the mean. Error bars denote the SE of the mean. *** p 
<.001. (A-B, E-F & G-H) regression lines show relationship between x and y by week. (A, C, E & 
G) Is the active condition, (B, D, F & H) is the placebo condition. 
Figures 4.15(G) and 4.15(H) present the relationship between condition, week and IQ, F(3,1727) 
= 4.37, p = .005, for the active and placebo conditions, respectively.  The former illustrates at 
lower IQ scores, the active condition demonstrated the slowest reaction time at endpoint, 
however, at higher IQ scores, performance was better at endpoint. Figure 4.15(H) indicates that 
faster reaction time was shown at endpoint by those with lower IQ scores in the placebo 
condition, whereas performance appeared to be similar in both test sessions at higher IQ scores. 
Inspection of post hoc comparisons revealed a trend towards those in the placebo condition 
Interaction between IQ*condition*week on Spatial Span (SSP): Reaction time for 
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responding more slowly at midpoint (3.66 ± 0.01) compared to their performance at endpoint 
(3.64 ± 0.01; t(62) = 2.46, p = .076) and those in the active condition responding significantly 
faster at midpoint (3.64 ± 0.01) than at endpoint (3.66 ± 0.01; t(62) = -3.10, p = .015) at an IQ 
score of 80.  Further, at an IQ score of 90 and 100, those in the placebo condition demonstrated 
significantly slower reaction times at midpoint (3.65 ± 0.01) than at endpoint (3.64 ± 0.01; t(62) 
= 4.15, p <.001). Lastly, at an IQ score of 100, those in the active condition were marginally 
significantly slower at midpoint (3.66 ± 0.02) than at endpoint (3.64 ± 0.02; t(62) = 2.59, p = 
.056). This became significant at an IQ score of 110 (3.68 ± 0.02 vs. 3.63 ± 0.03; t(62) = 3.13, p = 
.014). 
There was a significant condition*week interaction, F(1,62) = 5.87, p = .018 (Figure 4.15(I)).  
Inspection of post hoc comparisons revealed that those in the placebo condition were 
significantly slower at midpoint (3.65 ± 0.01) relative to endpoint (3.63 ± 0.01; t(62) = 4.32, p 
<.001).   
4.7.2.4.1.3 Highest span achieved 
No outlying observations were removed from the final model.  Baseline performance and the 
total number of attempts made to the highest span achieved were both significant covariates, 
F(1,63) = 21.98, p <.001 and F(10,41) = 36.41, p <.001, respectively.  Both covariates were 
positively related to performance at midpoint and endpoint.   No higher order interactions nor 
baseline*condition and baseline*week interactions were found to be significant.  There was a 
trend towards a main effect of condition, F(1,63) = 3.33, p = .073, shown in Figure 4.16.  Those 
in the active condition (5.19 ± 0.12) demonstrated better performance compared to those in the 
placebo condition (5.07 ± 0.11). 
Figure 4.16 Highest span achieved on the Spatial Span (SSP). The x axis is condition and the y 
axis is the highest span achieved (n) over midpoint and endpoint. Columns denote the least 
squares means. Error bars denote the SE of the least squares means. 
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4.7.3 Effect of intervention on subjective evaluation of appetite, mood, 
motivation and mental alertness  
Table 4.11 provides a summary of the means (± SE) for subjective evaluations completed prior 
to the cognitive measures at each test point for both conditions.   
Table 4.11 Mean (± SE) for subjective evaluations undertaken pre-cognitive measures by 
condition and week 
Outcome 
Baseline 
Week 0 
Mean ± SE 
Midpoint 
Week 3 
Mean ± SE 
Endpoint 
Week 6 
Mean ± SE 
Active vs. 
placebo 
Subjective hunger (n)     
Active  6.26 ± 0.65 5.61 ± 0.64 5.06 ± .0.66 F(1,67) = 
0.36, p = .550 Placebo 6.23 ± .0.51 5.90 ± .0.56 5.61 ± 0.60a 
Subjective 
cheerfulness (n) 
   
 
Active  7.94 ± .0.38 8.52 ± .0.40 8.29 ± .0.36 F(1,66) = 
2.73, p = .103 Placebo 7.97 ± .0.43 9.05 ± .0.28 8.89 ± .0.38a 
Subjective ratings of 
bad temper (n) 
   
 
Active 1.71 ± 0.35 1.29 ± 0.18 1.87 ± 0.36 F(1,67) = 
0.51, p = .478 Placebo 1.46 ± .0.24 1.87 ± .0.34 1.26 ± .0.13a 
Subjective energy 
levels (n) 
   
 
Active 8.19 ± 0.45 7.90 ± 0.47 8.03 ± 0.48 F(1,67) = 
1.89, p = .174 Placebo 7.90 ± 0.46 8.41 ± 0.40 8.63 ± 0.35a 
Keenness to try hard 
(n) 
   
 
Active 8.61 ± 0.36 8.87 ± 0.32 8.90 ± 0.32 F(1,67) = 
0.16, p = .692                        Placebo 8.85 ± 0.35 9.56 ± 0.20 9.37 ± 0.29a 
Subjective ease of 
distraction (n) 
   
 
Active 4.16 ± 0.63 3.23 ± 0.53 3.42 ± 0.54 F(1,66) = 
6.27, p = .015                         Placebo 2.51 ± 0.44 2.21 ± 0.37 2.08 ± 0.35a 
Perceived ease of 
focussing (n) 
   
 
Active 7.19 ± 0.56  7.55 ± 0.47 8.35 ± 0.42 F(1,66) = 
0.72, p = .399 Placebo 8.46 ± 0.35 8.54 ± 0.37 7.87 ± 0.46a 
Wakefulness (n)     
Active 7.19 ± 0.56 7.55 ± 0.47 8.35 ± 0.42 F(1,67) = 
0.13, p = .722 Placebo 7.31 ± 0.53 7.51 ± 0.53 7.87 ± 0.46a 
Notes: Higher values represent a greater magnitude. an=38. 
4.7.3.1 Subjective hunger 
No outlying observations were removed from the final model.  Baseline subjective hunger was 
a significant covariate, F(1,67) = 25.95, p <.001, which showed a positive correlation with 
subjective hunger at subsequent test points.  There was no significant main effect of condition, 
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F(1,67) = 0.36, p = .550, and no significant interaction between baseline*condition*week or 
baseline*condition, and these were removed from the final model. 
4.7.3.2 Subjective cheerfulness 
No outlying observations were removed from the final model.  Baseline subjective cheerfulness 
was a significant covariate, F(1,66) = 9.69, p = .003; this being positively correlated with 
subjective ratings of cheerfulness at midpoint and endpoint.  There was no significant main 
effect of condition, F(1,66) = 2.73, p = .103 and no significant baseline*condition interaction, 
F(1,66) = 1.48, p = .228.  Baseline*condition*week was also nonsignificant and removed from 
the final model. 
4.7.3.3 Subjective ratings of bad temper  
In the final model, 4 outlying observations were removed to normalise residuals.  Baseline 
subjective rating of bad temperedness was a significant covariate, F(1,67) = 30.41, p <.001, with 
this being positively correlated with perceptions of bad temperedness at midpoint and endpoint.  
There was no significant main effect of condition, F(1,67) = 0.51, p = .478, and no significant 
baseline*condition interaction and this was removed from the final model.  The analysis also 
revealed a significant interaction between baseline*condition*week, F(2,60) = 9.61, p <.001, 
which is shown in Figure 4.17(A) and 14.17(B), and a trend for baseline*week, F(1,60) = 3.01, p 
= .088. 
Inspection of post hoc comparisons in view of the baseline*condition*week interaction, 
revealed that at a log baseline subjective rating of 0.2 and greater (higher baseline self-
perception of bad temperedness), those in the placebo condition rated themselves significantly 
higher for bad temperedness compared to the active condition at midpoint (0.21 ± 0.03 vs. 0.06 
± 0.03; t(59) = 3.08, p = .016).  Moreover, at a log baseline subjective rating of 0.2 and greater, 
those in the the placebo condition rated themselves significantly higher for bad temperedness 
at midpoint (0.21 ± 0.03) relative to endpoint (0.09 ± 0.04; t(59) = 3.30, p = .009).  There was 
also a trend towards those in the active condition rating themselves as lower for bad 
temperedness at midpoint compared to endpoint at a log baseline subjective rating of 0.5 and 
greater (0.14 ± 0.06 vs. 0.28 ± 0.06; t(59) = -2.39, p = .090).   
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Figure 4.17 Subjective ratings of mood: Bad temper. The x axis represents log baseline 
subjective rating (n) and the y axis is the log self-rating (n) over subsequent test points 
Regression lines show relationship between x and y by week. (A) Is the active condition, (B) is 
the placebo condition. 
4.7.3.4 Subjective energy levels 
No outlying observations were removed from the final model.  Subjective rating for energy levels 
at baseline was a significant covariate, F(1,67) = 35.78,  p <.001, with subjective ratings at 
baseline being positively associated with subjective ratings of energy levels at later test points. 
There was no significant main effect of condition, F(1,67) = 1.89, p = .174, and no significant 
interaction between baseline*condition*week or baseline*condition, and these were removed 
from the final model. 
4.7.3.5 Keenness to try hard 
In the final model, one outlying observation was removed to normalise residuals.  Baseline 
subjective rating was a significant covariate, F(1,67) = 22.37,  p <.001, with subjective ratings at 
baseline being positively correlated with subjective ratings at midpoint and endpoint. There was 
no significant main effect of condition, F(1,67) = 0.16, p = .692 and no significant 
baseline*condition interaction, which was removed from the final model.  The analysis revealed 
a significant baseline*condition*week interaction, F(3,63) = 4.10, p = .010.   
Figure 4.18(A) (active) and 4.18(B) (placebo) present the relationship between baseline 
subjective ratings, condition and week.  Inspection of post hoc comparisons revealed those in 
the placebo condition rated themselves significantly higher at midpoint (0.76 ±  0.09) compared 
to endpoint (0.43 ± 0.09; t(64) = 3.57, p = .004) at a log baseline subjective rating of 0.1 to 0.6, 
Interaction between baseline*condition*week on subjective ratings of bad temper 
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inclusive. This was marginally significant at a log baseline subjective rating of 0.7 (0.92 ± 0.04 vs. 
0.81 ± 0.04; t(64) = 2.61, p = .054). 
 
 
Figure 4.18 Subjective ratings of motivation: Keenness to try hard. The x axis represents log 
baseline subjective rating (n) and the y axis is the log self-rating (n) over subsequent test points.  
Regression lines show relationship between x and y by week. (A) Is the active condition, (B) is 
the placebo condition. 
A main effect of week was marginally significant, F(1,63) = 3.96, p = .051, such that subjective 
ratings of keenness to try hard were higher at midpoint (0.88 ± 0.03) compared to endpoint 
(0.84 ± 0.03). A condition*week interaction was also significant, F(1,63) = 8.99, p = .004, such 
that those in the active condition were similarly keen on both test occasions (0.81 ± 0.04), while 
those in the placebo condition became less keen over time (midpoint:0.94 ± 0.04 vs. endpoint: 
0.87 ± 0.04).  However, post hoc comparisons did not reveal a significant difference.   
4.7.3.6 Subjective ease of distraction 
No outlying observations were removed from the final model. Baseline subjective rating for ease 
of distraction was a significant covariate, F(1,66) = 19.43, p <.001; this being positively associated 
with ease of distraction subjective ratings at midpoint and endpoint.  Baseline*condition*week 
was not significant and was removed from the final model.  A significant baseline*condition 
interaction was revealed, F(1,66) = 4.99, p = .029, shown in Figure 4.19. 
Inspection of post hoc comparisons revealed those in the placebo condition (0.12 ± 0.04) rated 
themselves significantly less easily distracted compared to those in the active condition (0.29 ± 
0.06; t(66) = -2.32, p = .024) at a log baseline subjective rating of 0.1. At a log baseline subjective 
Interaction between baseline*condition*week on subjective ratings of keenness to try 
hard 
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rating of 0.2, this same difference was marginally significant (0.18 ± 0.04 vs. 0.31 ± 0.05; t(66) = 
-1.99, p = .050). 
Figure 4.19 Subjective ratings of mental alertness: Ease of distraction. The x axis represents log 
baseline subjective rating (n) and the y axis is log self-rating (n) over subsequent test points.  
Regression lines show relationship between x and y by condition. 
A significant main effect of condition, F(1,66) = 6.27, p = .015, was also found.  Participants in 
the active condition reported being easily distracted to a greater extent (0.33 ± 0.05) compared 
to those in the placebo condition (0.24 ± 0.04).  However, post hoc comparisons did not reveal 
a significant difference.   
4.7.3.7 Perceived ease of focusing 
No outlying observations were removed from the final model.  Baseline perception of ease of 
focusing was a significant covariate, F(1,66) = 17.13, p <.001, with this being positively related 
to perceptions at midpoint and endpoint. There was no significant main effect of condition or 
baseline*condition interaction, F(1,66) = 0.72, p = .399 and F(1,66) = 1.94, p = .168, respectively.  
Baseline*condition*week was significant, F(1,65) = 4.80, p = .032, however, post hoc 
comparisons did not reveal a significant difference.  
A significant interaction between condition*week was also found, F(1,65) = 4.66, p = .035. 
Participants in the placebo condition reported being able to focus more easily than their 
counterparts in the active condition both at midpoint (0.75 ± 0.05 vs. 0.71 ± 0.06) and endpoint 
(0.71 ± 0.05 vs. 0.63 ± 0.06). However, post hoc comparisons did not reveal a significant 
difference. 
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4.7.3.8 Wakefulness  
No outlying observations were removed from the final model.  Baseline perceived wakefulness 
was a significant covariate, F(1,67) = 41.73, p <.001, with this being positively related to 
perceived wakefulness at subsequent time points.  There was no significant main effect of 
condition, F(1,67) = 0.13, p = .722, and no significant interaction between 
baseline*condition*week or baseline*condition, and these terms were removed from the final 
model.  There was a significant main effect of week, F(1,66) = 4.20, p = .045, such that subjective 
ratings of wakefulness were lower (less awake) at midpoint (0.72 ± 0.04) compared to endpoint 
(0.79 ± 0.04).  
4.7.4 Cognitive test evaluation ratings 
Table 4.12 provides a summary of the means (± SE) for subjective evaluations completed post-
cognitive measures at each test point for both conditions.   
Table 4.12 Mean (± SE) for subjective evaluations undertaken post-cognitive measures by 
condition and week 
Outcome 
Baseline 
Week 0 
Mean ± SE 
Midpoint 
Week 3 
Mean ± SE 
Endpoint 
Week 6 
Mean ± SE 
Active vs. 
placebo 
Perceived test 
battery difficulty (n) 
   
 
Active  3.35 ± 0.50 3.00 ± 0.45 3.65 ± .0.55 F(1,67) = 0.32, 
p = .574 Placebo 3.15 ± 0.38 3.05 ± 0.37 3.62 ± 0.37 
Perceived 
concentration during 
test battery (n) 
   
 
Active  8.77 ± .0.35 8.65 ± .0.45 8.42 ± .0.46 F(1,67) = 1.37, 
p = .247 Placebo 8.85 ± 0.30 9.05 ± .0.29 8.90 ± .0.37 
Perceived 
performance (n) 
   
 
Active  7.65 ± 0.46 7.68 ± 0.47 7.77 ± 0.49 F(1,67) = 1.73, 
p = .193 Placebo 8.49 ± 0.33 7.64 ± .0.47 7.38 ± .0.43 
Frustration (n)     
Active  2.71 ± 0.44 3.19 ± 0.48 2.81 ± 0.47 F(1,67) = 0.30, 
p = .585 Placebo 2.85 ± 0.44 2.67 ± 0.47 3.31 ± 0.52 
Note: Higher values represent a greater magnitude.  
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4.7.4.1 Perceived test battery difficulty 
No outlying observations were removed from the final model.  Baseline subjective rating of test 
difficulty was a significant covariate, F(1,67) = 25.61, p <.001; this being positively correlated 
with perceived test difficulty at midpoint and endpoint.  There was no significant main effect of 
condition, F(1,67) = 0.32, p = .574, and no significant interaction between 
baseline*condition*week or baseline*condition, and these were removed from the final model. 
4.7.4.2 Perceived concentration during the test battery 
In the final model, two outlying observations were removed to normalise residuals.  Perceived 
concentration during the test battery at baseline was a significant covariate, F(1,67) = 37.29, p 
<.001, which was positively associated with perceptions of concentration during the test battery 
at later test points. There was no significant main effect of condition, F(1,67) = 1.37, p = .247, 
and no significant interaction between baseline*condition*week or baseline*condition, and 
these were removed from the final model. 
4.7.4.3 Perceived performance 
No outlying observations were removed from the final model.  Baseline perceived performance 
was a significant covariate, F(1,67) = 20.09, p <.001, with this being positively related to cognitive 
test battery performance as perceived by participants at midpoint and endpoint.  There was no 
significant main effect of condition, F(1,67) = 1.73, p = .193, and no significant interaction 
between baseline*condition*week or baseline*condition, and these were removed from the 
final model. 
4.7.4.4 Frustration 
No outlying observations were removed from the final model.  Baseline subjective rating of 
frustration experienced during the cognitive test battery was a significant covariate, F(1,67) = 
17.72, p <.001, which was positively associated with perceived frustration experienced during 
the measures at midpoint and endpoint. There was no significant main effect of condition, 
F(1,67) = 0.30, p = .585, and no significant interaction between baseline*condition*week or 
baseline*condition, and these were removed from the final model.  There was a trend towards 
a condition*week interaction, F(1,68) = 2.86, p = .096.  Participants in the placebo condition 
appeared to experience greater frustration over time (0.23 ± 0.06 at midpoint, 0.32 ± 0.06 at 
endpoint), whereas those in the active condition felt less frustrated across the test sessions (0.35 
± 0.06 at midpoint, 0.29 ± 0.06 at endpoint).
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4.7.5 Summary of findings  
4.7.5.1 Effects of a 6 week GPL with SM intervention on cognitive performance in children aged 6-8 years 
A tabulated summary of cognitive performance outcomes following receiving Lacprodan® PL-20 or placebo for 6 weeks is shown in Table 4.13.  
Table 4.13 Tabulated summary of cognitive performance outcomes following 6 weeks of supplementation 
 Main effects Covariates 
Cognitive outcome Condition Week Baseline Age IQ Gender Trial 
Sum 
(total) of 
attempts 
Highest 
span 
achieved 
Processing speed: Choice Reaction Time (CRT) & Simple Reaction Time (SRT) 
Movement time 
(correct trials; CRT) 
NS NS S (p = <.001) - NS 
MS (p = 
.050) 
MS (p = 
.050) 
/ / 
Number of correct 
trials (CRT) 
NS NS S (p = .006) - - - / / / 
Reaction time 
(correct trials; CRT) 
S (p = .009) NS S (p <.001) - NS - S (p <.001) / / 
Number of correct 
trials (SRT) 
NS NS S (p = .003) - NS T (p = .084) / / / 
Reaction time 
(correct trials; SRT) 
NS S (p = .025) S (p <.001) - NS S (p = .031) S (p = .002) / / 
Movement time 
(correct trials; SRT) 
NS 
MS (p = 
.064) 
S (p <.001) 
MS (p = 
.058) 
NS - - / / 
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 Main effects Covariates 
Cognitive outcome Condition Week Baseline Age IQ Gender Trial 
Sum 
(total) of 
attempts 
Highest 
span 
achieved 
Verbal memory: Rivermead Behavioural Memory Test for Children (RBMT-C) 
Immediate recall NS NS S (p < .001) T (p = .073) - S (p = .047) / / / 
Delayed recall MS (p = .055) NS - 
MS (p = 
.065) 
T (p = .077) NS / / / 
Visuospatial recognition memory: Spatial Recognition Memory (SRM) 
Number of correct 
trials 
NS S (p = .047) T (p = .074) - - - / / / 
Reaction time 
(correct trials) 
S (p = .047) T (p = .071) S (p <.001) - 
MS (p = 
.051) 
- S (p <.001) / / 
Motor skills: Motor Screening Task (MOT) 
Reaction time NS NS S (p = .012) NS NS - S (p <.001) / / 
Distance NS S (p = .021) S (p = .034) - - S (p = .004) T (p = .094) / / 
Executive function (working memory): Spatial Span (SSP) 
Number of correct 
trials 
T (p = .086) NS NS S (p = .014) S (p = .007) S (p = .007) / S (p <.001) S (p <.001) 
Reaction time 
(correct trials) 
NS NS S (p <.001) - NS NS S (p <.001) S (p = .003) / 
Highest span 
achieved 
T (p = .073) NS S (p <.001) NS - - / S (p <.001) / 
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Table 4.13 continued. 
 Interaction terms 
Cognitive 
outcome 
Condition* 
week 
Baseline* 
condition 
Baseline*week Baseline*condition* 
week 
Trial*condition* 
week 
Age*condition* 
week 
IQ*condition* 
week 
Gender*condition* 
week 
Processing speed: Choice Reaction Time (CRT) & Simple Reaction Time (SRT) 
Movement 
time 
(correct 
trials; CRT) 
S (p = .003) - - S (p = .039) NS NS - S (p <.001) 
Number of 
correct trials 
(CRT) 
NS - NS - / - - S (p = .020) 
Reaction 
time 
(correct 
trials; CRT) 
S (p = .016) S (p = .018) - - - - S (p = .006) S (p <.001) 
Number of 
correct trials 
(SRT) 
S (p = .019) - - - / - MS (p = .063) S (p = .001) 
Reaction 
time 
(correct 
trials; SRT) 
NS - S (p = .021) - - - - S (p = .002) 
Movement 
time 
(correct 
trials; SRT) 
S (p = .005) S (p = .032) - - S (p = .038) S (p = .010) S (p = .001) S (p = .025) 
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 Interaction terms 
Cognitive 
outcome 
Condition* 
week 
Baseline* 
condition 
Baseline*week Baseline*condition* 
week 
Trial*condition* 
week 
Age*condition* 
week 
IQ*condition* 
week 
Gender*condition* 
week 
Verbal memory: Rivermead Behavioural Memory Test for Children (RBMT-C) 
Immediate 
recall 
MS (p = 
.065) 
- - - / NS - NS 
Delayed 
recall 
NS NS NS NS / - - NS 
Visuospatial recognition memory: Spatial Recognition Memory (SRM) 
Number of 
correct trials 
NS - - NS / - NS - 
Reaction 
time 
(correct 
trials) 
NS S (p = .045) MS (p = .062) S (p = .030) - NS NS NS 
Motor skills: Motor Screening Task (MOT) 
Reaction 
time 
S (p = .010) - S (p = .041) S (p <.001) NS MS (p = .060) S (p = .011) - 
Distance NS NS NS - NS NS - - 
Executive function (working memory): Spatial Span (SSP) 
Number of 
correct trials 
NS - - - / - NS NS 
Reaction 
time 
(correct 
trials) 
S (p = .018) - - S (p = .002) - S (p = .001) S (p = .005) S (p = .001) 
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 Interaction terms 
Cognitive 
outcome 
Condition* 
week 
Baseline* 
condition 
Baseline*week Baseline*condition* 
week 
Trial*condition* 
week 
Age*condition* 
week 
IQ*condition* 
week 
Gender*condition* 
week 
Highest 
span 
achieved 
NS - - - / - NS - 
Notes. MS: Marginally significant, NS: Nonsignificant, S: Significant. T; Trend; – indicates term removed from the final model for best fit, / indicates this 
was not entered into the model. 
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A summary of significant, marginally significant, and trends for covariates, main effects and 
interactions following the 6 week intervention is provided below: 
Baseline performance as a covariate by cognitive measure outcome: 
Cognitive performance at baseline was positively associated with subsequent cognitive 
performance on thirteen out of fifteen cognitive outcomes.  These measures were of memory 
performance (verbal memory: RBMT-C immediate recall and visuospatial memory: SRM reaction 
time for correct trials and number of correct trials), motor skills (MOT reaction time and 
distance), working memory (SSP highest span achieved and reaction time for correct trials), and 
processing speed (SRT and CRT number of correct trials and reaction and movement time for 
correct trials respectively). 
Age, IQ and gender of participants as covariates by cognitive measure outcome: 
Age, as expected, was positively correlated with performance, such that on a measure of 
memory performance (RBMT-C immediate and delayed recall), older participants recalled more 
items (trend for immediate recall, marginally significant for delayed recall). On a measure of 
working memory (SSP number of correct trials), older participants were also more accurate. On 
this same outcome measure, those with a higher IQ were more accurate (more correct trials).  
In addition, on separate memory measures, specifically SRM reaction time for correct trials, 
participants with a higher IQ took longer to respond (marginally significant), whilst on the RBMT-
C delayed recall, those with a higher IQ recalled more items (trend). Females recalled more items 
than boys on a measure of verbal memory (RMCT-C immediate recall) and were more accurate, 
responding closer to the stimulus, on a measure of motor skills (MOT distance). However, males 
performed better than females on a measure of working memory (SSP number of correct trials) 
and demonstrated faster reaction time and movement time on measures of processing speed 
(SRT reaction time for correct trials and CRT movement time (marginally significant)).  
Other covariates based upon individual participant performance by cognitive measure outcome: 
Trial, the total number of attempts at each span to the highest span achieved (by week) and 
highest span achieved (by week) were also added where appropriate as covariates to the model. 
Performance tended to fluctuate by trial, whereas performance was consistently positively 
associated with total number of attempts and highest span achieved on the SSP measure. 
Main effect of condition by cognitive measure outcome: 
Participants who received the placebo treatment recalled more items following a delay on a 
measure of verbal memory (RBMT-C, marginally significant) and demonstrated faster reaction 
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times on a measure of visuospatial memory (SRM reaction time for correct trials, trend).  
However, those in the active condition showed superior performance on a measure of working 
memory (SSP highest span achieved, trend). This was also observed (trend) on the same 
measure for the number of correct trials outcome, consistent with expectations given the 
number of correct trials was positively associated with highest span achieved.   
Interaction between condition and week by cognitive measure outcome: 
Those in the placebo condition also recalled more items compared to participants in the active 
condition on immediate verbal memory (RBMT-C, marginally significant), such that those in the 
active condition recalled significantly less items at midpoint relative to midpoint and endpoint 
performance of those in the placebo condition.  On a measure of processing speed (SRT), 
participants in the placebo condition showed significantly faster movement times than those in 
the active condition at midpoint.  However, participants in the active condition demonstrated 
significantly slower movement times at midpoint relative to their performance at endpoint. On 
a measure of motor skills (MOT reaction time), those in the placebo condition demonstrated 
faster reaction time at endpoint relative to those in the active condition (trend). Those in the 
placebo condition also got faster over time on a measure of working memory (SSP reaction time 
for correct trials).  The active condition illustrated faster movement time over time on a measure 
of processing speed (CRT movement time) – both significantly slower at midpoint compared to 
endpoint.   
Interaction between baseline performance and condition by cognitive measure outcome: 
Performance by condition differed as a function of baseline performance for SRM reaction time 
for correct trials (visuospatial memory), SRT movement time and CRT reaction time (processing 
speed). Specifically, those in the placebo condition showed significantly faster reaction times on 
SRM for correct trials at poorer baseline performance. This was also observed for movement 
time on SRT measure when baseline movement times were slow. On CRT reaction time, those 
in the placebo condition were significantly slower compared to those in the active condition 
when baseline performance was faster, however, when the baseline performance was slower, 
those in the placebo condition showed quicker reaction times (significant and marginally 
significant) relative to participants in the active condition.  
Interaction between baseline performance, condition and week by cognitive measure outcome: 
Performance by condition and week also varied as a function of baseline performance.  
Participants in the placebo condition were significantly faster than those in the active condition 
at endpoint when baseline performance was poorer (and significantly slower at midpoint vs. 
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endpoint) on SRM reaction time for correct trials (visuospatial). On the MOT (motor skills), those 
with faster baseline reaction times showed significantly faster reaction time following the 
placebo than active treatment at endpoint.  However, those in the active condition were 
significantly faster at midpoint compared to endpoint and those in the placebo condition 
responded more slowly at midpoint than at endpoint (marginally significant and a trend at 
different baseline performance). On the same measure at mid (marginally significant) to poorer 
(significant) baseline performance, those in the placebo condition were faster than those in the 
active condition at midpoint, however, at poorer baseline reaction times, participants in the 
active condition were significantly slower at midpoint relative to endpoint. Those in the placebo 
condition also demonstrated significantly faster reaction times compared to those in the active 
condition at endpoint at mid to poorer baseline performance (those in the placebo condition 
were also significantly slower at midpoint compared to endpoint) on the SSP measure (working 
memory). 
Interaction between age of participants and condition and week by cognitive measure outcome: 
Age*condition*week was a significant interaction on a measure of processing speed (SRT: 
movement time for correct trials) such that at 90 months of age, those in the placebo condition 
were significantly faster than those in the active condition at midpoint. However, those in the 
active condition were significantly slower at midpoint relative to endpoint at both 80 and 90 
months of age. Lastly, at 100 months of age, participants in the placebo condition moved 
significantly faster at midpoint relative to endpoint. On a measure of executive function (SSP 
reaction time for correct trials), participants in the placebo condition reacted significantly slower 
at midpoint compared to endpoint at 80 and 90 months of age. 
Interaction between IQ of participants and condition and week by cognitive measure outcome: 
An IQ*condition*week interaction was found for the MOT (motor skills), such that those in the 
placebo condition demonstrated (significantly and marginally significant) faster reaction times 
compared to those in the active condition at endpoint at an IQ score of 100 and 110. 
Furthermore, at an IQ of 80, those in the active condition demonstrated significantly faster 
performance at midpoint relative to endpoint, whilst there was a trend towards those in the 
placebo condition responding more slowly at midpoint compared to endpoint on the SSP 
(executive function). On this same measure, at an IQ of 90 and 100, participants in the placebo 
condition showed significantly better performance at endpoint than at midpoint; this same 
pattern of performance was demonstrated by those in the active condition at an IQ of 100 and 
110 (marginally significant/significant).  IQ*condition*week interaction was also found for SRT 
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(processing speed), such that at an IQ score of 90, 100 and 110, those in the placebo condition 
demonstrated (significant and marginally significant) faster movement times compared to those 
in the active condition at midpoint, although the active condition was significantly slower at 
midpoint relative to endpoint. On the other measure of processing speed (CRT), those in the 
placebo condition showed marginally significantly faster response latencies at endpoint relative 
to midpoint at an IQ of 100 and 110 (marginally significant/significant). 
Interaction between gender of participants and condition and week by cognitive measure 
outcome: 
Gender*condition*week interactions were found for both measures of processing speed 
(movement time, reaction time and number of correct trials). On SRT, both males in the active 
condition (significant) and those in the placebo condition (marginally significant) demonstrated 
greater accuracy at midpoint than endpoint.  Males in the placebo condition showed faster 
(marginally significant) movement times to females in the active condition at midpoint, although 
females in the active condition were slower (marginally significant) at midpoint compared to 
endpoint. On the same measure, females in the placebo condition responded significantly 
slower relative to males in the active condition at endpoint, although the reaction times of 
females in the placebo condition were significantly faster at midpoint compared to endpoint. 
On the CRT, males in the placebo condition completed less trials correctly than males in the 
active condition at endpoint (trend) and females in the active condition demonstrated 
significantly faster movement time over time, whereas females in the placebo condition showed 
significantly slower movement time over time. Females in the placebo condition showed slower 
reaction times (marginally significant) relative to males in the same condition at endpoint.  Males 
in the placebo responded marginally significantly faster over time.  
4.7.5.2 Effects of a 6 week GPL with SM intervention on subjective state in children 
aged 6-8 years 
A summary of significant, marginally significant, and trends for covariates, main effects and 
interactions following the 6 week intervention is provided below: 
Baseline self-ratings as a covariate on subjective state: 
Baseline self-perceptions were positively associated with subsequent self-ratings (at midpoint 
and endpoint) on all subjective evaluations concerning appetite, mood, motivation and mental 
alertness. 
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Main effect of condition on subjective state: 
Participants in the placebo condition rated themselves as more cheerful than those in the active 
condition (trend). 
Interaction between baseline self-ratings and condition on subjective state: 
Subjective ratings by condition varied as a function of baseline ratings for ease of distraction.  
For lower baseline ratings (less easily distracted), those in the placebo condition rated 
themselves (significantly and marginally significantly) less easily distracted compared to those 
in the active condition. 
Interaction between baseline self-ratings, condition and week on subjective state: 
Subjective ratings by condition and week also differed by baseline ratings. Participants in the 
placebo condition rated themselves higher for bad temperedness compared to those in the 
active condition at midpoint at lower-to-mid and higher baseline subjective ratings (significant).  
However, those in the placebo condition rated themselves higher for bad temperedness at 
midpoint relative to endpoint at the same baseline subjective responses (significant) and those 
in the active condition rated themselves as lower for bad temperedness at midpoint compared 
to endpoint (trend) at mid and higher baseline subjective ratings.  Further, at lower-to-mid 
baseline subjective ratings, participants in the placebo condition reported greater keenness to 
try hard perceptions at midpoint relative to endpoint (significant and marginally significant). 
4.7.5.3 Effects of a 6 week GPL with SM intervention on cognitive test evaluation 
ratings in children aged 6-8 years 
A summary of significant, marginally significant, and trends for covariates, main effects and 
interactions following the 6 week intervention is provided below: 
Baseline self-ratings as a covariate on cognitive test evaluations: 
Baseline subjective ratings were positively associated with subsequent subjective ratings (at 
midpoint and endpoint) cognitive test evaluation ratings. 
Interaction between condition and week on cognitive test evaluations: 
Perceived frustration experienced during the cognitive measures seemed to change by condition 
and week (trend), such that those in placebo condition became more frustrated from midpoint 
to endpoint whereas those in the active condition became less frustrated over time. 
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4.8 Discussion 
4.8.1 Overview of findings 
The primary aim of the intervention study reported in this Chapter was to investigate whether 
supplementing usual diet with a GPL and SM bovine milk-based supplement, Lacprodan® PL-20, 
for 6 weeks would confer a cognitive performance advantage in children aged 6 – 8 years.  A 
secondary aim was to assess whether supplementation with Lacprodan® PL-20 affected 
subjective evaluations of appetite, mood, motivation and mental alertness.  It was hypothesised 
that Lacprodan® PL-20 supplementation would promote cognitive function, and that this would 
translate to better performance on cognitive measures assessing memory, motor skills, working 
memory and processing speed. The findings of this study provide limited support for a benefit 
of Lacprodan® PL-20 supplemented for 6 weeks on cognitive performance in a sample of school-
aged children.   Lacprodan® PL-20 was also not found to influence subjective evaluations.  In 
respect of the primary outcome (CRT: Movement time), the lack of a significant (or marginally 
significant or trend) main effect of condition in favour of the active condition indicates that there 
was no advantage to those who received the active supplement. Baseline performance was 
positively related to performance on later test occasions, a common pattern seen across the 
measures. Interactions that remained significant following post hoc analysis indicated significant 
interactions between gender, condition and week, and condition and week. Females in the 
active condition were significantly slower at midpoint vs. endpoint, whilst females in the placebo 
condition were significantly faster at midpoint vs. endpoint.  The former most likely underlies 
the condition and week interaction, such that those in the active condition performed 
significantly slower at midpoint vs. endpoint.  Performance differences in favour of those in the 
active condition as shown on secondary outcomes include a trend towards superior 
performance (compared to the placebo condition) on the Spatial Span measure (working 
memory) for two outcomes including the number of correct trials and highest span achieved.  
Also on the CRT, there was a trend towards males in the active condition completing more trials 
correctly compared to males in the placebo condition at endpoint.  Inspection of the findings for 
reaction time and movement time on the CRT indicates that there was no significant difference 
in either of these outcomes between males of each condition.  This therefore suggests that there 
was no speed-accuracy trade-off by males in the placebo condition i.e. they got more correct 
but were not slower.  On the same measure, at faster baseline reaction time, the active condition 
demonstrated significantly faster reaction time relative to the placebo condition.   
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In terms of mood, baseline subjective ratings of bad temperedness were related to subsequent 
ratings.  Those in the placebo condition rated themselves significantly higher for bad 
temperedness compared to the active condition at midpoint. However, it was also found that at 
the same baseline subjective ratings, those in the placebo condition rated themselves 
significantly higher for bad temperedness at midpoint relative to endpoint.  There was also a 
trend for the active condition rating themselves lower at midpoint than at endpoint. Therefore, 
taken together, it can be concluded that subjective ratings of bad temperedness are 
independent of treatment condition.  
 
4.8.2 Possible explanations for the lack of a significant treatment effect on 
cognition and subjective evaluations following 6 week supplementation 
with Lacprodan® PL-20. 
 
4.8.2.1 Study quality 
The study design conformed to a randomised, double-blind, placebo-controlled study design, 
which is considered the gold-standard in intervention studies.  A randomised sequence was used 
for participant allocation to treatment condition in an effort to distribute both known and 
unknown factors that could independently influence the outcome(s) of an intervention equally 
across conditions (Eccles, Grimshaw, Campbell, & Ramsay, 2003).  However, there was a 
difference in the distribution of IQ, which was a significant covariate for some outcomes and 
may be a factor in the lack of effect/placebo advantage.  Supplements were concealed in 
TetraBrik® cartons, with only the colour and fruit character appearing on the front of each carton 
(to identify flavour) and a condition code differing between cartons. All experimental drinks 
(supplement) were matched on taste and appearance and were consumed in a controlled 
manner under supervision, and the quantity consumed was documented on each occasion. All 
research staff, schoolteachers and children were blind as to which children were allocated to 
either of the two conditions (double-blind) and research staff were only unblinded following the 
completion of data analysis. All outcome data has been analysed and reported according to the 
a priori plan of measures utilised in the study.  Taken together, the study demonstrates a low 
risk of bias and can be classed as being of good quality according to the Cochrane risk of bias 
tool for randomized clinical trials (Higgins et al., 2011).   
The study also demonstrated good practice by familiarising participants with the cognitive 
measures, allowing sufficient practice prior to the study.  This serves to reduce the extent of 
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practice effects, which are strongest between the first two study visits (Bell et al., 2018). Minimal 
improvements have been reported following a second test session in the context of multiple-
testing using neuropsychological measures (Beglinger et al., 2005).  In addition, parallel versions 
of the cognitive measures were used for practise, which is also recommended to minimise 
practice effects in the context of multiple testing (Beglinger et al., 2005; Bell et al., 2018). 
Based on the number of participants included in the per protocol analysis, observed difference 
in LS-means and variability (standard deviation) on the primary outcome, an a posteriori 
calculation determined the power of the present study to detect a difference between the active 
and placebo conditions by week (baseline, midpoint and endpoint) was 0.051, 0.055, and 0.070, 
respectively.  Furthermore, in order to achieve a power of 0.8, a sample size of 25,118, 6281 and 
1571 would be required at baseline, midpoint and endpoint, respectively.  It can therefore be 
concluded that the study was underpowered due to an insufficient number of participants. 
4.8.2.2 Statistical approach 
The statistical approach undertaken in the analysis of the data controlled for covariates that 
correlate with cognitive function i.e. age, IQ and gender (see section 4.6). Covariate adjustment 
can increase statistical power for continuous outcomes, as they may explain some of the 
variation in outcomes between participants, leading to smaller SEs for the treatment effect 
(Kahan, Jairath, Doré, & Morris, 2014). Importantly, the greater the correlation between a 
covariate and the outcome, the greater the increase in statistical power and reduction in SE 
(Pocock, Assmann, Enos, & Kasten, 2002).  In eleven of the fifteen cognitive outcomes, 
demographic characteristics (age, IQ and gender) were either significant, marginally significant 
or showed a trend.  Higher-order interactions included age on three outcomes; IQ featured in 
five outcomes and gender in six outcomes. Adjusting for IQ was especially important, as analysis 
of baseline demographic variables indicated that there was a marginally significant difference 
between the IQ of participants in the two conditions, such that IQ in the placebo condition was 
higher compared to those in the active condition.  Further analysis showed that this difference 
was due to those in the placebo condition scoring significantly higher than participants in the 
active condition on the WASI vocabulary subcomponent. Figure 4.5 shows the distribution of 
scores on this measure and indicates that males and females in the placebo condition tended to 
demonstrate better performance than males and females in the active condition. This significant 
difference between the two conditions in WASI vocabulary scores may account for the 
condition*week interaction and main effect of condition on the immediate and delayed recall 
outcomes, respectively, of the Rivermead Behavioural Memory Test (a measure of verbal 
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memory) that are in favour of those in the placebo condition.  Moreover, including baseline 
cognitive performance/subjective ratings as a covariate in the analysis adjusted for differences 
in performance on the cognitive measures/subjective ratings as assessed at baseline allowing an 
unbiased estimate of treatment effects (O’ Connell et al., 2017).  Baseline cognitive performance 
was a significant covariate in thirteen of fifteen outcomes underlining the importance for the 
analysis to be adjusted in this way.  Similarly, baseline subjective ratings were significant 
covariates on all subjective evaluation outcomes.  Therefore, it would be unwarranted to 
attribute the lack of a significant treatment effects to the statistical approach. 
4.8.2.3 Duration of intervention 
The half-life of GPLs in the human brain is currently unknown, making it difficult to estimate the 
optimal treatment length, assuming dietary consumption contributes to the incorporation of 
GPLs in the brain. A preliminary estimation of the half-life of DHA in the human brain (whole 
brain) is reported as 2.5 years, based on the global uptake of circulating unesterified DHA of 3.8 
± 1.7 mg per day and the reported 5 g of DHA in the human brain (Umhau et al., 2009).  
Consistent with this, another study has reported a daily whole brain incorporation rate of 3.8 ± 
2.5 mg per day for APOE ε4 noncarriers, whilst for APOE ε4 carriers, the rate was 4.6 ± 3.3 mg 
per day (Yassine et al., 2017).  Supplementation for 3 months equates to ~10% of this, therefore, 
the potential for even a slight increase in brain DHA levels following supplementation is likely to 
take at least a few months (Taha, Burnham, & Auvin, 2010).  The plasma half-life of lysoPC (a 
product of PC hydrolysis by phospholipase A2 (PLA2)), ≈5–10 minutes, is comparably longer than 
the plasma half-life of unesterified DHA (≈ 30 seconds) (Lacombe et al., 2018).  If the longer half-
life of lysoPC relative to unesterified DHA in plasma is represented in the human brain, it is likely 
that GPL supplementation will be necessary over many months before there is an opportunity 
for GPL cell membrane replacement. However, caution should be taken, as data in rodent and 
human studies show that blood DHA concentration does not correlate with brain DHA integrity 
(Kuratko & Salem, 2009).  This lack of relationship between plasma DHA content and brain DHA 
levels is also true of DHA esterified to PLs (Tu, Mühlhäusler, Yelland, & Gibson, 2013).  This 
suggests the 6 week duration of the current study is insufficient to affect brain levels of GPLs. 
4.8.2.4 Measurement of cognitive performance 
Computerised cognitive assessments are ideal when measuring cognitive performance, as 
flexible test difficulty levels reduce the likelihood of floor and ceiling effects.  Further, they afford 
standardisation of assessment, accurate recording of response times and automation of scoring 
(Wild, Howieson, Webbe, Seelye, & Kaye, 2008).  Given the design of the study reported in this 
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Chapter, practical considerations included portability of assessment, quick and easy set-up and 
automated data capture.  Another important consideration concerned the sensitivity of the 
cognitive assessment to detect subtle differences in cognitive performance following nutrient 
intervention. The impact of nutrition on cognitive performance is likely to be subtle given that it 
is one of multiple elements that impact the brain and cognitive function (Hughes & Bryan, 2003).  
To address these priorities and to enable the assessment of a range of cognitive domains, 
CANTAB was selected as the most suitable cognitive test battery for use in this study.  This was 
for a variety of reasons.  Firstly, it was compliant with Good Clinical Practice (GCP), having third 
party management of raw data. Secondly, it was suitable for use with young children (Isaacs & 
Oates, 2008).   Thirdly, consistent with the practical aspects, CANTAB offers touchscreen 
response (ease of responding) and automated test presentation.  
However, since the current study was conducted, a study assessing the internal consistency and 
1-year stability of seven measures of the CANTAB in Finnish school-aged children reported a 
Cronbach’s alpha reliability coefficient of .21 for the SRM measure.  Moreover, many of the SRM 
patterns were found not to correlate and of those that did, correlations were modest.  Overall 
it was concluded that the SRM was not a reliable measure (Syväoja et al., 2015).  CANTAB has 
also been found to show weak-to-moderate correlations with principal components derived 
from traditional neuropsychological test measures, suggesting CANTAB measures may reflect 
general cognition and may not be able to measure discrete cognitive functions (Smith, Need, 
Cirulli, Chiba-Falek, & Attix, 2013).  Consistent with this, confirmatory factor analysis revealed 
SSP highest span and CRT movement time did not consistently load onto the cognitive domain 
factors derived from traditional neuropsychological measures that assessed the same domains 
as the CANTAB measures were purported to assess. Although it was acknowledged that the lack 
of consistency may have been due to the CANTAB measures assessing a different component of 
the same cognitive domain or even multidimensional cognitive processes, for example, SSP 
showed shared variance, loading onto multiple factors (Lenehan, Summers, Saunders, Summers, 
& Vickers, 2016).   Moreover, the construct validity of CANTAB has been largely founded on its 
sensitivity to discriminate clinical populations from healthy populations (Lenehan et al., 2016).  
The findings outlined above raise some reservations about the suitability (sensitivity and 
specificity) of CANTAB to assess the effects of nutritional interventions in children.  
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4.9 Conclusion 
A randomised, double-blind, placebo-controlled, parallel group study was undertaken to 
examine the effect of supplementing a composite of GPLs and SM in school-aged children on 
cognitive performance and subjective state, specifically, appetite, mood, motivation and mental 
alertness.  As GPLs are known to support cognitive function in multiple ways, it was hypothesised 
that a 6 week intervention would lead to an improvement in performance on cognitive measures 
from the CANTAB battery assessing memory, motor skills, working memory and processing 
speed.  School children (n=132) aged 6 – 8 years were allocated to receive 6 weeks of the active 
(n=66) or placebo (n=66) bovine milk-based experimental drinks. Participants were seen in 
school 5 days per week and supplement drinks were consumed shortly before break-time in a 
controlled environment under supervision. The amount of supplement consumed on each 
occasion was assessed by weighing the supplement drinks prior to and post-consumption. 
Records of consumption per child were used to determine which participants should be included 
in a per protocol analysis (n=70).  Test occasions took place every three weeks, at baseline (week 
0), midpoint (week 3) and post-intervention at endpoint (week 6). The analysis of the study data 
adjusted for baseline cognitive performance/subjective rating (of subjective state), age, IQ and 
gender. The findings provided limited evidence for beneficial effects of the active supplement 
on cognitive performance.  The active group were more accurate and achieved a higher span on 
a measure of working memory (executive function).  However, for both outcomes, the 
performance differences by condition failed to reach statistical significance. There was also a 
trend towards males in the active condition demonstrating greater accuracy compared to males 
in the placebo condition at endpoint on a measure of processing speed.  Subjective state was 
not influenced by the active supplement.  Other possible explanations for the limited significant 
cognitive performance differences in favour of the active condition include the intervention 
period not being of a long enough duration and the possible inappropriate selection of a 
cognitive battery.  
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Chapter 5 A randomised placebo-controlled trial examining the 
effects of acute and chronic phospholipid intake on cognitive 
performance in adults aged 50 years and over with a subjective 
memory complaint (Study 2). 
 
5.1 Cognitive decline in both healthy ageing and age-related disease  
The strongest risk factor for cognitive decline is age (Troyer et al., 2014).  Not all cognitive 
functions are equally affected by increasing age. Extant literature indicates that processing 
speed frequently declines with age (Deary et al., 2009b; Ebaid, Crewther, MacCalman, Brown, & 
Crewther, 2017; Eckert, Keren, Roberts, Calhoun, & Harris, 2010; Zaninotto, Batty, Allerhand, & 
Deary, 2018), with decline identified as being independent of motor control (Ebaid et al., 2017).  
Other functions commonly observed as declining with age include executive function (Fjell, 
Sneve, Grydeland, Storsve, & Walhovd, 2016; Isingrini et al., 2015; Kirova, Bays, & Lagalwar, 
2015) and episodic memory (Harada, Love, & Triebel, 2013; Nyberg, 2017; Tromp, Dufour, 
Lithfous, Pebayle, & Després, 2015).   
Processing speed, the capability of processing information rapidly (Ebaid et al., 2017), has been 
suggested to underlie age-related variation in cognitive functioning (Salthouse, 1996).  Cognitive 
task performance on a range of tasks is vulnerable to, and restricted by, processing constraints 
and differences in the effectiveness of processes.  When processing speed is slow, performance 
is impaired due to a lack of time to complete relevant operations and the output from earlier 
processing may not be available when the results of subsequent processing are derived 
(Salthouse, 1996).  Processing speed has been assessed using a number of different variables, 
such as decision speed, perceptual speed and psychomotor speed (Salthouse, 2000).  There is 
evidence to suggest that processing speed mediates other cognitive functions, for example, 
along with working memory and inhibitory control, processing speed has been acknowledged as 
contributing to age-related changes in episodic memory (Head, Rodrigue, Kennedy, & Raz, 
2008).   
Importantly, deficits in executive functioning may be a marker of likely progression to AD (Clark 
et al., 2012; Irwin, Sexton, Daniel, Lawlor, & Naci, 2018) and particular executive functions may 
demonstrate greater sensitivity to global cognitive decline than others. In a prospective 
longitudinal study (n=71, of which n=51 were cognitively normal and n=20 had MCI), 
performance differences on measures requiring inhibition and switching were shown to 
151 
 
differentiate between participants who demonstrated a significant decline on the Dementia 
Rating Scale (DRS) and those who did not over a 1 year period.  Importantly, demographic 
characteristics and DRS score at baseline did not differ significantly between decliners and non-
decliners (Clark et al., 2012). Working memory, a type of executive function (Diamond, 2013), 
facilitates online monitoring and temporarily holding auditory and visual information in mind 
(Baddeley, 1986; Baddeley, Eysenck, & Anderson, 2015).  There is a great deal of empirical 
support for age-related decline in working memory function.  Specifically, age-related decline in 
verbal and visuospatial working memory has been observed with increasing task complexity 
(Cansino et al., 2013; Klencklen, Banta Lavenex, Brandner, & Lavenex, 2017).  In addition, 
increased susceptibility to intrusions (De Beni & Palladino, 2004), a decline (and absence in 
some) in the recency-effect in verbal working memory (Van den Noort, Haverkort, Bosch, 
Hugdahl, & Hugdahl, 2006), as well as an impairment in memory updating (De Beni & Palladino, 
2004) have been documented with increased age. 
Episodic memory is extremely vulnerable to cerebral ageing and neurodegeneration (Kinugawa 
et al., 2013), with deficits being more noticeable in tasks requiring recall rather than recognition 
(Nyberg et al., 2003).  Episodic memory decline is a frequent occurrence in ageing and decline 
in episodic memory, along with executive function, is a characteristic of pathological ageing 
(Aretouli & Brandt, 2010; Baudic et al., 2006).  Episodic memory performance tends to decline 
around 65 years of age (Kinugawa et al., 2013), although there is variation in onset and rate of 
decline (Gorbach et al., 2017).  Indeed, the episodic memory trajectory in older adults has been 
related to ethnic background, years in education and presence of ε4 allele at APOE gene (Lee et 
al., 2018).  Importantly, damage to the temporal lobe has been shown to impede re-
experiencing a past event and imagining future events (Race, Keane, & Verfaellie, 2011).  A 
critical part of the medial temporal lobe for episodic memory is the hippocampus and the 
involvement of the hippocampus in memory formation and maintenance is well established 
(Behrendt, 2013; Sadeh, Chen, Goshen-Gottstein, & Moscovitch, 2019; Wixted et al., 2018). In a 
longitudinal study, decline in episodic memory over 15 years in cognitively healthy individuals 
was significantly associated with reduced volume of the hippocampus over 4 years in those aged 
65 - 80 years but not in those aged 55 - 60 years (Gorbach et al., 2017).   
5.2 Age-related structural and functional brain changes and their 
association with cognitive function 
Increasing age is not only associated with cognitive decline and neurodegeneration (Corrada, 
Brookmeyer, Paganini-Hill, Berlau, & Kawas, 2010), but also regional brain atrophy and disrupted 
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connectivity both in terms of structure and function (Hafkemeijer et al., 2014).  The normal 
maturation of white matter has been suggested to follow an inverted U-trajectory with a 
maturation peak around midlife (Yeatman, Wandell, & Mezer, 2014).  Indeed, middle adulthood 
has been suggested as the turning point from development to ageing in respect of white matter 
coherence (Giorgio et al., 2010).  This is also reflected in findings from big data analytics, whilst 
grey matter continues to decrease from the second decade onwards (Coupé, Catheline, Lanuza, 
& Manjón, 2017).  This pattern is reportedly also shown for volume trajectories across the 
lifespan of almost all subcortical structures except for the amygdala and hippocampus, with the 
amygdala presenting a more stable volume trajectory until around 80 years of age, whilst the 
hippocampus also demonstrates an inverted-U pattern although it has a longer maturation 
period (Coupé et al., 2017).  There is also evidence that those areas that myelinate early show a 
more continuous trajectory of ageing relative to those that mature later (Sowell et al., 2003), 
while those that are the last to myelinate are also the earliest to deteriorate with age (Kochunov 
et al., 2007).   
Loss of grey matter density (Sowell et al., 2003), white matter integrity (Bennett et al., 2017) 
and cortical thickness (Fjell et al., 2009), the presence of white matter signal abnormalities 
(Lindemer, Greve, Fischl, Augustinack, & Salat, 2017) and disruption of structural and functional 
brain systems (Andrews-Hanna et al., 2007) are all associated with ageing even in the absence 
of neurological disease. Importantly, age-related alterations are not homogenous but can 
display individual differences in respect of brain substrates and cognitive functions (Persson et 
al., 2016; Raz et al., 2005).  Indeed, onset and rate of decline vary across individuals (Raz et al., 
2005). Notably, individual differences in respect of cognitive dysfunction with age and 
discrepancies between the extent of cerebral atrophy and clinical outcomes has been discussed 
previously in the context of cognitive reserve, brain reserve and brain maintenance (Nyberg, 
Lövdén, Riklund, Lindenberger, & Bäckman, 2012a).  For example, education as a proxy of 
cognitive reserve has been observed as attenuating age-related alterations in cognition (Farina, 
Paloski, de Oliveira, de Lima Argimon, & Irigaray, 2018; Roldán-Tapia, Cánovas, León, & García-
Garcia, 2017).  However, any resilience afforded by education may be limited in respect of 
protective effects (Lavrencic et al., 2018) and the stage in life a person receives further education 
may be an important factor (Thow et al., 2018).  That is, the likelihood of cognitive reserve 
facilitated by education is increased by recent educational experiences rather than remote (i.e. 
schooling), which is limited in its contribution, that is, towards premorbid cognitive function only 
(Wilson et al., 2019). 
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5.2.1 Changes in white matter integrity with ageing 
Diffusion Tensor Imaging (DTI) relies upon MRI signal detection, with the MRI signal intensity 
reflecting distance and direction of water diffusion (Alger, 2012).  Whereas fluid filled areas in 
the brain, and to a lesser extent grey matter diffusion, is non-directional (isotropic) and 
unrestricted, diffusion within white matter is anisotropic (exhibiting variations in physical 
properties when measured in different directions); tissue integrity is inferred based on rate and 
directionality of molecular diffusion (Bennett & Madden, 2014). In a review of cross-sectional 
and longitudinal studies using DTI to explore white matter integrity in ageing, a common finding 
includes decreased fractional anisotropy (degree of anisotropic diffusion) and increased mean 
diffusivity (average diffusion rate) with increasing age.  Although results showed individual 
differences and overlap across age ranges, the findings suggest deterioration in both the 
integrity and composition of white matter in ageing (Bennett & Madden, 2014).  Further, 
another common finding is that radial diffusivity (diffusion perpendicular to axonal bundles) 
tends to be increased in old age (Bennett & Madden, 2014; Bennett et al., 2010), this being a 
surrogate marker of myelin damage (Winklewski et al., 2018; Zhong et al., 2012).  Notably, in 
one study on age-related changes in grey and white matter across adulthood, reduction in 
fractional anisotropy was found to be driven by an increase in radial diffusivity, possibly 
reflecting alterations in myelin sheaths or loss of axons in fibre tracts (Giorgio et al., 2010).  
Previously, it was suggested that frontal brain regions were disproportionally affected by 
increasing age (Madden, Bennett, & Song, 2009; Sullivan et al., 2001; Sullivan & Pfefferbaum, 
2003), however, others have identified large age-related declines in posterior regions (Bennett 
et al., 2010; Giorgio et al., 2010; Salat et al., 2005). 
Numerous DTI studies have associated white matter integrity with cognitive function, where 
increased integrity is associated with superior cognitive performance.  For example, 
deterioration in white matter connections have been related to poorer episodic memory 
(Lockhart et al., 2012; Metzler-Baddeley, Jones, Belaroussi, Aggleton, & O’Sullivan, 2011; Sexton 
et al., 2010; Yassa, Muftuler, & Stark, 2010), a lack of adoption of the fast speed-accuracy trade-
off (Forstmann et al., 2011), and poorer executive function (Jacobs et al., 2013; Ystad et al., 
2011), reasoning and cognitive flexibility (Borghesani et al., 2013), grammar learning 
(Antonenko, Meinzer, Lindenberg, Witte, & Flöel, 2012), interindividual reaction time 
performance (Fjell, Westlye, Amlien, & Walhovd, 2011) and balance performance (Van Impe, 
Coxon, Goble, Doumas, & Swinnen, 2012) in older adults.  Notably, where effect sizes have been 
reported in studies that have observed these relationships, the largest were found for executive 
function and processing speed (Bennett & Madden, 2014).  There is also recent evidence 
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showing white matter integrity is compromised in those with subjective cognitive decline, and 
this is associated with poorer executive function performance (Ohlhauser, Parker, Smart, & 
Gawryluk, 2019).  Although in another study, white matter integrity was relatively preserved in 
those with subjective cognitive decline whilst being disrupted in those with amnestic MCI (aMCI) 
(Wang et al., 2016).  Alternatively, no difference was found in white matter integrity of normal 
and cognitively impaired-not demented (CIND) oldest old (90 - 103 years) (Bennett et al., 2017). 
Therefore, overall, the findings are inconclusive. 
5.2.2 The presence of white matter hyperintensities with age 
Increasing age is also associated with macrostructural changes in the brain.  That is, increasing 
age is a risk factor for white matter hyperintensities (WMHs; Zhuang, Chen, He, & Cai, 2018), 
which along with lacunas and microbleeds, are indicative of cerebral small vessel disease (Frey 
et al., 2019; Gouw et al., 2011).  WMHs are known to increase an individual’s risk of stroke and 
dementia (Prins & Scheltens, 2015; Wardlaw, Valdés Hernández, & Muñoz-Maniega, 2015). 
Specifically, increased deep WMHs have been found to promote the likelihood of vascular 
dementia (Smith et al., 2016). Interestingly, in a meta-analysis, the association between WMH 
and incident dementia was found for population-based studies but not in studies that examined 
high-risk populations (typically with mild cognitive impairment or a history of stroke).  However, 
it was suggested that this finding be considered with caution owing to small samples and 
methodological flaws (Debette & Markus, 2010).   
Crucially, WMHs have been associated with decline in global cognition, episodic, semantic and 
working memory and perceptual speed, and been found to contribute to an increased risk of 
developing MCI in a 6 year longitudinal study (adjusted for age, gender, total grey matter 
volume, vascular risk factors, and vascular diseases) in older adults assessed as cognitively 
normal at baseline (Boyle et al., 2016).  Moreover, increasing severity of periventricular 
hyperintensities identified in healthy older adults have been associated with greater decline in 
processing speed and executive function following adjustment for vascular risk and depressed 
mood (Prins et al., 2005), and development of persistent cognitive impairment after adjusting 
for age, APOE ε4 status, incident hypertension, intercranial volume, entry MMSE score, baseline 
hippocampus and ventricular cerebrospinal fluid volume and rate of ventricular cerebrospinal 
fluid volume change (Silbert, Howieson, Dodge, & Kaye, 2009).  Similarly, increases in white 
matter signal hyperintensity have been related to a decline in executive function over a ~2 year 
period in healthy adults aged 50 years plus (Kramer et al., 2007), whereas progression of 
periventricular hyperintensities has been associated with declines in processing speed over 3 
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years in healthy adults aged 60-90 years (van Dijk et al., 2008).  Additionally, progression of 
subcortical white matter hyperintensity volume has been related to decline in episodic memory 
in a longitudinal study (maximum follow‐up period of 18 years; x ̄9.1 years) that recruited healthy 
adults aged ≥ 65 years (Silbert, Nelson, Howieson, Moore, & Kaye, 2008).  Notably, in a review 
of studies considering the relationship between the location of WMHs and cognitive function in 
older adults, the association between periventricular hyperintensities and impaired memory, 
executive function and processing speed was identified to a greater extent relative to the 
association with subcortical hyperintensities.  Importantly, the review concluded that it was not 
possible to determine whether WMHs in different brain regions have differential effects on 
cognition.  However, caution must be exercised when considering these findings given that the 
review included studies that had recruited not only healthy older adults but also those with MCI 
and certain dementias (Bolandzadeh, Davis, Tam, Handy, & Liu-Ambrose, 2012).  
It has been proposed that WMHs as identified in conventional MRI scans represent the final 
stage of disease progression (Jokinen et al., 2015).  In contrast, DTI is able to detect subtle 
declines in white matter tract integrity even before WMHs are identifiable (Prins & Scheltens, 
2015).  The relationship between WMHs and cognition is not straightforward.  Indeed, WMHs 
may highlight a variety of symptoms, not necessarily related to cognitive dysfunction, or those 
with WMHs may even remain asymptomatic (Tomimoto, 2015).  Further, other types of brain 
damage, for example, grey matter atrophy, may confound any relationship between WMHs and 
cognitive dysfunction (Tomimoto, 2015; Xiong & Mok, 2011).   
5.2.3 Grey matter volume reductions with age 
A longitudinal study across 6 years that recruited healthy adults aged 21 – 80 years examined 
age-related alterations in topological organisation of structural brain networks.  Using 
measurements of regional grey matter volume, more localised organisation was identified in 
middle-to-old aged individuals (> approximately 50 years of age). This pattern of activity was the 
opposite of that seen in those identified as young to middle-aged, who showed greater global 
efficiency (< approximately 50 years of age; Wu et al., 2013).  Consistent with this, examination 
of structural covariance networks to study the pattern of covariance in grey matter volumes 
across different regions of the cortex revealed age-related topological changes. For younger 
individuals (18-23 years), topological organisation tended to be more distributed whereas 
middle-aged individuals (30-58 years) had more localised topology, which was sustained in those 
aged 61-89 years (Li et al., 2013).  Age-related grey matter volumetric reductions have been 
observed in frontal, temporal and parietal lobes, whilst the occipital lobe seems to be relatively 
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unaffected (Ramanoël et al., 2018).  Similarly, in a 4-year longitudinal study, the highest rates of 
regional grey matter loss in non-demented 65-82 year olds (n=1,172) were in the frontal and 
parietal cortices, temporal cortex as well as in the hippocampi and the middle and superior 
occipital gyri.  Moreover, the annual rate of global grey matter atrophy was significantly larger 
for women, chiefly in the frontal and parieto-occipital cortices, whereas the bilateral hippocampi 
showed age-related accelerated atrophy, which was similar across gender.  Interestingly, 
educational attainment was found not to attenuate grey matter loss, which may reflect 
education promoting cognitive reserve (e.g. connectivity efficiency) rather than the number of 
neurons (Crivello, Tzourio-Mazoyer, Tzourio, & Mazoyer, 2014).  Grey matter atrophy, WMHs 
and white matter integrity (fractional anisotropy) have been found to be independently 
associated with cognitive function but of these, grey matter volume was more closely associated 
with cognitive performance in a sample, aged 60 years and over, of cognitively healthy and 
impaired adults.  This finding is likely due to grey matter atrophy representing damage to 
neuronal soma, dendrites and synapses, thereby causing impairment in nodes in the neural 
networks, whereas WMHs and deterioration in white matter integrity may only impede tract 
transmission between regions that may be connected by multiple fibre pathways (He et al., 
2012).   
Global grey matter volume corrected for brain atrophy has been suggested as predicting 
executive function in cognitively healthy older adults, with those with larger grey matter 
volumes showing better performance on the Trail Making Test B (Laubach et al., 2018). 
Importantly, grey matter network disintegration was found to partially mediate the relationship 
between age and cognitive function.  Specifically, grey matter integrity of the fronto-occipital, 
temporal, limbic, cuneal and secondary somatosensory networks has been associated with 
memory performance.  Integrity of the cerebellar, fronto-parietal, temporal, secondary 
somatosensory, limbic and sensorimotor networks was associated with executive function in 
healthy older adults (Koini et al., 2018).   
5.2.4 Alterations in functional connectivity with age 
The measurement of functional connectivity (FC) aligns with the notion that coordinated activity 
between distinct, segregated brain regions supports cognition and where connectivity decreases 
imply compromised information transfer between brain regions (Hermundstad et al., 2013; Sala-
Llonch, Bartrés-Faz, & Junqué, 2015).  Resting-state FC is measured by taking fMRI scans 
sequentially during a period of undirected wakefulness (resting-state fMRI) to identify low 
frequency BOLD fluctuations that are correlated across distant brain areas (Sala-Llonch et al., 
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2015).  Resting-state FC of healthy adults (59-74 years) has shown decreased connectivity 
relative to younger adults within and between functional networks except for somatomotor and 
visual networks, which demonstrated an increase (Geerligs, Renken, Saliasi, Maurits, & Lorist, 
2015). Moreover, age-related differences in intrinsic connectivity patterns have also been seen 
in a sample of healthy young and middle-aged adults (18-65 years).  Specifically, with increasing 
age, increases in FC were seen in paralimbic cortical and subcortical regions, whilst decreases 
were found in visual cortex and several nodes of the DMN, a resting-state functional network, 
including the medial prefrontal, posterior cingulate (although this disappeared when head 
motion was controlled for), precuneus, lateral parietal and middle frontal gyrus. The increase in 
connectivity shown was proposed to reflect age-related changes in emotion processing and 
regulation capacity (Hampson et al., 2012).   
The reduction in FC in the DMN is consistent with previous findings using resting-state fMRI in 
healthy adults (Andrews-Hanna et al., 2007; Betzel et al., 2014; Onoda, Ishihara, & Yamaguchi, 
2012; Song et al., 2014; Tomasi & Volkow, 2012; Wang et al., 2010).  Notably, the DMN has 
received most attention compared to other resting-state functional networks (Sala-Llonch et al., 
2015; Tao et al., 2015) and reduced FC has been proposed to be a potential biomarker for AD 
(Balthazar, de Campos, Franco, Damasceno, & Cendes, 2014; Mohan et al., 2016), in which FC 
reduction is particularly acute (Dennis & Thompson, 2014; Klaassens et al., 2017).   
Integrity of the network associations with the default mode regions in healthy adults has been 
implicated in cognitive function.  Previous research reports reduced FC is associated with poorer 
working memory performance (Hampson, Driesen, Skudlarski, Gore, & Constable, 2006; 
Sambataro et al., 2010), associative memory (Wang et al., 2010), episodic memory, processing 
speed and executive function composites (Andrews-Hanna et al., 2007), verbal and visual 
memory (Sala-Llonch et al., 2014) and general intelligence (van den Heuvel, Stam, Kahn, & 
Hulshoff Pol, 2009).  Also, within-DMN FC has been specifically associated with episodic memory 
(Greicius, Srivastava, Reiss, & Menon, 2004; Staffaroni et al., 2018).  
5.2.5 Interim summary: Age-related cognitive decline and structural and 
functional brain changes, and their association with cognitive function 
Ageing is the strongest risk factor for cognitive decline.  Cognitive domains including processing 
speed, executive function and memory are found to be predominantly compromised with age.  
Anatomical and functional brain alterations are associated with healthy ageing and cognitive 
impairment.  A decline in grey matter volume is seen post the first 10 years of life, whilst white 
matter coherence starts to diminish in mid-life.  Volume trajectories of most subcortical 
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structures follow the same pattern as grey matter volume decline except for the amygdala, the 
trajectory of which is more stable, and the hippocampus, which peaks during midlife. The stable 
development of the amygdala until 80 years of age may explain emotional stability observed in 
ageing (Scheibe & Carstensen, 2010).  
With increasing age, grey matter has been observed as showing more localised organisation.  In 
healthy older adults, the highest rates of regional grey matter loss have been reported in frontal 
and parietal cortices, temporal cortex, hippocampi and the middle and superior occipital gyri. 
Global grey matter volume has been related to cognition, with greater volume being more 
favourable for executive function.  DTI has revealed that white matter integrity and composition 
deteriorates with age, which has been found to relate to poorer cognitive performance in 
multiple domains such as episodic memory, executive function, processing speed, reasoning as 
well as balance.  Further, myelin damage is also associated with ageing, possiby reflecting axonal 
loss, which is commonly observed in normal ageing and in age-related diseases (Salvadores, 
Sanhueza, Manque, & Court, 2017).  Similarly, poorer global cognition as well as reduced 
memory, executive function and processing speed performance has also been related to the 
presence of WMHs, the likelihood of which is increased with age. Moreover, WMHs have also 
been found to increase the risk of stroke and cognitive impairment (both MCI and DM). 
However, WMH lesions are not consistently associated with cognitive dysfunction and in some 
cases, there may be no symptoms at all.  Grey matter volume was found to associate more 
closely with cognitive performance in cognitively healthy and impaired older adults relative to 
WMHs and white matter integrity, which are all independently related to cognitive function. 
Resting-state FC measures show coordinated activity of spatially-distinct brain regions when at 
rest (undirected wakefullness) and also show age-related differences. Reduced FC in the DMN, 
a resting-state functional network, is important for memory, executive function, processing 
speed and general intelligence, and has been proposed as a potential biomarker for AD. 
5.3 Cell membranes in ageing  
5.3.1 Decline in cell membrane lipids in healthy ageing 
Exploration of the membrane lipid composition in the frontal and temporal cortices in healthy 
adults (no pathological changes; 20 – 100 years of age) has revealed that PLs diminish linearly 
from 20 years of age (Svennerholm, Boström, Jungbjer, & Olsson, 1994).  It has been reported 
that the rate of decline in PL quantity is slow between the ages of 20 and 80, after which, it 
becomes fairly marked (Svennerholm, Boström, Helander, & Jungbjer, 1991; Svennerholm et al., 
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1994). Reductions in myelin lipids have also been identified as occurring from 20 years of age 
also (Svennerholm et al., 1994). Ageing is also associated with a decline in cerebral omega-3 
PUFA levels owing to reduced absorption, decreased capacity to cross the blood-brain barrier 
(BBB) and reduced conversion of shorter-chained FAs to longer FAs (Yehuda, 2012).  
Furthermore, as discussed in Chapter 2 (section 2.6), the supply of omega-3 PUFA from a 
Western diet is suboptimal for the aged brain (Woo, 2011).   
However, as discussed in Chapter 2, impairment of mitochondrial bioenergetic function and 
increased oxidative stress promote lipid peroxidation, which disturbs the physicochemical 
properties of membrane lipids and their normal behaviour.  For a full discussion concerning 
mitochondrial dysfunction, oxidative stress and inflammation, and the impact of these on GPLs 
as well as the potential for GPL supplementation to restore and ameliorate both respectively, 
see Chapter 2 (sections 2.7.5 and 2.7.6).  
5.3.2 Cell membrane alterations in neurodegeneration 
Degradation of cellular membranes is a hallmark of neuronal degeneration.  Pronounced 
alterations in neural membrane GPL composition have been observed in neurological disorders 
(Shamim, Mahmood, Ahsan, Kumar, & Bagga, 2018).  Neurological disorders and 
neurodegenerative disease both involve uncontrolled lipid metabolism (Shamim et al., 2018).  
Changes in the molecular species of GPLs have also been identified such that PC containing DHA 
(PC-DHA) have been found to be selectively depleted in the grey matter of patients with AD; and 
in brain regions with pronounced Aβ deposition, the extent of PC-DHA reduction was 
significantly related to disease duration (Yuki et al., 2014).  Post-mortem brain sample studies 
highlighted abnormal metabolism of PLs in AD during the 1980s and 1990s.  Crucially, a previous 
study reported that increased membrane PL degradation, including reductions in PC and PE, was 
specific to AD and no other forms of neurodegeneration, such as Parkinson’s disease (Nitsch et 
al., 1992). Findings from experimental studies suggest PL deterioration intensifies the formation 
of amyloid, which has a reciprocal effect, and the viability of cholinergic neurons may be 
vulnerable to the degradation of choline containing compounds including PC (Klein, 2000). The 
study of autopsy brain samples from AD patients has further revealed that concentrations of PI 
and PE are significantly reduced, and the availability of PA has also been found to be lower in 
the superior temporal gyrus in AD brains.  These findings were not affected by APOE genotype 
(Pettegrew, Panchalingam, Hamilton, & McClure, 2001).  More recently, other findings from AD 
post-mortem brain tissues report that pooled data from the frontal cortex, temporal cortex, and 
cerebellum showed significant reductions in the levels of PC, phosphatidylcholine plasmalogen, 
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and lysoPC (Grimm et al., 2011). Further, AD has been observed as being associated with 
aberrant lipid profiles in lipid rafts taken from the frontal cortex (Martín et al., 2010).  Similarly, 
alterations in the lipid rafts from frontal and entorhinal cortices in AD brains have been identified 
in the initial stages of the disease.  Alterations in the lipid matrix impacted lipid classes and FAs 
in cortical lipid rafts and these alterations were paralleled by a rise in microviscosity, membrane 
order and amyloid precursor protein accumulation within rafts (Diaz, Fabelo, Ferrer, Marin, & 
Martin, 2017). 
AD is accompanied by increased lipid peroxidation (Shamim et al., 2018), leading to the 
formation of α, β-unsaturated aldehydes, which in turn mediate inflammation (Lee & Park, 
2013).  As discussed in Chapter 2 (section 2.7.6) inflammation is associated with 
neurodegenerative diseases (Amor, Puentes, Baker, & van der Valk, 2010; Chitnis & Weiner, 
2017; Stephenson, Nutma, van der Valk, & Amor, 2018).  Oxidising conditions brought on by ROS 
cause protein cross-linking and Aβ aggregation (Shamim et al., 2018).  Indeed, Aβ plaques 
identified in AD have been associated with oxidative damage and PET studies have shown 
reduced brain metabolism prior to the development of neuropsychological impairment and 
anatomical alterations (Sullivan & Brown, 2005).  Accumulation of neurotoxic proteins in AD 
typically co-occurs with mutations in mtDNA, impairment of mitochondrial integrity and 
oxidative phosphorylation, depletion of ATP and greater oxidative stress and subsequent 
necrosis (Aufschnaiter et al., 2017). Importantly, mitochondrial generation of ATP is directly 
linked to the regulation of synthesis, trafficking and degradation of GPLs (Paradies, Paradies, 
Ruggiero, & Petrosillo, 2013), therefore, depletion of ATP will likely have consequences for these 
processes.  Mitochondrial derived ROS are frequently seen in neurodegenerative disease and 
can result in lipid peroxidation and changes in membrane lipid composition (Aufschnaiter et al., 
2017), as discussed in Chapter 2 (section 2.7.5).   
Changes in mitochondrial associated membranes (MAMs) are claimed to play a role in several 
neurodegenerative diseases (Vance, 2014).  Mitochondrial dysfunction as seen in AD, 
amyotrophic lateral sclerosis, Huntington’s disease and Parkinson’s disease (Lezi & Swerdlow, 
2012) is known to happen early on in these disease states, suggesting this may be at the root of 
these neurodegenerative diseases, with protein oligomerization following as a result (Lane, 
Hilsabeck, & Rea, 2015).  Consistent with this, mitochondrial abnormality has been identified as 
a universal prelude to neurodegeneration (Kidd, 2005).  Indeed, brain samples from patients 
with MCI show elevated levels of aldehydes, suggesting a possible role of lipid peroxidation in 
the early stages of neurodegeneration (Butterfield et al., 2006; Reed et al., 2008; Reed, Pierce, 
Markesbery, & Butterfield, 2009).   
161 
 
5.4 Previous empirical findings reporting positive effects of GPLs on 
cognitive function  
In respect of the aims of the present study (see section 5.5), the systematic research review in 
Chapter 3 identified two studies of particular interest.  The first reported a treatment advantage 
(300 mg of bovine cortex PS per day) on immediate and delayed visual and verbal associative 
(Name-face association) acquisition and delayed recall at 3 and 6 weeks following the start of 
the intervention in a sample of middle-aged adults meeting the criteria for AAMI (Crook et al., 
1991).  The second found a benefit of PS-DHA/EPA (300 mg PS, 79 mg DHA+EPA) after 15 weeks 
of treatment in a sample of older adults with subjective memory complaints.  Specifically, 
beneficial treatment effects were reported for immediate verbal recall (trial 1 of Rey Auditory 
Verbal Learning Test (RAVLT), while sub-group analysis including participants that demonstrated 
better performance at baseline found a benefit for immediate verbal recall, verbal total learning 
(sum of scores of trial 1-5) and delayed verbal recall (Vakhapova et al., 2010).  Also of interest 
are the three studies that reported a treatment advantage following the administration 
Lacprodan® PL-20 for either 3 (Hellhammer et al., 2010) or 6 weeks (Boyle et al., 2019; Schubert 
et al., 2011). Positive treatment effects reported included a significant reduction in reaction time 
on an attention switch measure (Boyle et al., 2019), significantly better visual-spatial memory 
performance, although this was found only after post-hoc analysis split by age (Schubert et al., 
2011), and marginally significantly faster reaction time on a measure of verbal recognition 
memory after controlling for inter-individual variation in cortisol concentration (Hellhammer et 
al., 2010). However, unlike the participants recruited in the present study, the samples in these 
studies included young adults and the experimental procedure aimed to induce acute stress to 
enable exploration of the potential protective effects of PLs on cognitive function.  
Other empirical work undertaken to explore treatment effects of GPLs in cognitively healthy 
older adults with subjective memory complaints not meeting the criteria for inclusion in the 
systematic research review (Chapter 3) have also reported a benefit to cognitive function.  Moré 
et al. (2014) recruited adults who reported some memory problems in daily life in a single-centre 
randomised, double-blind, placebo-controlled, parallel group study.  Participants consumed 
capsules containing either 100 mg PS + 80 mg PA mixed with lecithin or a placebo (500 mg 
lecithin) three times per day for 3 months.  The PS + PA condition demonstrated significantly 
better performance on the information, visual memory and memorising numbers components 
of the Wechsler Memory Scale compared to those in the placebo condition. In a pilot study 
(open-label), eight older adults with subjective memory complaints took PS-omega-3 capsules 
that provided 300 mg PS and 37.5 mg EPA + DHA per day for 6 weeks (Richter, Herzog, Cohen, 
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& Steinhart, 2010).  Significant improvements were reported for delayed verbal recall (word list) 
and reaction time of detections in the vigilance task.  However, although these findings are 
promising, this pilot study used a small sample, did not use a control group and did not correct 
for multiple testing despite using the Cognitive Drug Research battery to assess participants.  
Therefore, the findings should be considered with caution.  
5.4.1 Interim summary: Age-related changes to cell membranes and GPL 
supplementation studies in adults with a subjective memory complaint. 
PL reduction in cell membranes has been identified in frontal and temporal cortices from twenty 
years of age in healthy adults.  Ageing is also accompanied by reduced cerebral levels of omega-
3 PUFA due to changes in absorption, poorer capacity to reach the brain and reduced FA 
conversion of shorter-chained FAs.  Moreover, comsuming a Westernised diet contributes to 
suboptimal provision of omega-3 PUFA for the aged brain. 
Cellular membrane degradation is a typical characteristic of neuronal degeneration (e.g. 
dementia).  Alterations in brain membrane GPL concentrations and composition including their 
constituent FAs, and aberrant lipid metabolism are recognised in neurological disorders, 
although the presentation of such may vary by disease state. Similarly, alterations in lipid rafts 
have been associated with AD with a concomitant reduction in lipid fluidity, increase in 
membrane order and amyloid precursor protein accumulation within rafts. Mitochondrial 
dysfunction and oxidative stress leading to lipid peroxidation and inflammation are observed in 
normal ageing and in neurodegeneration.  In AD, inflammation is related to Aβ aggregation seen 
prior to the development of neuropsychological impairment and anatomical alterations.  This 
accumulation may have a knock-on effect on the regulation of synthesis, trafficking and 
degradation of GPLs, due to depletion of ATP.  Importantly, mitochondrial dysfunction may have 
a causal effect in numerous neurodegenerative diseases.  
Previous studies that have found a benefit of GPL supplementation on cognitive function that 
are of relevance to the present study have recruited middle-aged and older adults with 
subjective memory complaints and reported treatment-related improvements in memory. In 
addition, three studies supplementing Lacprodan® PL-20 to explore whether the composite 
supplement protects against stress-induced cognitive performance impairments also reported 
a benefit to memory and vigilance in young adults.  
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5.5 Aims of Study 2 and related hypotheses 
The primary aim of the study presented in this Chapter was to assess whether acute (90 minutes) 
and/or chronic (12-weeks) supplementation of Lacprodan® PL-20 enhances cognitive 
performance on measures assessing memory and executive function in adults aged 50 years or 
over with a subjective memory complaint (SMC).  Adults with a SMC were recruited to the study, 
as SMCs have been claimed to potentially provide an early clinical marker of deterioration prior 
to the onset of MCI due to AD (Burmester, Leathem, & Merrick, 2016; Jessen et al., 2010; Slot et 
al., 2019; Studart & Nitrini, 2016).  Hence this sample enabled the opportunity to explore 
whether a GPL supplement (also containing SM) could foster cognitive performance 
improvements in an at-risk group (i.e. those at risk of further cognitive decline). Indeed, diet and 
nutrition are reported to be important modifiable risk factors that may provide the potential to 
delay or even prevent the onset of cognitive decline (Caracciolo, Xu, Collins, & Fratiglioni, 2014; 
van de Rest, Berendsen, Haveman-Nies, & de Groot, 2015).  In view of the potential for GPLs to 
protect and facilitate cognitive function (Chapter 2, section 2.7), their involvement in supporting 
cellular function, and the reported benefit of GPL supplementation in a similar sample (Crook et 
al., 1991; Moré et al., 2014; Vakhapova et al., 2010), it was hypothesised that supplementation 
with Lacprodan® PL-20 would promote better cognitive performance relative to the control 
group on the cognitive measures employed in the study.  In line with empirical work indicating 
age-related decrements in cognitive function (see sections 5.1 and 5.2), it was hypothesised that 
cognitive performance would be inversely correlated with age.  Further, given that individuals 
with higher IQ scores typically perform better on measures assessing mental abilities (Checa & 
Fernández-Berrocal, 2015; Haier, 2014), it was also hypothesised that those with a higher IQ 
score would show superior performance relative to those with a lower IQ score.  Females were 
expected to show a performance advantage on measures examining verbal memory 
(Asperholm, Nagar, Dekhytar & Herlitz, 2019; Herlitz & Yonker, 2002; McCarrey, An, Kitner-
Triolo, Ferrucci & Resnicj, 2016) and face-name associative memory (see Table 5.3) (Herlitz & 
Yonker, 2002). There is some evidence to suggest a male advantage for pattern separation 
performance (reviewed in Yagi & Galea, 2019).  It was therefore anticipated that males may 
show greater performance than females on a measure assessing this (see Table 5.3). No further 
hypotheses could be proposed regarding gender performance differences, either because such 
differences have not been identified in the previous literature, they do not exist (e.g. N-back; 
Schmidt et al., 2009) or there are inconsistent findings. A secondary aim was to explore whether 
Lacprodan® PL-20 supplementation had any effect on self-perceptions of cognitive failures as 
measured by the Cognitive Failures Questionnaire (Broadbent, Cooper, FitzGerald, & Parkes, 
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1982).  Consistent with the expectation of Lacprodan® PL-20 being favourable for cognitive 
function, it was hypothesised that those allocated to receive the supplement would report 
experiencing less cognitive failures over the intervention period.  Again, based upon the inverse 
relationship between age and cognitive function (see sections 5.1 and 5.2), it was further 
anticipated that the frequency of cognitive failures would be greater for older participants. 
5.6 Methods 
5.6.1 Participants 
Fifty adults aged 50 years and over were recruited to take part in the study from across 
Yorkshire.  All participants were cognitively healthy but felt that their memory had 
deteriorated with age and therefore presented with a SMC.  Of the fifty recruited to the 
study, two participants withdrew following baseline (week 0) assessment and one other 
participant withdrew post-midpoint (week 6) assessment making the final sample 47 
participants.  A CONSORT figure showing the flow of participants through each phase of the trial 
is shown by Figure 5.1. 
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Figure 5.1 CONSORT figure showing the flow of participants through each phase of the trial 
(screening, randomisation and intervention). 
5.6.1.1 Eligibility criteria 
The inclusion and exclusion criteria used to assess volunteer eligibility is presented in Table 5.1.  
During initial contact from an individual expressing an interest in the study, the researcher 
confirmed they were 50 years of age or over and had a SMC.   The latter was ascertained by 
asking the individual ‘Do you feel that your memory is worse than it used to be?’.  Any individual 
not 50 years of age or over and/or who did not present with a SMC were informed that they 
were not eligible for the study.  Medication and supplement use were also queried.  All reported 
medications were checked for side effects.  In cases where medication use increased the risk of 
experiencing cognitive or mood disturbances, individuals were asked whether they had 
experienced such side effects.  Providing no side effects of either nature had been experienced 
n=26 not randomised 
- 9 were unable to 
complete one of the 
cognitive measures at 
screening; 
- 14 scored < 26 on the 
Montreal Cognitive 
Assessment; 
- 1 scored ≥5 on the 
Geriatric Depression 
Scale; 
- 2 were unable to 
n=50 eligible and 
randomised 
n=24 allocated to the placebo 
condition. 
 
Discontinued intervention (n=1) 
Completed intervention (n=23). 
 
n=26 allocated to the active 
condition. 
 
Discontinued intervention (n=2) 
Completed intervention (n=24). 
 
n=76 healthy adults were invited to a screening 
appointment: 
 
 
- Study requirements and participant information 
sheet discussed; 
- Supplement sampled (2 flavours); 
- Familiarisation with test measures; 
- Informed consent; 
- Assessed against inclusion and exclusion criteria.  
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and the medication had been taken continually for a minimum of 6 months, the individual was 
invited to be screened.  The remaining eligibility criteria were checked during the screening 
appointment during which the researcher went through each criterion with individuals in 
person. All measures used in assessing eligibility are covered in section 1.6.3.1.   
Table 5.1 Inclusion and exclusion criteria for study sample 
Inclusion criteria  Exclusion criteria 
- Aged ≥ 50 years;  - Any self-reported psychiatric or medical 
disorder that could interfere with cognitive 
function; 
- Presents with a subjective memory complaint;  - Use of any drugs directly active on CNS, 
including prescription, herbal and diet 
supplements; 
- Has adequate intellectual function; - Evidence of delirium, confusion or other 
disturbance of consciousness; 
- Has capacity to consent to participation and is 
willing to consume supplement and complete 
consumption diary daily for 12 weeks; 
- Self-reported neurological disorders including 
dementia, Parkinson's disease, stroke, focal 
brain lesions, multiple sclerosis, and epilepsy; 
- Willing and able to participate in screening and 
testing measures on four occasions (screening x 
1, testing x 4); 
- Current diagnosis or history of alcoholism or 
drug dependence; 
- Able to follow verbal and simple written 
instructions in English; 
- History of any of infective or inflammatory 
brain disease; 
- Has normal vision and hearing, with 
appropriate corrective aids if required; 
- History of head injury; 
- Able to understand cognitive testing 
instructions and responding requirements; 
- Has colour vision deficiency and/or dyslexia; 
- Comfortable with a researcher conducting 
screening and testing measures. 
- Are lactose intolerant and/or suspects or know 
they have an allergy to any ingredient in the 
active and placebo supplements.a 
Note. aA list of ingredients was shown at screening. 
5.6.1.2 Recruitment 
A study advert (Appendix 29) was placed locally around the University campus, in Community 
and Leisure Centres, and in local Libraries.  A recruitment advertisement with details of the study 
was emailed to members of the University mailing lists and to individuals who had previously 
expressed a wish to be contacted concerning future research studies.  The advertisement was 
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also emailed to Marks and Spencer stores across West Yorkshire with a request that it be placed 
on staff noticeboards.   The advertisement was also posted on a closed Facebook group.  Details 
of the study were registered with the NIHR Join Dementia Research initiative, which has both 
cognitively impaired and cognitively healthy adult volunteers.  The study was also advertised in 
local magazines and the Yorkshire Evening Post, in which it featured as part of a wider focus on 
how to promote healthy cognition.  Individuals who met the initial eligibility criteria concerning 
age, having a SMC and not experiencing any medication side-effects (where medication was 
taken) were sent a participant information sheet (Appendix 30).  The researcher then made 
contact a week later to follow-up and schedule a screening appointment where appropriate.  
5.6.2 Experimental design 
This study conformed to a randomised, double-blind, placebo-controlled, parallel groups design 
comprising two treatment conditions.  A breakdown of the allocation by condition is provided 
in the CONSORT diagram (Figure 5.1).  Allocation to condition using a pre-prepared 
randomisation list took place prior to screening.  This avoided the risk of unblinding an individual 
during their screening in the case of any minor differences between the active and placebo 
supplements (e.g. colour) when they sampled the intervention products.  Block randomisation 
(quasi-randomisation) was used to allocate individuals to a condition.  This promotes equality in 
the demographic characteristics across experimental conditions (Efird, 2011).  Experimental 
blocks were created based on gender, age and level of education.  Participants were seen on 
four occasions including one screening session and four test sessions (time 1 – 4) as shown in 
Figure 5.2. 
Figure 5.2 Study appointment schedule. 
5.6.2.1 Sample size calculation 
An a priori power calculation was conducted based upon the Attention Switching Task (switch 
cost reaction time outcome) measure administered as part of a 6 week randomised, double-
blind, placebo-controlled, parallel groups trial that supplemented the diet of males (n=54) over 
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the age of 18 with Lacprodan® PL-20 (Boyle et al., 2019).  To detect a difference in log hazard of 
-0.1758 between placebo and treatment group with a SE of 0.0392, a sample size of 53 was 
determined i.e. 27 per arm.   
5.6.2.2 Ethical approval 
This study received ethical approval from the Institute of Psychological Science Research Ethics 
Committee (ref no:PSC-129; date approved: 14/11/2017).  An amendment was subsequently 
submitted on 14th February 2018 to allow screening appointments to be undertaken in the 
homes of those interested in participating in the study (ref no:PSC-289).  This amendment was 
approved on 14th February 2018. A fieldwork risk assessment had previously been completed 
and submitted with the initial application for ethical approval (PSC-129). 
During the screening appointment, participants were given written and verbal information 
about the purpose of the study and all procedures.  Participants were made aware they could 
withdraw at any point without having to give a reason. Permission was sought from all 
participants that withdrew from the study for the use of their data collected up until the point 
they withdrew.  Participants were also asked to contact the researcher in the first instance in 
case of any adverse events.  Ongoing oral assent was obtained from the participants throughout 
the trial.  
5.6.3 Intervention 
5.6.3.1 Supplements  
Either an active or placebo isovolumetric supplement drink was consumed by participants over 
12 weeks: 
a) Active: Containing Lacprodan® PL-20 (10.67 g PL-20 with 120ml water); 
b) Placebo: Matched for taste and appearance against the active supplement. 
The ingredients within the active and placebo supplements (%) are provided in Table 5.2 by 
flavour.  
Table 5.2 Composition of active and placebo supplements by flavour (%). 
Ingredient 
Chocolate 
active 
Strawberry 
Active 
Chocolate 
placebo 
Strawberry 
placebo 
Lacprodan® PL-20 54.00 54.86 0.00 0.00 
Sugar, sucrose, (white) 0.00 18.87 0.00 16.32 
Maltodextrin 0.00 0.00 60.13 60.96 
Nesquik, Cocoa powder 19.43 0.00 16.84 0.00 
Strawberry Flavour 0.00 0.51 0.00 0.44 
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Ingredient 
Chocolate 
active 
Strawberry 
Active 
Chocolate 
placebo 
Strawberry 
placebo 
Skim Milk Powder  25.30 25.71 21.93 22.23 
Cocoa 1.27 0.00 1.10 0.00 
Red colouring 0.00 0.05 0.00 0.04 
The composition of Lacprodan® PL-20, specifically, the quantities of GPLs and SM have been 
described previously in Chapter 4 (section 4.5.3.1).  Participants were required to take one 
supplement per day at a time convenient for them.  However, the researcher encouraged 
participants to take the supplement at a regular time to enable the consumption of the 
supplement to become a routine and therefore increase the likelihood of remembering to take 
it each day.  Supplements were in powdered form and were added to 120ml water prior to oral 
consumption.  Two flavours were available, strawberry and chocolate.  Single supplement 
portions were contained in individual sachets that required dry storage.  Participants were 
expected to consume 84 sachets over the 12-week intervention period.  All supplement packs 
were similar in appearance and identified with only a 3-digit code.  Supplement shelf-life was 
extended to March 2019 following microbiological assessment by Arla Food Ingredients P/S, 
Denmark.  This enabled the study to recruit participants over a longer period. 
5.6.3.2 Known drug reactions and interaction with other therapies 
An expert panel approved Lacprodan® PL-20 as part of nutrition bars and milk-based nutritional 
beverages as safe, suitable and GRAS in July 2014 (see Appendix 5).  As both supplements 
contain ingredients available from / used in regular food products only, it was not anticipated 
that the supplements will interact with other therapies or lead to a drug reaction. All adverse 
events were recorded (see section 5.6.3.5). 
5.6.3.3 Study restrictions  
Participants were asked to maintain their usual diet throughout the 12-week study period.  
5.6.3.4 Assessment of compliance 
A consumption diary (excerpt: Appendix 31) was supplied to participants, who were asked to 
record consumption of the supplements daily.  In addition, participants were required to store 
all part-empty and fully empty sachets, which were collected by the researcher at midpoint and 
endpoint appointments (up to 42 each time).  This afforded an additional measure of 
consumption.  On collection, a record was made as to the number of days the supplement had 
been taken for as indicated on the consumption diary as well as the total number of empty 
sachets returned.  In the case of part-empty sachets, it was recommended by Arla Food 
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Ingredients P/S, Denmark, that the amount of remaining supplement be weighed and deducted 
from the total weight of the supplement contained in each sachet.  However, all returned 
sachets from participants were fully empty. In the case of an inconsistency in respect of the 
number of empty sachets returned and the number of days the participant had indicated they 
had taken the supplement for in the consumption diary, clarification was sought from the 
participant.  Where a participant could not be sure or where clarification could not be gained, 
the lesser of the two (count vs. sachets returned) was recorded as the number of days the 
supplement had been taken for. 
The inclusion of a participant in the PP analyses was determined by their consumption of the 
supplement across the intervention period.  It was recommended by Arla Food Ingredients P/S, 
Denmark, that participants who had consumed the supplement drinks on at least 33 days 
between test sessions (33 of 42 days from baseline to midpoint and 33 of 42 days from midpoint 
to endpoint) were eligible to be included in the PP analysis (n=50).  
5.6.3.5 Adverse events 
Participants were advised during the screening appointment in cases of an adverse event taking 
place whilst enrolled on the study to contact the researcher as soon as possible following the 
onset of the symptom(s). Adverse events were recorded using an adverse event form (see 
Appendix 32). Each case was followed until the matter was resolved.  The researcher liaised with 
Arla Food Ingredients Group P/S throughout.  Participants were able to leave the study at any 
point. Adverse events which occurred during the study are described in section 5.12. 
5.6.3.6 Blinding  
Both participants and researchers were blind to the treatment condition (active/placebo) 
throughout the study and data analysis.  Both treatments were matched for colour and taste as 
far as possible. 
5.6.4 Screening 
The screening appointment lasted between 1 hour 30 minutes to 2 hours.  Appointments took 
place in the Human Appetite Research Unit (HARU), School of Psychology, or if requested, in the 
home of an individual interested in the study.  At the start of the appointment, the researcher 
fully briefed individuals by going through the participant information sheet, ensuring they fully 
understood the expectations of study participants. All questionnaires to be completed 
throughout the study and the supplement consumption diary were talked through.  A sample of 
either the active or placebo supplement (pre-determined by condition allocation) in both 
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flavours were prepared prior to the appointment, enabling individuals to try these after checking 
that they were not allergic or had an intolerance to any of the ingredients.  Once the individual 
had confirmed they enjoyed the supplement and felt comfortable with the expectation that they 
would consume the supplement daily over the 12-week intervention period, individuals 
completed a practice version of the cognitive measures to be used during each test session.  
Individuals were informed the data collected as part of this activity would not be used for any 
purpose, and that the activity simply allowed the individual to become familiar with the 
measures and provide the researcher an opportunity to ensure the individual fully 
comprehended the test requirements.  It also served to minimise practise effects likely to affect 
later cognitive performance where an individual entered the study.  Before being asked to sign 
the consent form (Appendix 33), individuals were given the opportunity to ask questions.    
Following this form being signed, screening measures and questionnaires were then 
administered (see sections 5.6.4.1 and 5.6.4.2), after which, the waist:hip ratio of willing 
individuals was measured as per standard operating procedures (Appendix 34).   
If during the screening appointment, an individual met the criteria for cognitive impairment 
and/or depression, the individual was informed of this by the researcher who then went through 
the assessment measure with them and how their score had led to this conclusion.  In addition, 
it was made clear that the assessment used to screen for cognition/mood (whichever applied) 
is a quick measurement that is convenient for use in the study and as such, it would be advisable 
for them to see their GP in the interests of a fuller, more comprehensive examination being 
undertaken.  Also, in respect of the Montreal Cognitive Assessment (MoCA; Nasreddine et al., 
2005) used to assess cognition, it was explained that the test specificity is 50%, which can lead 
to false positives.  Fifteen individuals met the criteria for cognitive impairment or depression 
(see Figure 5.1).  Contact details of support services such as counselling available in Leeds and 
Bradford were made available to these fifteen individuals.  
5.6.4.1 Screening measures 
SMCs have consistently been found to be associated with depression (Balash et al., 2013; Brigola 
et al., 2015; Buckley et al., 2013; Lehrner et al., 2014; Montejo Carrasco et al., 2017; Sousa, 
Pereira, & Costa, 2015).  Poorer cognitive function, physical function and state of health are also 
related to depression in older adults (Gale et al., 2011) and increasing age raises the likelihood 
of each of these (Bishop, Lu, & Yankner, 2010; Harada et al., 2013; Metti, Best, Shaaban, Ganguli, 
& Rosano, 2018; Murman, 2015; Payette et al., 2011; Sibbritt, Byles, & Regan, 2007).  It has been 
proposed that cognitive impairment represents a core feature of depression, with deficits 
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identified in attention, memory and executive function domains, as demonstrated by depressed 
patients (Rock, Roiser, Riedel, & Blackwell, 2014).  Consistent with this, increased severity of 
depression has been found to be significantly related to reduced performance in processing 
speed, episodic memory and executive function (McDermott & Ebmeier, 2009).  In order to 
control for the risk of cognitive dysfunction associated with depression, the Geriatric Depression 
Scale 15-item questionnaire (GDS-15; Yesavage & Sheikh, 1986) was administered at the 
screening appointment to screen for depression.  One individual met the criteria for depression 
and therefore was not recruited to the study.  
Additionally, the MoCA (Nasreddine et al., 2005) was undertaken during the screening 
appointment to ensure participants did not have cognitive impairment either due to having MCI 
or dementia.  There are two types of MCI, namely aMCI and non-amnestic-MCI (naMCI), both of 
which have different presentations in respect of structural alterations in the brain and patterns 
of performance on cognitive measures (Csukly et al., 2016). aMCI is distinguished from naMCI 
by the presence of memory impairment, with both subtypes affecting either single or multiple 
domains (Dugger et al., 2015; Petersen et al., 2014). SMCs have been identified as a risk factor 
for incident aMCI (Zammit, Lipton, Katz, Derby, & Hall, 2017). With this in mind, the MoCA was 
chosen to screen for cases of cognitive impairment, as this has been reviewed favourably as a 
brief screening measure in detecting aMCI (Ozer, Young, Champ, & Burke, 2016) but also MCI 
more generally and dementia (Wojtowicz & Larner, 2017).  Fourteen individuals met the criteria 
for cognitive impairment and therefore was not recruited to the study. 
5.6.4.1.1 Geriatric Depression Scale 15-item questionnaire (GDS-15) 
To screen for cases of clinical depression, a short form of the full Geriatric Depression Scale 
(Yesavage et al., 1982), the GDS-15 (Yesavage & Sheikh, 1986), was employed.  This measure 
consists of 15 questions, which respondents complete individually by selecting either ‘yes’ or 
‘no’ (Appendix 35). Responses that are indicative of possible depression are scored a 1 otherwise 
a score of 0 is given for each item.  A composite score is calculated from the 15 items, with a 
total score of ≥5 suggesting depression. Minimum and maximum total scores are between 0 – 
15, with a total score between 5-10 indicating mild depression, and a total score of ≥11 
suggesting severe depression.  Reliability coefficient (Cronbach’s alpha; rα) has been reported as 
rα = .80, with an overall sensitivity and specificity of 97% and 95% respectively (Nyunt, Fones, 
Niti, & Ng, 2009).   
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5.6.4.1.2 Montreal Cognitive Assessment (MoCA) 
The MoCA (Nasreddine et al., 2005)  was developed to identify MCI earlier relative to other 
clinical tools such as the Mini Mental State Examination (Trzepacz, Hochstetler, Wang, Walker, 
& Saykin, 2015) and scores can range from 0 - 30, with higher scores suggesting better 
performance (Appendix 36).  Items concern orientation, drawing figures, verbal fluency naming 
objects, memory, recall, attention, vigilance, processing speed, repetition and abstraction. 
Administration takes ~10 minutes and the administration and scoring instructions for the MoCA 
suggests a score of ≥ 26 is classed as non-demented (Nasreddine et al., 2005; Smith, Gildeh, & 
Holmes, 2007).  One point is added to the final score when an individual has 12 years or less of 
formal education (Nasreddine et al., 2005).  The MoCA has been shown to demonstrate a high 
sensitivity using this cut off score for MCI and DM identification, 83% and 94%, respectively, 
however, specificity is fairly poor - 50% for both (Smith et al., 2007).  Confirmatory factor analysis 
has led to the proposal of a two-factor model factorial structure; the first factor being memory 
(memory, language and orientation subtests) and the second factor being Attention/Executive 
Functions (attention, executive functions and visuospatial abilities subtests) (Duro, Simões, 
Ponciano, & Santana, 2010). 
5.6.4.1.3 Wechsler Abbreviated Scale of Intelligence (WASI) 
To assess of intelligence, the WASI (Wechsler, 1999) was employed. This measure was 
administered as previously described in Chapter 4 (section 4.5.4.1.1).  
5.6.4.1.4 Ishihara colour blindness test 
Colour deficiency was tested for due to two of the cognitive measures used on test days 
requiring participants to pay close attention to coloured pictorial presentations.   This measure 
was administered as previously described in Chapter 4 (section 4.5.4.1.2). No participants were 
identified as having colour vision deficiencies. 
5.6.4.2 Self-report forms completed during screening 
5.6.4.2.1 Sociodemographic form 
Sociodemographic details (Appendix 37) were recorded including age, gender, level of education 
(‘A’ level or equivalent or higher, ‘O’ level or equivalent, trade (commercial or clerical), none), 
language spoken at home and in country of birth, employment status, and marital status.  
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5.6.4.2.2 Socioeconomic indicator 
A measure of level of deprivation, previously used in a survey of household resources and 
standards of living (Townsend, 1979), comprising eight questions was utilised (Appendix 38).  
The total score reflects the number of items an individual does not have due to not being able 
to afford them rather than not wanting them but otherwise being able to afford them.  Income 
has been acknowledged as influencing cognitive performance in adults aged 50 years and above 
in a study that used cross-sectional data from the World Health Organization Study on Global 
Ageing and Adult Health (SAGE) Wave 1 (2007–2010) (Basu, 2013). Moreover, an indicator of 
cognition (processing speed) was found to be significantly associated with poverty index scores 
after controlling for ethnicity, age, health status, gender and childhood socioeconomic status 
(Zhang et al., 2015).   
5.6.5 Testing procedure 
Ethical approval was obtained to conduct test appointments either in the Human Appetite 
Research Unit (HARU) or in participants’ homes, depending on what was most convenient for 
each participant.  The date and time of the first test appointment (baseline) determined the date 
and time of subsequent appointments (assuming the availability of the participant and 
researcher).  Appointments took place during the morning, afternoon and evenings to 
accommodate participant availability; however, preference was given towards morning 
appointments, as this time of the day is more favourable when assessing cognitive performance 
in older adults (Anderson, Campbell, Amer, Grady, & Hasher, 2014; Knight & Mather, 2013; 
West, Murphy, Armilio, Craik, & Stuss, 2002).   
5.6.5.1 Test session 
At the start of each test appointment, participants completed three questionnaires measuring 
subjective state: State Anxiety Scale (S-anxiety; Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 
1983), Stress Arousal Checklist (SACL; Mackay, Cox, Burrows, & Lazzerini, 1978) and the Profile 
of Mood States – Short form (POMS; Shacham, 1983).  Hence, participants’ anxiety, stress, 
arousal and mood could be accounted for at the time of cognitive measure completion.  
Importantly, these subjective states have been identified as affecting cognitive performance. 
For example, acute cognitive performance anxiety has been shown to impair performance on 
an N-back measure (Angelidis, Solis, Lautenbach, van der Does, & Putman, 2019), while acute 
stress has been observed as affecting performance on a stroop-like task  (Kohn, Hermans, & 
Fernández, 2017).  Further, acute mood (induced positive and negative moods) is known to 
effect task-switch performance (Hsieh & Lin, 2019).  In addition, participants also completed the 
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Cognitive Failures Questionnaire (CFQ) (Broadbent et al., 1982) to document cognitive slip 
occurrence over the 6 weeks prior to the appointment. This was followed by presentation of the 
cognitive measures in a set order (parallel versions were used for each appointment).  The 
researcher remained with the participant whilst they completed the questionnaires and 
cognitive tests in case the participant had any questions or experienced any difficulty. This also 
allowed the researcher to audio record responses to two of the measures.  At the end of the 
baseline and midpoint appointments, participants were provided with 45 sachets of supplement 
and a supplement consumption diary. At the end of midpoint and the final appointment 
(endpoint), empty/part-empty supplement sachets and completed consumption diaries were 
collected by the researcher.  Each test appointment took approximately 1 hour to complete, and 
participants received £10.00 to cover any travel expenses and compensate for time lost.  
The baseline appointment took place 7 days after the screening appointment subject to 
participant availability and was split over two parts.  To test whether there is an acute benefit 
of consuming Lacprodan® PL-20 on cognitive performance, following completing the cognitive 
measures for the first time since screening, participants were given their first dose of the 
supplement prior to a 90-minute break, after which time the questionnaires and cognitive 
measures were administered for a second time.    Only dose 1 was taken in the company of the 
researcher, with all subsequent doses being taken by participants in their own homes.  Figure 
5.3 presents the test appointment schedule and details of appointment agendas. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Schedule of study appointments.  
 
Endpoint (week 12) 
 
* POST DOSE 84 * 
 
- Pre-test questionnaires: 
S-anxiety, SACL, POMS, 
CFQ; 
- Cognitive measures. 
 
 
Midpoint (week 6) 
 
* POST DOSE 42 * 
 
- Pre-test questionnaires: 
S-anxiety, SACL, POMS, 
CFQ; 
- Cognitive measures. 
 
 
Baseline (week 0) 
 
Pre-dost testing: 
- Pre-test questionnaires: 
S-anxiety, SACL, POMS, 
CFQ; 
- Cognitive measures. 
 
* DOSE 1 CONSUMED * 
 
+90 minutes post-
ingestion of first dose: 
 
- Pre-test questionnaires: 
S-anxiety, SACL, POMS, 
CFQ; 
- Cognitive measures. 
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5.6.5.1.1 Self-report measures completed during test sessions 
5.6.5.1.1.1 State-Trait Anxiety Inventory (STAI) 
The STAI (Spielberger et al., 1983) is comprised of 2 subscales, each consisting of 20 questions. 
The Trait Anxiety Scale (T-Anxiety) assesses the relatively stable propensity to be anxious, 
whereas The State Anxiety Scale (S-Anxiety – Appendix 39) evaluates how anxious the 
respondent feels at the time of completing the scale.  The former taps into states of calmness, 
security and confidence, whereas the latter focuses on tension, nervousness, apprehension, 
worry and arousal of the autonomic nervous system.  Respondents can select a single response 
as per the frequency of feelings ‘in general’ on the T-Anxiety (Almost Never, Sometimes, Often, 
Almost always).  For the S-Anxiety, responses are in the context of their current feelings ‘at this 
moment’ (Not at all, Somewhat, Moderately so, Very much so).  Responses indicating a lower 
frequency (T-Anxiety) and a lesser prevalence (S-Anxiety) produce a lower score, e.g. ‘Almost 
Never’ / ‘Not at all’ correspond to a score of 1, whereas, ‘Almost always’ / ‘Very much so’ 
correspond to a score of 4. Nineteen of the 40 items are anxiety-absent items. Scores on these 
items are reversed. Overall, a higher score represents greater anxiety.  Reliability coefficients of 
the STAI range between rα = .86 - .95 and test-retest reliability coefficients range between r = 
.65 - .75 over a 2-month period (Spielberger et al., 1983). 
5.6.5.1.1.2 The Stress Arousal Checklist (SACL) 
The SACL (Mackay et al., 1978) is a mood adjective checklist of 30 adjectives (Appendix 40) that 
distinguish between stress (18 items, e.g. ‘comfortable’, ‘nervous’, ‘tense’) and arousal (12 
items, e.g. ‘activated’, ‘drowsy’, ‘idle’). Respondents are asked to indicate how much each 
adjective represents how they are feeling at the time of completing the checklist using a 4-point 
Likert scale (long scoring method: Definitely feel = 4, Feel more or less = 3, Do not understand 
the adjective / cannot decide = 2, Definitely not feel = 1). Scores are reversed on negatively 
weighted items. The possible minimum and maximum scores are 18 – 72 and 12 – 48 on the 
stress and arousal sections of the checklist respectively. Reliability coefficients for the stress 
section are between rα = .86 – .89 and for the arousal section, rα = .74 – .84 (King, Burrows, & 
Stanley, 1983; Mackay et al., 1978; Mccormick, Walkey, & Taylor, 1985).  
5.6.5.1.1.3 The Profile of Mood States – Short form (POMS-SF) 
The POMS-SF (Shacham, 1983) is a mood adjective checklist of 37 items (Appendix 41) that 
measures 6 dimensions of distinct, transient affective states (Tension-Anxiety, Depression – 
Dejection, Anger – Hostility, Fatigue – Inertia, Vigour – Activity and Confusion – Bewilderment).  
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Respondents are asked to indicate how much each adjective represents how they are feeling at 
the time of completing the form.  A Total Mood Disturbance (TMD) and individual dimension 
scores can be calculated based upon responses according to a 5-point Likert scale (Not at all = 
0, A little = 1, Moderately = 2, Quite a bit = 3, Extremely = 4).  For this study, only the TMD score 
was analysed and this was calculated in line with a previous method (Curran, Andrykowski, & 
Studts, 1995).  Reliability coefficients for the POMS-SF subscale scores range between rα = .76 - 
.95, and for the TMD, rα = .87 - .92. Confirmatory factor analysis supports the 6-factor 
interpretation (Depression, Vigour, Anger, Tension, Confusion and Fatigue) (F. Baker, Denniston, 
Zabora, Polland, & Dudley, 2002; Curran et al., 1995; Shacham, 1983). 
5.6.5.1.1.4 Cognitive Failures Questionnaire (CFQ) 
The CFQ (Broadbent et al., 1982) measures everyday cognitive failures reflecting errors and slips 
in functioning (Wallace, Kass, & Stanny, 2002).  In a review of cognitive failures in daily life in 
healthy populations, cognitive failures were suggested to reflect fluctuations in cognitive 
capacity (Carrigan & Barkus, 2016).  Functionally, cognitive failures are minor slips that result in 
the usual smooth flow of either a physical or mental intended action being disrupted (Broadbent 
et al., 1982).  The CFQ is a 25-item self-report measure in which respondents are asked to 
indicate how often they have experienced each failure over the previous 6 months (Appendix 
42). For the purpose of this study, the reference period was altered to 6 weeks. This enabled 
measurement of cognitive failures between each chronic test session.  Respondents select 1 of 
5 possible responses available from a 5-point Likert scale (Very Often = 4, Quite Often = 3, 
Occasionally = 2, Very rarely = 1, Never = 0).  A total score is calculated by summing all item 
responses, with a higher score representing a greater number of cognitive failures.  Reliability 
coefficients range between rα = .85 - .90. Studies examining the structure of the CFQ using Factor 
analysis have reported 3, 4 and 5 factors, however, all have identified memory and action slips 
as core factors (Broadbent et al., 1982; Pollina, Greene, Tunick, & Puckett, 1992; J. C. Wallace et 
al., 2002).   
5.6.5.1.2 Assessment of cognitive performance 
The order of the cognitive measures that were administered along with respective completion 
times, the cognitive domains assessed, and outcome variables generated are listed in Table 5.3.
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Table 5.3 Order and nature of cognitive measure presentation during test sessions 
Cognitive measure Cognitive domain(s) assessed Outcome(s) Measure duration 
Visual Verbal Learning 
Test (VVLT) 
Assesses episodic verbal immediate and delayed 
memory of two-word lists, A and B.  
Number of words correctly recalled in any order: 
1. Rate of learning (word list A). A higher score is 
better; 
2. New learning (word list B). A higher score is better; 
3. Retroactive interference. A lower score is better; 
4. Proactive interference. A lower score is better; 
5. Delayed recall. A higher score is better. 
10 - 15 minutes in 
total 
N-back Task Dependent on age: 41-60-year olds:- attentional 
and executive processes; > 60-year olds:- 
attentional and executive processes (including 
updating) and verbal memory.  
1. Target accuracy: total of correctly identified 
targets as a % of the total number of targets 
(number of targets identified/66*100). A higher 
score is better; 
2. Total accuracy: total of correctly identified targets 
– number of false alarms as a % of the total 
number of targets (number of targets identified -
false alarms/66*100). A higher score is better; 
3. Reaction time (RT) for identification of targets. A 
faster time is better; 
4. RT for identification of non-targets. A faster time is 
better. 
5 minutes 
Face-Name Associative 
Memory Exam 
Assesses associative memory between pictorial 
(visual working memory) and verbal (verbal 
memory) presentations.   
1. The total of fore- and surnames correctly recalled 
immediately. A higher score is better; 
2. The total of fore- and surnames correctly recalled 
after a delay. A higher score is better. 
5 minutes in total 
Attention Switching 
Task 
Assesses executive function (cognitive flexibility) 1. Target accuracy: total of correctly identified 
targets by trial type (switch, nested, pre-switch). A 
higher score is better; 
2. Target RT: RT of correctly identified targets by trial 
type (switch, nested, pre-switch). A faster time is 
better; 
3 minutes 
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Cognitive measure Cognitive domain(s) assessed Outcome(s) Measure duration 
3. Switch cost (within each presentation colour i.e. 
blue / red): 
- accuracy (as a % of the total number of targets 
(number of targets identified/72*100) for switch 
trials (trial 1 (switch) – trial 2 (nested)) and 
repeat trials (trial 3 (pre-switch) – trial 2 
(nested)). A higher score is better;  
- RT for switch trials (trial 1 (switch) – trial 2 
(nested)) and repeat trials (trial 3 (pre-switch) – 
trial 2 (nested)). A faster time is better. 
Pattern Separation Task Assesses episodic memory 1. Pattern separation score: pattern separation rate – 
similar bias rate. A higher score is better; 
2. Recognition score: hit rate – false alarm rate. A 
higher score is better.   
4 minutes 30 
seconds 
Rapid Visual 
Information Processing 
Task (RVIP) 
Assesses working memory and visual sustained 
attention 
1. Total hits (targets). A higher score is better; 
2. Total false alarms. A lower score is better; 
3. RT for hits. A faster time is better. 
6 minutes 
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5.6.5.1.2.1 Cognitive measures 
As discussed in section 5.1, age-related cognitive decline is associated with both healthy and 
unhealthy ageing.  In both cases, processing speed, memory and executive functioning can 
become compromised (Harada et al., 2013; Hedden & Gabrieli, 2004). Notably, declines in 
episodic and working memory are more likely to accompany advancing age than other types of 
memory, such as procedural (Nyberg, Lövdén, Riklund, Lindenberger, & Bäckman, 2012b).  As 
indicated in Table 5.3, all cognitive measures used in the present study target these domains.   
The selection of cognitive measures employed in the current study was informed by previous 
research (see section 5.4) that recruited adults with subjective memory complaints and found 
significant treatment effects on memory performance: a Name face association measure 
(acquisition and delayed recall; Crook et al., 1991) and verbal memory on the RAVLT (Vakhapova 
et al., 2010).  In addition, other studies were considered that have reported a benefit of 
Lacprodan® PL-20 in spite of these recruiting younger adults and assessing participants under 
conditions of acute stress, particularly Boyle et al. (2019), who utilised the Attention Switching 
Task.  The Pattern Separation Task was utilised to assess the potential for the derivative of PI, 
PI(4,5)P2, to support LTD induction in the CA1 subregion of the hippocampus, which is thought 
to be involved in pattern separation (see section 2.7.2). Based on the empirical studies reviewed 
in Chapter 3, it was concluded that there is a paucity of literature exploring the effects of GPL 
supplementation in the areas of working memory performance and sustained attention. The 
present study therefore seeks to address this. 
Cognitive measures were presented on a Hewlett-Packard laptop using PsychoPy software 
(Peirce et al., 2019) and included practise trials (except for VVLT and the Face-Name Associative 
Memory Exam, as this would increase memory load and therefore most likely interfere with test 
performance).  Where stimuli were re-presented during a single test session, re-presentations 
were randomised to avoid the serial position effect i.e. words on the VVLT measure and faces 
on the Face-Name Associative Memory Exam. 
5.6.5.1.2.1.1 Visual Verbal Learning Test (VVLT) 
Similar to other verbal memory measures including the Californian Verbal Learning Test (CVLT; 
Delis, Kramer, Kaplan, & Ober, 1987), the Hopkins Verbal Learning Test (HVLT; Brandt, 1991) and 
the Rey Auditory Learning Test (RAVLT; Rey, 1941), the VVLT measures episodic verbal learning 
of a list of unrelated words.  Essentially, the measure is a visual analogue of the RAVLT and 
examines immediate memory span, new learning, susceptibility to interference (retroactive and 
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proactive) and long-term memory (+30-minute delay post-word list presentation). Two-word 
lists (List A and B) of 16 words each were visually presented in a random order, one word at a 
time, for 1 second with a 2 second inter-stimulus interval.  Participants recalled the words 
verbally in any order over a one-minute interval. Recall of the word lists was audio recorded.   
List A was presented repeatedly on 3 occasions before List B was shown (trials A1-A3).  List B is 
intended to interfere with the memory for words in List A. After the recall of List B (trial B1), 
participants were instructed to recall List A (trial A4) once again without list A being re-
presented.  Delayed memory for List A (trial A5) was assessed by asking participants to recall this 
list within 1 minute after a 30-minute interval, again in the absence of List A being re-presented.  
Participants completed other cognitive measures during the 30-minute interval between the 
immediate and delayed recall stages.  Different word lists were used for each test session 
(parallel versions) and versions were counterbalanced across test sessions. Word lists were 
selected from the MRC linguistic database and matched on concreteness, imageability, 
familiarity, age of acquisition and word length. 
The outcome variable for each trial was the number of correctly recalled words. For rate of 
learning, the analysis included trials A1-A3, where trial was added to the model to explore how 
performance varied across trials A1-A3 (inclusive). New learning explored performance for trial 
B1.  Retroactive interference is characterised by the learning of new material interfering with 
the recall of old material.  In this way, the number of words forgotten was calculated as the 
difference between the number of words correctly recalled on Trial A3 and Trial A4. 
Alternatively, proactive interference is the interference of old material on the recall of new 
material. This was calculated as the difference between correct recall of words from Trial A1 and 
Trial B1. The number of correct words recalled for Trial A5 determined the delayed memory 
score. 
5.6.5.1.2.1.2 Pattern Separation Task  
Pattern separation is the storage of similar or partially overlapping representations as distinct 
memories thus avoiding interference between memories (Deng, Aimone, & Gage, 2010; Yassa 
& Stark, 2011). Pattern separation is a crucial aspect of episodic memory (Leal & Yassa, 2018) 
and is vulnerable to age-related deficits (Stark & Stark, 2017).  Numerous studies using both 
animals and humans, as well as computational models of hippocampal learning, indicate 
functional roles of the dentate gyrus  and the CA1 (Hanert et al., 2019) and CA3 subregions of 
the hippocampus  (Bakker, Kirwan, Miller, & Stark, 2008; Lacy, Yassa, Stark, Muftuler, & Stark, 
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2011; Leutgeb, Leutgeb, Moser, & Moser, 2007; Leutgeb & Leutgeb, 2007) in pattern separation.  
From middle-age, the volume of the hippocampus has been shown to reduce in healthy adults 
(Driscoll et al., 2009), which has been associated with a decline in episodic memory and dentate 
gyrus (cortical region within the hippocampal formation) function (Kramer et al., 2007; Small, 
Tsai, DeLaPaz, Mayeux, & Stern, 2002).   
This is a continuous recognition task adapted from a visual short-term memory task (Smith, 
McKeown, & Bunce, 2017) in which door stimuli (pictures of doors obtained from Baddeley, 
Hitch, Quinlan, Bowes, & Stone, 2016) were presented for 2 seconds with a 2.5 second inter-
stimulus interval sequentially over 60 trials. On the presentation of each door, participants were 
instructed to identify whether the door had not been seen previously (classed as new), was 
similar to a door that has been seen previously (classed as similar) or had been presented 
previously (classed as old).  Reponses were made by pressing number keys 1, 2 and 3 on the 
keyboard, respectively, within the 2 second item presentation time.  Pattern separation and 
recognition scores were calculated based on the following matrix (Table 5.4): 
 Response type made 
 
 
Door type 
presented 
 New Old Similar 
New Correct rejection 
rate 
False alarm rate Similar bias rate 
Old Miss rate Hit rate Incorrect 
Similar Incorrect Pattern completion 
rate 
Pattern separation 
rate 
Table 5.4 Pattern Separation Task score matrix 
Door pairs were matched on perceptual and categorical similarity. Specifically, all door pairs 
were independently rated as being perceptually similar (Smith et al., 2017). Four intervening 
items (doors) were presented between each old pair and similar pair.  Each trial block of 60 trials 
comprises 20 single ‘new’ doors, 10 ‘similar’ door pairs and 10 ‘old’ door pairs.  Different door 
stimuli were used for each test session (parallel versions) and the presentation of each of the 60 
trial blocks were counterbalanced across test sessions.   
5.6.5.1.2.1.3 Face-Name Associative Memory Exam 
The lack of relatedness between a person’s face and their name makes associating one with the 
other a particularly difficult task (Werheid & Clare, 2007). An adaption of the Face-Name 
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Associative Memory Exam (Rentz et al., 2011; Sperling et al., 2001) was administered in which 
participants were shown (familiarisation stage) 10 colour photographs of unfamiliar male or 
female faces (from shoulders up on a plain background) with blank expressions, one at a time (5 
male, 5 female in each test session) for 2 seconds. Following this, the same photographs were 
presented individually for 5 seconds along with name details (a forename and surname situated 
centrally underneath each photograph). Participants were asked to associate the name details 
with the corresponding photograph.  Subsequently, participants were asked to recall 
(immediate recall) the full name (forename and surname) verbally on the re-presentation of 
each of the 10 photographs (presented successively for 5 seconds), which was audio recorded.  
Following a 30-minute interval, participants were shown the same photographs individually and 
asked to recall (delayed recall) the corresponding name details verbally for the second time, 
which was also audio recorded (5 seconds were allowed per photograph). Participants 
completed other cognitive measures during the 30-minute interval between the immediate and 
delayed recall stages. The order of presentation of each photograph across the measure was 
randomised and the presentation of each was followed by an inter-stimulus interval of 250 
milliseconds (ms).   
Older adults regularly struggle with remembering proper names (Leirer, Morrow, Sheikh, & 
Pariante, 1990). The lack of context hinders the formation of an association between a name 
and a novel face, which is complex (Werheid & Clare, 2007) and places more of a demand on 
cognition (Rentz et al., 2011). Previous work that assessed recognition memory for face-name 
pairs indicated that greater activation in the anterior hippocampal formation bilaterally and left 
inferior prefrontal cortex accompanied successful recognition (Sperling et al., 2003).  
Performance on the face-name task has been found to be inversely associated with Aβ 
deposition in frontal and precuneus, posterior cingulate, and lateral parietal cortices in 
cognitively healthy older adults, irrespective of cognitive reserve (Rentz et al., 2011). Moreover, 
evidence suggests that the face-name task is sensitive to memory impairments as seen in 
prodromal and early stages of AD (Werheid & Clare, 2007). 
Males and females featured in each photograph used in this study were aged 50 years or over 
at the time of the photograph being taken (database: Minear & Park, 2004).  It was thought that 
this was most appropriate given the age range of the study sample.  Selection of the photographs 
was determined following a validation study (ref no: 17-0138; date approved: 16-May-2017) 
that explored which photographs from a possible 280 were similar for attractiveness and 
distinctiveness. The attractiveness and distinctiveness of facial stimuli has been shown to affect 
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memory performance (Wiese, Altmann, & Schweinberger, 2014).  Adults aged 50 years or over 
(n=13) were recruited for the purpose of the validation study.  Participants viewed photographs 
(n=280) of unfamiliar male or female faces with blank expressions on a laptop (from shoulders 
up on a plain background) and rated  each for attractiveness and distinctiveness using a 7-point 
Likert scale (1-7 inclusive) featured below each photograph.  Specifically, all participants saw 
each photograph during a familiarisation stage. Following this, each participant was shown each 
photograph for a second and third time (immediately after the familiarisation stage).  On the 
second presentation, participants were asked to rate each person for attractiveness, whereas 
on the third presentation, participants rated each for distinctiveness. There was no time limit on 
each presentation and participants were able to take a comfort break when needed.  The Likert 
scale anchor points represented extreme ratings (not at all attractive/distinctive – very 
attractive/distinctive).  Participants were instructed to think of a distinctive face as one that 
could be classed as unusual, that would stand out in a crowd of more typical faces.   
Forenames associated with each photograph were taken from the Top Names of the 1960s as 
published by the Social Security Administration (Federal Agency) 
(https://www.ssa.gov/oact/babynames/decades/names1960s.html). Forenames were selected 
randomly from the list for each gender.  Attention was paid towards the nationality of each to 
ensure the use of those selected were not specific to a particular country.  Forenames were 
taken from this period (as opposed to more recent years), as the youngest participants were 
born within this decade and it was therefore expected that such names would be more 
representative.  Surnames associated with the photographs were derived from The Oxford 
Dictionary of Family Names in Britain and Ireland 
(https://global.oup.com/academic/product/the-oxford-dictionary-of-family-names-in-britain-
and-ireland-9780199677764?cc=gb&lang=en&) and were randomly selected.  All forenames 
and surnames were of two syllables and 6 letters in length.  Photograph and name pairings, and 
the allocation of the 20 face-name pairing trials to each block (1 block per test session) was 
randomised.  The presentation of each block was counterbalanced across test sessions and 
different face-name pairs were employed on each session (parallel versions).  No photograph or 
name was used more than once. 
5.6.5.1.2.1.4 Attention Switching Task  
This measure required participants to switch their visual attention (perceptual switching) 
depending on a visual cue (colour of stimuli) presented in each trial based upon the rule for that 
trial set (rule switch).  Whilst performing the measure, multiple goals operate simultaneously, 
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and the behaviour exhibited by participants is dependent upon the conditions of each trial and 
the specific rule in operation.  During rule switching, working memory is updated so that the 
correct behaviour is performed (Ravizza & Carter, 2008). Poorer performance is typically seen 
immediately following task switch (first trial of new rule implementation) indicated by greater 
error and longer response latencies. This is referred to as the switch cost (Monsell, 2003). 
Importantly, the left inferior frontal junction has been reported to play a crucial role in task-
switching and stronger connectivity between this and the bilateral posterior parietal cortex, the 
right middle frontal gyrus, and the bilateral middle occipital gyrus, in which the left inferior 
frontal junction acts as a hub to bring together task switch-related information, is related to 
better performance in task-switching i.e. reduced switch cost (Yin, Wang, Pan, Liu, & Chen, 
2015). These findings complement other reports that the inferior frontal junction coordinates 
thoughts and actions as per internal goals (Brass, Derrfuss, Forstmann, & von Cramon, 2005; 
Derrfuss, Brass, Neumann, & von Cramon, 2005). 
The task-switch measure is based upon a measure that combines a task-switch paradigm with a 
Go/No-go task (Wylie, Javitt, & Foxe, 2003) and administration of the measure followed a 
previous study considering the benefits of Lacprodan® PL-20 (Boyle et al., 2019).  Letter-number 
pairs e.g. ‘M + 9’ or ‘7 + R’, were presented in a quasi-random sequence in succession for 1 
second with an inter-stimulus interval of 120 ms.  The stimuli set included 8 letters (vowels: A, 
E, I, and U; consonants: G, K, M, and R) and 8 numbers (even: 2, 4, 6, and 8; odd: 3, 5, 7, and 9).  
Every three trials, letter-number pairs were presented in alternating colours (e.g. red or blue).  
The colour determined the rule for that trial set and therefore, the required response.  For 
example, participants were asked to respond by pressing the space bar when the letter in the 
pair was a vowel but not respond when it was a consonant when the pair was presented in red.  
Alternatively, participants were asked to respond (space bar press) when the number in the pair 
was even but not when it was odd when the pair was presented in blue.  Target trials (vowel 
letters and even numbers) were balanced across trials within each colour (24 for trial 1, 24 for 
trial 2 and 24 for trial 3 by colour) with a 50% probability of being presented amongst the 144 
trials.  Neighbouring trials featured different letters and numbers.  Half of the trials (n=72) 
included congruent pairs (e.g. 8 + U) whereas the remaining 72 trials included incongruent pairs 
(e.g. K + 2). Parallel versions were used across test sessions in which only the colours differed 
i.e. the letter-number pairs remained consistent across test sessions. The presentation of each 
test version was counterbalanced across test sessions. 
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Two of the outcomes for this measure, switch cost accuracy and reaction time, are calculated 
by comparing switch and pre-switch trials to the nested trial by subtracting. Here, nested trials 
are the comparator trial (control) with a level of performance least affected by the switch. 
Therefore, performance can be compared to this trial to indicate the level at which a cost in 
performance is evident.  
5.6.5.1.2.1.5 Rapid Visual Information Processing Task (RVIP) 
This measure is a serial discrimination task (Neale, Johnston, Hughes, & Scholey, 2015) devised 
by Bakan (Bakan, 1959) and is designed to assess working memory and visual sustained attention 
(Coull, Frith, Frackowiak, & Grasby, 1996; Neale et al., 2015).  With respect to task completion, 
it has been suggested that a right frontoparietal network supports sustained attention, whereas 
a left frontoparietal network facilitates the phonological loop component of working memory 
(Coull et al., 1996).  However, more recently, functional neuroimaging research using block 
analysis has shown increased activation in frontal, parietal, occipital and cerebellar regions 
(Neale et al., 2015).  Event related potential analysis has shown similar activation when 
considering correct responses only, particularly in the activation of the medial and inferior 
frontal and precuneus and cerebellum areas (Neale et al., 2015).  
Single digits (1-9) were presented in a quasi-random sequence one at a time in the centre of the 
screen, each being presented for 600 ms (100 per minute).  Digits were presented with no inter-
stimulus interval.  Participants were asked to respond when they identified three consecutive 
odd or even numbers (targets) by pressing the space bar. Eight targets were randomly presented 
per minute, 48 in total.  Parallel versions were used for each test session, with version 
presentation being counterbalanced across test sessions. 
5.6.5.1.2.1.6 N-back Task 
This measure is a continuous performance task and has been frequently used to measure 
working memory (Gajewski, Hanisch, Falkenstein, Thönes, & Wascher, 2018; Yaple, Stevens, & 
Arsalidou, 2019).  N-back can be presented in various forms including visual, auditory, and 
olfactory, placing demands on separate processing systems (Owen, McMillan, Laird, & Bullmore, 
2005).  Working memory load is manipulated by altering the distance between trials that are 
compared (1, 2 or 3 trials back), with 3 back being the most difficult.  Gajewski and colleagues 
(2018) have reported age-related differences in performance, with reaction times increasing and 
accuracy decreasing progressively with increasing age.  Findings from a meta-analysis of fMRI 
studies assessing N-back performance across the healthy adult lifespan indicates the parietal 
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and cingulate cortices as well as the insula, claustrum and cerebellum are engaged during the 
task for all ages.  However, prefrontal cortex engagement illustrates a gradual linear decline with 
age, which is absent in older adults (Yaple et al., 2019).  Correlating performance on the N-back 
with other measures of cognitive function has also revealed age differences.  Specifically, 
younger adults have been found to employ mainly executive functions, whilst performance by 
middle-aged adults has been found to involve attentional and executive functions.  Moreover, 
older adults have been found to typically utilise attentional, updating and verbal memory 
functions and executive functions to a lesser extent (Gajewski et al., 2018). 
This measure employed a working memory load of 2 (2-back) in which a series of digits (0-9) 
were presented one at a time in a quasi-random sequence in blocks of 50 trials.  Administration 
of the measure followed a previous study considering the benefits of Lacprodan® PL-20 (Boyle 
et al., 2019).  Digits were presented for 500 ms (single trial) with an inter-stimulus interval of 1 
second, and 4 blocks of trials were presented at each test session.  Participants were asked to 
respond on all trials, for both non-targets and targets by pressing the number keys 1 and 2 on 
the keyboard, respectively.  A target is classified as the presentation of the same digit being 
shown in both the current trial and two trials back (3, 0, 3), whereas a non-target is identified 
when there is a lack of correspondence between the digits (2, 0, 3).  Target stimuli were 
presented randomly with a probability of 33% (over the 200 trials) and the first three trials were 
always non-targets.  Parallel versions were used for each test session, with version presentation 
being counterbalanced across test sessions. 
5.7 Data analysis 
The analysis of the data collected in the present study was carried out in two separate stages.  
The first stage involved analysing cognitive measure data collected prior to and following acute 
supplementation i.e. time 1 (baseline, pre-first dose) and time 2 (+90 minutes post-first dose). 
The second stage involved analysing cognitive and subjective data (Cognitive Failures 
Questionnaire) collected prior to and following chronic supplement administration i.e. baseline 
(pre-first dose), midpoint (+6 weeks baseline, after 42 supplement doses) and endpoint (+12 
weeks baseline, after 84 supplement doses).  
As with Study 1 (Chapter 4), baseline performance, age, IQ and gender were controlled for in 
the analysis of the cognitive measure data and subjective data from the Cognitive Failures 
Questionnaire.  In respect of the first data analysis stage, controlling for baseline performance 
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(time 1) resulted in data being available for one test point only, time 2 (+90 minutes post-first 
dose). Due to this, the factor time was removed from the model following independent 
statistical advice (Quadt Consultancy BV, personal communication), which meant the main 
effect of time and interactions with time could not be requested.  As for the second data analysis 
stage, this was similar to that carried out on the data from Study 1 (see section 4.6).  
In the present study, the Attention Switching Task (switch cost reaction time) was the primary 
outcome variable, whilst other cognitive and subjective measures were secondary outcome 
variables.  Cognitive measure data were extracted from PsychoPy (Peirce et al., 2019) and 
entered in Excel and checked for accuracy.  Participant responses from the Visual Verbal 
Learning Test (VVLT) and the Face-Name Associative Memory Exam were audio recorded and 
scored according to the marking scheme.  Subjective data was also scored.  Scores were tallied 
by participant and week, entered and checked for accuracy in Excel.  
Trial was included in a model as a nominal variable for the Attention Switching Task outcomes 
and the rate of learning outcome of the VVLT where this led to an improvement in the model fit 
(Quadt Consultancy BV, personal communication).  The total number of correct trials obtained 
(total correct) at each test point was also entered in a model as a covariate for all reaction time 
outcome measures of the N-back task and the Rapid Visual Information Processing Task, again, 
where this led to an improvement in model fit. This also applied to target accuracy and switch 
cost accuracy in the analysis of target reaction time and switch cost reaction time, respectively, 
from the Attention Switching Task measure.  Responses to subjective state questionnaires 
(POMS, SACL and STAI) were analysed prior to cognitive measure data analysis to determine 
whether anxiety and/or mood were statistically different between conditions prior to cognitive 
test administration. No statistical differences in the subjective responses of participants were 
found and therefore these variables were not included as covariates in the analysis of cognitive 
measure data.  
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5.8 Results 
Fifty participants enrolled on to the study and completed the acute assessment. Two 
participants withdrew following this, prior to midpoint (data collected at midpoint corresponds 
to forty-eight participants).  One further participant withdrew for health reasons between 
midpoint and endpoint (data collected at endpoint corresponds to forty-seven participants).  
Forty-seven participants complete the full trial (see Figure 5.1).  
5.8.1 Adverse events 
Five participants reported adverse events following supplementing their usual diet with the 
study supplement.  One participant (active condition) withdrew from the study after having an 
allergic reaction to the supplement within days of commencing the intervention.  At their final 
appointment, a second participant (placebo condition) revealed they had been experiencing a 
variety of symptoms including pains in their stomach, belching and diarrhoea for 9 weeks over 
the course of the 12-week intervention period. However, they suspected these symptoms were 
due to stress.  A third participant (active condition) reported high potassium levels and a fourth 
(active condition) reported increased systolic blood pressure whilst on the study but it is thought 
that these conditions are unrelated to supplementation with the study products and both 
completed the study and were included in the analysis. A fifth participant (active condition) 
experienced diarrhoea following consuming the supplement for one week and withdrew from 
the study. Thus, 3 of the participants who reported adverse events were included in the analysis. 
5.8.2 Participant characteristics 
The characteristics of the 50 middle-aged and older adults with a subjective memory complaint 
that met the experimental drink consumption threshold (per protocol analysis) across the 12 
weeks are presented in Table 5.5.  
Table 5.5 Participant characteristics of those included in the analyses from the two conditions 
 Active 
(n=26) 
Mean ± SE 
/Median (Range) 
Placebo 
(n=24) 
Mean ± SE /Median 
(Range) 
Active vs. placebo condition 
Age (months) 742.88 ± 14.79 749.42 ± 16.30 t(48) = -.30, p = .767a 
IQ 118.0 (98, 130) 118.5 (87, 129) U = 350.5, p = .453 
Gender                               
M                    7 (50%)  7 (50%)  Χ2(1, N = 50) =.03, p = .860 
F 19 (53%) 17 (47%)  
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 Active 
(n=26) 
Mean ± SE 
/Median (Range) 
Placebo 
(n=24) 
Mean ± SE /Median 
(Range) 
Active vs. placebo condition 
Language 
spoken at home 
  
Χ2(1, N = 50) =.94, p = 1.00b 
English 25 24  
Arabic  1 0  
Employed   Χ2(1, N = 50) =.79, p = .407 
Yes 13 15  
No 13 9  
SES 3 (11%) 0 (0%) U = 288.0, p = .170 
Waist:hip ratioc 0.86 (0.69, 1.07) 0.82 (0.72, 1.06) U = 248.5, p = .217 
aEqual variances assumed. bExact test. cWaist/hip measurements. SES: Socioeconomic status 
5.8.3 Acute effect of intervention on cognitive performance in middle-aged 
and older adults with a subjective memory complaint 
5.8.3.1 Measures of executive function performance 
Table 5.6 provides a summary of the means (± SE) across measures of executive function 
performance for active and placebo conditions. 
Table 5.6 Mean (± SE) on measures of executive function performance (Attention Switching 
Task, Rapid Visual Information Processing and N-back Task) by condition and test occasion 
Outcome 
Time 1 
 (pre-first dose)a 
Mean ± SE 
Time 2 
(+90 minutes post 
time 1 & first 
dose) 
Mean ± SE 
Active vs. placebo 
Attention Switching Task: 
Switch cost reaction time 
(s) 
   
Active (switch trials) 0.27 ± 0.56 -0.24 ± 0.59 
F(1,91) = 7.46, p = .008 
Placebo (switch trials) -0.44 ± 0.65 -0.75 ± 0.58 
Active (repeat trials) 1.09 ± 0.43 0.64 ± 0.46 
Placebo (repeat trials) -0.03 ± 0.62 -0.12 ± 0.56 
Attention Switching Task: 
Switch cost accuracy (%) 
   
Active (switch trials) -1.21 ± 1.10 -2.56 ± 1.16 
F(1,92) = 0.02, p = .898 
Placebo (switch trials) -1.34 ± 1.31 -2.10 ± 1.22 
Active (repeat trials) 1.15 ± 0.75 0.99 ± 0.96 
Placebo (repeat trials) 0.70  ± 0.99 0.65 ± 1.01 
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Outcome 
Time 1 
 (pre-first dose)a 
Mean ± SE 
Time 2 
(+90 minutes post 
time 1 & first 
dose) 
Mean ± SE 
Active vs. placebo 
Attention Switching Task: 
Target accuracy (n) 
   
Active (switch trials)  12.82 ± 0.82 13.85 ± 0.95 
F(1,142) = 0.96, p = 
.328 
Placebo (switch trials) 13.12 ± 0.69 13.65 ± 0.86 
Active (nested trials)  13.69 ± 0.89 15.69 ± 0.96 
Placebo (nested trials) 14.08 ± 1.14 15.17 ± 1.07 
Active (pre-switch trials)  14.52 ± 0.99 16.41 ± 1.11 
Placebo (pre-switch trials) 14.59 ± 1.01 15.64 ± 1.05 
Attention Switching Task: 
Target reaction time (s) 
   
Active (switch trials)  9.08 ± 0.63 9.97 ± 0.70 
F(1,141) = 4.24, p = 
.041 
Placebo (switch trials) 9.36 ± 0.72 9.72 ± 0.77 
Active (nested trials)  8.81 ± 0.70 10.21 ± 0.62 
Placebo (nested trials) 9.80 ± 0.84 10.47 ± 0.74 
Active (pre-switch trials)  9.90 ± 0.72 10.85 ± 0.73 
Placebo (pre-switch trials) 9.76 ± 0.79 10.35 ± 0.72 
Rapid Visual Information 
Processing (RVIP): Hits (n) 
  
 
Active  18.00 ± 1.94 19.92 ± 2.00 
F(1,46) = 6.80, p = .012 
Placebo 16.88 ± 1.68 15.17 ± 1.87 
Rapid Visual Information 
Processing (RVIP): False 
alarms (n) 
   
Active  16.85 ± 2.65 14.04 ± 1.73 
F(1,42) = 0.44, p = .508 
Placebo 22.17 ± 3.36 19.05 ± 3.48 
Rapid Visual Information 
Processing (RVIP): Reaction 
time for hits (s) 
   
Active  0.46 ± 0.00 0.46 ± 0.00 F(1,864) = 8.41, p = 
.004 Placebo 0.46 ± 0.01 0.47 ± 0.00 
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Notes. aTime 1 represents baseline performance; n: the number of trials; s: seconds. For more 
information on cognitive outcomes, please refer to Table 5.3. 
5.8.3.1.1 Attention Switching Task 
5.8.3.1.1.1 Switch cost reaction time 
No outlying observations were removed from the final model. Accuracy was a significant 
covariate, F(1,91) = 324.43, p <.001, this being positively related to switch cost reaction time. 
There was a trend towards gender being a significant covariate, F(1,91) = 2.89, p = .093, with 
females (-0.21 ± 0.15) responding more quickly compared to males (0.28 ± 0.24). Baseline 
performance and age were not significant covariates, F(1,91) = 0.03, p = .863 and F(1,91) = 1.27, 
p = .262, respectively. IQ was also not a significant covariate and was removed from the final 
model. There was a marginally significant interaction between baseline*condition, F(1,91) = 
3.86, p = .052. 
Outcome 
Time 1 
 (pre-first dose)a 
Mean ± SE 
Time 2 
(+90 minutes post 
time 1 & first 
dose) 
Mean ± SE 
Active vs. placebo 
N-back Task: Target 
accuracy (%) 
   
Active  57.46 ± 4.55 59.03 ± 4.70 
F(1,44) = 7.55, p = .009 
Placebo 50.44 ± 4.93 55.87 ± 4.07 
N-back Task: Total  
accuracy (%) 
   
Active  49.13 ± 4.21 52.97 ± 4.31 
F(1,44) = 3.57, p = .066 
Placebo 44.95 ± 4.81 51.39 ± 3.88 
N-back Task: Reaction time 
for targets (s) 
   
Active  0.53 ± 0.00 0.52 ± 0.00 F(1,1891) = 1.98, p = 
.160 Placebo 0.56 ± 0.00 0.55 ± 0.00 
N-back Task: Reaction time 
for nontargets (s) 
   
Active  0.54 ± 0.00 0.53 ± 0.00 F(1,4971) = 147.23, p 
<.001 Placebo 0.54 ± 0.00 0.53 ± 0.00 
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There was a significant main effect of condition, F(1,91) = 7.46, p = .008 (Figure 5.4(A)), such that 
those in the active condition (0.36 ± 0.19) responded significantly slower than those in the 
placebo condition (-0.29 ± 0.19).   
There was also a significant main effect of trial (switch costs vs. repeat costs), F(1,91) = 6.38, p = 
.013, shown in Figure 5.4(B). Just as with accuracy, reaction time switch costs (0.36 ± 0.19) were 
significantly greater compared to repeat costs (-0.30 ± 0.19) across both conditions.  There was 
no significant trial*condition interaction, F(1,91) = 0.00, p = .989.  
 
Figure 5.4 Switch cost reaction time on the Attention Switching Task. (A) The x axis is condition 
and the y axis is switch cost reaction time (s) over midpoint and endpoint. Columns denote the 
least squares means. Error bars denote the SE of the least squares means. (B) The x axis 
represents trials and the y axis is the switch cost reaction time (s) over midpoint and endpoint.  
Columns denote the least squares means. Error bars denote the SE of the least squares means.* 
p <.05, ** p <.01.  
5.8.3.1.1.2 Switch cost accuracy 
No outlying observations were removed from the final model. Baseline was a significant 
covariate, F(1,92) = 11.63, p = .001, with this being positively related to performance at time 2. 
Age was a significant covariate, F(1,92) = 4.44, p = .038, such that better performance was shown 
with increasing age. IQ and gender were not significant covariates, F(1,92) = 0.58, p = .447 and 
F(1,92) = 1.62, p = .206, respectively. There was a significant main effect of trial (switch cost vs. 
repeat cost), F(1,92) = 5.55, p = .021 (Figure 5.5).  Accuracy switch costs (-2.27 ± 0.76) were 
significantly higher (less accurate) compared to repeat costs (0.12 ± 0.74) across both conditions.  
There was no significant main effect of condition, F(1,92) = 0.02, p = .898.  Trial*condition was 
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also nonsignificant, F(1,92) = 0.12, p = .727.  There was also no significant baseline*condition 
interaction, and this term was removed from the final model. 
Figure 5.5 Switch cost accuracy on the Attention Switching Task.  The x axis represents trials 
and the y axis is the switch cost accuracy (%) over midpoint and endpoint.  Columns denote the 
least squares means. Error bars denote the SE of the least squares means. * p <.05 
5.8.3.1.1.3 Target accuracy 
One outlying observation was removed from the final model. Baseline target accuracy was a 
significant covariate, F(1,142) = 168.68, p <.001, which was positively correlated with 
performance at time 2. Age, IQ and gender were not significant covariates and were removed 
from the final model.  There was no significant main effect of condition or trial, F(1,142) = 0.96, 
p = .328 and F(2,142) = 1.11, p = .334, respectively.  Further, trial*condition was not significant, 
F(2,142) = 0.06, p = .939.  There was also no significant baseline*condition interaction, and this 
term removed from the final model. 
5.8.3.1.1.4 Target reaction time 
No outlying observations were removed from the final model.  Accuracy, as expected, was a 
significant covariate, F(1,141) = 605.26, p < .001, such that the greater the number of targets 
identified, the longer the reaction time. Baseline target reaction time was not a significant 
covariate, F(1,141) = 0.92, p = .339.  Age, IQ and gender were also not significant covariates and 
were removed from the final model.  There was a significant baseline*condition interaction, 
F(1,141) = 6.20, p = .014, such that there was consistency in performance across test sessions; 
those who were slower at baseline remained slower at time 2, and this was also the case for 
those who were faster at baseline. In respect of condition, those in the active condition were 
marginally slower compared to those in the placebo condition before and after treatment.   
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Inspection of post hoc comparisons revealed that participants in the active condition (10.44 ± 
0.41) were significantly slower than those in the placebo condition (9.49 ± 0.39; t(141) = 2.00, p 
= .048) if their baseline reaction time for targets was 1. The participants in the active condition 
(10.41 ± 0.36) were marginally significantly slower than those in the placebo condition (9.59 ± 
0.35; t(141) = 1.91, p = .058) if their baseline reaction time for targets was 2.  There was a trend 
towards participants in the active condition (10.38 ± 0.32) responding more slowly than their 
counterparts in the placebo condition (9.69 ± 0.32; t(141) = 1.81, p = .073) if their baseline 
reaction time for targets was 3 or 4.  There was also a trend towards those in the active condition 
(10.14 ± 0.15) demonstrating faster reaction time relative to those in the placebo condition 
(10.49 ± 0.14; t(141) = -1.71, p = .090) if their baseline reaction time for targets was 11. Finally, 
those in the active condition (10.11 ± 0.19) were significantly faster than those in the placebo 
condition (10.59 ± 0.16; t(141) = -2.07, p = .040) if their baseline reaction time for targets was 
12 or greater (slower reaction time).  No other post hoc comparisons were significant. 
There was a significant main effect of condition, F(1,141) = 4.24, p = .041, such that participants 
in the active condition (10.18 ± 0.13) demonstrated faster reaction time for targets compared 
to their counterparts in the placebo condition (10.33 ± 0.13), however, post hoc tests did not 
reveal a significant difference.  
There was also a significant main effect of trial, F(2,141) = 5.90, p = .004, shown in Figure 5.6.  
As expected, irrespective of condition, participants demonstrated slowest target reaction times 
on switch trials i.e. on occasions when a new rule had to be applied to make a correct response. 
Following this, target reaction time decreased, such that the fastest reaction time for targets 
was demonstrated for the pre-switch trial. Inspection of post hoc comparisons revealed there 
was a significant difference in reaction time for switch trials vs. nested trials and for switch trials 
vs. pre-switch trials. Specifically, reaction time was significantly slower on switch trials (10.71 ± 
0.16) compared to nested trials (10.08 ± 0.16; t(141) = 2.73, p = .019) and pre-switch trials (9.97 
± 0.16; t(141) = 3.20, p = .005) across both conditions. There was no significant trial*condition 
interaction, F(2,141) = 1.41, p = .248.   
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Figure 5.6 Reaction time for targets on the Attention Switching Task.  The x axis represents trial 
type and the y axis is the reaction time (s) for targets over midpoint and endpoint.  Columns 
denote the least squares means. Error bars denote the SE of the least squares means. * p <.05, 
** p <.01. 
5.8.3.1.2 Rapid Visual Information Processing Task (RVIP) 
5.8.3.1.2.1 Hits 
One outlying observation was removed from the final model.  Baseline performance was a 
significant covariate, F(1,46) = 158.97, p <.001, and was positively related to performance at 
time 2. Age, IQ and gender were not significant covariates and were removed from the final 
model. There was a significant main effect of condition, F(1,46) = 6.80, p = .012 (Figure 5.7).  
Figure 5.7 presents that those in the active condition (0.35 ± 0.03) were significantly more 
accurate (more correct trials) than participants in the placebo condition (0.25 ± 0.03). There was 
no significant baseline*condition interaction, and this term was removed from the final model. 
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Figure 5.7 Hits achieved on the Rapid Visual Information Processing Task (RVIP). The x axis is 
condition and the y axis is the number of hits (n) over midpoint and endpoint. Columns denote 
the mean. Error bars denote the SE of the mean.* p <.05 
5.8.3.1.2.2 False alarms 
Two outlying observations were removed from the final model.  Baseline performance was a 
significant covariate, F(1,42) = 91.37, p <.001, such that this showed a positive relationship with 
the incidence of false alarms at time 2.  IQ was a significant covariate, F(1,42) = 10.44, p = .002, 
and was negatively correlated with performance i.e. the prevalence of false alarms decreased 
with increasing IQ. Gender was not a significant covariate, F(1,42) = 0.55, p = .461.  Age was also 
not a significant covariate and was removed from the final model. There was no significant main 
effect of condition, F(1,42) = 0.44, p = .508.  There was also no significant baseline*condition 
interaction, F(1,42) = 1.19, p = .281. 
5.8.3.1.2.3 Reaction time for hits 
Eleven outlying observations were removed from the final model. Baseline reaction time was a 
significant covariate, F(1,864) = 83.16, p <.001, with baseline performance being positively 
correlated with reaction time at time 2.  Age was a significant covariate, F(1,864) = 12.54, p 
<.001, such that with increasing age, reaction time became slower. Gender was also a significant 
covariate, F(1,864) = 8.02, p = .005, with females reacting significantly more quickly (0.72 ± 0.01) 
relative to males (0.78 ± 0.02).  As expected, the total number of correct trials (hits) was also a 
significant covariate, F(1,864) = 25.49, p <.001, such that reaction time was negatively correlated 
with the number of correct trials.  IQ and trial were not significant covariates and were removed 
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from the final model.  There was a significant interaction between baseline*condition, F(1,864) 
= 10.86, p = .001, shown in Figure 5.8. 
Figure 5.8 Reaction time for hits on the Rapid Visual Information Processing Task (RVIP). The 
x axis represents log baseline reaction time (s) for hits and the y axis is the log reaction time (s) 
for hits over subsequent test points.  Regression lines show relationship between x and y by 
condition. 
Figure 5.8 shows that at faster baseline reaction time, those in the active condition 
demonstrated faster performance compared to participants in the placebo condition. However, 
the opposite was shown at slower baseline reaction latencies. Inspection of post hoc 
comparisons revealed those in the active condition (0.45 ± 0.04) were significantly faster than 
those in the placebo condition (0.58 ± 0.04; t(864) = -2.37, p = .018) if their log of baseline 
reaction time was 0.4 or lower (faster baseline reaction time).  Those in the active condition 
(0.55 ± 0.03) were also marginally significantly faster than the placebo condition (0.63 ± 0.03; 
t(864) = -1.96, p = .050) at a log of baseline reaction time of 0.5.  Conversely, participants in the 
active condition (0.83 ± 0.02) were significantly slower than those in the placebo condition (0.76 
± 0.02; t(864) = 3.16, p = .002) if their log of baseline reaction time was 0.8 or above (slower 
reaction time).  No other post hoc comparisons were significant. 
A significant main effect of condition was also found, F(1,864) = 8.41, p = .004. Inspection of post 
hoc comparisons revealed a trend towards those in the active condition (0.77 ± 0.01) 
demonstrating slower reaction latencies compared to those in the placebo condition (0.73 ± 
0.02; t(864) = 1.80, p = .072). 
 
Interaction between baseline*condition on Rapid Visual Information Processing Task 
(RVIP): Reaction time for hits 
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5.8.3.1.3 N-back Task 
5.8.3.1.3.1 Target accuracy 
 No outlying observations were removed from the final model. Baseline performance was a 
significant covariate, F(1,44) = 84.60, p <.001, such that baseline target accuracy was positively 
associated with subsequent performance at time 2. IQ was a significant covariate, F(1,44) = 7.30, 
p = .010, being positively related to greater target accuracy, such that those with a higher IQ 
achieved better target accuracy.  There was a trend towards gender being a significant covariate, 
F(1,44) = 2.89, p = .096, with females (7.48 ± 0.17) achieving greater target accuracy relative to 
males (6.91 ± 0.28).  Age was not a significant covariate and was removed from the final model.  
There was a significant baseline*condition interaction, F(1,44) = 6.90, p = .012 (Figure 5.9).  
Inspection of post hoc comparisons revealed that those in the active condition (5.25 ± 0.29) 
showed significantly poorer target accuracy compared to those in the placebo condition (6.27 ± 
0.29; t(44) = -2.47, p = .018) if their square root baseline target accuracy was 5 or lower (poorer 
performance).  Moreover, performance by those in the active condition (6.13 ± 0.23) was 
marginally significantly less accurate to that of those in the placebo condition (6.76 ± 0.23; t(44) 
= -1.96, p = .056) if their square root baseline target accuracy was 6.  No other post hoc 
comparisons were significant. 
 
Figure 5.9 Target accuracy on the N-back Task. The x axis represents square root baseline target 
accuracy (%) and the y axis is the square root target accuracy (%) over subsequent test points.  
Regression lines show relationship between x and y by condition. 
Interaction between baseline*condition on N-back Task: Target accuracy 
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There was also a significant main effect of condition, F(1,44) = 7.55, p = .009, such that those in 
the active condition performed less well (7.09 ± 0.21) relative to those in the placebo condition 
(7.30 ± 0.22),  however, post hoc tests did not reveal a significant difference. 
5.8.3.1.3.2 Total accuracy 
No outlying observations were removed from the final model. Baseline total accuracy was a 
significant covariate, F(1,44) = 65.56, p <.001, with this being positively correlated with 
performance at time 2. IQ was a significant covariate, F(1,44) = 7.21, p = .010, such that total 
accuracy increased with increasing IQ. Gender was not a significant covariate, F(1,44) = 2.12, p 
= .152.  Age was also not a significant covariate and was removed from the final model.  There 
was a marginally significant baseline*condition interaction, F(1,44) = 3.82, p = .057 and condition 
was also marginally significant, F(1,44) = 3.57, p = .066.  Performance between the two 
conditions differed such that participants in the placebo condition (51.08 ± 2.65) achieved 
greater total accuracy compared to those in the active condition (50.16 ± 2.56).  
5.8.3.1.3.3 Reaction time for targets 
No outlying observations were removed from the final model. Baseline was a significant 
covariate, F(1,1891) = 252.76, p <.001, with this being positively related to reaction time for 
targets at time 2. Trial was a significant covariate, F(1,1891) = 5.25, p = .022, with performance 
fluctuating across the trials. As expected, the total number of correct trials achieved was a 
significant covariate, F(1,1891) = 6.90, p = .009, and reaction time decreased as a function of a 
greater number of correct trials obtained. There was a trend towards gender being a significant 
covariate, F(1,1891) = 2.79, p = .095, with females (-0.28 ± 0.00) reacting to targets faster than 
males (-0.29 ± 0.00). IQ was not a significant covariate, F(1,1891) = 1.30, p = .255.  Age was not 
a significant covariate and was removed from the final model.  There was no significant main 
effect of condition, F(1,1891) = 1.98, p = .160, and no significant baseline*condition interaction, 
F(1,1891) = 1.56, p = .211. 
5.8.3.1.3.4 Reaction time for nontargets 
Seventeen outlying observations were removed from the final model.  Baseline was a significant 
covariate, F(1,4971) = 228.61, p <.001, and was positively associated with reaction time for 
nontargets at time 2. Age was a significant covariate, F(1,4971) = 3.87, p = .049, with reaction 
time increasing with age. IQ was also a significant covariate, F(1,4971) = 172.29, p <.001, such 
that those with a higher IQ responded more slowly compared to those with a lower IQ. Gender 
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was a significant covariate, F(1,4971) = 19.18, p <.001, with males (0.52 ± 0.00) responding 
significantly more quickly compared to females (0.53 ± 0.00). Trial and the total number of 
correct trials achieved were also significant covariates, F(1,4971) = 4.92, p = .027 and F(1,4971) 
= 335.01, p <.001, respectively.  Reaction time for nontargets by trial varied and decreased with 
increasing number of correct trials achieved. There was a significant baseline*condition 
interaction, F(1,4971) = 138.37, p <.001, shown in Figure 5.10(A). 
Figure 5.10(A) indicates that at faster baseline reaction time for nontargets, those in the active 
condition showed faster performance compared to those in the placebo condition, however, 
the opposite was found at slower baseline reaction time, such that those in the active condition 
demonstrated slower performance relative to those in the placebo condition.  Inspection of post 
hoc comparisons revealed that those in the active condition (0.52 ± 0.00) responded significantly 
faster than those in the placebo condition (0.53 ± 0.00; t(4971) = -2.97, p = .003) if their baseline 
reaction time for nontargets was 0.55 or less (faster performance).  Conversely, participants in 
the active condition were significantly slower at responding (0.56 ± 0.00) compared to those in 
the placebo condition (0.54 ± 0.00; t(4971) = 5.08, p <.001) if their baseline reaction time for 
nontargets was 0.60 or greater (slower performance).  
Figure 5.10 Reaction time for nontargets on the N-back Task. (A) The x axis represents baseline 
reaction time (s) for nontargets and the y axis is reaction time (s) for nontargets over subsequent 
test points. Regression lines show relationship between x and y by condition. (B) The x axis is 
condition and the y axis is reaction time (s) for nontargets over midpoint and endpoint. Columns 
denote the mean. Error bars denote the SE of the mean.*** p <.001.  
Interaction between baseline*condition 
on N-back Task: Reaction time for 
nontargets 
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There was also a significant main effect of condition, F(1,4971) = 147.23, p <.001 (Figure 5.10(B)).  
Inspection of post hoc comparisons revealed those in the active condition (0.52 ± 0.00) 
demonstrated significantly faster performance relative to the placebo condition (0.53 ± 0.00; 
t(4971) = -4.64 p <.001). 
5.8.3.2 Measures of memory performance 
Table 5.7 provides a summary of the means (± SE) across measures of memory performance for 
active and placebo conditions.   
Table 5.7 Mean (± SE) on measures of memory performance (Pattern Separation Task, Face-
Name Associative Memory and Visual Verbal Learning Test) by condition and test occasion 
Outcome 
Time 1 
 (pre-first dose)a 
Mean ± SE 
Time 2 
(+90 minutes post 
time 1 and first 
dose) 
Mean ± SE 
Active vs. 
placebo 
Pattern Separation Task: 
Pattern separation score (n) 
  
 
Active  -4.08 ± 1.07 -3.92 ± 0.93 F(1,44) = 1.04, p 
= .312 Placebo -3.96 ± 0.90 -2.75 ± 0.83 
Pattern Separation Task: 
Recognition score (n) 
   
Active  2.58 ± 0.48 1.96 ± 0.72 F(1,45) = 4.60, p 
= .038 Placebo 2.54 ± 0.47 1.67 ± 0.59 
Face-Name Associative Memory 
Exam: Immediate recall (n) 
   
Active  5.5 ± 0.52 4.12 ± 0.48 F(1,46) = 0.00, p 
= .978 Placebo 4.38 ± 0.62 3.71 ± 0.46 
Face-Name Associative Memory 
Exam: Delayed recall (n) 
   
Active  4.85 ± 0.58 2.69 ± 0.44 F(1,46) = 3.60, p 
= .064 Placebo 3.5 ± 0.57 2.83 ± 0.50 
Visual Verbal Learning Test 
(VVLT): Rate of learning (n)  
   
Active (trial A1) 7.85 ± 0.56 7.04 ± 0.55 
F(1,140) = 0.11, p 
= .737 
Placebo (trial A1) 7.75 ± 0.40 6.54 ± 0.47 
Active (trial A2) 10.27 ± 0.56 9.62 ± 0.44 
Placebo (trial A2) 10.38 ± 0.49 9.50 ± 0.50 
Active (trial A3) 11.38 ± 0.48 10.96 ± 0.48 
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Outcome 
Time 1 
 (pre-first dose)a 
Mean ± SE 
Time 2 
(+90 minutes post 
time 1 and first 
dose) 
Mean ± SE 
Active vs. 
placebo 
Placebo (trial A3) 11.21 ± 0.51 10.96 ± 0.53 
Visual Verbal Learning Test 
(VVLT): New learning (n) 
   
Active  7.04 ± 0.53 6.69 ± 0.52 F(1,44) = 0.16, p 
= .689 Placebo 6.08 ± 0.54 6.21 ± 0.58 
Visual Verbal Learning Test 
(VVLT): Retroactive interference 
(n) 
   
Active  2.96 ± 0.46 5.23 ± 0.58 F(1,45) = 1.46, p 
= .233 Placebo 2.79 ± 0.32 4.08 ± 0.43 
Visual Verbal Learning Test 
(VVLT): Proactive interference 
(n) 
   
Active  0.81 ± 0.49 0.35 ± 0.48 F(1,45) = 0.09, p 
= .770 Placebo 1.67 ± 0.48 0.33 ± 0.51 
Visual Verbal Learning Test 
(VVLT): Delayed recall (n) 
   
Active  8.23 ± 0.60 5.5 ± 0.78 F(1,44) = 3.94, p 
= .053 Placebo 7.83 ± 0.75 6.42 ± 0.71 
Notes. aTime 1 represents baseline performance; n: the number of trials; s: seconds. For more information 
on cognitive outcomes, please refer to Table 5.3. 
5.8.3.2.1 Pattern Separation Task 
5.8.3.2.1.1 Pattern separation score 
Two outlying observations were removed from the final model (see section 4.6). Baseline 
performance was a significant covariate, F(1,44) = 30.71, p <.001, such that this showed a 
positive relationship with behavioural pattern separation performance at time two.  There was 
a trend towards gender being a significant covariate, F(1,44) = 3.05, p = .088, with males (0.58 ± 
0.04) obtaining a higher score than females (0.49 ± 0.03).  Age and IQ were not significant 
covariates and were removed from the final model. There was no significant main effect of 
condition, F(1,44) = 1.04, p = .312.  There was also no significant baseline*condition interaction, 
and this term was removed from the final model. 
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5.8.3.2.1.2 Recognition score 
No outlying observations were removed from the final model. Baseline performance was a 
significant covariate, F(1,45) = 36.05, p <.001, being positively correlated with recognition score 
at the subsequent test point. Gender was not a significant covariate, F(1,45) = 0.37, p = .547.  
Age and IQ were not significant covariates also and were removed from the final model.  There 
was a significant baseline*condition interaction, F(1,45) = 8.25, p = .006 (Figure 5.11). Inspection 
of post hoc comparisons revealed those in the active condition (0.41 ± 0.04) obtained 
significantly higher recognition scores compared to those in the placebo condition (0.31 ± 0.04; 
t(45) =2.03, p = .048) if their log baseline recognition score was 0.4 or greater (improved 
performance). 
There was also a significant main effect of condition, F(1,45) = 4.60, p = .038, such that 
participants in the active condition obtained a higher recognition score (0.33 ± 0.03) compared 
to those in the placebo condition (0.28 ± 0.03). However, post hoc comparisons did not reveal a 
significant difference. 
Figure 5.11 Recognition score on the Pattern Separation Task. The x axis represents log baseline 
recognition score (n) and the y axis is the log recognition score (n) over subsequent test points.  
Regression lines show relationship between x and y by condition. 
5.8.3.2.2 Face-Name Associative Memory Exam 
5.8.3.2.2.1 Immediate recall 
No outlying observations were removed from the final model. Baseline immediate recall 
performance was a significant covariate, F(1,46) = 10.60, p = .002, and was positively associated 
Interaction between baseline*condition on Pattern Separation Task: Recognition score 
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with performance at time 2. Gender was not a significant covariate, F(1,46) = 1.97, p = .167.  Age 
and IQ were not significant covariates also and were removed from the final model. There was 
no significant main effect of condition, F(1,46) = 0.00, p = .978.  There was also no significant 
baseline*condition interaction, and this term was removed from the final model. 
5.8.3.2.2.2 Delayed recall 
No outlying observations were removed from the final model. Baseline performance was a 
significant covariate, F(1,46) = 45.09, p <.001, and was positively related to delayed recall at time 
2.  IQ was not a significant covariate, F(1,46) = 2.03, p = .161.  Age and gender were not significant 
covariates also and were removed from the final model.  Condition was marginally significant, 
F(1,46) = 3.60, p = .064.  Performance between the two conditions differed such that those in 
the placebo condition (3.25 ± 0.35) recalled more items correctly compared to those in the active 
condition (2.31 ± 0.34). There was no significant baseline*condition interaction, and this term 
was removed from the final model. 
5.8.3.2.3 Visual Verbal Learning Test (VVLT) 
5.8.3.2.3.1  Rate of learning (word list A) 
One outlying observation was removed from the final model. Baseline performance was a 
significant covariate, F(1,140) = 25.36,  p <.001, such that performance at baseline was positively 
related to performance at time 2.  Age and IQ were also significant covariates, F(1,140) = 7.21, 
p = .008 and F(1,140) = 17.22,  p <.001, respectively.  Rate of learning reduced with age, whereas 
rate of learning was augmented by increased IQ.  Gender was not a significant covariate and was 
subsequently removed from the final model.  There was a significant main effect of trial, F(2,140) 
= 20.29,  p <.001, such that rate of learning improved over successive trials (Figure 5.12).  
Inspection of post hoc comparisons revealed there was a significant difference in the number of 
items correctly recalled, with significantly less items being correctly recalled for trial 1 (7.41 ± 
0.32) compared to trials 2 (9.38 ± 0.29; t(140) = -4.44, p <.001) and 3 (10.43 ± 0.30; t(140) = -
6.32, p <.001). Moreover, significantly less items were correctly recalled on trial 2 (9.38 ± 0.29) 
relative to trial 3 (10.43 ± 0.30; t(140) = -2.55, p = .031). There was no significant main effect of 
condition, F(1,140) = 0.11, p = .737.  There was also no significant trial*condition interaction, 
F(2,140) = 0.06, p = .941, nor a significant baseline*condition interaction, and this term was 
removed from the final model. 
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Figure 5.12 Rate of learning on the Visual Verbal Learning Test (VVLT). The x axis represents 
trial and the y axis is the rate of learning (n) over midpoint and endpoint.  Columns denote the 
mean. Error bars denote the SE of the mean. * p <.05, *** p <.001. 
5.8.3.2.3.2  New learning (word list B) 
No outlying observations were removed from the final model. Baseline was a significant 
covariate, F(1,44) = 15.69, p <.001, with the number of items recalled from list B at baseline 
being positively related to performance at time 2.  Age was also a significant covariate, F(1,44) 
= 4.30, p = .044, with performance worsening with age. Gender was not a significant covariate, 
F(1,44) = 0.92, p = .343.  IQ was also nonsignificant and removed from the final model. There 
was no significant main effect of condition, F(1,44) = 0.16, p = .689, and no significant 
baseline*condition interaction, F(1,44) = 0.16, p = .690. 
5.8.3.2.3.3  Retroactive interference (Trial A3-Trial A4) 
No outlying observations were removed from the final model.  Baseline and gender were not 
significant covariates, F(1,45) = 2.43, p = .126 and F(1,45) = 0.54, p = .468, respectively. Age and 
IQ were also not significant covariates and were removed from the final model. There was no 
significant main effect of condition, F(1,45) = 1.46, p = .233, and no significant 
baseline*condition interaction, F(1,45) = 0.26, p = .609. 
5.8.3.2.3.4  Proactive interference (Trial A1-Trial B1) 
No outlying observations were removed from the final model. Age was a significant covariate, 
F(1,45) = 4.46, p = .040, such that better performance was demonstrated by younger 
participants. Baseline and gender were not significant covariates, F(1,45) = 1.38, p = .247 and 
Main effect of trial on Visual Verbal Learning Test (VVLT): Rate of learning 
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F(1,45) = 0.79, p = .379, respectively. IQ was also not a significant covariate and was removed 
from the final model. There was no significant main effect of condition, F(1,45) = 0.09, p = .770.  
There was also no significant baseline*condition interaction, and this term was removed from 
the final model. 
5.8.3.2.3.5 Delayed recall  
No outlying observations were removed from the final model.  Baseline was a significant 
covariate, F(1,44) = 36.21, p <.001, and was positively related to performance at time 2.  Age 
was also a significant covariate, F(1,44) = 6.05, p = .018, such that performance showed age-
related decline. Gender was not a significant covariate, F(1,44) = 0.13, p = .722. IQ was also 
nonsignificant and removed from the final model. The main effect of condition just failed to 
reach significance, F(1,44) = 3.94, p = .053.  Performance between the two conditions differed 
such that those in the active condition (5.23 ± 0.53) recalled less items correctly compared to 
those in the placebo condition (6.51 ± 0.54).  There was no significant baseline*condition 
interaction, F(1,44) = 2.01, p = .164. 
 
5.8.4 Chronic effect of intervention on cognitive performance in middle-aged 
and older adults with a subjective memory complaint 
5.8.4.1 Measures of executive function performance 
Table 5.8 provides a summary of the means (± SE) across measures of executive function 
performance for active and placebo conditions.   
Table 5.8 Mean (± SE) on measures of executive function performance (Attention Switching 
Task, Rapid Visual Information Processing and N-back Task) by condition and week 
Outcome 
Baseline 
(week 0)a 
Mean ± SE 
Midpoint 
(week 6)a 
Mean ± SE 
Endpoint 
(week 12)b 
Mean ± SE 
Active vs. 
placebo 
Attention Switching 
Task: Switch cost 
reaction time (s) 
  
 
 
Active (switch trials) 0.29 ± 0.56 -1.08 ± 0.52 -1.09 ± 49 
F(1,45) = 
0.05, p = .833 
Placebo (switch trials) -0.44 ± 0.65 -0.32 ± 0.60 -0.87 ± 0.73 
Active (repeat trials) 0.88 ± 0.36 -0.19 ± 0.36 0.10 ± 0.30 
Placebo (repeat trials) -0.03 ± 0.62 0.35 ± 0.55 0.08 ± 0.39 
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Outcome 
Baseline 
(week 0)a 
Mean ± SE 
Midpoint 
(week 6)a 
Mean ± SE 
Endpoint 
(week 12)b 
Mean ± SE 
Active vs. 
placebo 
Attention Switching 
Task: Switch cost 
accuracy (%) 
  
 
 
Active (switch trials) -0.91 ± 1.12 -3.59 ± 0.97 -3.27 ± 0.80 
F(1,45) = 
2.85, p = .098 
Placebo (switch trials) -1.34 ± 1.31 -1.89 ± 1.26 -2.82 ± 1.39 
Active (repeat trials) 0.89 ± 0.69 0.33 ± 0.74 0.14 ± 0.59 
Placebo (repeat trials) 0.70 ± 0.99 0.72 ± 1.01 0.24 ± 0.81 
Attention Switching 
Task: Target accuracy 
(n) 
  
 
 
Active (switch trials)  12.88 ± 0.88 14.04 ± 0.91 14.77 ± 0.83 
F(1,45) = 
0.65, p = .426 
Placebo (switch trials) 13.12 ± 0.69 12.85 ± 0.85 13.40 ± 0.92 
Active (nested trials)  13.54 ± 0.94 16.63 ± 0.96 17.13 ± 0.67 
Placebo (nested trials) 14.08 ± 1.14 14.21 ± 1.13 15.43 ± 1.03 
Active (pre-switch trials)  14.18 ± 1.04 16.86 ± 0.84 17.23 ± 0.76 
Placebo (pre-switch 
trials) 
14.59 ± 1.01 14.73 ± 1.03 15.60 ± 0.93 
Attention Switching 
Task: Target reaction 
time (s) 
  
 
 
Active (switch trials)  9.02 ± 0.68 10.31 ± 0.65 10.88 ± 0.64 
F(1,46) = 
0.65, p = .424 
Placebo (switch trials) 9.36 ± 0.72 9.28 ± 0.67 9.53 ± 0.71 
Active (nested trials)  8.74 ± 0.73 11.39 ± 0.60 11.97 ± 0.48 
Placebo (nested trials) 9.80 ± 0.84 9.60 ± 0.80 10.40 ± 0.75 
Active (pre-switch trials)  9.62 ± 0.75 11.20 ± 0.54 12.07 ± 0.48 
Placebo (pre-switch 
trials) 
9.76 ± 0.79 9.95 ± 0.75 
10.49 ± 0.65 
Rapid Visual 
Information Processing 
(RVIP): Hits (n) 
  
 
 
 
Active  18.25 ± 2.08 20.00 ± 2.14 18.75 ± 2.36 F(1,43) = 
0.46, p = .502 Placebo 16.88 ± 1.68 15.17 ± 1.92 17.35 ± 1.93 
Rapid Visual 
Information Processing 
(RVIP): False alarms (n) 
  
 
 
Active  17.46 ± 2.83 17.46 ± 1.88 17.92 ± 1.96 
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Outcome 
Baseline 
(week 0)a 
Mean ± SE 
Midpoint 
(week 6)a 
Mean ± SE 
Endpoint 
(week 12)b 
Mean ± SE 
Active vs. 
placebo 
Placebo 22.17 ± 3.36 17.96 ± 3.40 
21.65 ± 4.87 F(1,41) = 
7.22, p = .010 
Rapid Visual 
Information Processing 
(RVIP): Reaction time 
for hits (s) 
  
 
 
Active  0.45 ± 0.00 0.45 ± 0.00 0.46 ± 0.00 F(1,42) = 
1.88, p = .178 Placebo 0.46 ± 0.01 0.47 ± 0.01 0.46 ± 0.01 
N-back Task: Target 
accuracy (%) 
  
 
 
Active  56.94 ± 4.92 61.24 ± 5.18 61.05 ± 4.24 F(1,45) = 
3.36, p = .073 Placebo 50.44 ± 4.93 54.67 ± 4.00  58.17 ± 4.33 
N-back Task: Total 
accuracy (%) 
  
 
 
Active  48.99 ± 4.55 54.29 ± 5.80 54.17 ± 4.90 F(1,45) = 
4.66, p = .036 Placebo 44.95 ± 4.81 49.12 ± 4.19 53.89 ± 4.37 
N-back Task: Reaction 
time for targets (s) 
  
 
 
Active  0.53 ± 0.00 0.52 ± 0.00 0.53 ± 0.00 F(1,43) = 
3.60, p = .064 Placebo 0.56 ± 0.00 0.55 ± 0.00 0.54 ± 0.00 
N-back Task: Reaction 
time for nontargets (s) 
  
 
 
Active  0.54 ± 0.00 0.53 ± 0.00 0.52 ± 0.00 F(1,42) = 
0.02, p = .878 Placebo 0.54 ± 0.00 0.53 ± 0.00 0.53 ± 0.00 
Notes. an=48; bn=47; n: the number of trials; s: seconds. For more information on cognitive outcomes, 
please refer to Table 5.3. 
5.8.4.1.1 Attention Switching Task 
5.8.4.1.1.1 Switch cost reaction time 
No outlying observations were removed from the final model.  Accuracy was a significant 
covariate, F(1,127) = 487.83, p <.001, this being positively related to switch cost reaction time.  
Baseline and gender were not significant covariates, F(1,127) = 1.25, p = .266 and F(1,45) = 1.11, 
p = .297, respectively. Age and IQ were also nonsignificant covariates and were removed from 
the final model. There was no significant main effect of condition, F(1,45) = 0.05, p = .833 and 
no significant baseline*condition interaction, and this term was removed from the final model.  
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No higher order interactions were significant.  There was a significant baseline*week 
interaction, F(1,127) = 4.07, p = .046, and a significant interaction between condition and week, 
F(1,42) = 5.36, p = .026, however, post hoc comparisons did not reveal any significant 
differences.   
There was a main effect of trial (switch costs vs. repeat costs), F(1,47) = 11.66, p = .001, shown 
in Figure 5.13.  This shows that reaction time switch costs were significantly greater for switch 
trials (-0.03 ± 0.15) than repeat trials (-0.59 ± 0.14).  Trial*condition and trial*condition*week 
interactions were not significant and were removed from the final model. 
 
Figure 5.13 Switch cost reaction time on the Attention Switching Task. The x axis is trials and 
the y axis is switch cost reaction time (s) over midpoint and endpoint. Columns denote the least 
squares means. Error bars denote the SE of the least squares means.** p <.01 
5.8.4.1.1.2 Switch cost accuracy 
One outlying observation was removed from the final model.  Baseline switch cost accuracy was 
a significant covariate, F(1,127) = 26.81, p <.001, such that performance at baseline was 
positively associated with performance at midpoint and endpoint. IQ was a marginally significant 
covariate, F(1,45) = 3.88, p = .055, such that those with lower IQ scores were more accurate. Age 
and gender were not significant covariates and removed from the final model.  There were 
significant baseline*condition*week, F(1,127) = 3.97, p = .049, gender*condition*week, F(4,41) 
= 3.17, p = .023, and baseline*condition,  F(1,127) = 5.28, p = .023, interactions.   
The baseline*condition*week interaction is presented in Figure 5.14(A) and 5.14(B).  Inspection 
of post hoc comparisons revealed those in the active condition (Figure 5.14(A)) were significantly 
less accurate (-2.55 ± 1.55) compared to those in the placebo condition (Figure 5.14(B); 4.97 ± 
1.36; t(41) = -3.66, p = .004) at midpoint at a baseline switch cost accuracy of 10. Also at a 
Main effect of trial on Attention Switching Task: Switch cost reaction time 
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baseline switch cost accuracy of 10, those in the active condition at midpoint (-2.55 ± 1.55) were 
significantly less accurate than those in the placebo condition at endpoint (3.69 ± 1.40; t(41) = -
2.99, p = .023), and there was a trend towards those in the active condition demonstrating less 
accuracy at midpoint (-2.55 ± 1.55) relative to endpoint (2.05 ± 1.55; t(41) = -2.50, p = .074).  No 
other post hoc comparisons were significant. 
Figure 5.14(C) and 5.14(D) present the gender*condition*week interaction. Figure 5.14(C) 
indicates that females in the active condition demonstrated better performance at midpoint, 
whereas males in the same condition showed greater switch cost accuracy at endpoint. In the 
placebo condition (Figure 5.14(D)), both females and males performed better at midpoint 
relative to endpoint.   Inspection of post hoc comparisons revealed that males in the active 
condition (-5.17 ± 1.22) demonstrated marginally significantly poorer performance compared to 
females in the placebo condition (-0.59 ± 0.77 t(41) = -3.19, p = .050) at midpoint. Further, 
females in the active condition (-0.17 ± 0.78) showed significantly greater cost switch accuracy 
compared to males in the same condition (-5.17 ± 1.22; t(41) = 3.43, p = .027) at midpoint.  No 
other post hoc comparisons were significant. 
Figure 5.14(E) shows the interaction between baseline and condition. Inspection of post hoc 
comparisons revealed those in the active condition showed significantly poorer switch cost 
accuracy (-0.25 ± 1.24) compared to those in the placebo condition (4.33 ± 1.12; t(45) = -2.73, p 
= .009) at a baseline switch cost accuracy of 10. This was a trend at a baseline switch cost 
accuracy of 0 (-2.21 ± 0.60 vs. -0.76 ± 0.61; t(45) = -1.69, p = .098).  No other post hoc 
comparisons were significant. 
There was also a trend towards a main effect of condition, F(1,45) = 2.85, p = .098, and a 
significant main effect of trial, F(1,47) = 28.65, p <.001.  The main effect of trial (switch costs vs. 
repeat costs) is presented in Figure 5.14(F). Accuracy switch costs (-2.91 ± 0.50) were 
significantly higher (less accurate) compared to repeat costs (-0.16 ± 0.50) across both 
conditions.  There was no significant trial*condition interaction, and this term was removed 
from the final model.  Trial*condition*week was also nonsignificant, F(3,43) = 0.92, p = .439. 
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Figure 5.14 Switch cost accuracy on the Attention Switching Task. (A-B) The x axis represents 
baseline switch cost accuracy (%) and the y axis is switch cost accuracy (%) over subsequent test 
points. Regression lines show relationship between x and y by week. (C-D) The x axis represents 
 
Interaction between baseline*condition*week on Attention Switching Task: Switch cost 
accuracy 
    
 
 
  
    
Interaction between gender*condition*week on Attention Switching Task: Switch cost 
accuracy 
  
Interaction between baseline*condition 
on Attention Switching Task: Switch cost 
accuracy 
Main effect of trial on Attention Switching 
Task: Switch cost accuracy 
  
 
  
 
A B 
C D 
E F 
-7
-6
-5
-4
-3
-2
-1
0
1
2
Sw
it
ch
 c
o
st
 a
cc
u
ra
cy
 (%
)
Midpoint Endpoint 
-7
-6
-5
-4
-3
-2
-1
0
1
2
Midpoint Endpoint 
-4
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
0.5
1
Sw
it
ch
 c
o
st
 a
cc
u
ra
cy
 (%
)
TrialsSwitch Repeat 
*** 
Baseline switch cost accuracy (%) 
Baseline switch cost accuracy (%) 
Week 
Active: r = 0.29, p <.01 
Placebo: r = 0.58, p <.001 
Trials 
p =.049 
p =.023 
p =.023 
p <.001 
Sw
it
ch
 c
o
st
 a
cc
u
ra
cy
 (
%
) 
Sw
it
ch
 c
o
st
 a
cc
u
ra
cy
 (
%
) 
213 
 
 
 
 week and the y axis is switch cost accuracy (%) over midpoint and endpoint. Lines denote the 
mean. Error bars denote the SE of the mean. (E) The x axis represents baseline switch cost 
accuracy (%) and the y axis is switch cost accuracy (%) over subsequent test points. Regression 
lines show relationship between x and y by condition. (F) The x axis represents trials and the y 
axis is switch cost accuracy (%) over midpoint and endpoint. Columns denote the least squares 
means. Error bars denote the SE of the least squares means. *** p <.001. (A & C) Is the active 
condition, (B & D) is the placebo condition. 
5.8.4.1.1.3 Target accuracy 
One outlying observation was removed from the final model. Baseline performance was a 
significant covariate, F(1,218) = 85.67, p <.001, which was positively correlated with accuracy on 
later test points. Age was also a significant covariate, F(1,45) = 5.70, p = .021, such that older 
participants were less accurate.  IQ and gender were not significant covariates and were 
removed from the final model.  There was also no significant main effect of condition, F(1,45) = 
0.65, p = .426, nor a significant baseline*condition interaction, and this term was removed from 
the final model. No higher order interactions other than IQ*condition*week (F(4,218) = 3.52, p 
= .008) were significant.  
Figure 5.15(A) and 5.15(B) present how performance differed as a function of IQ, condition and 
week. Figure 5.15(A) shows those in the active condition were more accurate at endpoint 
compared to midpoint irrespective of IQ.  Figure 5.15(B) presents a clear interaction such that 
at lower IQ scores, those in the placebo condition performed better at midpoint relative to 
endpoint, whereas at higher IQ scores, performance was superior at endpoint than at midpoint.  
Inspection of post hoc comparisons revealed at an IQ score of 100, those in the active condition 
(18.24 ± 1.33) were significantly more accurate compared to those in the placebo condition 
(13.50 ± 1.09; t(41) = 2.76, p = .041) at endpoint. This same relationship was marginally 
significant at an IQ score of 90 (19.48 ± 2.07 vs. 12.62 ± 1.58; t(41) = 2.63, p = .056) and 110 
(17.01 ± 0.70 vs. 14.38 ± 0.69; t(41) = 2.66, p = .052). Moreover, those in the active condition 
were significantly more accurate (17.01 ± 0.70) at endpoint than those in the placebo condition 
at midpoint (13.98 ± 0.68; t(41) = 3.10, p = .018) at an IQ score of 110. This was marginally 
significant at an IQ score of 120 (15.77 ± 0.69 vs. 13.46 ± 0.60; t(41) = 2.53, p = .070). There was 
a trend towards those in the active condition performing more accurately (16.32 ± 0.71) 
compared to those in the placebo condition (13.98 ± 0.68; t(41) = 2.39, p = .096) at midpoint at 
an IQ of 110 and higher.  Finally, those in the placebo condition were significantly less accurate 
at midpoint (13.46 ± 0.60) relative to endpoint (15.27 ± 0.62; t(41) = -3.77, p = .003) at an IQ 
score of 120.  No other post hoc comparisons were significant. 
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There was a significant interaction between condition and week, F(1,41) = 5.15, p = .029, shown 
in Figure 5.15(C). Inspection of post hoc comparisons revealed those in the active condition 
(15.91 ± 0.58) were significantly more accurate compared to those in the placebo condition at 
midpoint (13.67 ± 0.57; t(41) = 2.77, p = .040). Further, those in the active condition were 
significantly more accurate at endpoint (16.27 ± 0.58) relative to those in the placebo condition 
at midpoint (13.67 ± 0.57; t(41) = 3.20, p = .014).  Finally, those in the placebo condition were 
significantly less accurate at midpoint (13.67 ± 0.57) compared to endpoint (14.91 ± 0.59; t(41) 
= -2.72, p = .045). No other post hoc comparisons were significant. 
 
 
Figure 5.15 Target accuracy on the Attention Switching Task. (A-B) The x axis represents IQ and 
the y axis is accuracy (n) for targets over midpoint and endpoint. Regression lines show 
relationship between x and y by week. (C) The x axis represents week and the y axis is accuracy 
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 (n) for targets over midpoint and endpoint. Columns denote the mean. Error bars denote the 
SE of the mean. (D) The x axis represents trial type and the y axis is accuracy (n) for targets over 
midpoint and endpoint. Columns denote the least squares means. Error bars denote the SE of 
the least squares means. * p <.05, *** p <.001. (A) Is the active condition, (B) is the placebo 
condition.  
 
There was also a significant main effect of trial, F(2,92) = 16.20, p <.001, Figure 5.15 (D).  As 
expected, irrespective of condition, there was a performance decrement for switch trials. 
Whereas performance was similar across nested and pre-switch trials. Inspection of post hoc 
comparisons revealed that performance was significantly less accurate on switch trials (14.05 ± 
0.43) compared to nested trials (15.81 ± 0.43; t(92) = -5.10, p <.001) and pre-switch trials (15.72 
± 0.43; t(92) = -4.77, p <.001).  There was no significant trial*condition interaction, F(2,92) = 
1.27, p = .285.  A main effect of week was also significant, F(1,41) = 5.37, p = .026, such that 
participants were less accurate at midpoint (14.79 ± 0.41) than at endpoint (15.59 ± 0.41). 
5.8.4.1.1.4 Target reaction time 
No outlying observations were removed from the final model.  Accuracy was a significant 
covariate, F(1,220) = 1075.44, p <.001, such that reaction time increased with greater accuracy.  
Baseline, age, IQ and gender were all nonsignificant covariates and removed from the final 
model.  There was no significant main effect of condition, F(1,46) = 0.65, p = .424.  There was a 
significant interaction between baseline*condition*week, F(1,220) = 4.09, p = .045, 
baseline*condition, F(1,220) = 5.02, p = .026 and baseline*week, F(1,220) = 4.73, p = .031.   
Figure 5.16(A) and 5.16(B) show the relationship between baseline performance, condition and 
week, which appears to be driven by the difference in performance between midpoint and 
endpoint in both conditions at slower baseline reaction time.  Inspection of post hoc 
comparisons revealed those in the active condition were marginally significantly slower (11.61 
± 0.40) compared to those in the placebo condition at midpoint (10.22 ± 0.40; t(41) = 2.56, p = 
.065) at a baseline reaction time of 1. This became a trend at a baseline reaction time of 2 (11.48 
± 0.36 vs. 10.26 ± 0.37; t(41) = 2.47, p = .079).  Moreover, those in the active condition at 
midpoint (11.61 ± 0.40) were significantly slower than those in the placebo condition at endpoint 
(9.95 ± 0.41; t(41) = 2.99, p = .024) at a baseline reaction time of 1 to 4, inclusive (faster baseline 
reaction time). This was marginally significant at a baseline reaction time of 5 (11.08 ± 0.26 vs. 
10.11 ± 0.28; t(41) = 2.63, p = .056) and a trend at a baseline reaction time of 6 (10.95 ± 0.23 vs. 
10.15 ± 0.25; t(41) = 2.41, p = .090).  At a baseline reaction time of 10, there was a trend for the 
active condition to respond more quickly at midpoint (10.43 ± 0.18) than at endpoint (10.82 ± 
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0.19; t(41) = -2.49, p = .077).  This was significant at a baseline reaction time of 11 and higher 
(slower baseline reaction time) (10.30 ± 0.20 vs. 10.81 ± 0.20; t(41) = -3.03, p = .021).  No other 
post hoc comparisons were significant. 
The interaction between baseline reaction time and condition is shown below in Figure 5.16(C). 
This clearly shows those in the placebo condition demonstrated faster reaction time relative to 
those in the active condition at quicker baseline reaction time.  The convergence of the 
regression lines suggests that performance by condition was similar at poorer baseline 
performance.  Inspection of post hoc comparisons revealed those in the active condition were 
significantly slower (11.26 ± 0.35) compared to those in the placebo condition (10.09 ± 0.35; 
t(46) = 2.47, p = .017) at a baseline reaction time of 1 to 6, inclusive (faster baseline reaction 
time).  This was marginally significant at a baseline reaction time of 7 (10.84 ± 0.18 vs. 10.31 ± 
0.20; t(46) = 1.98, p = .054) and a trend at a baseline reaction time of 8 (slower baseline reaction 
time) (10.77 ± 0.17 vs. 10.34 ± 0.18; t(46) = 1.70, p = .095).  No other post hoc comparisons were 
significant. 
There was a significant main effect of trial, F(2,94) = 12.99, p <.001.  Figure 5.16(D) shows the 
difference in reaction time between each trial type. As expected, reaction time was markedly 
increased on switch trials but similar on nested and pre-switch trials.  Inspection of post hoc 
comparisons revealed reaction time was significantly slower on switch trials (10.91 ± 0.14) 
compared to nested trials (10.37 ± 0.14; t(94) = 4.27, p <.001) and pre-switch trials (10.31 ± 0.14; 
t(94) = 4.67, p <.001).  Trial*condition and trial*condition*week interactions were not significant 
and both terms were removed from the final model.  As with target accuracy, there was also a 
significant main effect of week, F(1,41) = 5.83, p = .020, however, post hoc comparisons did not 
reveal a significant difference. 
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Figure 5.16 Target reaction time on the Attention Switching Task. (A-B) The x axis represents 
baseline reaction time (s) for targets and the y axis is reaction time (s) for targets over 
subsequent test points. Regression lines show relationship between x and y by week. (C) The x 
axis represents baseline reaction time (s) for targets and the y axis is reaction time (s) for targets 
over subsequent test points. Regression lines show relationship between x and y by condition.  
(D) The x axis represents trial type and the y axis is reaction time (s) for targets over midpoint 
and endpoint. Columns denote the least squares means. Error bars denote the SE of the least 
squares means. *** p <.001. (A) Is the active condition, (B) is the placebo condition. 
5.8.4.1.2 Rapid Visual Information Processing Task (RVIP) 
5.8.4.1.2.1 Hits 
No outlying observations were removed from the final model.  The number of hits identified at 
baseline was a significant covariate, F(1,43) = 137.44, p <.001, which was positively associated 
with performance on later test occasions.  Age and IQ were also significant covariates, F(1,43) = 
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4.94, p = .032 and F(1,43) = 7.82, p = .008, respectively.  The number of hits decreased with age 
but increased with higher IQ. Gender was not a significant covariate and was removed from the 
final model.  There was also no significant main effect of condition, F(1,43) = 0.46, p = .502, and 
no significant baseline*condition interaction, and this term was removed from the model.  No 
higher order interactions were significant other than a trend for IQ*condition*week, (F(3,35) = 
2.45, p = .080).   
5.8.4.1.2.2 False alarms 
Four outlying observations were removed from the final model.  The number of false alarms at 
baseline was a significant covariate, F(1,41) = 61.25, p <.001, which was positively correlated 
with false alarm rate at midpoint and endpoint.  Age was also a significant covariate, F(1,41) = 
6.30, p = .016, such that greater false alarms were committed with age. IQ and gender were not 
significant covariates and were removed from the final model.  No higher order interactions 
were significant. There was a significant baseline*condition interaction and a trend towards a 
baseline*week interaction, F(1,41) = 7.46, p = .009 and F(1,38) = 3.08, p = .087, respectively.   
Figure 5.17 shows the interaction between baseline performance and condition, and indicates 
that with superior baseline performance, those in the placebo condition committed less false 
alarms compared to those in the active condition.  However, at poorer baseline performance, 
the opposite is demonstrated, such that those in the active condition committed less false 
alarms relative to those in the placebo condition.  Consistent with this, inspection of post hoc 
comparisons revealed those in the active condition (13.98 ± 1.63) committed significantly more 
false alarms compared to those in the placebo condition (8.85 ± 1.82; t(41) = 2.10 p = .042) if 
their baseline false alarm rate was 10.  Conversely, at a baseline false alarm rate of 40 and above 
(poorer baseline performance), those in the active condition (27.53 ± 2.57) committed 
significantly less false alarms than those in the placebo condition (36.59 ± 3.61; t(41) = -2.06, p 
= .046). No other post hoc comparisons were significant. 
There was also a significant main effect of condition, F(1,41) = 7.22, p = .010, such that a greater 
number of false alarms were committed by those in the active condition (17.51 ± 1.43) 
compared to those in the placebo condition (16.08 ± 1.49), however, post hoc tests did not 
reveal a significant difference. 
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Figure 5.17 False alarms on the Rapid Visual Information Processing Task (RVIP). The x axis 
represents baseline number of false alarms (n) and the y axis is number of false alarms (n) over 
subsequent test points. Regression lines show relationship between x and y by condition. 
5.8.4.1.2.3 Reaction time for hits  
Nine outlying observations were removed from the final model.  Baseline reaction time for hits 
was a significant covariate, F(1,42) = 29.43, p <.001, this being positively related to with 
performance at midpoint and endpoint. IQ was a significant covariate, F(1,42) = 4.52, p = .039, 
with response latencies being greater for those with higher IQ scores. Trial and the number of 
hits achieved (total correct) were also significant covariates, F(1,1628) = 5.34, p = .021 and 
F(1,1628) = 10.07, p = .002, respectively, with performance fluctuating across each.  Gender was 
marginally significant, F(1,42) = 3.80, p = .058, with females (0.67 ± 0.01) responding more 
quickly compared to males (0.72 ± 0.02).  Age was not a significant covariate and was removed 
from the final model.  There was no significant main effect of condition, F(1,42) = 1.88, p = .178 
and no significant baseline*condition interaction, F(1,42) = 2.16, p = .149.  No higher order 
interactions were significant.  There was a significant baseline*week interaction, F(1,1628) = 
5.29, p = .022, and a significant main effect of week, F(1,41) = 4.66, p = .037, however, post hoc 
tests did not reveal a significant difference. 
5.8.4.1.3 N-back Task 
5.8.4.1.3.1 Target accuracy 
One outlying observation was removed from the final model.  Baseline target accuracy was a 
significant covariate, F(1,45) = 96.29, p <.001, and was positively associated with performance 
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at subsequent test sessions.  Age, IQ and gender were not significant covariates and were 
removed from the final model.  No higher order interactions were significant nor was 
baseline*condition, and this term was removed from the final model.  There was a marginally 
significant baseline*week interaction, F(1,33) = 3.68, p = .064.  Additionally, there was a trend 
towards a main effect of condition, F(1,45) = 3.36, p = .073.  Those in the active condition (60.18 
± 2.67) obtained greater target accuracy compared to those in the placebo condition (58.07 ± 
2.71).   
5.8.4.1.3.2 Total accuracy 
Three outlying observations were removed from the final model. Baseline total accuracy was a 
significant covariate, F(1,45) = 89.13, p <.001, such that baseline performance was positively 
related to performance at later test points. Age, IQ and gender were not significant covariates 
and were removed from the final model.  No higher order interactions were significant nor was 
baseline*condition, and this term was removed from the final model.  There was a significant 
baseline*week interaction, F(1,31) = 4.94, p = .034, and a significant main effect of condition, 
F(1,45) = 4.66, p = .036.  The main effect of condition is shown in Figure 5.18, which indicates 
that those in the active condition (56.83 ± 2.76) demonstrated significantly greater total 
accuracy compared to those in the placebo condition (52.97 ± 2.77).   
 
 
 
 
 
 
 
 
221 
 
 
 
Figure 5.18 Total accuracy on the N-back Task. The x axis is condition and the y axis is total 
accuracy (%) over midpoint and endpoint. Columns denote the mean. Error bars denote the SE 
of the mean.* p <.05 
5.8.4.1.3.3 Reaction time for targets 
No outlying observations were removed from the final model.  Baseline performance was a 
significant covariate, F(1,43) = 111.90, p <.001, such that this was positively associated with 
performance at midpoint and endpoint.  Age, IQ, gender, trial and the number of targets 
achieved (total correct) were not significant and were removed from the final model.  No higher 
order interactions were significant nor was baseline*condition, F(1,43) = 1.50, p = .228.  There 
was a marginally significant main effect of condition, F(1,43) = 3.60, p = .064, such that those in 
the active condition (0.727 ± 0.00) demonstrated slower response latencies compared to those 
in the placebo condition (0.726 ± 0.00).  
5.8.4.1.3.4 Reaction time for nontargets 
Thirty-eight outlying observations were removed from the final model.  Baseline reaction time 
for nontargets was a significant covariate, F(1,42) = 18.63, p <.001, with this being positively 
correlated with performance on subsequent test occasions. Trial and the number of targets 
achieved (total correct) were significant covariates, F(1,9423) = 15.42, p <.001 and F(1,9423) = 
108.22, p <.001, respectively, with performance fluctuating across the trials.  IQ was also a 
significant covariate, F(1,42) = 4.61, p = .038, such that reaction time for nontargets increased 
with higher IQ scores. Gender was not a significant covariate, F(1,42) = 2.28, p = .139, and nor 
was age, which was removed from the final model. There was no significant main effect of 
condition, F(1,42) = 0.02, p = .878.   IQ*condition*week and age*condition*week were 
significant, F(3,9423) = 2.88, p = .034, and F(4,9423) = 5.04, p = .001, respectively. There was also 
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a significant baseline*condition interaction, F(1,42) = 14.35, p = .001, and a significant 
interaction between condition and week, F(1,45) = 4.82, p = .033.  
Figure 5.19(A) and 5.19(B) shows the relationship between IQ, condition and week.  In the active 
condition (Figure 5.19(A)), participants with lower IQ scores tended to react to nontargets more 
slowly at midpoint compared to endpoint, conversely, those with higher IQ scores responded 
similarly across both weeks. However, in the placebo condition (Figure 5.19(B)), those with 
lower IQ scores tended to show faster reaction time at midpoint, however, again, those with 
higher IQ scores responded similarly across both test sessions.  Inspection of post hoc 
comparisons revealed a trend towards those in the active condition (0.51 ± 0.01) demonstrating 
faster reaction time compared to those in the placebo condition (0.54 ± 0.01; t(45) = -2.40, p = 
.091) at endpoint and an IQ score of 120.  Also at an IQ score of 120, there was a trend towards 
those in the active condition at endpoint (0.51 ± 0.01) responding more quickly to nontargets 
relative to those in the placebo condition at midpoint (0.54 ± 0.01; t(45) = -2.41, p = .089). This 
same pattern of performance was marginally significant at an IQ score of 130 (0.52 ± 0.02 vs. 
0.56 ± 0.01; t(45) = -2.53, p = .068).  Finally, those in the active condition reacted significantly 
more slowly at midpoint (0.53 ± 0.03) than at endpoint (0.50 ± 0.03; t(45) = 2.72, p = .044) at an 
IQ score of 90 to 120, inclusive.  No other post hoc comparisons were significant.  
Figure 5.19(C) and 5.19(D) present the relationship between age, condition and week.  
Irrespective of condition, younger participants demonstrated faster reaction time for nontargets 
at endpoint compared to midpoint, whilst older participants showed faster performance at 
midpoint.  Inspection of post hoc comparisons revealed significant within condition differences 
in performance only. Specifically, at 700 months of age (approximately 58 years of age), those 
in the active condition responded significantly slower at midpoint (0.52 ± 0.01) than at endpoint 
(0.50 ± 0.01; t(45) = 5.48, p <.001).  At 900 months of age (75 years of age), those in the placebo 
condition reacted significantly faster at midpoint (0.53 ± 0.01) compared to endpoint (0.55 ± 
0.01; t(45) = -3.06, p = .019).  No other post hoc comparisons were significant. 
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Figure 5.19 Reaction time for nontargets on the N-back Task. (A-B) The x axis is IQ and the y 
axis is reaction time (s) over midpoint and endpoint.  (C-D) The x axis represents age (months) 
and the y axis is reaction time (s) over midpoint and endpoint. (A-D) Regression lines show  
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relationship between x and y by week.  (E) The x axis is baseline reaction time (s) and the y axis 
is the reaction time (s) over subsequent test points. Regression lines show relationship between 
x and y by condition. (F) the x axis is week and the y axis is reaction time (s) over midpoint and 
endpoint. Columns denote the mean. Error bars denote the SE of the mean. *** p <.001. (A & 
C) Is the active condition, (B & D) is the placebo condition. 
The relationship between baseline and condition is shown in Figure 5.19(E), which indicates 
those in the active condition demonstrated faster reaction time at quicker baseline performance 
compared to those in the placebo condition.  Only at particularly slow baseline performance is 
this pattern of performance reversed, such that those in the placebo condition show faster 
reaction latencies compared to those in the active condition.  Consistent with this, post hoc 
comparisons revealed those in the active condition demonstrated significantly faster reaction 
time for nontarget trials compared to those in the placebo condition if their baseline reaction 
time for nontargets was 0.5 or below (0.50 ± 0.01 vs. 0.53 ± 0.01; t(42) = -2.73, p = .009).  
However, at a baseline reaction time for nontargets of 0.6, those in the active condition (0.55 ± 
0.01) responded marginally significantly more slowly to nontargets compared to those in the 
placebo condition (0.53 ± 0.01; t(42) = 1.98, p = .054).  No other post hoc comparisons were 
significant. 
The significant condition*week interaction is depicted in Figure 5.19(F), which shows the 
relationship between condition and week in which those in the active condition show faster 
reaction time for nontargets at endpoint than at midpoint, whereas there was no difference in 
the placebo condition over time.  Inspection of post hoc comparisons revealed those in the 
active condition demonstrated significantly slower reaction time at midpoint (0.53 ± 0.01) 
compared to endpoint (0.51 ± 0.01; t(45) = 4.98, p <.001).  No other post hoc comparisons were 
significant. Lastly, there was a significant main effect of week, F(1,45) = 11.38, p = .002, with 
performance being significantly slower at midpoint (0.53 ± 0.01) relative to endpoint (0.52 ± 
0.01).   
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5.8.4.2 Measures of memory performance 
Table 5.9 provides a summary of the means (± SE) across measures of memory performance for 
active and placebo conditions.   
Table 5.9 Mean (± SE) on measures of memory performance (Pattern Separation Task, Face-
Name Associative Memory and Visual Verbal Learning Test) by condition and week 
Outcome 
Baseline  
(week 0)a 
Mean ± SE 
Midpoint  
(week 6)a 
Mean ± SE 
Endpoint 
(week 12)b 
Mean ± SE 
Active vs. 
placebo 
Pattern Separation 
Task: Pattern 
separation score (n) 
    
Active  -3.96 ± 1.14 -3.33 ± 1.22 -4.17 ± 1.06 F(1,45) = 5.08, p 
= .029 Placebo -3.96 ± 0.90 -3.58 ± 0.89 -2.43 ± 0.81 
Pattern Separation 
Task: Recognition 
score (n) 
  
 
 
Active  2.46 ± 0.45 2.75 ± 0.56 2.96 ± 0.88 F(1,44) = 0.17, p 
= .685 Placebo 2.54 ± 0.47 2.96 ± 0.56 3.87 ± 0.59 
Face-Name 
Associative Memory 
Exam: Immediate 
recall (n) 
  
 
 
Active  5.46 ± 0.55 6.13 ± 0.75 5.63 ± 0.92 F(1,43) = 1.76, p 
= .192 Placebo 4.38 ± 0.62 5.29 ± 0.69 5.26 ± 0.64 
Face-Name 
Associative Memory 
Exam: Delayed recall 
(n) 
  
 
 
Active  4.83 ± 0.62 4.83 ± 0.65 4.38 ± 0.80 F(1,42) = 0.04, p 
= .837 Placebo 3.50 ± 0.57 3.92 ± 0.75 4.26 ± 0.63 
Visual Verbal 
Learning Test (VVLT): 
Rate of learning (n)  
  
 
 
Active (trial A1) 7.83 ± 0.60 8.21 ± 0.43 8.58 ± 0.52 
F(1,43) = 2.25, p 
= .141 
Placebo (trial A1) 7.75 ± 0.40 7.83 ± 0.45 8.04 ± 0.42 
Active (trial A2) 10.13 ± 0.59 11.04 ± 0.41 11.58 ± 0.44 
Placebo (trial A2) 10.38 ± 0.49 10.71 ± 0.49 11.00 ± 0.54 
Active (trial A3) 11.50 ± 0.50 12.29 ± 0.44 12.92 ± 0.52 
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Outcome 
Baseline  
(week 0)a 
Mean ± SE 
Midpoint  
(week 6)a 
Mean ± SE 
Endpoint 
(week 12)b 
Mean ± SE 
Active vs. 
placebo 
Placebo (trial A3) 11.21 ± 0.51 12.04 ± 0.42 12.30 ± 0.48 
Visual Verbal 
Learning Test (VVLT): 
New learning (n) 
  
 
 
Active  2.83 ± 0.58 6.96 ± 0.52 7.29 ± 0.56 F(1,44) = 0.44, p 
= .512 Placebo 6.08 ± 0.54 6.20 ± 0.55 5.52 ± 0.58 
Visual Verbal 
Learning Test (VVLT): 
Retroactive 
interference (n) 
  
 
 
Active  3.00 ± 0.49 2.54 ± 0.43 3.67 ± 0.47 F(1,40) = 2.86, p 
= .098 Placebo 2.79 ± 0.32 2.92 ± 0.40 2.39 ± 0.37 
Visual Verbal 
Learning Test (VVLT): 
Proactive 
interference (n) 
  
 
 
Active  0.83 ± 0.53 1.25 ± 0.46 1.29 ± 0.33 F(1,42) = 0.60, p 
= .442 Placebo 1.67 ± 0.48 1.63 ± 0.42 2.52 ± 0.54 
Visual Verbal 
Learning Test (VVLT): 
Delayed recall (n) 
  
 
 
Active  8.14 ± 0.64 8.96 ± 0.58 9.33 ± 0.70 F(1,43) = 6.27, p 
= .016 Placebo 7.83 ± 0.75 9.00 ± 0.74 9.09 ± 0.62 
Notes. an=48; bn=47; n: the number of trials; s: seconds. For more information on cognitive outcomes, 
please refer to Table 5.3. 
5.8.4.2.1 Pattern Separation Task 
5.8.4.2.1.1  Pattern separation score 
No outlying observations were removed from the final model.  Baseline performance was a 
significant covariate, F(1,45) = 47.15, p <.001, with this being positively related to pattern 
separation performance at subsequent test sessions.  Age, IQ, and gender were all nonsignificant 
covariates and were removed from the final model.  All higher order interactions were also 
nonsignificant, as was baseline*condition, and this term was removed from the final model. 
There was a significant main effect of condition, F(1,45) = 5.08, p = .029, shown in Figure 5.20, 
which indicates those in the active condition (-3.74 ± 0.66) achieved significantly lower pattern 
separation scores compared to those in the placebo condition (-2.66 ± 0.67). 
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Figure 5.20 Pattern separation score on Pattern Separation Task. The x axis represents 
condition and the y axis is the pattern separation score (n) over midpoint and endpoint.  Columns 
denote the least squares means. Error bars denote the SE of the least squares means.  
5.8.4.2.1.2  Recognition score 
One outlying observation was removed from the final model.  Baseline recognition score was 
significant covariate, F(1,44) = 21.91, p <.001, and was positively associated with performance 
at midpoint and endpoint. Age, IQ and gender were all nonsignificant covariates and removed 
from the final model.  There was no significant main effect of condition, F(1,44) = 0.17, p = .685, 
nor was there a significant interaction between baseline*condition, F(1,44) = 0.69, p = .410.  
There were significant baseline*condition*week, F(1,38) = 5.73, p = .022, and 
gender*condition*week, F(4,38) = 4.99, p = .003, interactions.  
Figure 5.21(A) and 5.21(B) show the relationship between baseline performance and week by 
condition. This interaction appears to be a function of the difference in performance 
demonstrated at midpoint and endpoint by those in the active condition at better baseline 
performance.  Inspection of post hoc comparisons revealed a trend towards those in the active 
condition obtaining higher recognition scores (7.33 ± 0.96) compared to those in the placebo 
condition (4.00 ± 0.99;  t(38) = 2.42, p = .090) at endpoint if their baseline recognition score was 
6.  No other post hoc comparisons were significant. 
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Figure 5.21 Recognition score on the Pattern Separation Task. (A-B) The x axis represents 
baseline recognition score (n) and the y axis is recognition score (n) over subsequent test points. 
Regression lines show relationship between x and y by week. (C-D) The x axis represents week 
and the y axis is recognition score (n) over midpoint and endpoint. Lines denote the mean. Error 
bars denote the SE of the mean. (A & C) Is the active condition, (B & D) is the placebo condition.  
Figure 5.21(C) and 5.21(D) present the relationship between gender, condition and week.  In the 
active condition (Figure 5.21(C)), males performed better than females on both test occasions 
(as shown by the parallel lines). Whilst in the placebo condition (Figure 5.21 (D)), females 
obtained a higher recognition score at endpoint relative to midpoint, whereas males performed 
better at midpoint than at endpoint.  Inspection of post hoc comparisons revealed a trend 
towards males in the active condition (4.97 ± 0.96) demonstrating better performance 
compared to males in the placebo condition at endpoint (0.87 ± 0.97; t(38) = 3.00, p = .081).  
Females in the placebo condition (4.94 ± 0.58) illustrated significantly higher recognition 
performance relative to males in the same condition at endpoint (0.87 ± 0.97; t(38) = 3.55, p = 
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.021).  There was also a trend towards females in the placebo condition achieving a lower 
recognition score at midpoint (2.92 ± 0.58) compared to endpoint (4.94 ± 0.58; t(38) = -2.97, p 
= .086).  No other post hoc comparisons were significant. 
5.8.4.2.2 Face-Name Associative Memory Exam 
5.8.4.2.2.1 Immediate recall 
No outlying observations were removed from the final model.  The number of names recalled 
immediately at baseline was a significant covariate, F(1,43) = 53.27, p <.001, such that this was 
positively related to immediate recall at midpoint and endpoint.  Age was also a significant 
covariate, F(1,43) = 5.37, p = .025, with older participants recalling fewer names correctly 
compared to younger participants.  IQ and gender were not significant covariates and were 
removed from the final model.   There was no significant main effect of condition, F(1,43) = 1.76, 
p = .192; baseline*condition was also nonsignificant, F(1,43) = 0.68, p = .414.  There was a 
significant baseline*condition*week interaction, F(1,39) = 5.39, p = .026, however, post hoc 
comparisons did not reveal any significant differences.  There was also a significant 
condition*week interaction, F(1,39) = 4.83, p = .034, such that participants in the active 
condition demonstrated poorer immediate recall compared to those in the placebo condition at 
midpoint (5.25 ± 0.54 vs. 5.92 ± 0.58) and endpoint (4.77 ± 0.54 vs. 5.58 ± 0.60), however, post 
hoc comparisons did not reveal any significant differences. 
5.8.4.2.2.2 Delayed recall 
No outlying observations were removed from the final model.  The number of names recalled 
after a delay at baseline was a significant covariate, F(1,42) = 70.94, p <.001 and was positively 
correlated with performance at subsequent test sessions. Age was also a significant covariate, 
F(1,42) = 4.67, p = .036, such that performance became poorer with age. IQ was not a significant 
covariate, F(1,42) = 0.00, p = .957, nor was gender, and this term was removed from the final 
model.  There was no significant main effect of condition, F(1,42) = 0.04, p = .837 and 
baseline*condition was also not significant, F(1,42) = 0.11, p = .736.  There was a significant 
baseline*condition*week interaction, F(2,40) = 6.23, p = .004, and IQ*condition*week was 
marginally significant, F(3,40) = 2.69, p = .059.  
The baseline*condition*week interaction is shown in Figure 5.22. Figure 5.22(A) shows that at 
poorer baseline performance, participants in the active condition recalled more items correctly 
following a delay at midpoint, whilst those that demonstrated better delayed recall at baseline, 
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recalled more items successfully at endpoint. The opposite pattern of performance was shown 
by those in the placebo condition (Figure 5.22(B)). Inspection of post hoc comparisons revealed 
a trend towards those in the active condition (0.17 ± 0.74) recalling less items correctly following 
a delay compared to those in the placebo condition (2.48 ± 0.58; t(40) = -2.52, p = .072) at 
endpoint at a baseline delayed recall score of 1 and 2 (1.27 ± 0.61 vs. 3.16 ± 0.49; t(40) = -2.47, 
p = .081).  Participants within the active condition recalled significantly more items after a delay 
at midpoint (2.10 ± 0.74) compared to endpoint (0.17 ± 0.74; t(40) = 2.89, p = .030) at a baseline 
delayed recall score of 1 and 2 (2.81 ± 0.61 vs. 1.27 ± 0.61; t(40) = 2.78, p = .040). This pattern 
of performance became a trend at a baseline delayed recall score of 3 (3.53 ± 0.50 vs. 2.37 ± 
0.50; t(40) = 2.50, p = .074). No other post hoc comparisons were significant.  
There was also a significant main effect of week, F(1,40) = 6.72, p = .013, however, post hoc 
comparisons did not reveal a significant difference.  
Figure 5.22 Delayed recall on the Face-Name Associative Memory Exam. The x axis represents 
baseline number of items correctly recalled (n) and the y axis is the number of items correctly 
recalled (n) over subsequent test points. Regression lines show relationship between x and y by 
week. (A) Is the active condition, (B) is the placebo condition.  
5.8.4.2.3 Visual Verbal Learning Test (VVLT) 
5.8.4.2.3.1 Rate of learning (word list A) 
One outlying observation was removed from the final model.  Baseline performance was a 
significant covariate, F(1,225) = 14.07, p <.001, such that rate of learning at baseline was 
positively associated with performance at later test sessions.  Age and IQ were significant 
covariates, F(1,43) = 6.13, p = .017 and F(1,43) = 11.73, p = .001, respectively. Rate of learning 
showed an age-related decline and those with higher IQ scores achieved greater rate of learning 
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compared to those with lower IQ scores. Gender was also a significant covariate, F(1,43) = 5.77, 
p = .021, such that females (10.86 ± 0.23) performed better than males (9.82 ± 0.36).  There was 
no significant main effect of condition, F(1,43) = 2.25, p = .141 and no significant 
baseline*condition interaction, and this term was removed from the final model.  No higher 
order interactions other than age*condition*week, F(3,225) = 5.10, p = .002, were significant.   
Figure 5.23(A) and 5.23(B) show how performance varied as a function of age, condition and 
week.  In the active condition (Figure 5.23(A)), younger participants demonstrated better 
performance at endpoint compared to midpoint, whereas, older participants showed a greater 
rate of learning at midpoint relative to endpoint.  Performance differences by week in the 
placebo condition are less discernible for younger participants.  Older participants in the placebo 
condition (Figure 5.23(B)) performed better at endpoint compared to midpoint.  Inspection of 
post hoc comparisons revealed those in the active condition at endpoint (11.75 ± 0.39) 
demonstrated significantly better performance compared to those in the placebo condition at 
midpoint (10.26 ± 0.39; t(42) = 2.69, p = .048) and at endpoint (10.12 ± 0.40; t(42) = 2.90, p = 
.029) at 700 months of age (approximately 58 years of age).  Within condition at this same age, 
participants in the active condition demonstrated significantly poorer performance at midpoint 
(10.63 ± 0.39) than at endpoint (11.75 ± 0.39; t(42) = -3.97, p = .002). No other post hoc 
comparisons were significant. 
There was also a significant condition*week interaction, F(1,42) = 13.31, p <.001. Those in the 
active condition achieved a greater rate of learning on both test occasions relative to those in 
the placebo condition, particularly at endpoint.  Moreover, participants in the active condition 
showed the greatest improvement in performance over time. Consistent with this, inspection of 
post hoc comparisons revealed participants in the active condition demonstrated marginally 
significantly poorer performance at midpoint (10.35 ± 0.32) compared to their performance at 
endpoint (10.96 ± 0.32; t(42) = -2.56, p = .065).  No other post hoc comparisons were significant. 
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Figure 5.23 Rate of learning on the Visual Verbal Learning Test (VVLT). (A-B) The x axis is age 
(months) and the y axis the rate of learning (n) over midpoint and endpoint. Regression lines 
show relationship between x and y by week. (C) The x axis represents trial and the y axis is the 
rate of learning (n) over midpoint and endpoint.  Columns denote the mean. Error bars denote 
the SE of the mean. *** p <.001.  (A) Is the active condition, (B) is the placebo condition.  
There was also a significant main effect of trial, F(2,94) = 81.73, p <.001, shown in Figure 5.23(C), 
which shows incremental learning over the first three trials of the measure.  Inspection of post 
hoc comparisons revealed, irrespective of condition, that participants recalled significantly less 
items correctly for trial 1 (8.38 ± 0.27) compared to trial 2 (10.77 ± 0.24; t(94) = -10.27, p <.001).  
Moreover, participants recalled significantly less items correctly for trial 1 (8.38 ± 0.27) than for 
trial 3 (11.88 ± 0.25; t(94) = -12.66, p <.001).  Lastly, participants also recalled significantly less 
items correctly for trial 2 (10.77 ± 0.24) compared to trial 3 (11.88 ± 0.25; t(94) = -5.66, p <.001).  
There was no significant trial*condition interaction, and this term was removed from the final 
model. 
Interaction between age*condition*week on Visual Verbal Learning Test (VVLT): Rate of 
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5.8.4.2.3.2 New learning (word list B) 
No outlying observations were removed from the final model.  Baseline performance was a 
significant covariate, F(1,44) = 33.11, p <.001, and was positively related to performance on 
subsequent test sessions. Gender was not a significant covariate, F(1,44) = 0.45, p = .505. Age 
and IQ were also not significant covariates and were removed from the final model. There was 
no significant main effect of condition, F(1,44) = 0.44, p = .512, and no significant interaction 
between baseline*condition, and this term was removed from the final model. No higher order 
interactions were significant. There was a significant condition*week interaction, F(1,42) = 5.09, 
p = .029, however, post hoc comparisons did not reveal any significant differences.  
5.8.4.2.3.3 Retroactive interference (Trial A3-Trial A4) 
Two outlying observations were removed from the final model.  Age was a significant covariate, 
F(1,40) = 7.55, p = .009, such that performance got worse with age. Gender was also a significant 
covariate, F(1,40) = 7.48, p = .009, with females (3.04 ± 0.21) performing inferior to males (1.89 
± 0.35). IQ was not a significant covariate, F(1,40) = 0.31, p = .582, nor was baseline performance, 
which was removed from the final model.  No higher order interactions were significant. There 
were significant baseline*condition and condition*week interactions, F(2,40) = 6.60, p = .003 
and F(1,41) = 5.53, p = .024, respectively.  
Figure 5.24(A) shows the baseline*condition interaction, such that at superior baseline 
performance, those in the active condition display less retroactive interference compared to 
those in the placebo condition, whereas the opposite is seen at poorer baseline performance.  
Inspection of post hoc comparisons revealed a trend towards those in the active condition (1.40 
± 0.44) performing better than those in the placebo condition (2.71 ± 0.65; t(40) = -1.69, p = 
.098) if their baseline retroactive interference score was 0.  Whereas at a baseline retroactive 
interference score of 5 and above, those in the active condition (3.34 ± 0.34) performed less well 
relative to those in the placebo condition (2.19 ± 0.44; t(40) = 2.12, p =.041).   
The interaction between condition and week is shown in Figure 5.24(B). Inspection of post hoc 
comparisons revealed the performance by those in the active condition at midpoint (1.66 ± 0.40) 
was significantly better compared to their performance at endpoint (3.39 ± 0.38; t(41) = -3.10, 
p =.018).  No other post hoc comparisons were significant. 
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Figure 5.24 Retroactive interference on the Visual Verbal Learning Test (VVLT). (A) The x axis 
represents baseline retroactive interference (n) and the y axis is retroactive interference (n) over 
subsequent test points.  Regression lines show relationship between x and y by condition. (B) 
The x axis is week and the y axis is retroactive interference (n) over midpoint and endpoint. 
Columns denote the mean. Error bars denote the SE of the mean. * p <.05.   
There was also a trend towards a main effect of condition, F(1,40) = 2.86, p = .098, such that 
participants in the placebo condition (2.41 ± 0.28) demonstrated less retroactive interference 
compared to those in the active condition (2.53 ± 0.27), and a marginally significant main effect 
of week, F(1,41) = 3.89, p = .055, with performance being better at midpoint (2.07 ± 0.28) than 
at endpoint (2.86 ± 0.28).   
5.8.4.2.3.4 Proactive interference (Trial A1-Trial B1) 
Two outlying observations were removed from the final model.  Baseline, age and IQ were not 
significant covariates, F(1,42) = 1.15, p = .290, F(1,42) = 0.32, p = .577 and F(1,42) = 0.43, p = 
.516, respectively.  Gender was also nonsignificant and was removed from the final model.  
There was no significant main effect of condition, F(1,42) = 0.60, p = .442.   There was a 
marginally significant baseline*condition interaction, F(1,42) = 3.56, p = .066.  There was also a 
significant baseline*week interaction, F(1,38) = 4.15, p = .049.  No higher order interactions were 
significant other than a marginally significant interaction for gender*condition*week, F(4,38) = 
2.56, p = .054. 
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5.8.4.2.3.5 Delayed recall  
No outlying observations were removed from the final model.  Baseline performance was a 
significant covariate, F(1,43) = 39.85, p <.001, such that this was positively associated with 
performance at later test sessions. Gender was not a significant covariate, F(1,43) = 2.38, p = 
.130.  Age and IQ were also nonsignificant and were removed from the final model.  There was 
a marginally significant baseline*condition interaction, F(1,43) = 3.68, p = .062.  No higher order 
interactions were significant other than IQ*condition*week, F(4,38) = 3.37, p = .019, which is 
shown in Figure 5.25 (A - midpoint) and 5.25(B - endpoint).  
On both test occasions, below an IQ score of 110, participants in the active condition correctly 
recalled more items following a delay relative to those in the placebo condition, whilst above 
this IQ score, better performance was demonstrated by participants in the placebo condition.  
Inspection of post hoc comparisons revealed those in the active condition (10.82 ± 1.13) 
correctly recalled significantly more items following a delay compared to those in the placebo 
condition (6.56 ± 1.01; t(38) = 2.80, p =.038) at endpoint at an IQ score of 100.  This became a 
trend at an IQ score of 110 (9.88 ± 0.61 vs. 7.76 ± 0.64; t(38) = 2.39, p =.096).  Moreover, those 
in the active condition (10.82 ± 1.13) recalled significantly more words correctly following a delay 
at endpoint compared to those in the placebo condition at midpoint at an IQ score of 100 (6.12 
± 1.01; t(38) = 3.10, p =.018).  This pattern of performance was a trend at an IQ score of 110 
(9.88 ± 0.61 vs. 7.74 ± 0.63; t(38) = 2.43, p =.089).  No other post hoc comparisons were 
significant. 
Lastly, there was a main effect of condition, F(1,43) = 6.27, p = .016, as shown in Figure 5.25(C). 
Participants in active condition (9.07 ± 0.44) obtained a greater delayed recall score than those 
in the placebo condition (8.58 ± 0.46).   
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Figure 5.25 Delayed recall on the Visual Verbal Learning Test (VVLT). (A-B) The x axis represents 
IQ score and the y axis is delayed recall (n). Regression lines show relationship between x and y 
by condition. (C) The x axis is condition and the y axis is delayed recall (n) over midpoint and 
endpoint. Columns denote the mean. Error bars denote the SE of the mean.* p <.05.  (A) Is 
midpoint, (B) is endpoint.   
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5.8.5 Chronic Effect of intervention on subjective evaluation of cognitive 
failures  
5.8.5.1 Cognitive Failures Questionnaire 
Two outlying observations were removed from the final model.  Subjective evaluation of 
cognitive failures at baseline was a significant covariate, F(1,44) = 77.74, p <.001, such that self-
ratings at baseline were positively associated with evaluations at subsequent test points.  Age, 
IQ and gender were not significant covariates and were removed from the final model.  There 
was no significant main effect of condition, F(1,44) = 1.21, p = .277 and no significant interaction 
between baseline and condition, F(1,44) = 0.53, p = .473.  There were significant 
baseline*condition*week, F(1,41) = 5.16, p = .028, baseline*week, F(1,41) = 4.89, p = .033 and 
condition*week, F(1,41) = 4.89, p = .033, interactions.   
The baseline*condition*week interaction is shown in Figure 5.26(A) and 5.26(B).  In the active 
condition (5.26(A)), those who rated themselves as low for cognitive failures at baseline 
subsequently rated themselves as experiencing greater cognitive failures at endpoint relative to 
midpoint. With increasing baseline rating, greater cognitive failures were experienced at 
midpoint compared to endpoint. In the placebo condition (Figure 5.26(B)), self-perceptions of 
cognitive failures experienced were similar across both test points. Inspection of post hoc 
comparisons revealed a trend towards those in the active condition experiencing greater 
cognitive failures at midpoint (0.56 ± 0.04) compared to endpoint (0.47 ± 0.03; t(41) = 2.47, p = 
.080) at a baseline rating of 0.6. This became significant at a baseline rating of 0.7 and above 
(greater cognitive failure experienced) (0.65 ± 0.05 vs. 0.51 ± 0.04; t(41) = 2.72, p = .045). No 
other post hoc comparisons were significant. 
In view of the significant condition*week interaction, participants in the active condition rated 
themselves as experiencing greater cognitive failures compared to those in the placebo group 
at both midpoint (0.43 ± 0.03 vs. 0.39 ± 0.03) and endpoint (0.40 ± 0.03 vs. 0.36 ± 0.03). However, 
post hoc comparisons did not reveal any significant differences.  
 
 
238 
 
 
 
 
Figure 5.26 Self-reported cognitive failures. The x axis is baseline subjective evaluation (n) and 
the y axis is subjective evaluation (n) over subsequent test points. Regression lines show 
relationship between x and y by week. (A) Is the active condition, (B) is the placebo condition.   
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5.8.6 Summary of findings 
5.8.6.1 Effects of acute GPL with SM supplementation on cognitive performance in middle-aged and older adults with a subjective memory 
complaints 
A tabulated summary of the effect of the acute intervention on cognitive performance is shown in Table 5.10.  
Table 5.10 Tabulated summary of cognitive performance outcomes following acute supplementation 
 Main effects Covariates 
Cognitive 
outcome 
Condition Trial Baseline Age IQ Gender Trial 
Total 
correct 
Accuracy  
Attention Switching Task 
Switch cost 
reaction time 
S (p = .008) S (p = .013) NS NS - T (p = .093) / / S (p <.001) 
Switch cost 
accuracy 
NS S (p = .021) S (p <.001) S (p = .038) NS NS / / / 
Target 
accuracy 
NS NS S (p <.001) - - - / / / 
Target reaction 
time 
S (p = .041) S (p = .004) NS - - - / / S (p <.001) 
Rapid Visual Information Processing Task 
Hits S (p = .012) / S (p <.001) - - - / / / 
False alarms NS / S (p <.001) - S (p = .002) NS / / / 
Reaction time 
for hits 
S (p = .004) / S (p <.001) S (p <.001) - S (p = .005) - S (p <.001) / 
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 Main effects Covariates 
Cognitive 
outcome 
Condition Trial Baseline Age IQ Gender Trial 
Total 
correct 
Accuracy  
N-back Task 
Target 
accuracy 
S (p = .009) / S (p <.001) - S (p = .010) T (p = .096) / / / 
Total accuracy MS (p = .066) / S (p <.001) - S (p = .010) NS / / / 
Reaction time 
for targets 
NS / S (p <.001) - NS T (p = .095) S (p = .022) S (p = .009) / 
Reaction time 
for nontargets 
S (p <.001) / S (p <.001) S (p = .049) S (p <.001) S (p <.001) S (p = .027) S (p <.001) / 
Pattern Separation Task 
Pattern 
separation 
score 
NS / S (p <.001) - - T (p = .088) / / / 
Recognition 
score 
S (p = .038) / S (p <.001) - - NS / / / 
Face-Name Associative Memory Exam 
Immediate 
recall 
NS / S (p = .002) - - NS / / / 
Delayed recall MS (p = .064) / S (p <.001) - NS - / / / 
Visual Verbal Learning Test 
Rate of 
learning 
NS S (p <.001) S (p <.001) S (p = .008) S (p <.001) - / / / 
New learning NS / S (p <.001) S (p = .044) - NS / / / 
Retroactive 
interference 
NS / NS - - NS / / / 
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 Main effects Covariates 
Cognitive 
outcome 
Condition Trial Baseline Age IQ Gender Trial 
Total 
correct 
Accuracy  
Proactive 
interference 
NS / NS S (p = .040) - NS / / / 
Delayed recall MS (p = .053) / S (p <.001) S (p = .018) - NS / / / 
 
 
Table 5.10 continued. 
  Interaction terms 
 
  Interaction terms 
Cognitive outcome Baseline*condition Trial*condition 
 
Cognitive outcome Baseline*condition Trial*condition 
Attention Switching Task  Pattern Separation Task 
Switch cost reaction 
time 
MS (p = .052) NS 
 
Pattern separation 
score 
- / 
Switch cost accuracy - NS  Recognition score S (p = .006) / 
Target accuracy - NS  Face-Name Associative Memory Exam 
Target reaction time S (p = .014) NS  Immediate recall - / 
Rapid Visual Information Processing Task  Delayed recall - / 
Hits - /  Visual Verbal Learning Test 
False alarms NS /  Rate of learning - NS 
Reaction time for hits S (p = .001) /  New learning NS / 
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  Interaction terms 
 
  Interaction terms 
Cognitive outcome Baseline*condition Trial*condition 
 
Cognitive outcome Baseline*condition Trial*condition 
N-back Task 
 
Retroactive 
interference 
NS / 
Target accuracy S (p = .012) /  Proactive interference - / 
Total accuracy MS (p = .057) /  Delayed recall NS / 
Reaction time for 
targets 
NS / 
    
Reaction time for 
nontargets 
S (p <.001) / 
    
Notes. Accuracy: target accuracy used in target reaction time analysis / switch cost accuracy used in switch cost reaction time analysis; MS: Marginally 
significant, NS: Nonsignificant, S: Significant. Total correct: number of correct trials; T; Trend; – indicates term removed from the final model for best fit, / 
indicates this was not entered into the model.
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A summary of significant, marginally significant, and trends for covariates, main effects and 
interactions following acute supplementation is provided below: 
Baseline performance as a covariate by cognitive measure outcome: 
Cognitive performance at baseline (time 1, pre-first dose) was positively related to performance 
at time 2 (+90 minutes post-time 1 and first dose) on sixteen out of twenty cognitive measure 
outcomes assessing memory performance (Pattern Separation Task: Pattern separation score 
and recognition score; Visual Verbal Learning Test: Rate of learning, new learning, delayed recall; 
Face-Name Associative Memory Exam: Immediate and delayed recall), and executive function 
(Rapid visual Information Processing:  hits, false alarms and reaction time for hits; N-back: Target 
accuracy, total accuracy, reaction time for targets and reaction time for nontargets; Attention 
Switching Task: target accuracy and switch cost accuracy). 
Age, IQ and gender of participants as covariates by cognitive measure outcome: 
Despite participants not differing statistically on age, IQ and gender at study entry, these 
demographic characteristics  were significant covariates on a number of outcomes. Age was 
significant on seven outcomes, such that age-related decline (poorer performance with 
increased age) for verbal memory outcomes (Visual Verbal Learning Test: Rate of learning, new 
learning, proactive interference and delayed recall) and for reaction time on executive function 
measures (Rapid Visual Information Processing: reaction time for hits and N-back: reaction time 
for nontargets) was observed.  Conversely, accuracy switch costs improved with increasing age 
on a measure of executive function (Attention Switching Task), however, this was a weak linear 
correlation with considerable variation.  IQ was a significant covariate on 5 outcomes, with 
improved accuracy being associated with higher IQ scores for verbal memory (Visual Verbal 
Learning Test: Rate of learning) and for executive function (Rapid Visual Information Processing: 
false alarms and N-back: target accuracy and total accuracy). However, higher IQ was also 
associated with longer reaction time for nontargets on the N-back task, perhaps representing a 
speed accuracy trade off. Gender was a significant factor on two outcomes and showed a trend 
on four.  Nevertheless, there was no clear indication of either gender demonstrating significantly 
superior performance for accuracy or reaction time or in any specific cognitive domain. With 
respect to executive function, females showed significantly faster reaction time than males for 
hits on the Rapid Visual Information Processing, whilst males demonstrated significantly faster 
response latencies to that of females for nontargets on the N-back task.  Moreover, there were 
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trends towards females responding faster than males for switch costs on the Attention Switching 
Task and towards targets on the N-back task.  There were also trends towards females showing 
greater target accuracy to males on the N-back task.  On the Pattern Separation Task, males 
scored higher than females (pattern separation score).  
Main effect of condition by cognitive measure outcome: 
Condition (active vs placebo) differed significantly for three executive function outcomes.  Those 
in the active condition achieved significantly more hits on the Rapid Visual Information 
Processing Task and demonstrated significantly faster performance for nontargets on the N-back 
task compared to those in the placebo condition. Notably, this main effect of condition on the 
N-back task was qualified by a baseline*condition interaction, such that the significantly faster 
reaction time shown by those in the active condition was observed only for those with faster 
baseline reaction times. At slower baseline response time, participants in the active condition 
were significantly slower than those in the placebo condition. Condition also significantly 
affected performance on the Attention Switching Task whereby those in the placebo condition 
were significantly faster for switch costs compared to those in the active condition. This again 
was qualified by a marginally significant baseline*condition interaction, which indicated that 
those in the active condition demonstrated significantly slower reaction time relative to those 
in the placebo condition at faster baseline performance.  Furthermore, those in the placebo 
condition achieved marginally greater total accuracy (N-back Task) than their counterparts in 
the active condition. There was a corresponding marginally significant baseline*condition 
interaction, such that at poorer baseline performance, participants in the placebo condition 
performed better than those in the active condition.  Conversely, the opposite pattern of 
performance was shown at greater baseline total accuracy; an advantage shown by those in the 
active condition. On a measure assessing memory performance, participants in the placebo 
condition recalled marginally more items correctly following a delay (Face-Name Associative 
Memory Exam and Visual Verbal Learning Test). There was also a trend towards those in the 
active condition demonstrating slower reaction latencies compared to participants in the 
placebo condition for hits on the Rapid Visual Information Processing Task. Again, there was a 
corresponding baseline*condition interaction that indicated that those in the active condition 
responded significantly faster than those in the placebo condition at faster baseline reaction 
time, whereas at slower baseline performance, participants in the placebo condition 
demonstrated significantly faster responses than those in the active condition.   
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Interaction between baseline performance and condition by cognitive measure outcome: 
Significant baseline*condition interactions (in the absence of a main effect of condition) were 
further found on one measure assessing memory performance and two measures sensitive to 
executive performance. With respect to the recognition score outcome of the Pattern 
Separation Task, at superior baseline performance, those in the active condition achieved 
significantly higher recognition scores compared to those in the placebo condition. On the N-
back task, those in the active condition demonstrated significantly poorer target accuracy 
compared to those in the placebo condition at poorer baseline performance. Lastly, on the 
Attention Switching Task (target reaction time), at quicker baseline target reaction time, 
participants in the active condition responded slower than those in the placebo condition, 
however, at poorer baseline performance, participants in the active condition demonstrated 
faster responses to those in the placebo condition.  
 
Overall, it appears that whilst there were some benefits of an acute dose of the active 
supplement, these benefits were mainly demonstrated in participants with higher levels of 
performance at baseline. 
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5.8.6.2 Effects of chronic GPL with SM supplementation on cognitive performance and subjective evaluation of cognitive failures in middle-
aged and older adults with a subjective memory complaints 
A tabulated summary of the effect of the chronic intervention on cognitive performance is shown in Table 5.11.  
Table 5.11 Tabulated summary of cognitive performance outcomes following chronic supplementation 
 Main effects Covariates 
Cognitive 
outcome 
Condition Week Trial Baseline Age IQ Gender Trial 
Total 
correct 
Accuracy  
Attention Switching Task 
Switch cost 
reaction time 
NS NS S (p = .001) NS - - NS / / S (p <.001) 
Switch cost 
accuracy 
T (p = .098) NS S (p <.001) S (p <.001) - 
MS (p = 
.055) 
- / / / 
Target accuracy NS S (p = .026) S (p <.001) S (p <.001) S (p = .021) - - / / / 
Target reaction 
time 
NS S (p = .020) S (p <.001) - - - - / / S (p <.001) 
Rapid Visual Information Processing Task 
Hits NS NS / S (p <.001) S (p = .032) S (p = .008) - / / / 
False alarms S (p = .010) NS / S (p <.001) S (p = .016) - - / / / 
Reaction time 
for hits 
NS S (p = .037) / S (p <.001) - S (p = .039) 
MS (p = 
.058) 
S (p = .021) S (p = .002) / 
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 Main effects Covariates 
Cognitive 
outcome 
Condition Week Trial Baseline Age IQ Gender Trial 
Total 
correct 
Accuracy  
N-back Task 
Target accuracy T (p = .073) NS / S (p <.001) - - - / / / 
Total accuracy S (p = .036) NS / S (p <.001) - - - / / / 
Reaction time 
for targets 
MS (p = 
.064) 
NS / S (p <.001) - - - - - / 
Reaction time 
for nontargets 
NS S (p = .002) / S (p <.001) - S (p = .038) NS S (p <.001) S (p <.001) / 
Pattern Separation Task 
Pattern 
separation 
score 
S (p = .029) NS / S (p <.001) - - - / / / 
Recognition 
score 
NS NS / S (p <.001) - - - / / / 
Face-Name Associative Memory Exam 
Immediate 
recall 
NS NS / S (p <.001) S (p = .025) - - / / / 
Delayed  
recall 
NS S (p = .013) / S (p <.001) S (p = .036) NS - / / / 
Visual Verbal Learning Test 
Rate of learning NS NS S (p <.001) S (p <.001) S (p = .017) S (p = .001) S (p = .021) / / / 
New learning NS NS / S (p <.001) - - NS / / / 
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 Main effects Covariates 
Cognitive 
outcome 
Condition Week Trial Baseline Age IQ Gender Trial 
Total 
correct 
Accuracy  
Retroactive 
interference 
T (p = .098) 
MS (p = 
.055) 
/ - S (p = .009) NS S (p = .009) / / / 
Proactive 
interference 
NS NS / NS NS NS - / / / 
Delayed  
recall 
S (p = .016) NS / S (p <.001) - - NS / / / 
 
Table 5.11 continued. 
 Interaction terms 
Cognitive 
outcome 
Cond* 
week 
Baseline* 
condition 
Baseline* 
week 
Trial* 
condition 
Baseline* 
condition* 
week 
Trial* 
condition* 
week 
Age* 
condition* 
week 
IQ* 
condition* 
week 
Gender* 
condition* 
week 
Attention Switching Task 
Switch cost 
reaction time 
S (p = .026) - S (p = .046) - NS - - NS NS 
Switch cost 
accuracy 
NS S (p = .023) NS - S (p = .049) NS - - S (p = .023) 
Target 
accuracy 
S (p = .029) - - NS - - NS S (p = .008) NS 
Target 
reaction time 
NS S (p = .026) S (p = .031) - S (p = .045) - - NS NS 
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 Interaction terms 
Cognitive 
outcome 
Cond* 
week 
Baseline* 
condition 
Baseline* 
week 
Trial* 
condition 
Baseline* 
condition* 
week 
Trial* 
condition* 
week 
Age* 
condition* 
week 
IQ* 
condition* 
week 
Gender* 
condition* 
week 
Rapid Visual Information Processing Task 
Hits NS - - / - / NS T (p = .080) NS 
False alarms NS S (p = .009) T (p = .087) / - / - - NS 
Reaction time 
for hits 
NS NS S (p = .022) / - / - - NS 
N-back Task 
Target 
accuracy 
NS - MS (p = .064) / NS / NS - NS 
Total accuracy NS - S (p = .034) / NS / NS - NS 
Reaction time 
for targets 
NS NS - / - / NS NS - 
Reaction time 
for nontargets 
S (p = .033) S (p = .001) - / - / S (p = .001) S (p = .034) - 
Pattern Separation Task 
Pattern 
separation 
score 
NS - - / - / NS - NS 
Recognition 
score 
NS NS NS / S (p = .022) / - - S (p = .003) 
Face-Name Associative Memory Exam 
Immediate 
recall 
S (p = .034) NS NS / S (p = .026) / - - NS 
Delayed recall NS NS - / S (p = .004) / - MS (p = .059) - 
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 Interaction terms 
Cognitive 
outcome 
Cond* 
week 
Baseline* 
condition 
Baseline* 
week 
Trial* 
condition 
Baseline* 
condition* 
week 
Trial* 
condition* 
week 
Age* 
condition* 
week 
IQ* 
condition* 
week 
Gender* 
condition* 
week 
Visual Verbal Learning Test 
Rate of 
learning 
S (p <.001) - - - - - S (p = .002) - NS 
New learning S (p = .029) - - / - / - - NS 
Retroactive 
interference 
S (p = .024) S (p = .003) - / - / - - NS 
Proactive 
interference 
NS MS (p = .066) S (p = .049) / - / - - MS (p = .054) 
Delayed recall NS MS (p = .062) - / - / - S (p = .019) NS 
Notes. Accuracy: target accuracy used in target reaction time analysis / switch cost accuracy used in switch cost reaction time analysis; MS: Marginally 
significant, NS: Nonsignificant, S: Significant. Total correct: number of correct trials; T; Trend; – indicates term removed from the final model for best fit, / 
indicates this was not entered into the model. 
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A summary of significant, marginally significant, and trends for covariates, main effects and 
interactions following chronic supplementation is provided below: 
Baseline performance as a covariate by cognitive measure outcome: 
Consistent with the analysis of the cognitive measure data obtained following acute supplement 
administration, cognitive performance at baseline was a significant covariate and positively 
associated with subsequent performance on sixteen out of twenty cognitive measure outcomes. 
Of those that assessed memory performance, these included Pattern Separation Task (pattern 
separation score and recognition score), Face-Name Associative Memory Exam (immediate and 
delayed recall) and the Visual Verbal Learning Test (rate of learning, new learning and delayed 
recall).  Of those that assessed executive function, these included the Rapid Visual Information 
Processing Task (hits, false alarms, reaction time for hits), N-back (target and total accuracy, and 
reaction time for targets and nontargets) and the Attention Switching Task (target accuracy and 
switch cost accuracy).  In addition, baseline evaluations on the Cognitive Failures Questionnaire 
also predicted subsequent evaluations. 
Age, IQ and gender of participants as covariates by cognitive measure outcome: 
Age was significant on seven cognitive measure outcomes, with performance showing age-
related decline on outcome measures including the Face-Name Associative Memory Exam 
(immediate and delayed recall), Visual Verbal Learning Test (rate of learning and retroactive 
interference), Rapid Visual Information Processing Task(hits and false alarms) and on the 
Attention Switching Task (target accuracy). IQ was significant on four cognitive outcomes and 
marginally significant on one other. A higher IQ significantly predicted more accurate 
performance on the Visual Verbal Learning Test (rate of learning) and Rapid Visual Information 
Processing Task (hits). However, as with the findings from the analysis of the cognitive data 
following acute supplementation, IQ was a significant covariate for reaction time performance, 
such that response latencies were greater for those with higher IQ scores on Rapid Visual 
Information Processing Task (reaction time for hits) and the N-back task (reaction time for 
nontargets). Again, this may represent a speed accuracy trade off with respect to the Rapid 
Visual Information Processing measure, whereas the longer response times shown on the N-
back task may represent more cautious executive decision making.  IQ was further marginally 
significant on the Attention Switching Task (switch cost accuracy), with those with lower IQ 
scores demonstrating greater switch cost accuracy, however, this was represented by a weak 
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correlation.  Gender was significant on two outcomes assessing memory performance and 
marginally significant on one outcome assessing executive function.  As with the findings derived 
from the analysis of cognitive data following acute analysis, there is no clear indication of either 
gender showing a significant advantage. Specifically, females demonstrated significantly better 
performance than males on the rate of learning outcome of the Visual Verbal Learning Test, 
whilst males showed significantly less retroactive interference compared to females on the same 
measure. Consistent with post-acute supplementation performance, females responded faster 
than males for hits on the Rapid Visual Information Processing Task, however, this was only a 
marginally significant difference. 
Main effect of condition by cognitive measure outcome: 
Significant or marginally significant main effects of condition or trends towards an effect of 
condition were typically qualified by a corresponding baseline*condition and 
baseline*condition*week interactions, further highlighting the association between baseline 
performance and subsequent performance. Exceptions to this occurred for the Pattern 
Separation Task (pattern separation score): those in the active condition demonstrated 
significantly poorer performance to those in the placebo condition; N-back (target accuracy): 
trend towards participants in the active condition showing greater accuracy to those in the 
placebo condition; N-back (total accuracy): significant difference in favour of those in the active 
condition; N-back (reaction time for targets): those in the active condition demonstrated 
marginally significantly slower response times compared to those in the placebo condition.  
Participants in the active condition demonstrated significantly superior performance to those in 
the placebo condition on the Visual Verbal Learning Test for delayed recall, however, this main 
effect of condition was qualified by a marginally significant baseline*condition interaction and 
a significant IQ*week*condition interaction. Performance (pooled across midpoint and 
endpoint) was superior in the active condition but only at higher levels of baseline performance. 
Furthermore, there was a stronger effect of condition in favour of the active condition at 
endpoint in those with an IQ score of 100 (with a trend for those with an IQ score of 110). There 
was a trend towards superior performance on the Visual Verbal Learning Test for retroactive 
interference (lower retroactive interference) demonstrated by those in the placebo condition 
relative to the active condition. However, this was qualified by significant baseline*condition 
and condition*week interactions. Notably, at better baseline performance (lower retroactive 
interference), there was a trend towards participants in the active condition performing better 
than those in the placebo condition. However, participants in the active condition demonstrated 
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significantly greater retroactive interference to those in the placebo condition at poorer baseline 
performance.  In addition, those in the active condition performed better at midpoint than at 
endpoint.  Participants in the placebo condition also showed superior performance to those in 
the active condition on the Rapid Visual Information Processing Task (false alarms: significant). 
However, this was qualified by a significant baseline*condition interaction, such that 
participants in the active condition committed significantly more false alarms at better baseline 
performance but significantly less at poorer baseline performance to those in the placebo 
condition. Post hoc comparisons were inconclusive in respect of the main effect of condition.  
Participants in the placebo condition further showed superior performance to those in the active 
condition on the Attention Switching Task (switch cost accuracy: trend). This trend towards a 
benefit for placebo was qualified by baseline*condition*week (where those in the placebo 
condition demonstrated better performance compared to those in the active condition at 
midpoint depending on their baseline performance) and gender*condition* week (the effect of 
week depended upon gender in the active condition but not the placebo condition) interactions. 
Two-way and higher order interactions featuring participants’ demographics in the absence of a 
significant main effect of condition by cognitive measure outcome: 
For the Pattern Separation Task (recognition score), there were significant 
baseline*condition*week and gender*condition*week interactions.  On the Face-Name 
Associative Memory Exam (delayed recall), there was a significant baseline*condition*week 
interaction and a marginally significant IQ*condition*week interaction. For the Visual Verbal 
Learning Test (rate of learning), there were significant condition*week and age*condition*week 
interactions. On the same cognitive measure (proactive interference), there were marginally 
significant baseline*condition and gender*condition*week interactions.  For the N-back task 
(reaction time for nontargets), there were significant baseline*condition, condition*week, 
IQ*condition*week and Age*condition*week interactions.  On the Attention Switching Task, 
there were significant condition*week and IQ*condition*week interactions for target accuracy; 
significant baseline*condition and baseline*condition*week interactions for target reaction 
time; significant baseline*condition*week, gender*condition*week and baseline*condition 
interactions, however, there was also a  trend towards a main effect of condition for switch cost 
accuracy, and a significant condition*week interaction for switch cost reaction time. Post hoc 
comparisons were inconclusive for the condition*week interaction for switch cost reaction time.  
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Interaction between baseline self-ratings, condition and week on cognitive failures: 
There was a significant baseline*condition*week interaction for the Cognitive Failures 
Questionnaire.   These data indicated an interaction between baseline evaluations and 
subsequent evaluations (at midpoint and endpoint) in the active condition but not in the placebo 
condition. Specifically, participants in the active condition reported experiencing greater 
cognitive failures at midpoint compared to endpoint if they had reported more cognitive failures 
at baseline.  
5.9 Discussion 
5.9.1 Overview of findings 
The primary aim of the present study was to examine whether acute (cognitive assessment +90 
minutes post-first dose) and/or chronic (12 week) supplementation of Lacprodan® PL-20 led to 
an improvement in cognitive function, specifically memory and executive function in adults aged 
50 years and over with a SMC. A supplementary research question concerned whether 
Lacprodan® PL-20 would result in a reduction in the frequency of cognitive failures experienced 
by those who participated in the study.  It was hypothesised that Lacprodan® PL-20 
supplementation would lead to improvements in cognitive function demonstrated by superior 
performance on the cognitive measures compared to those in the placebo condition.   In 
addition, it was expected that improvements in cognitive function would lead to a decrease in 
the prevalence of cognitive failures. As with Study 1, the findings following both the acute and 
chronic administration of Lacprodan® PL-20 suggest limited efficacy of the product to promote 
improvements to cognitive function.  Following acute administration, there was a significant 
difference in performance by condition on the primary outcome (Attention Switching Task: 
Switch cost reaction time), however, this was in favour of the placebo condition. Regarding the 
secondary outcomes, a benefit of Lacprodan® PL-20 supplementation was seen on the Rapid 
Visual Information Processing measure (Hits) and on the N-back Task (reaction time for 
nontargets).  This main effect of condition for reaction time for nontargets was qualified by a 
baseline*condition interaction, such that those in the active condition were significantly faster 
than participants in the placebo condition at faster baseline performance, whilst participants in 
the placebo condition were significantly faster than those in the active condition at slower 
baseline reaction time. With respect to the findings following chronic supplementation, on the 
primary outcome, there was no significant/marginally significant/trend towards a main effect of 
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condition. There was a significant interaction between condition and week, however, post hoc 
comparisons were inconclusive.  Performance differences in favour of those in the active 
condition as shown on secondary outcomes include superior performance to those in the 
placebo condition on the N-back Task including greater target accuracy (trend) and total 
accuracy (significant). However, participants in the active condition also demonstrated 
marginally significantly slower reaction times for targets relative to those in the placebo 
condition, suggesting a speed-accuracy trade-off.  For those in the active condition who reported 
experiencing greater cognitive failures at baseline, there was a reduction in the extent of these 
from midpoint to endpoint. However, no differences were found between the two conditions 
and evaluations by those in the placebo group were similar across both weeks.   
Cognitive performance between conditions tended to differ as a function of baseline 
performance, as indicated by the many baseline*condition interactions (as well as the less 
frequent baseline*condition*week interactions).  Consistent with this, cognitive performance at 
baseline was typically found to be a significant predictor of subsequent performance observed 
on later test occasions.  The findings based on the cognitive measure data obtained following 
both acute and chronic supplementation suggest that treatment benefits of Lacprodan® PL-20 
were mainly demonstrated in participants with higher levels of performance at baseline.  Other 
studies that supplemented similar samples (middle-aged/older adults with SMCs) with GPLs 
(Crook et al., 1991; Moré et al., 2014; Vakhapova et al., 2010) also reported that their study 
findings differed as a function of baseline performance.  Similarly, baseline evaluation of 
cognitive failures was found to be a significant covariate.  Baseline performance differences can 
undermine efforts to explore treatment effects.  This is also the case for other baseline 
characteristics, such as age, IQ and gender.  Despite attempting to control for the influence of 
these variables by using stratified randomisation when allocating participants to condition (block 
randomisation in which level of education was used as a proxy for IQ, see section 5.6.2), 
demographic variables were found to be significant predictors of performance.  That said, it 
could be argued that level of education was a poor proxy for IQ in that for adults over 50 years 
of age, going on to further education when they were younger may have been dependent upon 
their family situation and whether enrolling in higher education was financially viable.  To reduce 
differences that exist between the conditions, individuals’ cognitive measure performance could 
be assessed, and their demographic details collected, prior to study enrolment for the purpose 
of tightening inclusion criteria.  For example, with respect to IQ, IQ*condition*week significant 
interactions were found on the Verbal Visual Learning Test (delayed recall), the N-back Task 
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(reaction time for nontargets) and the Attention Switching Task (target accuracy) following the 
chronic analysis.  Overall, those in the active group tended to demonstrate greater accuracy and 
faster reaction time than their counterparts in the placebo condition, typically at endpoint, if 
they had IQ scores ranging from 90 to 120.  These results suggest that participant recruitment 
in similar studies might be best focussed on those with average (100) IQ and the range confined 
to +/- 1 SD i.e. 85 to 115. 
5.9.2 Possible explanations for the limited significant treatment effects on 
cognition performance following acute and chronic supplementation with 
Lacprodan® PL-20 
 
5.9.2.1 Study quality and statistical approach 
Considering the strengths and weaknesses of the current study, many of the strengths of Study 
1 (section 4.8.2) apply to the present study. The study design conformed to a randomised, 
double-blind, placebo-controlled study design and supplement products were matched for taste 
and appearance and packaged in identical sachets except for a 3-digit code used for 
identification. Researchers remained blind at the time of data analysis and were unblinded only 
following completion of data analysis. The outcome data from all measures utilised in the 
present study was analysed and reported following the administration of all measures that were 
planned to be utilised in the study a priori.  It can therefore be concluded that the study 
demonstrates a low risk of bias and can be classed as being of good quality in accordance with 
the Cochrane risk of bias tool for randomized clinical trials (Higgins et al., 2011).  Moreover, 
including an opportunity for participants to become familiar with the measures during the 
screening appointment and using parallel versions of these on all test occasions reduces the 
extent of practice effects (Beglinger et al., 2005; Bell et al., 2018). The statistical approach 
employed in the analysis of the data obtained following acute and chronic administration was 
also consistent with Study 1 with respect to controlling for baseline data and participant 
demographic characteristics (see section 4.8.2.2. for the merits of this approach).   
As with Study 1, an a posteriori calculation was performed for both the acute and chronic 
interventions.  Based on the number of participants included in each analysis, observed 
difference in LS-means and variability (standard deviation) on the primary outcome, an a 
posteriori calculation determined the power to detect a difference between the active and 
placebo conditions was 0.722 and 0.05 in respect of the acute and chronic interventions, 
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respectively.  Additionally, a sample size of 61 and 1,445,954 would be required to achieve 
power of 0.8 in respect of the acute and chronic interventions, respectively.  It can therefore be 
concluded that both parts of the study were underpowered due to an insufficient number of 
participants. 
5.9.2.2 Duration of intervention 
In view of the duration of intervention, particularly the acute administration but also the 
duration of the chronic administration of Lacprodan® PL-20, the length of treatment may have 
not been sufficient to induce alterations at the level of the cell membrane of adequate strength 
to effect a positive impact on cognitive function (see section 4.8.2.3). However, three 
randomised, double-blind, placebo-controlled design studies that recruited a similar sample to 
that used in the present study did report a benefit of GPL supplementation. Crook and 
colleagues (1991) reported a benefit of PS sourced from bovine cortex after 3 weeks on a Name-
face association measure and after 12 weeks on the Wechsler Memory Scale Logical Memory 
Subtest (Form A).  Vakhapova et al. (2010) found a favourable effect of PS-DHA/EPA after 15 
weeks of consumption on immediate verbal recall of a word list, whilst a composite of PS + PA 
for 3 months led to positive treatment effects on the information, visual memory and 
memorising numbers components of the Wechsler Memory Scale (Moré et al., 2014).  However, 
despite the apparent similarity in the sample (adults with a SMC), there are significant 
differences between these studies and the current one discussed under 5.9.3, which might 
explain the discrepancy in research findings.  Importantly, Moré et al. (2014) also conducted 
kinetic analysis of soy-PS in 8 overnight-fasted healthy volunteers and reported the level of PS 
in serum peaked 90 minutes post single ingestion of 5 capsules each containing 100 mg PS + 80 
PA. This finding is promising, as it provides support towards PS potentially being available for 
uptake into the brain 90 minutes after oral consumption, which informed the timing between 
first dose and cognitive testing in the present study.  Crucially, just as with PL-DHA in that it is 
not clear how quickly or to what extent brain DHA levels respond to alterations in plasma PL-
DHA (Lacombe et al., 2018), it is currently unknown how GPLs present in the brain correspond 
to those available in serum. Thus, it should not be assumed that concentrations of GPLs within 
the brain have a direct relationship with GPLs available within serum or that we can infer the 
timing or rate of uptake.   
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5.9.2.3 Measurement of cognitive performance 
As discussed previously (see section 5.4), the selection of cognitive measures for use in the 
current study was informed by the findings of similar studies that have reported positive 
treatment effects following GPL supplementation.  Evidence concerning which cognitive 
domains are typically compromised with increasing age and the facilitation and protection of 
cognitive function by GPLs was reviewed (see sections 5.1 and 2.7, respectively).  It was 
important to select measures that were sensitive and salient to the study sample i.e. those that 
assessed memory function.  As such, the selection of measures to assess cognitive function was 
considered and well-informed. 
5.9.2.4 Compliance  
Supplements were consumed by participants in their homes for convenience in this free-living 
study.  Compliance with the study protocol required participants to consume the supplement 
daily. Compliance was measured using a consumption diary and the return of supplement 
sachets.  Supplement consumption was also discussed face-to-face on each test occasion.  
However, unlike in Study 1, no direct measurement of compliance could be taken. Records 
concerning participant consumption may therefore not reflect the actual frequency or pattern 
of supplement intake across experimental conditions. 
5.9.3 Current findings in the context of previous empirical evidence  
The findings of the current study are not consistent with previous studies that have explored the 
potential advantage of GPL intake to cognitive performance in adults with SMCs and observed 
positive treatment effects (Crook et al., 1991; Moré et al., 2014; Vakhapova et al., 2010).  The 
difference in study findings may reflect a difference in analytical approach, the potential for 
practice effects, study inclusion criteria and GPL composition. Moré et al. (2014) failed to control 
for potential confounding variables, such as baseline cognitive performance and demographic 
variables in the analysis of their data.  Failing to account for confounding variables in an analysis 
threatens the validity of inferences made about cause and effect (Pourhoseingholi, Baghestani, 
& Vahedi, 2012).  Similarly, although Crook et al. (1991) included baseline performance data as 
a covariate in their analysis, they failed to account for IQ.  Vakhapova and colleagues (2010) 
controlled for baseline performance and cognitive function (MMSE score; participant 
demographics were removed from the final model due to being nonsignificant), however, the 
reported improvements in performance on the RAVLT, which enabled them to conclude a 
benefit of PS-DHA/EPA may have been undermined by practice effects.  Indeed, practice effects 
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have been reported on measures assessing immediate and delayed recall of word lists (Bell et 
al., 2018).  The validity of subjective memory complaints reported by participants in the current 
study were not assessed using, for example, a questionnaire or a neuropsychological measure.  
Both Vakhapova et al. (2010) and Crook et al. (1991) used a memory complaint questionnaire 
and required individuals to score above a cut-off to be eligible to participate.  Eligibility also 
depended upon an individual’s performance on a neuropsychological battery (Vakhapova et al., 
2010) or on a standardised memory assessment (Crook et al., 1991), which was used to ratify 
the complaint. In the absence of a formal assessment of memory function in the present study, 
it is impossible to know whether the participants have experienced similar prior declines in 
memory and therefore would meet the same eligibility criteria.  As such, comparing the findings 
of the current study with the findings of either of the two previous studies may be erroneous.  
Moreover, the composition of the GPL supplement provided by both Vakhapova et al. (2010) 
and Crook et al. (1991) contained DHA (PS-DHA and PS sourced from bovine cortex, respectively) 
unlike Lacprodan® PL-20, which is sourced from bovine milk.  This again makes it difficult to draw 
comparisons between the studies, given PS enriched with DHA is known to promote cognitive 
function in multiple ways (see section 3.5.1).  
5.10 Conclusion 
A randomised, double-blind, placebo-controlled, parallel groups study was undertaken to 
examine whether providing Lacprodan® PL-20 as a single dose (acute) and chronically (12 weeks) 
would promote cognitive performance. The analysis of the study data adjusted for baseline 
cognitive performance/subjective evaluation of cognitive failures, age, IQ and gender. The 
findings provided limited evidence as to the efficacy of the active supplement on cognitive 
performance and benefits were mainly demonstrated in participants with higher levels of 
performance at baseline.  The degree of self-reported cognitive failures reduced over time in 
those that received the active supplement and reported experiencing them to a greater extent 
at baseline, however, no between condition differences were found.  These findings are not 
consistent with other studies that have supplemented similar experimental samples with GPLs. 
This difference in the study findings may reflect heterogeneity in analytical approach, study 
eligibility criteria and supplement composition.  
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6. General discussion 
This chapter provides a summary of the key findings of this thesis in relation to the original thesis 
aims presented in Chapter 1.  The implications of the findings are discussed in the context of 
previous research, limitations of the work undertaken and recommendations for future research 
are outlined.  
Due to the bioactive properties of GPLs, particularly with respect to their potential to support 
cognition discussed in Chapter 2, a number of intervention studies have explored the benefits 
of acute and chronic administration to cognitive performance.  In some cases, the quality of 
these supplementation studies has been lacking with regard to the study design and/or the 
analytical procedure. Importantly, the work undertaken for this thesis aimed to address the 
limited existing empirical findings concerning GPL supplementation in children and adults with 
a SMC.  Supplementing Lacprodan® PL-20 at both ends of the lifespan enabled the examination 
of its potential to facilitate cognitive performance during periods of potential vulnerability.  That 
is, childhood is a critical time for cognitive development, as demonstrated by the continued 
development of the prefrontal cortex (Giedd, 2004) and corresponding cognitive functions, such 
as memory consolidation (Preston & Eichenbaum, 2013), working memory (Lara & Wallis, 2015) 
and attentional control (Rossi et al., 2009).  Conversely, later life is associated with decline in 
cognitive function, illustrated for example, by reduced memory function (Harada et al., 2013; 
Nyberg, 2017; Tromp et al., 2015).  During this time, the function of cellular membranes may be 
compromised, as a consequence of increasing age and factors such as oxidative stress (Nicolson, 
2016; Nicolson & Ash, 2014, 2017). Adults with SMCs may be at a stage prior to MCI in the 
eventual development of AD (Reisberg & Gauthier, 2008; Saykin et al., 2006).  Supplementing 
adults with a SMC but no objective cognitive impairment possibly confers the greatest likelihood 
of detecting an effect if the particular nutritional intervention can confer a benefit compared to 
adults with cognitive impairment, such as MCI (Miquel et al., 2018). 
6.1 Key findings 
The systematic research review (Chapter 3) identified ten intervention studies, which met the 
inclusion criteria. Seven of these studies supplemented GPLs, whilst the remaining three 
administered a composite supplement, Lacprodan® PL-20, that was used in the two empirical 
studies reported in this thesis.  In brief, the review identified a benefit of PS, PS-DHA/EPA and 
Lacprodan® PL-20 supplementation, which was mainly evident for the enhancement of memory 
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performance. Moreover, the review highlighted the absence of empirical research which 
examined the effect of GPLs on cognitive performance in children or adolescents.  The quality 
of the studies reviewed varied.  Controlling for covariates known to correlate with cognitive 
performance (age, IQ, gender) and baseline performance to provide a more precise estimate of 
treatment effect(s) was rarely performed.  In three studies exploring the extent to which PLs 
buffer the effects of acute stress on cognitive performance (Hellhammer et al., 2010; Parker et 
al., 2011; Schubert et al., 2011), there was no measurement of cognitive performance taken 
prior to the intervention (so an absence of a true baseline). Across the studies that reported the 
effects of chronic supplement administration (≥ 2 week), only the minority reported monitoring 
supplement intake (3/8; Boyle et al., 2019; Cheatham et al., 2012; Vakhapova et al., 2010). Other 
methodological issues include evidence of practice effects in at least one study (Baumeister et 
al., 2008), small sample sizes  (n=8-16) (Baumeister et al., 2008; Harris et al., 1983; Rosadini et 
al., 1990), and none of the included studies provided justification for the  cognitive measures 
employed in terms of their sensitivity to identify nutrient-induced changes in cognitive function. 
The aim of Study 1 (n=70; Chapter 4) was to address the absence of empirical research exploring 
the potential of GPLs to effect cognitive performance in school-aged children using a suitable 
randomised controlled design and carefully selected measures of cognitive function.  This study 
aimed to examine the relationship between Lacprodan® PL-20 supplementation for 6 weeks and 
performance on six cognitive measures assessing four cognitive domains as well as subjective 
evaluations of appetite, mood, motivation and mental alertness.  The impact of Lacprodan® PL-
20 supplementation on cognitive performance was limited to a trend towards those in the active 
condition correctly responding to marginally more trials and reaching a higher span on a 
measure of working memory (Spatial Span). Performance on cognitive measures was found to 
vary as a function of baseline performance, which often interacted with condition and week.  
Performance at baseline was positively correlated with later performance at midpoint (week 3) 
and endpoint (week 12) on all but two of the cognitive measures irrespective of condition. 
Participants’ demographic characteristics including age, IQ and gender were also found to be 
associated with performance on the cognitive outcomes.  Better performance was 
demonstrated by older participants. Having a higher IQ was also related to improved 
performance on most outcomes, however, on a measure sensitive to visuospatial memory, 
those with a higher IQ were generally slower. Females showed superior accuracy when their 
motor skills were assessed and superior performance on a measure of verbal memory.  The 
advantage demonstrated by females on the verbal memory measure is unsurprising given 
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females tended to score more highly compared to males on the WASI vocabulary subtest 
(Wechsler, 1999) at baseline (reviewed in section 4.7.1).  However, males exhibited faster 
reaction and movement time relative to females.  Higher order interactions were also found that 
varied by age, IQ and gender; nonetheless, there was no consistent relationship with Lacprodan® 
PL-20 supplementation.  Baseline subjective ratings were also positively associated with 
subsequent self-ratings.  Moreover, there was a trend towards participants in the placebo 
condition rather than those in the active condition to rate themselves as more cheerful.  For 
ease of distraction, of those who perceived themselves as less easily distracted at baseline, 
participants in the placebo condition reported being significantly less easily distracted relative 
to those in the active condition.  Whilst at lower-to-mid and higher baseline subjective ratings, 
those in the placebo condition perceived themselves to be significantly higher on a scale of bad 
temperedness compared to participants in the active condition at midpoint.  Nevertheless, at 
the same baseline subjective ratings, those in the placebo condition also perceived themselves 
as significantly more bad tempered at midpoint vs. endpoint, whilst there was a trend towards 
participants in the active condition reporting feeling less bad tempered at midpoint relative to 
endpoint.  There was a trend for perceived frustration to vary by condition and week, such that 
those in the placebo condition appeared to feel increasingly frustrated over time, whereas those 
in the active condition became less frustrated from midpoint to endpoint.  
Study 2 (n=50) built on the existing empirical literature and examined the effect of GPL plus SM 
supplementation in middle-aged and older adults with SMCs.  In addition, this study also sought 
to add to the limited knowledge of PL effects on cognitive performance following acute 
administration.  Specifically, Study 2 aimed to explore whether consumption of Lacprodan® PL-
20 after a single dose (acute) and chronically would lead to gains in cognitive performance 
measures of  memory and executive function assessed at after 6 (midpoint) and 12  weeks 
(endpoint) of administration.  Performance gains shown by those in the active condition 
following both acute and chronic intake of Lacprodan® PL-20 were again minimal.  In the absence 
of a corresponding baseline*condition or baseline*condition*week interaction(s), performance 
gains included significantly more hits on the Rapid Visual Information Processing Task (acute) 
and greater target accuracy (trend) and total accuracy (significant) on the N-back Task (chronic) 
were observed. However, as participants in the active condition were marginally significantly 
slower when responding to targets on the N-back Task (chronic), the accuracy performance 
advantage may indicate a speed-accuracy trade-off.  Similarly, there was a trend towards those 
in the active condition demonstrating slower reaction time for hits on the Rapid Visual 
Information Processing Task (acute), but a corresponding baseline*condition interaction 
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indicated that this was only at slower baseline performance.  Cognitive performance differences 
between conditions were found to vary depending on baseline performance and to a lesser 
extent, performance at baseline and week, both following acute (no baseline*condition*week 
interactions were requested for the acute analysis, see section 5.7) and chronic 
supplementation.  Importantly, it was typically found that any benefit of Lacprodan® PL-20 was 
mainly demonstrated by participants with higher levels of performance at baseline.  Following 
both acute and chronic administration of Lacprodan® PL-20, baseline performance was a 
significant predictor of later performance for the majority of cognitive outcomes. Age, IQ and 
gender were also related to performance.  Following both acute and chronic supplementation, 
where age was a significant covariate, performance showed age-related decline except on the 
Attention Switching Task, such that switch cost accuracy improved with age (following acute 
administration only).  However, this correlation was weak and there was substantial variation in 
performance.  This along with the fact that it was not observed following chronic 
supplementation suggests the relationship should not be accepted at face value.  A higher IQ 
significantly predicted greater performance except for reaction time outcomes on the N-back 
Task (acute and chronic) and Rapid Visual Information Processing Task (chronic), such that those 
with lower IQ scores showed faster response times. This may represent a speed accuracy trade-
off and/or more cautious decision making (executive function).  In addition, those with a lower 
IQ score also showed marginally significant greater switch cost accuracy (chronic), although 
again, this was only a weak correlation.  Gender was also a significant covariate, with males and 
females demonstrating superior performance across several measures, both for accuracy and 
response latencies (acute and chronic).  A consistent finding (acute and chronic) includes 
females demonstrating faster reaction time for hits on the Rapid Visual Information Processing 
Task.  Of the studies reviewed in Chapter 3 that recruited a similar sample to the present study, 
Vakhapova et al. (2010) entered participant demographics in their initial model, however, these 
were subsequently removed, as they were found not to be significant.  The benefit of 
Lacprodan® PL-20 consumption on frequency of cognitive slips was also examined across the 12 
weeks.  Those in the active condition who reported experiencing greater cognitive failures at 
baseline reported a reduction in the extent of these over time.  Importantly, this reported 
moderation was in the absence of any consistent improvement shown on the cognitive 
measures. This reflects the notion that SMCs may not correspond with actual performance on 
cognitive tests, suggesting that those who present with a SMC may reflect a proportion of the 
population sometimes referred to as the “worried well”. These are often high functioning 
individuals accustomed to relying on their cognitive capacity who notice very quickly when this 
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seems to lapse, even though their day to day functioning is ostensibly unimpaired. Conversely, 
however, it has been reported that SMCs may represent subtle changes in resting-state 
functional connectivity that are not detected by neuropsychological tests (Kawagoe, Onoda, & 
Yamaguchi, 2019).  There was no difference in the subjective evaluations on the CFQ at baseline 
between conditions. As this finding applies only to those who reported greater cognitive failures 
at baseline, it may be that they are particularly concerned about their memory 
function/observant of such slips and were invested in the study, the combination of which led 
to a placebo effect.  
Both Study 1 and Study 2 were underpowered (power of <0.8) due to an insufficient number of 
participants (see sections 4.8.2.1 and 5.9.2.1. for a posteriori estimations). For Study 1, it was 
calculated that 58 participants were required per treatment arm, whilst with respect to Study 2, 
it was estimated that 27 participants were required per treatment arm.  Given the observed 
difference in LS-means and the observed standard deviation, in order to achieve a power of 0.8, 
a sample size of 25,118, 6281 and 1571 would be required at baseline, midpoint and endpoint, 
respectively, for Study 1, and a sample size of 61 and 1,445,954 would be required in respect of 
the acute and chronic interventions, respectively.   
The use of multiple cognitive measures sensitive to a wide range of cognitive functions afforded 
a comprehensive assessment of cognitive performance in both studies. However, it is 
acknowledged that including multiple cognitive tests with multiple outcomes increases the risk 
of false positives i.e. Type 1 error rate, and while post hoc tests control for this, it is likely that 
some of the effects reported are type 1 errors. 
6.1.1 Influence of participant baseline characteristics on cognitive 
performance 
Taken together, the findings of both studies indicate that participants’ demographic 
characteristics and baseline performance on the cognitive measures had a greater impact on 
cognitive performance than the active supplement.  As expected, in Study 1, better performance 
was demonstrated by older children.  This is consistent with the literature on cognitive 
development during childhood that indicates that childhood is characterised as a period of brain 
maturation, this being associated with increasing sophistication of cognitive function (see 
section 4.2). Conversely, cognitive performance reduced with increasing age in the adults who 
participated in Study 2 for all but one outcome, such that age was a significant covariate.  These 
findings reflect empirical work that has identified age-related decrements in cognitive function 
(see sections 5.1 and 5.2).  In both studies, IQ was also a significant predictor of performance of 
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participants.  This is a common finding in the assessment of cognitive function, that is, that IQ 
accounts for a high proportion of the variance (Mohn et al., 2014).  Furthermore, the positive 
relationship between IQ and performance (with the exception of a few outcomes) is in 
accordance with the observation that individuals with higher IQ scores typically perform better 
on measures assessing mental abilities (Checa & Fernández-Berrocal, 2015; Haier, 2014). With 
regard to gender, the performance advantage demonstrated by males in Study 1 aligns with 
previous research suggesting gender differences in visual processing emerge from 4-7 years of 
age, with males being beneficiaries (Palejwala & Fine, 2015).  The superior verbal memory 
performance demonstrated by females in Study 1 has previously been discussed in relation to 
baseline performance on the WASI vocabulary subtest (Wechsler, 1999).  In Study 2, there were 
three trends following the acute analysis towards females outperforming males on measures of 
executive function.  Of particular interest concerns reaction time for targets and target accuracy 
on the N-back Task.  However, given males were significantly faster at identifying nontargets 
compared to females on the same task, the trends towards superior performance, particularly 
towards reaction time for targets, as shown by females should be considered within the wider 
context.  The common finding that cognitive performance by condition varied as a function of 
performance at baseline across both studies is especially important.  As reported in Chapter 3, 
of the eight studies included in the systematic review that assessed participants at baseline, only 
three of these controlled for baseline performance. In cases where this does not happen, 
estimates of main effects will be less precise (O’ Connell et al., 2017), meaning researchers may 
misinterpret their findings. All in all, it is critical that future intervention studies (and research 
more widely) controls for possible confounding or causally prior variables in the analysis of their 
data.  
6.2 Recommendations for the composition of GPL species and 
corresponding fatty acid profiles to affect cognitive performance in 
future research  
6.2.1 Composition of the active supplement used in both studies in this thesis 
As described in section 4.5.3.1, Lacprodan® PL-20 is a bovine milk-derived PL-enriched protein 
concentrate (Sokol, Ulven, Færgeman, & Ejsing, 2015).  Shotgun lipidomics analysis using 
MS/MSALL of Lacprodan® PL-20 identified 6 lipid classes along with their FA composition (Sokol 
et al., 2015).  Polyunsaturated FAs including AA and DPA present in Lacprodan® PL-20 were 
mainly identified as PE, PS and PI species and the molar abundance was identified as <5 mol% 
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across all lipid classes evaluated (Sokol et al., 2015). A breakdown of the PL constituents of 
Lacprodan® PL-20 and their relative FAs attached is listed in Table 6.1. 
Table 6.1 Composition of molecular PL species in Lacprodan® PL-20 (Sokol et al., 2015) 
Lipid classes Molar abundance (mol%) Molecular FA composite (most 
abundant species)a 
PE 35 PE 18:1b /18:1c (34 mol%) 
PC 18 PC 16:0d /18:1c  (23 mol%) 
PS 9 PS 18:0e /18:1c  (38 mol%) 
PI  5 PI 18:0 /18:1c (39 mol%) 
Sphingomyelin 8 - 
Notes.aTriglycerides tended to have saturated and short-chain FA moieties determined by 
MS/MSALL analysis; bOleic acid; csn-1 location / sn-2 location; dPalmitic acid; eStearic acid. 
One suggestion for the limited efficacy of Lacprodan® PL-20 in promoting improvements in 
cognitive performance relates to its lipid composition.  Importantly, Lacprodan® PL-20 is 
intended for infant formula.  Infant formula tends to mimic the nutritional composition of breast 
milk as far as possible (Martin, Ling, & Blackburn, 2016). Specifically, the composition of mature 
breast milk is used as a guide (Wiedeman et al., 2018).  Notably, in mature breast milk, 
approximately half of the FAs are saturated FAs, with palmitic acid (16:0) contributing a large 
proportion of this (Delplanque, Gibson, Koletzko, Lapillonne, & Strandvik, 2015; Koletzko, 2017). 
Stearic acid (18:0) also features as a major saturated FA, whereas oleic acid (18:1) is the 
predominant monounsaturated FA (Bravi et al., 2016). It is therefore apparent that Lacprodan® 
PL-20 is well matched to mature breast milk in respect of its FA profile.  The similarity between 
Lacprodan® PL-20 and breast milk is further supported by work that has quantified PL classes 
present in human milk.  That is, the molecular abundance of GPLs in Lacprodan® PL-20 is in 
accordance with the GPL concentrations identified in human milk (Giuffrida et al., 2013).  
6.2.2 Suitability of the active supplement for use in children and adults for 
cognitive performance enhancement 
Lacprodan® PL-20 may be a suitable alternative to breast milk to support the cognitive 
development of infants. Evidence in support of this comes from a study that supplemented 
neonatal piglets with either 0%, 0.8% or 2.5% Lacprodan® PL-20 from postnatal day 2 – 28. Those 
supplemented Lacprodan® PL-20 demonstrated greater accuracy and faster reaction time on a 
spatial T-maze task. Moreover, changes in phosphatidylcholine-related metabolites in the 
hippocampus were found to reflect diet (Liu et al., 2014).  Nonetheless, this does not mean that 
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this same GPL and FA profile is likely to confer benefits for brain or cognitive development or 
enhance cognitive function in  children or prevent cognitive decline/improve cognitive function 
in middle-aged and older adults.  For instance, palmitic acid is required by infants to promote 
growth and meet metabolic energy needs (Innis, 2016).  However, in adults with chronic disease, 
palmitic acid has received much attention due to the reports of adverse health effects (Innis, 
2016). Essentially, palmitic acid is the most abundant saturated FA in the body and can be 
obtained from diet where it is present in high quantities in meats and dairy products (Schommer, 
Marwarha, Nagamoto-Combs, & Ghribi, 2018), however, palmitic acid can also be synthesised 
de novo (Guest, Garg, Bilgin, & Grant, 2013). Importantly, as palmitic acid can be synthesised 
endogenously, the regulated tissue content of palmitic acid is not sensitive to alterations in 
intake (Carta, Murru, Banni, & Manca, 2017). Disruption of the homeostatic balance of palmitic 
acid associated with uncontrolled de novo synthesis is implicated in and activated by 
physiopathological conditions including neurodegenerative disease and chronic nutritional 
imbalance (Carta et al., 2017).  The consequences of this include systemic inflammatory 
response and metabolic dysregulation leading to insulin resistance and dysregulation in fat 
deposition.  Specifically, palmitic acid has been observed to induce TLR4 receptor activation in 
hypothalamic microglia and stimulate the release of cytokines, leading to inflammation and 
neuronal stress (Valdearcos et al., 2014). Consistent with this, in a recent review, palmitic acid 
was implicated in inflammatory responses, since it is a toll-like receptor agonist, whilst it’s 
metabolic products lead to increased ROS generation, which in turn strengthens TLR4-induced 
signalling (Korbecki & Bajdak-Rusinek, 2019). Moreover, both palmitic acid and stearic acid have 
been observed to impair glucose metabolism and mitochondrial function (Hirabara, Curi, & 
Maechler, 2010). In Parkinson’s disease, both saturated FAs have been found to be 
pathologically augmented in lipid rafts (Mesa-Herrera, Taoro-González, Valdés-Baizabal, Diaz, & 
Marín, 2019).  Oleic acid, on the other hand, has received attention for its neuroprotective 
effects (Mazza et al., 2018) in the context of the Mediterranean diet (MedDi), where it 
contributes to the monounsaturated FA content in the form of extra-virgin olive oil 
(Trichopoulou, 2007).  Higher adherence to the MedDi has been reviewed favourably in respect 
of cognition in that it has been associated with a reduced risk of cognitive impairment 
(Psaltopoulou et al., 2013; Singh et al., 2014; Wu & Sun, 2017), better cognitive function and 
lower rates of cognitive decline (Lourida et al., 2013).  However, oleic acid is one of a number of 
bioactive constituents of the diet (Omar, 2019), whilst polyphenolic compounds (Hornedo-
Ortega et al., 2018), PUFAs, antioxidants, vitamins and minerals (Knight, Bryan, & Murphy, 2016) 
have also been cited.  
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6.2.3 GPL and FA composition recommendations for future supplementation 
studies 
In view of the above and in consideration of the points raised previously in sections 2.6, 2.7.6.2 
and 4.3, a better FA profile to be supplemented would include FAs for which there is sensitivity 
with respect to dietary intake and which show promise in terms of potential effects on  cognitive 
function.  Suitable candidates include DHA and EPA.  It is acknowledged that to date, empirical 
work that has supplemented either or both long-chain polyunsaturated fatty acids (LC-PUFA) in 
combination have not revealed overwhelmingly favourable findings in terms of enhancing or 
maintaining cognitive function in children or in adults. This was the case for the 9 RCTs reviewed 
in Chapter 4 (section 4.3.1) that supplemented school-aged children.  Elsewhere, conflicting 
findings have been reported as to the benefits of DHA supplementation on cognitive function 
across the lifespan (Derbyshire, 2018; Ghasemi Fard et al., 2019).  However, there is plenty of 
evidence to suggest that DHA and EPA are involved in various processes that support cognitive 
function.  In addition to those discussed previously (see sections 2.7.6.2 and 4.3), DHA as well as 
EPA are known to slow the degradation of neural tissue (Bazan, 2007; Calon et al., 2004) 
and improve the endothelial function (Wang et al., 2012), thereby potentially impacting cerebral 
blood flow (CBF) (O’Donovan et al., 2019). Notably, CBF has been classed as a 
sensitive physiological marker of cerebrovascular function and has been suggested to be one of 
the mechanisms by which polyphenols contribute to improvements in cognitive functioning 
(Joris, Mensink, Adam, & Liu, 2018).  This mechanism could also apply to DHA and/or EPA. DHA 
and EPA also reduce morbidity and mortality from cardiovascular disease (Massaro, Scoditti, 
Carluccio, & De Caterina, 2008), which in turn reduces the risk of subsequent neurodegeneration 
(Ng, Turek, & Hakim, 2013).  The inconsistent findings reported following omega-3 PUFA 
supplementation might be accounted for by the variations in basal levels (Derbyshire, 2018; 
Ghasemi Fard et al., 2019; Ostermann & Schebb, 2017), where the larger the distance between 
basal PUFA status and the “change threshold”, the greater the effect of supplementation 
(Keenan et al., 2012).  In addition, other factors that contribute to variation in findings include 
issues in study design and analysis, inadequate intervention duration, inappropriate dosage of 
treatments, age or gender bias within conditions, and inadequate power due to small samples 
(Ghasemifard, Turchini, & Sinclair, 2014).   
In respect of the GPL molar abundance, it could be argued that it would be advantageous to 
increase the relative abundance of both PI and PS. As discussed earlier in this thesis (see section 
2.7), a derivative of PI, PI(3,4,5)P3, supports the uptake of glucose, LTP and LTD, whereas 
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PI(4,5)P2 also supports LTP, is involved in neuronal function via its regulation of voltage-gated 
potassium and calcium channels and preparation of synaptic vesicles, and is implicated in PKC 
activation.  To date, the use of PI as a single supplement has not been explored.  With regard to 
PS, one of the conclusions of the systematic research review (Chapter 3) was that PS may offer 
the potential to facilitate cognitive performance.  Of the five studies that supplemented PS 
(Baumeister et al., 2008; Crook et al., 1991; Parker et al., 2011; Rosadini et al., 1990; Vakhapova 
et al., 2010), two of these did not report positive treatment effects, one acute (Rosadini et al., 
1990) and one chronic (Baumeister et al., 2008).  It was proposed that that this lack of a benefit 
was due to the supplement dose being too low (Rosadini et al., 1990), practice effects 
(Baumeister et al., 2008) and inadequate sample size leading to a lack of power to detect an 
effect (Baumeister et al., 2008; Rosadini et al., 1990).   In brief, PS may contribute to 
improvements in cognitive performance due to its role in PKC activation, therefore having an 
indirect role in synaptic remodelling and neurotrophic activity in the hippocampus (see section 
2.7.3). Furthermore, PS in the brain is enriched with DHA, sufficient quantities of which aid 
neuronal communication (see section 3.5.1).  
In keeping with previous GPL studies which have reported cognitive performance enhancements 
following GPL administration, one of which supplemented PS with DHA and EPA (Vakhapova et 
al., 2010), the other PS sourced from bovine cortex (high DHA content) (Crook et al., 1991), 
esterification of PS and PI to DHA and EPA respectively may further make both GPLs ideal 
candidates for augmenting cognitive performance.  After all, in the brain, PS is enriched with 
DHA while PI is enriched with EPA (Chen et al., 2009).  This remains speculative, however, since 
no studies have examined this combination. 
6.3 Limitations of the studies presented in this thesis  
6.3.1 Study placebo product 
A placebo group offers the opportunity to include a condition in which there is maximal 
treatment separation from the experimental condition (Castro, 2007).  However, this is 
dependent upon the placebo being a pharmacologically inert substance (Gupta & Verma, 2013).  
The placebo in Study 2 contained maltodextrin as an ingredient to ensure comparable viscosity 
between treatment products and therefore minimise the risk of unblinding the research team 
and participants.  Maltodextrins comprise a class of carbohydrates and are applied in a range of 
foods (Hofman, Buul, & Brouns, 2016).  A recent study reported feeding piglets a formula 
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containing either digestible maltodextrin or lactose as the main carbohydrate source (28% total 
nutrient composition) from 1 – 9 weeks of age.  The piglets fed the maltodextrin-based formula 
demonstrated improved long-term spatial memory compared to the piglets fed the lactose-
based formula at 12 – 17 weeks of age, 3 – 6 weeks post-treatment termination (Clouard, Le 
Bourgot, Respondek, Bolhuis, & Gerrits, 2018). Moreover, a 6.4% maltodextrin solution used 
every 10 minutes during 65 minutes of moderately high-intensity exercise as a mouth-rinse 
solution was found to attenuate exercise-induced decline in performance on the Stroop test, a 
measure of executive function, in young adults.  It was suggested that this result was a function 
of the maltodextrin mouth-rinse inhibiting excessive release of the stress hormones, 
norepinephrine and epinephrine (Konishi et al., 2017).  Indeed, executive function performance 
can be disrupted by high levels of norepinephrine release (Clark & Noudoost, 2014).  Conversely, 
ad libitum access for 17 days to a maltodextrin solution (10.4% w/v maltodextrin powder vs. 
10% w/v sucrose) was observed to produce impaired performance on a location recognition task 
in rats following of access to maltodextrin (Kendig, Lin, Beilharz, Rooney, & Boakes, 2014). Taken 
together, the findings from these studies suggest that maltodextrin is a nutritionally active 
ingredient that can affect cognitive function.  By implication, the placebo product supplemented 
in the present study may have unintentionally influenced the cognitive performance of those in 
the placebo condition and confounded the study findings. This reflects the wider issue 
concerning the selection of an appropriate placebo in food and nutrition research, and highlights 
that the lack of nutritionally inert food components mean that ingredients which could affect a 
response may be included in placebo foods that therefore undermine the experimental 
comparison (Harris & Johns, 2011).  
6.3.2 Compliance  
Supplement consumption was directly monitored in Study 1 (Chapter 4) enabling accurate 
measurement of intake.  In Study 2 (Chapter 5), supplements were consumed by participants in 
their homes for convenience and compliance was checked by use of a consumption diary and 
the collection of empty/part empty supplement sachets. Hence, records concerning participant 
consumption used in Study 2 may not be a true representation of supplement intake.  Biological 
measures offer another option for monitoring compliance.  Two studies reviewed in the 
systematic research review (Chapter 3) that supplemented PC evaluated supplement intake by 
determining blood choline concentrations, which was found to be raised following supplement 
consumption (Cheatham et al., 2012; Harris et al., 1983).  It is acknowledged that had a biological 
measure been used in Study 2 instead of the diary system, it is probable that this would have 
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resulted in a different conclusion regarding participant compliance and as consequence, which 
participants would have been eligible for inclusion in the PP analysis.  However, the practicalities 
of this type of compliance monitoring are considerable and can result in greater participant 
attrition or lower rates of recruitment in the first place.  
6.3.3 Serial cognitive testing and order effects 
The order of administration of each of the cognitive measures in both studies reported in this 
thesis remained the same on each test occasion. Both studies employed a verbal memory 
measure comprised of immediate and delayed recall components, with a fixed time frame 
between each. By following the same order of administration, the period between each 
component could be consistent. This in addition to following a repeated measures design in both 
studies inevitably increased the possibility of observing performance gains due to familiarity 
with the experimental procedure, the research staff and the cognitive measures employed.  To 
reduce the potential for practice effects to interfere with any true effect(s) of treatment, test 
practice versions were administered in both studies prior to baseline (familiarisation).  It has 
been proposed that practice effects are strongest between the first two study visits (Bell et al., 
2018).  Therefore, including a familiarisation stage aimed to reduce the degree to which such 
effects confounded study findings.  In a further effort to minimise their possibility, cognitive 
measures were counterbalanced on each test occasion.  Despite these efforts, there was 
evidence of an effect of practice.  For example, in Study 2, this was most evident on measures 
of executive function (both accuracy and reaction time).  
6.3.4 Optimal duration of intervention 
The ideal period for supplementation with GPLs leading to membrane lipid replacement in the 
brain and the potential subsequent promotion of cognitive function is currently unknown.   
Based upon the plasma half-life of unesterified DHA, Section 4.8.2.3 suggested that GPL 
supplementation should take place over a period of months. As with PS-DHA, there is a lack of 
knowledge concerning how long it takes for GPLs to reach the brain and in what quantities they 
are taken up.  A further complication concerns exogenous PLs being unprotected from oxidation 
and degradation during digestion, mainly in the small intestine (Nicolson & Ash, 2017).  As a 
consequence, it is likely that there will be a loss in the availability of undamaged PLs for uptake, 
which further adds to the length of intervention required.  The use of fructooligosaccharides and 
antioxidants can be used to protect GPLs from phospholipases, acidity and bile salts (Hendry, 
1993; Vereyken, Chupin, Demel, Smeekens, & De Kruijff, 2001), thus promoting PL integrity.  
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6.4 Conclusion  
Overall, the findings from the PL intervention studies presented in this thesis add to the existing 
heterogeneous evidence of the potential for dietary PLs to moderate cognitive performance. 
Effects were not greater or more consistent in children as opposed to adults with a SMC, despite 
the use of different cognitive test batteries, each of which had demonstrated sensitivity to the 
effects of nutritional interventions in these samples previously. Differences in the types of PLs 
administered in these and previous studies and the specific measures of cognitive function 
employed may underpin some of the heterogeneity in the results seen.  The overriding influence 
of baseline as a predictor of subsequent performance, which accounted for a large proportion 
of the variance across many of the outcome measures in the studies reported in this thesis is an 
important factor in the failure to demonstrate any effect of the GPL intervention. Controlling 
statistically for divergent baseline performance revealed no significant, consequential effects of 
PL intake. The importance of a potentially active placebo in Study 2 cannot be underestimated.  
Similarly, the relative cognitive capacity of the adults sampled in whom only a subjective 
memory complaint was reported may have meant that the sample was not likely to respond to 
the PL intervention.  However, where effects were shown, these were in those adults in the 
normal range of IQ (within 1 SD of the population mean).  The potential protective effects of GPL 
(Chapter 2) intake may be limited to individuals who are perhaps more likely to be compromised 
cognitively than the relatively high functioning older adults recruited to the study presented in 
this thesis. More generally, observed modulatory effects of dietary interventions on cognitive 
performance are often small and inconsistently reported (Mcdaniel, Maier, & Einstein, 2003). 
The sensitivity of such manipulations, if they are bioactive, may only be demonstrated in sub-
groups with specific nutritional or cognitive vulnerabilities yet sub-group analysis has been 
criticised as fishing (Pocock et al., 2002). 
Equally, the possibility that PLs in the form/composition of Lacprodan® PL-20 have no effect on 
cognitive function is a plausible hypothesis, which is supported by the results of the studies 
presented in this thesis. The hypothesis that PL intake may have potential protective effects in 
other groups of participants remains to be tested.  There are, for example, suggestive data for 
effects of cognitive function under conditions of stress (Boyle et al., 2019; Hellhammer et al., 
2010; Parker et al., 2011; Schubert et al., 2011), although there are a number of limitations with 
these findings.  Moreover, there is strong physiological mechanistic data (explored in Chapter 
2), which suggests that certain GPLs and FAs in other combinations or concentrations could 
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confer beneficial or protective effects on cognition in the developing child or the ageing adult.  
Future research could profitably explore the effects of these on sensitive measures of cognitive 
function in vulnerable samples of individuals.  
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Appendix 1. Nomenclature, chain length and degree of saturation of fatty acids referred to 
throughout the thesis 
 
 
 
  
Fatty acid Type 
Chain length 
(number of carbon 
atoms) 
Degree of saturation 
(number of double bonds) 
Alpha-linolenic 
acid (ALA) 
Polyunsaturated 
(omega-3) 
18 3 
Arachidonic acid 
(AA) 
Polyunsaturated 
(omega-6) 
20 4 
Docosahexaenoic 
acid (DHA) 
Polyunsaturated 
(omega-3) 
22 6 
Docosapentaenoic 
acid (DPA) 
Polyunsaturated 
(omega-3) 
22 5 
Eicosapentaenoic 
acid (EPA) 
Polyunsaturated 
(omega-3) 
20 5 
Lignoceric acid Saturated 24 0 
Linoleic acid (LA) 
Polyunsaturated 
(omega-6) 
18 2 
Nervonic acid 
Monounsaturated 
(omega-9) 
24 1 
Oleic acid 
Monounsaturated 
(omega-9) 
18 1 
Palmitic acid Saturated 16 0 
Stearic acid Saturated 18 0 
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Appendix 2. Cognitive search terms, limits and tags used in the systematic research review 
 
CINAHL  
Search terms Search strategy 
Cognition Keyword search 
Cognition  MeSH search 
Memory Keyword search 
Memory / false memory / 
memory, short term 
MeSH search 
(memory as main term plus narrower terms)  
Attention Keyword search 
Attention  MeSH search 
Visual-spatial Keyword search 
Visualspatial Keyword search 
Visuo-spatial Keyword search 
Visuospatial Keyword search 
Spatial perception MeSH search 
Recall Keyword search 
Recall Comes under memory 
Recognition  Keyword search 
Recognition (psychology) MeSH search 
Problem solving Keyword search 
Problem solving MeSH search 
Reaction time Keyword search 
Reaction time MeSH search 
Response time  Keyword search 
Response time Comes under reaction time 
Vigilance  Keyword search 
Arousal MeSH search 
Executive function Keyword search 
Executive function MeSH search 
Psychomotor  Keyword search 
Psychomotor performance/ 
motor skill 
MeSH search 
(psychomotor performance as main term plus 
broader term) 
Sphingolipid  Keyword search 
Acidic glycosphingolipid Keyword search 
Ganglioside  Keyword search 
Phosphosphingolipid Keyword search 
Sphingomyelin Keyword search 
Glycerophospholipid Keyword search 
Phosphatidylethanolamine Keyword search 
Phosphatidylcholine Keyword search 
Phosphatidylcholines MeSH search 
Phosphatidylserine Keyword search 
Phosphatidylinositol Keyword search 
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Embase Classic + Embase 1947 
Search terms Search strategy MeSH synonyms  
Cogniti$ Multiple search (.mp)  
Cognition  MeSH search Cognitive accessibility 
Cognitive balance 
Cognitive dissonance 
Cognitive function 
Cognitive structure 
Cognitive symptoms 
Cognitive task 
Cognitive thinking 
Neurobehavioural manifestations  
Volition 
 
Memory Multiple search (.mp)  
Memory/ or associative memory/ or 
auditory memory/ or autobiographical 
memory/ or declarative memory/ or 
episodic memory/ or explicit memory/ or 
false memory/ or implicit memory/ or 
long term memory/ or memory 
consolidation/ or olfactory memory/ or 
procedural memory/ or prospective 
memory/ or recall/ or recognition/ or 
reference memory/ or repetition priming/ 
or retrospective memory/ or semantic 
memory/ or sensory memory/ or short 
term memory/ or spatial memory/ or 
tactile memory/ or verbal memory/ or 
visual memory/ or word list recall/ or 
word recognition/ or working memory/ 
MeSH search 
(memory as main term 
plus narrower terms)  
Item recall 
Memory function 
Nonspatial memory 
Remembering 
Reminiscence  
 
Attention Multiple search (.mp)  
Attention/ or alertness/ or awareness/ or 
consciousness/ or distractibility/ or 
mental concentration/ or selective 
attention/ 
MeSH search 
(Attention as main 
term plus narrower 
terms) 
Attentiveness 
Visual-spatial Multiple search (.mp)  
Visualspatial Multiple search (.mp)  
Depth perception MeSH search Depth discrimination 
Perception, depth 
Perception, space 
Perception, visuospatial 
Space perception 
Spatial perception 
Vision disparity 
Visuospatial perception 
 
Visuo-spatial Multiple search (.mp)  
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Visuospatial Multiple search (.mp)  
Recall Multiple search (.mp)  
Recall MeSH search Free recall 
Mental recall 
Recall phenomenon  
 
Recognition  Multiple search (.mp)  
Recognition MeSH search Form recognition 
Recognition (psychology) 
 
Problem solving Multiple search (.mp)  
Problem solving MeSH search  
Reaction time Multiple search (.mp)  
Reaction time MeSH search Time reactivity 
Time, reaction 
 
Response time  Multiple search (.mp)  
Response time MeSH search Choice reaction time 
Reaction time, choice 
 
Vigilance  Multiple search (.mp)  
Alertness  MeSH search Mental alertness 
Psychical alertness 
Task, vigilance 
Vigilance 
Vigilance task 
 
Executive function Multiple search (.mp)  
Executive function MeSH search Cognitive control 
Executive control 
 
Psychomotor  Multiple search (.mp)  
Psychomotor performance/ or 
psychomotor activity 
MeSH search 
(psychomotor 
performance as main 
term plus broader 
term) 
Psychomotor skill 
Psychomotor task 
Psychic activity 
Psychomotor function 
 
Sphingolipid  Multiple search (.mp)  
Sphingolipids Multiple search (.mp)  
Sphingolipid  MeSH search  
Acidic glycosphingolipid Multiple search (.mp)  
Acidic glycosphingolipids Multiple search (.mp)  
Glycosphingolipid MeSH search  
Ganglioside  Multiple search (.mp)  
Gangliosides Multiple search (.mp)  
Ganglioside MeSH search  
Phosphosphingolipid Multiple search (.mp)  
Phosphosphingolipids Multiple search (.mp)  
Sphingomyelin Multiple search (.mp)  
Sphingomyelins Multiple search (.mp)  
Sphingomyelin MeSH search  
Glycerophospholipid Multiple search (.mp)  
Glycerophospholipids Multiple search (.mp)  
Glycerophospholipid MeSH search  
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Phosphatidylethanolamine Multiple search (.mp)  
Phosphatidylethanolamines Multiple search (.mp)  
Phosphatidylethanolamine MeSH search  
Phosphatidylcholine Multiple search (.mp)  
Phosphatidylcholines Multiple search (.mp)  
Phosphatidylcholine MeSH search  
Phosphatidylserine Multiple search (.mp)  
Phosphatidylserines Multiple search (.mp)  
Phosphatidylserine MeSH search  
Phosphatidylinositol Multiple search (.mp)  
Phosphatidylinositols Multiple search (.mp)  
Phosphatidylinositol MeSH search  
MEDLINE(R) 1946  
Search terms Search strategy 
Cogniti* Multiple search (.mp) 
Cognition  MeSH search 
Memory Multiple search (.mp) 
Memory/ or deja vu/ or memory, episodic/ or memory, long-term/ 
or memory consolidation/ or memory, short-term/ or mental recall/ 
or "recognition (psychology)"/ or repetition priming/ or "retention 
(psychology)"/ or spatial memory/ 
MeSH search 
(memory as main term plus 
narrower terms)  
Attention Multiple search (.mp) 
Attention MeSH search 
Visualspatial Multiple search (.mp) 
Visual spatial Multiple search (.mp) 
Space perception MeSH search 
Visuospatial Multiple search (.mp) 
Visuo spatial Multiple search (.mp) 
Recall Multiple search (.mp) 
Recognition  Multiple search (.mp) 
Problem solving Multiple search (.mp) 
Problem solving/ or heuristics/ MeSH search 
(problem solving as main term 
plus narrower term) 
Reaction time Multiple search (.mp) 
Reaction time MeSH search 
Response time  Multiple search (.mp) 
Vigilance  Multiple search (.mp) 
Arousal MeSH search 
Executive function Multiple search (.mp) 
Executive function MeSH search 
Psychomotor  Multiple search (.mp) 
Psychomotor performance/ or motor skills/ MeSH search 
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(psychomotor performance as 
main term plus narrower term) 
Sphingolipid  Multiple search (.mp) 
Sphingolipids  Multiple search (.mp) 
Sphingolipids MeSH search 
Acidic glycosphingolipid Multiple search (.mp) 
Acidic glycosphingolipids Multiple search (.mp) 
Acidic glycosphingolipids MeSH search 
Ganglioside  Multiple search (.mp) 
Gangliosides Multiple search (.mp) 
Gangliosides MeSH search 
Phosphosphingolipid Multiple search (.mp) 
Phosphosphingolipids Multiple search (.mp) 
Sphingomyelin Multiple search (.mp) 
Sphingomyelins Multiple search (.mp) 
Sphingomyelins MeSH search 
Glycerophospholipid Multiple search (.mp) 
Glycerophospholipids Multiple search (.mp) 
Glycerophospholipids MeSH search 
Phosphatidylethanolamine Multiple search (.mp) 
Phosphatidylethanolamines Multiple search (.mp) 
Phosphatidylethanolamines MeSH search 
Phosphatidylcholine Multiple search (.mp) 
Phosphatidylcholines Multiple search (.mp) 
Phosphatidylcholines MeSH search 
Phosphatidylserine Multiple search (.mp) 
Phosphatidylserines Multiple search (.mp) 
Phosphatidylserines MeSH search 
Phosphatidylinositol Multiple search (.mp) 
Phosphatidylinositols Multiple search (.mp) 
Phosphatidylinositols MeSH search 
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PubMed 
Search terms Search strategy 
Cogniti* Title/Abstract (TIAB) 
Cognition MeSH:noexp 
Memory Title/Abstract (TIAB) 
Memory MeSH search 
Attention  Title/Abstract (TIAB) 
Attention MeSH search 
Visual-spatial Title/Abstract (TIAB) 
Visualspatial Title/Abstract (TIAB) 
Visuo-spatial Title/Abstract (TIAB) 
Visuospatial Title/Abstract (TIAB) 
Spatial Processing MeSH search 
Recall Title/Abstract (TIAB) 
Mental Recall MeSH search 
Recognition  Title/Abstract (TIAB) 
Problem solving Title/Abstract (TIAB) 
Problem solving MeSH search 
Reaction time Title/Abstract (TIAB) 
Reaction time MeSH search 
Response time  Title/Abstract (TIAB) 
Vigilance  Title/Abstract (TIAB) 
Arousal MeSH search 
Executive function Title/Abstract (TIAB) 
Executive function MeSH search 
Psychomotor  Title/Abstract (TIAB) 
Psychomotor Performance MeSH search 
Sphingolipid  Title/Abstract (TIAB) 
Sphingolipids Title/Abstract (TIAB) 
Sphingolipids MeSH:noexp 
Acidic glycosphingolipid Title/Abstract (TIAB) 
Acidic glycosphingolipids Title/Abstract (TIAB) 
Acidic glycosphingolipids MeSH:noexp 
Ganglioside  Title/Abstract (TIAB) 
Gangliosides Title/Abstract (TIAB) 
Gangliosides MeSH:noexp 
Phosphosphingolipid Title/Abstract (TIAB) 
Phosphosphingolipids Title/Abstract (TIAB) 
Sphingomyelin Title/Abstract (TIAB) 
Sphingomyelins Title/Abstract (TIAB) 
Sphingomyelins MeSH search 
Glycerophospholipid Title/Abstract (TIAB) 
Glycerophospholipids Title/Abstract (TIAB) 
Glycerophospholipids MeSH:noexp 
Phosphatidylethanolamine Title/Abstract (TIAB) 
Phosphatidylethanolamines Title/Abstract (TIAB) 
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Phosphatidylethanolamines MeSH search 
Phosphatidylcholine Title/Abstract (TIAB) 
Phosphatidylcholines Title/Abstract (TIAB) 
Phosphatidylcholines MeSH:noexp 
Phosphatidylserine Title/Abstract (TIAB) 
Phosphatidylserines Title/Abstract (TIAB) 
Phosphatidylserines MeSH search 
Phosphatidylinositol Title/Abstract (TIAB) 
Phosphatidylinositols Title/Abstract (TIAB) 
Phosphatidylinositols MeSH:noexp 
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Appendix 3. Table 3.A Summary of studies included in the systematic review 
Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
Cheatham et 
al. (2012) 
Nutrasal 
PhosChol 
supplement
: 750 mg 
choline/d as 
PC 
Healthy 
pregnant 
women (n=99). 
All mothers 
intended to 
breastfeed for 
≥ 90 days. 
Actual: all 
infants were 
breast fed for a 
minimum of 45 
days.  
 
Age (21 - 41 
years) at 
conception - 
PhosChol 
condition: 30.2 
± 3.8, placebo 
condition: 30.8 
± 4.9.  
 
Infants:- 
PhosChol 
condition 
Mothers kept a 3-
day food diary 
immediately prior 
to 30-week 
gestation & 45-day 
postpartum visits - 
recorded all food 
and drink 
consumed on two 
typical weekdays, 
and 1 day at the 
weekend. Levels of 
choline intake and 
betaine were 
estimated. Each 
day (out of three) 
analysed 
individually, then 
averaged per ppt.  
Total choline 
intake = av. 
amount ingested 
per day + level in 
the supplement 
(750mg/0mg) x 
(a) Short-term 
visuospatial memory 
delayed response task. 
Administered twice per 
test point. Toy chosen 
by infant was hidden in 
wells - either 2-wells or 
3 embedded within a 
table.  Six trials for each 
with delays of 3,9,15 
secs ordered 3, 9, 15, 3, 
9, 15. Outcome = 
selection of correct well 
signified by infant 
reach/visual regard if 
infant reached with 
both hands. 
(b) Long-term episodic 
memory - deferred 
imitation (infant 
required to model an 
action demonstrated by 
a researcher after a 15 
minute delay). Infant 
expected to imitate 
Food diary: only significant 
difference between the 
two conditions at each of 
the 2 diary completion 
points - experimental 
condition had a greater 
betaine intake (p < .05) at 
30- week gestation.  
 
Data reduction 
Short-term visuospatial 
memory task: identified ≥ 
4 trials required for a 
reliable data point. Where 
infants had completed ≤ 3 
trials, data regarded as 
missing. % correct 
calculated - correct 
responses / number of 
trials where the infant had 
made a response (out of 
12).  Loss of 39-46 ppt 
scores on second 
administration of task (at 
each test point) suggested 
None x 
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Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
(n=49). Length 
of gestation 
(weeks): 39.5 ± 
1.6. 
 
Placebo 
condition 
(n=50). Length 
of gestation 
(weeks): 39.3 ± 
1.4. 
 
Significant 
difference in 
BMI and 
weight 
between the 
two mothers in 
the two 
conditions at 
conception, 
with those in 
the control 
condition being 
heavier and 
having a higher 
BMI (p< .05). 
ppts compliance 
rate. Significant 
difference found 
in betaine intake 
at 30-week 
gestation between 
the two conditions 
(p < .05).  
 
Single-centre 
RDBPC parallel 
group study. 
Intervention from 
18-week gestation 
- 90 days 
postpartum, 6 per 
day.    
(1) Experimental 
condition: 
Nutrasal gel 
capsules 
containing choline 
(750 mg/d), with 
each capsule 
containing 833 mg 
PC.  
(2) Control 
action demonstrated by 
researcher following 
delay. Four x object-
action sets per test 
point. Infant explored 
object for 30 secs 
followed by researcher 
modelled target action 
3 times within 30 secs x 
4 objects = 4 minutes 
per test point. After 15-
minute delay, each 
object represented 
individually- infant 
freely explored for 30 
secs. Outcome = if 
target action was 
displayed by infant (% 
correct within age) 
(c) Language 
development using the 
MacArthur-Bates Short 
Form Vocabulary 
Checklist: level I, 
number of words 
spoken from a pre-
identified list of 89 
infants either tired, bored 
or frustrated with task on 
second administration. 
Therefore, only % correct 
scores from first 
administration at each test 
point average together 
were used.  
Long-term episodic 
memory: Paired sample t-
test showed no differences 
between the scores from 
the two test points within 
each age (10/12 months), 
so scores averaged 
together = % correct within 
age computed.  
 
Age effects were found:-
significant improvement in 
performance from 10 - 12 
months on the short-term 
visuospatial memory task, 
the long-term memory 
task and words spoken (all 
p < 0.0001).   
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Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
condition: Corn oil 
gel capsules.  
 
All infants tested 
two times 7-10 
days apart at 10 
and 12 months (4 
test points).  This 
was scheduled in 
line with 
estimated due 
date. 
words selected from 
the vocabulary checklist 
of the MacArthur-Bates 
Communicative 
Development Inventory 
(CDI): Words and 
Gestures.  
(d) Composite index of 
global development. 
Mullen Scales of Early 
Learning, AGS edition 
to assess motor, 
language and cognitive 
development. 
Administration of fine 
motor & visual 
reception was at the 
first test point, gross 
motor & expressive + 
receptive language at 
the second test point at 
each age. 
 
No significant difference in 
the performance of the 
two conditions at either 10 
or 12 months. Marginal 
significance was found for 
an effect of condition for 
the percentage correct on 
the Long-Term Episodic 
Memory Task (p = .056) at 
12-months, with those in 
the placebo condition 
demonstrating better 
performance. Finding did 
not remain when betaine 
intake at 30-week 
gestation was added to the 
analysis (covariate) - 
significantly higher in the 
PhosChol condition (p < 
.05). 
 
Stepwise regression 
analyses (backward 
elimination): betaine 
intake at 30-week 
gestation was a negative 
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Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
predictor of short-term 
visuospatial memory 
delayed response 
performance at 10 months 
when task was novel (p = 
.061). Betaine intake at 45 
days postpartum was a 
significant positive 
predictor short-term 
visuospatial memory 
delayed response task 
performance when the 
task was novel (p = .058), 
words spoken (p = .017) 
and global development 
(composite measure) (p = 
.026) at 12 months.  
Choline intake at 45 days 
postpartum - same 
patterns of prediction. 
Harris et al. 
(1983) 
Lecithin 
(PC) 
Healthy adults 
(n=9); Male: 3. 
Age: 22-55; 
39.9 ± 10.3 
years. 
Single-centre 
RDBPC cross-over 
(oral dose; acute 
supplementation). 
Ppts randomly 
allocated to: 
(1) Aqueous 
(a) Categorised serial 
learning task.  Parallel 
versions - a list of 10 
items of either animals, 
cities or vegetables 
were memorised. 
Outcome = the number 
There was no significant 
difference in the 
performance between the 
two conditions.  The 
number of errors made on 
the uncategorised word 
recognition task was also 
None x 
353 
 
 
 
Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
flavoured 
suspension of 20g 
lecithin. 
(2) Equal volume 
of a taste- and 
appearance - 
matched placebo 
containing sugar, 
corn oil, flour, 
water gelatine & 
peppermint 
flavour.  
 
Three testing 
sessions. The first 
= practice. Second 
and third took 
place 5 hours post-
supplement.  
Experimental 
sessions were at 
least 48 hours 
apart. Used 
parallel versions 
for cognitive 
measures. 
 
of trials required for 3 
sequential correct 
recitations of the list 
during learning stage 
and number of words 
recalled in the correct 
order 30 minutes post 
learning stage.  
The following were 
presented in random 
order: 
(b) A test of retrieval 
from long-term 
memory. Ppts had to 
produce in 1 minute as 
many nouns as possible 
from a set category - 
colours, sports, flowers, 
boys' names, fruits. 
Outcome = number of 
items averaged across 
two trials.  
(c) Paired associates 
learning task. Ppts had 
to memorise 5 sets of 
words pairs. Used high 
and low-imagery forms. 
analysed. Again, no main 
effect of treatment was 
found. 
 
Higher mean choline level 
in plasma was observed 
post-lecithin 
supplementation. 
 
No relationship between 
extent of choline increase 
and cognitive 
performance. 
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Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
Blood was taken at 
the same time of 
testing to measure 
choline levels. 
Outcome = number of 
trials required to learn 
the sets if high and low-
imagery words used for 
target & stimulus.  
(d) Uncategorised word 
recognition task. Ppts 
had to recognise 15 
target words from a list 
of 60 words. Score 
adjusted for guessing. 
(e) Digit/symbol 
subtask of WAIS. 
Outcome = 
psychomotor speed. 
Rosadini et 
al. (1990) 
PS Healthy male 
adults (n=8). 
Age: 21-28; 
24.5 ± 1.7 
years. 
Single-centre 
RDBPC cross-over 
study (acute 
supplementation).  
 
25 mg, 50 mg, 75 
mg of PS or 
matching placebo 
administered 
intravenously (3 
minute infusion) 
according to a 
(a) EEG recordings (in 
baseline conditions, 
continuously during 
infusion and 10, 30, 90, 
180 and 360 minutes 
after PS/placebo 
administration) were in 
3-min segments, in 
resting conditions and 
with the eyes closed; 
 
Following each post-
No significant differences 
were identified for any of 
the cognitive measures. 
None x 
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Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
balanced order 
(Latin-square 
design) provided 
by the 
manufacturer. 
 
Sessions at weekly 
intervals began 
after a normal 
night's sleep and 
at least 2 hours 
after a light 
standardized meal 
at 14.00. 
supplement EEG 
recording (@10, 30, 90, 
180 and 360 minutes 
post-PS/placebo 
administration): 
(b) Short-Term 
Retention Test for 
sequences of letters; 
(c) Backward Digit Span 
Test; 
(d) Immediate 
Retention Test for 
sequences of colours. 
Baumeister 
et al. (2008) 
PS from soy Healthy males 
(n=16). Age: 25 
± 3 years 
 
PS condition 
(n=8): Age 24 ± 
3 years. 
 
Control 
condition 
(n=8): Age 26 ± 
2. 
Single-centre 
RDBPC parallel 
group study.  Ppts 
took 1 x 
nutritional bar per 
day for 6 weeks:- 
 
(1) 35 g IQ PLUS 
brain bar 
containing 200 mg 
soy-based PS; 
(2) 35 g placebo 
bar (0 mg PS).  
(a) Stroop word-colour 
interference 
(computerised):  
Congruent, incongruent 
and neutral conditions. 
Outcomes: RT. 
(b) D2 concentration 
test: 
Within a pre-set time, 
ppts have to cross out 
specific letters that are 
arranged in rows. Two 
types of error can occur 
Ppts increased their 
performance over time (in 
both conditions) but there 
were no significant 
between-condition 
differences or any 
interactions between 
condition x trial x time. 
None x 
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Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
 
Bars equal on kcal, 
protein, 
carbohydrate, fat 
and vitamins (1.4 
mg vitamin B1, 1.4 
mg vitamin B6, 42 
mg vitamin C, 4.6 
mg vitamin E, 2.8 
mg niacin, 4.2 mg 
pantothenic acid). 
 
During the 6 
weeks, food intake 
was recorded 3 
days p/w to 
ensure ppts had 
the same diet over 
the 6 week period. 
 
On test days 
(baseline) and 
endpoint), ppts 
consumed a 
standardised 
breakfast.  Acute 
stress was induced 
- omission (target 
letters not crossed out) 
and confusion (non-
target letters crossed 
out). Outcomes: Total 
number of letters 
worked on calculated 
as concentration 
performance (CP), 
omissions (O) and false 
answers (F). 
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characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
using delayed 
auditory feedback 
(DAF) and 
cognitive 
measures 
administered 
(stroop then D2 
test) following this 
on both test 
occasions, with 
cognitive 
measures being 
interrupted by EEG 
measurement (2 
minutes) 
immediately after 
each. 
Parker et al. 
(2011) 
 
PS from soy Healthy, 
physically 
active* males 
(n=18). Age: 
22.5 ± 2.2 
years. 
 
*participated 
in lower body 
resistance 
Single-centre 
RDBPC cross-over 
study. Ppts took 2 
x serving’s per day 
for 2 weeks:- 
 
(1) IQPLUS Foods 
LLC containing 200 
mg soy-based PS 
per serving (400 
(a) Serial subtraction 
task: Two-minute timed 
test where ppts 
subtracted 7 from a 
random 4-digit number. 
Outcomes: RT and 
accuracy - average time 
per correct calculation, 
number of correct 
Paired samples t-test 
analysed performance at 
pre-exercise bout only:-  
average time per correct 
calculation (seconds) 
reduced and number of 
correct calculations 
increased following PS vs. 
placebo (p = .001, .07, 
respectively).   
None + 
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characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
exercise at 
least once p/w 
for the prior 3 
months. 
mg per day); 
(2) Matching 
placebo (rice 
flour).  
 
No washout 
period. 
 
Cognitive measure 
administered 
during a 
familiarisation 
visit, then post 14 
and 28 days (at 
the end of each 14 
day 
supplementation 
period). 
 
On test days, ppts 
administered 
cognitive measure 
pre-acute exercise 
bout, then 5 and 
60 minutes post-
acute exercise 
bout. 
calculations, number of 
errors (mistakes). 
 
2 x 3 repeated measures 
ANOVA: No significant 
main effect of condition. 
Significant main effect for 
time (p = .02) where there 
was a significant decrease 
in time per correct 
calculation across both 
conditions between pre- 
and 60 minutes post-acute 
exercise bout. There was 
also a significant time x 
condition interaction (p = 
.007) with the PS condition 
demonstrating quicker 
average time per correct 
calculation vs. placebo at 
pre-acute exercise bout 
only. 
 
No significant differences 
were found for serum 
cortisol, total testosterone, 
or cortisol to testosterone 
ratio by condition or 
condition and time. 
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Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
Boyle et al. 
(2019) 
PL-20 
bovine milk 
concentrate 
High stress 
vulnerable 
(high 
perfectionist*) 
males 
(n=54**). 
 
PL condition 
(n=26): Age 
22.04 ± 0.76. 
 
Control 
condition 
(n=27): Age 
20.81 ± 0.34.  
 
*Score of ≥ 13 
on 
Perfectionism: 
organisation 
subscale. 
 
**n=1 
removed owing 
to non-
compliance 
Single-centre 
RDBPC parallel 
group study.  Ppts 
took 1 x milk drink 
per day for 6 
weeks (each in 
plain white 
TetraBrik carton):- 
(1) 250 ml milk 
drink containing 
2.7g of PLs per day 
(including 300 mg 
PS); 
(2) 250 ml placebo 
(0% PLs).  
 
Fat content of 
placebo matched 
to PL drink by 
adding butter oil 
containing only 
triglycerides. 
 
Upon arrival at 
study laboratory, 
ppts consumed a 
standardised meal 
(a) N-back task 
(memory load of 2). 
Outcome: Accuracy and 
RT; 
(b) Attention switch 
task. Outcome: 
Accuracy and RT. 
Switch costs (within 
colour, trial 1 (switch) - 
trial 2 (nested) and 
repeat costs (within 
colour, trial 3 (pre-
switch) - trial 2 
(nested). 
(a) No significant 
difference. 
(b) Significant main effect 
of drink on RT repeat cost 
where PL condition 
incurred significantly lower 
performance costs on 
repeat trials vs. placebo 
condition (p= 0.01). 
 
PL drink did not 
significantly attenuate the 
cortisol response but 
marginal significance was 
found for reduced 
anticipatory subjective 
stress ratings post-
intervention, PL milk drink 
vs. the placebo (p = .06).  
PL drink condition also 
reported significantly 
increased subjective 
energy and arousal during 
peak stress exposure 
following 6 week 
intervention (p = .03). 
None + 
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Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
with study 
drink intake. 
to standardise 
baseline 
nutritional state.   
 
Cognitive measure 
delivered post-
acute psychosocial 
stressor (TSST and 
SECPT) on visit 1 
(baseline) and visit 
2 (endpoint). 
 
Ppts consumed 
drinks each 
morning for 6 
weeks. 
Schubert et 
al. (2011) 
PL-20 
bovine milk 
concentrate 
Chronically 
stressed men* 
(n=75)**. Age: 
30-51. 
 
0.5% PL 
condition 
(n=25). Age: 
39.76 ± 1.29.  
1% PL 
condition 
Single-centre 
RDBPC parallel 
group study. Ppts 
took 1 x milk drink 
per day for 6 
weeks:- 
 
(1) 250 ml bovine 
milk enriched with 
0.5% PL per carton 
(150 mg; SM 
(a) VISGED Visual 
Memory Test 
(electronic): Recall 
(immediate) of the 
position of symbols on 
a city map. Outcome: 
person parameter 
representing the ppts 
level of skill for the 
task. 
Age accounted for in the 
analyses of memory data - 
established 2 groups of 
similar age using a median 
split at 41 years. Ppts 
assigned to either middle-
aged group (30-40 years) 
or older group (41-51 
years). Data of n=71 were 
available for analysis (30-
40 years, n=33; 41-51 
None + 
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Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
(n=24). Age: 
39.04 ± 1.28.  
Placebo 
condition 
(n=24). Age: 
40.35 ± 1.35.  
 
*As assessed 
by the Trier 
Inventory of 
Chronic Stress. 
 
**Data not 
obtained for 
n=2 – n=1 
placebo, n=1 
1.0% PL 
0.12%, PC 0.14%, 
PE 0.14%, PS 
0.06%, PI 0.04%); 
(2) 250 ml bovine 
milk enriched with 
1.0% PL per carton 
(300 mg; SM 
0.23%, PC 0.28%, 
PE 0.28%, PS 
0.12%, PI 0.08%); 
(3) 250 ml placebo 
bovine milk with 
0% PL per carton. 
 
Cognitive measure 
delivered after 42 
day 
supplementation 
period before and 
post-acute stress 
exposure (TSST). 
 
Ppts consumed 
drinks at 
breakfast. 
years, n=8).  Older group: 
0.5% PL n=11, 1.0% PL 
n=16, placebo n=11. 
 
Prior to acute stress 
exposure: placebo and 
1.0% PL condition had 
higher scores in memory 
performance vs. 0.5% PL 
condition, but this was not 
significant. 
 
Post-acute stress 
exposure: No main effect 
of age, time, condition. 
Time x age x condition 
interaction: visual memory 
performance significantly 
better in the 1.0% PL older 
group vs. placebo and 
0.05% PL older groups (p = 
.042).  Performance by 
placebo older group was 
lower post-acute stress 
exposure, but this was not 
significant. 0.5% PL older 
group maintained similar 
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(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
memory performance. 
 
1.0% PL milk drink 
condition demonstrated 
higher cortisol levels, 
whereas the placebo has 
the lowest levels before 
and after acute stress 
exposure, but this was not 
significant. 
Hellhammer 
et al. (2010) 
PL-20 
bovine milk 
concentrate 
Healthy male 
adults (n=45)*. 
Age: 30-55. 
 
PL condition 
(n=23): Age 
41.61 ± 7.18. 
 
Control 
condition 
(n=22): Age 
41.43 ± 6.82.  
 
*Further 
analysis: 
sample split 
based on group 
Single-centre 
RDBPC study 
parallel group 
study.  Ppts took 1 
x milk drink per 
day for 3 weeks:- 
 
(1) 0.325L milk 
drinks containing 
13.5g of PLs per 
day (5% SM, 5% 
PC, 4% PE, 2.3% 
PS, 1.5% PI); 
(2) 0.325L placebo 
compound. 
 
Cog measure 
(a) Item recognition 
test: Twenty trials. 
Presentation of 3-4 
uppercase letters, 
followed by recognition 
display of 2-4 
uppercase letters. Ppts 
responded either 
yes/no - whether or not 
one of the targets was 
identical to one of the 
stimuli in the 
recognition display. 
Processing load 
manipulated by the 
number of comparisons 
that had to be made in 
Trend (p = 0.09) with the 
PL condition 
demonstrating quicker RTs 
vs. placebo. After 
controlling for inter-
individual variation in 
cortisol concentration, this 
effect became marginally 
significant (p = 0.06). 
 
Further analysis 
determined that the PL 
composite milk drink also 
dampened endocrine and 
psychological stress 
High vs. low stress 
analyses not 
conducted on 
cognitive measures. 
+ 
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Subgroup/Further 
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Effect 
summary 
median into 
high vs. low 
stress groups 
based on Trier 
Inventory of 
Chronic Stress 
scores. No 
demographics 
reported for 
these groups 
delivered after 3 
week 
supplementation 
period 20 minutes 
before and 10 
minutes post-
acute stress 
exposure (TSST). 
 
Ppts consumed 
drinks 30 minutes 
before breakfast. 
order to respond. 
Outcomes: Error and RT 
response but only in highly 
stressed individuals. 
Crook et al. 
(1991) 
PS derived 
from bovine 
cortex (BC-
PS). 
Adults with 
age-associated 
memory 
impairment 
(AAMI) 50-75 
years (n=149). 
Mean age of 64 
years.  
 
BC-PS 
condition 
(n=74; 
Male=45.9%): 
Age 62.61 ± 
6.31. 
Multicentre 
RDBPC parallel 
group study.  
300mg of BC-PS 
per day with a 
matched placebo 
(capsules) for 12 
weeks.  
 
Paper 
neuropsychologica
l test administered 
at baseline & 
endpoint.  
Computerised 
(a) Paper 
neuropsychological 
tests: Benton Visual 
Retention Test; WMS 
Logical Memory 
Subtest (Form A); WMS 
Associative Learning 
Subtest (Form A).  
 
(b) Computerised 
psychometric battery: 
normative data 
showing age associated 
performance decline 
(a) No significant 
difference was found 
between the experimental 
and control conditions. 
 
(b) Significantly better 
performance was 
demonstrated by the BC-
PS condition on Name Face 
Association: Acquisition at 
weeks 3 and 6 (p < .001); 
on Name Face Association: 
Delayed recall at weeks 3 
(p = .04) and 6 (p = .03); 
and on Facial Recognition 
Cluster analysis of 
baseline data 
identified two 
subgroups.  First 
subgroup (n=92) had 
relatively good 
memory function. 
Second subgroup 
(n=57) had relatively 
poor memory 
function. Subgroup 
entered into the 
model as a main 
effect and subgroup x 
treatment as an 
+ 
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Design and 
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(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
Control 
condition 
(n=75; 
Male=37.3%): 
Age 64.88 ± 
6.81.  
 
Subgroup 
analysis: 
First subgroup 
(n=92)  
Age 61.6 years. 
Second 
subgroup 
(n=57) Age 
64.3. 
 
Ppts scored at 
least 27 on 
MMSE. 
psychometric 
battery 
undertaken at 
baseline then at 
weeks 3, 6, 9, 12 
and 16 (last visit 
+4 weeks after 
treatment ended). 
Clinical global 
rating scale done 
at week 12 and 16 
(ratings of 
improvement). 
was used to select 
primary and secondary 
subtests: 
Primary: Name Face 
Association: 
Acquisition; Name Face 
Association:  Delayed 
recall; Facial 
Recognition (delayed 
non-matching to 
sample paradigm); 
Telephone number 
recall (with 
interference); 
Misplaced objects 
recall.  
Secondary: Selective 
reminding: Acquisition; 
Selective reminding: 
Delayed recall; First-
Last Names: 
Acquisition; Divided 
attention. 
(c) Clinical global rating 
scale undertaken by a 
study 
psychologist/registered 
at week 12 (p = .01), 
whereas this was 
marginally significant at 
week 3 (p = .05).  
 
(c) No significant 
difference was found 
between the experimental 
and control conditions. 
interaction term.  
Significant differences 
were identified on all 
primary measures and 
3/4 secondary 
measures. This 
difference in 
performance was 
consistently seen in 
subgroup 2 - those in 
the control condition 
performed less well 
vs. BC-PS condition.  
 
(a) Ppts in BC-PS 
condition scored 
significantly higher on 
the Logical Memory 
Subtest of the WMS 
(Form A; paragraph 
recall; p < .03) at 
week 12. 
 
(b) Significantly better 
performance was 
demonstrated by the 
BC-PS condition on 
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Reported findings 
Subgroup/Further 
analyses 
Effect 
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nurse during interview 
with ppt. 12 items: 
10/12 on specific 
cognitive symptoms 
and 2/12 on overall 
cognitive status. 
Name Face 
Association: 
Acquisition at weeks 3 
(p= .01), 6 (p = .04) 
and 12 (p = .01); on 
Name Face 
Association: Delayed 
recall at week 12 (p = 
.04) but marginally 
significant at week 3 
(p = .05); on Facial 
Recognition at weeks 
3 (p = .03), 6 (p = .02), 
12 (p = .02) and 16 (p 
= .01); on Telephone 
number recall at week 
16 (p < .001) and on 
Misplaced objects 
recall at week 6 (p < 
.001) and week 16 (p 
= .03).  
 
(c) Ppts in BC-PS 
condition scored 
significantly higher on 
2 items at week 12: 
memory for names of 
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Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
persons after 
introductions (p = 
.02); and ability to 
maintain 
concentration when 
reading, conversing or 
performing tasks (p = 
.02).  Marginal 
significance was seen 
at week 12 for overall 
global change in 
cognitive status (p = 
.05); and visual 
analogue scale of 
global improvement 
(p = .05).  These 
perceived 
improvements were 
lost at week 16, when 
a follow-up found no 
significant 
differences. 
Vakhapova et 
al. (2010) 
Vayacog: PS 
conjugated 
to omega-3 
LC PUFA - 
attached to 
Adults with 
memory 
complaints 
between 50-90 
years (n=131)* 
Single-centre 
RDBPC parallel 
group study.  Ppts 
took 3 x capsules 
per day for 15 
(a) Rey Auditory Verbal 
Learning Test (RAVLT). 
Sub scores - immediate 
memory recall (trial 1), 
verbal total learning 
(a) Significant 
improvement in number of 
words recalled in 
immediate recall trial for 
the PS-DHA/EPA condition 
Ppts with relatively 
good cognitive 
performance at 
baseline - fulfilled 
2/3: MMSE score > 
+ 
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Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
the glycerol 
backbone 
 
PP analysis 
PS-DHA/EPA 
condition 
(n=60; 
Male=48%):  
Age 72.9 ± 
8.20. 
Control 
condition 
(n=62; 
Male=53%): 
Age 73.01 ± 
8.28. 
 
Subgroup 
analysis: 
PS-DHA/EPA 
condition 
(n=40; 
Male=37.5%):  
Age 71.8 ± 
8.14. 
Control 
condition 
(n=38; 
Male=44.7%):  
weeks:- 
 
(1) PS-DHA/EPA 
(300 mg PS, 79 mg 
DHA+EPA, 
DHA/EPA ratio 3:1) 
per day. 
(2) Placebo 
(cellulose - 
matched, 
identically 
looking). 
 
Cog measures 
delivered at 
baseline and 
endpoint. Clinical 
Global Impression 
of Change (CGI-C) 
given at week 7 
and endpoint.  
 
 
 
 
(sum of scores of trial 
1-5), delayed recall 
(trial 8), recognition 
(hits, trial 9); 
(b) Rey Complex Figure 
Test (RCFT) - 
visuospatial 
perception/constructio
n and memory. 
Outcome = task 
duration (copy time, 
secs) and accuracy 
(copy quality), 
immediate recall, 
delayed recall; 
(c) CGI-C. Scores range 
from 1-7, lower 
meaning improvement, 
higher meaning 
deterioration, 4 
meaning no change. 
Interviewer 
independent of testing 
- no knowledge of how 
the ppt performed on 
cognitive measures. 
Ppts who scored 
vs. control (p = .041). No 
significant differences 
between conditions for the 
rest of the RAVLT tasks; 
however, improvement 
occurred more commonly 
in the PS-DHA/EPA 
condition than in the 
placebo condition in 2 of 3 
items. ITT analysis of 
immediate recall scores 
from 131 ppts revealed 
marginal significance (p = 
.069) for the PS-DHA/EPA 
condition vs. controls.  
 
(b)Trend in copy time in 
favour of PS-DHA/EPA 
condition (p = .079) vs. 
control. Overall, in all trials 
for this measure except for 
the delayed recall trial 
(similar improvement in 
both conditions), more 
improvement shown by 
PS-DHA/EPA condition. 
 
26*; baseline 
performance in RAVLT 
delayed recall trial > 
PP group mean (7 
words); academic 
education > 12 years. 
Included 78 ppts 
(n=40 PS-DHA/EPA / 
n=38 control 
condition). 
 
*inclusion criteria = 
MMSE score ≥ 26 for 
ppts without a college 
education. 
 
(a) Significant 
improvements 
demonstrated by PS-
DHA/EPA condition 
for immediate recall 
(p = .006), total 
learning (p = .002) 
and delayed recall (p 
= .045). There was no 
significant difference 
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Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
Age 72.2 ± 
8.34. 
 
*n=9 were 
excluded from 
the PP analysis 
(n=6 from 
placebo group, 
n=3 from PS-
DHA/EPA 
condition): 1 
due to short 
interval 
between visits 
and 8 failed to 
meet post-
specified 
compliance 
criteria (≥65%). 
 
All ppts scored 
at least ≥ 26 on 
MMSE and ≤ 
0.5 on the 
Clinical 
themselves as 
improved from last visit 
(scores of either 1, 2, 
3), in at least 1/2 visits 
(weeks 7/15), classified 
as improved; unless 
ppts rated improved at 
week 7 and 
deterioration at week 
15.  Otherwise, 
classified as unchanged 
(score 4) or worse 
(scores of either 5, 6, 
7). 
(d) NexAde 
computerised cognitive 
tool. Subtasks - symbol 
spotting, pattern 
identification, pattern 
recall, digit-symbol 
substitution, digit span 
forward, digit span 
backward and delayed 
pattern recall. Outcome 
= 8 composite scores 
relating to focused 
attention, sustained 
(c) No significant 
difference found. 
However, more ppts in PS-
DHA/EPA condition were 
classified as clinically 
improved (37%/n=22) vs. 
control condition 
(27%/n=17). 
 
(d) No significant 
differences. 
 
Responder analysis 
Ppts classified as 
responders when 
improvement in RAVLT 
immediate recall was at 
least 2 words & when they 
had an overall 
improvement in the CGI-C. 
Following intervention, a 
significant correlation 
between responder status 
and treatment was found, 
p = .034 in PP analysis: 
responders in the PS-
DHA/EPA condition = 22%, 
for the recognition 
trial. 
 
(b) Marginal 
significance was 
found for copy 
duration where the 
PS-DHA/EPA 
condition showed the 
largest improvement 
(p = .055). Accuracy 
remained stable in 
both conditions - 
indicating the 
improvement 
observed in the time 
to complete the copy 
task was not at the 
expense of the quality 
of the copied figure 
 
(c) No significant 
difference found. 
However, more ppts 
in PS-DHA/EPA 
condition were 
classified as clinically 
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Reference Ingredient 
Sample 
characteristics 
Design and 
intervention 
Cognitive measures 
(battery and sub tests) 
Reported findings 
Subgroup/Further 
analyses 
Effect 
summary 
Dementia 
Rating Scale. 
attention, memory 
recognition and recall, 
visuospatial learning, 
spatial short-term 
memory, executive 
functions and mental 
flexibility. 
control condition = 8% 
(n=13 and n=5, 
respectively).  Also, 
significant association 
found for ITT analysis p = 
.035: PS-DHA/EPA 
condition = 23%, control 
condition = 9%. 
improved (40%/n=16) 
vs. control condition 
(32%/n=12). 
 
(d) NexAde 
No significant 
differences. 
 
Responder analysis 
Significant correlation 
found between 
responder status and 
treatment (p = .016) 
in the PP analysis: PS-
DHA/EPA condition = 
25%/n=10, control 
condition = 5%/n=2. 
Key: + positive treatment effect; x no treatment effect; AAMI: Age-associated memory impairment; BC-PS: bovine cortex phosphatidylserine; CGI-C: Clinical 
Global Impression of Change; DHA: Docosahexaenoic acid; EEG: Electroencephalogram; EPA: Eicosapentaenoic acid; ITT: Intention-to-treat; LC PUFA: Long 
chain polyunsaturated fatty acid; MMSE: Mini-Mental State Examination; PC: Phosphatidylcholine; PE: Phosphatidylethanolamine; PI: Phosphatidylinositol; 
PL: Phospholipid; PP: Per protocol; Ppts: Participants; PS: Phosphatidylserine, PS-DHA/EPA: Phosphatidylserine-Docosahexaenoic acid/Eicosapentaenoic acid; 
RAVLT: Rey Auditory Verbal Learning Test; RCFT: Rey Complex Figure Test; RDBPC: Randomised, double-blind, placebo-controlled; SECPT: Socially evaluated 
cold-pressor test; SM: Sphingomyelin; TSST: Trier Social Stress Test; WAIS: Wechsler Adult Intelligence Scale; WMS: Wechsler Memory Scale.  
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Appendix 4. Study 1 opt-out permission letters 
 
Institute of Psychological Sciences 
Leeds LS2 9JT 
Dear Parent/Carer,  
An intervention study of the effects of enriched milk compared with non-enriched 
milk on cognitive performance and subjective state in 6-8 year old school children 
My name is Claire Champ and I am a Research Officer from the University of Leeds.  I 
am leading a team who are conducting a study in your pupils’ school. This work is a 
research collaboration between the University of Leeds and a food (milk) manufacturing 
company. Some results from the study will be used towards an educational qualification 
by members of the research team. We are supervised by Professor Louise Dye and Dr 
Clare Lawton at the Institute of Psychological Sciences. 
We would like to invite your child to take part in a study examining how two different 
milk drinks affect children’s performance over a period of 6 weeks. The study milk drinks 
are A) Cow’s milk and B) Cow’s milk enriched with a milk ingredient already present in 
cow’s milk. This ingredient is a type of fat that is thought to be beneficial for cognitive 
performance.  
This letter is designed to provide you with enough information about the study in order 
for you to make an informed decision about your child’s participation. 
The tests are administered using touch screen laptops and most children find them good 
fun.  We would like children aged 6-8 years to take part and would test your child on 3 
occasions within the 6 week period. The tasks should take about 30 minutes and will take 
place during the school day on the school premises.  The tasks will include tests of 
different abilities such as reaction time and memory. These tasks are not intended to be 
stressful and are appropriate for your child’s age group. Half way through the tasks your 
child will be given a 5 minute refresher break. They will also be asked to complete some 
simple questionnaires asking them about their hunger and mood at each session. Your 
child will have to option to stop the tests and leave the study at any time. 
During the 6 weeks of testing each child will be randomly assigned to consuming either 
Milk A or Milk B on 5 days per week (i.e. on Mondays-Fridays). Allocation to each milk 
type will be decided by chance – rather like tossing a coin. There is an equal chance that 
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your child will receive Milk A or Milk B. Neither you nor the researchers will be able to 
choose which milk your child receives. Children will, however, be able to choose between 
banana, strawberry or raspberry flavoured milk. University staff will be responsible for 
delivering the study milk to school, for giving this out to the children and for supervising 
milk consumption during school hours. 
All the children who take part will undergo a colour blindness test to make sure that they 
can see the colours used in the touch screen computerised tests and complete the Wechsler 
Abbreviated Scale of Intelligence (WASI). If your child is found to be colour-blind we 
will pass this information on to you via the school. 
This study has received ethical approval from the Institute of Psychological Sciences 
Research Ethics Committee (Ref 14-0101; date of approval 17/05/2014). All of the 
information collected from your child during the study will be kept strictly confidential 
and will only be used for the purposes of this research. Participation in the study is 
completely voluntary. If you decide to allow your child to take part they are free to 
withdraw at any time without providing a reason. All results from the study will be kept 
strictly anonymous and at no point will any identifiable personal information be linked 
with the results. At the end of the study both teachers and parents will be invited to a post 
study dissemination event where top line results will be presented by us and our 
supervisors. 
This study will take place in school during the period of Wednesday, 3rd September until 
Wednesday, 22nd October. 
If you are you happy for your child to participate in this study then you do not need to do 
anything further. We will assume that you are happy for your child to take part unless you 
inform the school otherwise using the slip below.  
Please note: School staff will ensure that children who have an allergy or who are 
intolerant to cow’s milk do not take part in this study.  
If you have any questions about the study please contact: 
Claire Champ or Fiona Croden on 0113 343 5753 or milkstudy@leeds.ac.uk 
(study email) 
Alternatively you can email or phone our project supervisors Professor Louise Dye and 
Dr Clare Lawton at the Institute of Psychological Sciences: 
Prof Louise Dye: 0113 3435707 or l.dye@leeds.ac.uk 
Dr Clare Lawton: 0113 3435741 or c.l.lawton@leeds.ac.uk  
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An intervention study of the effects of enriched milk compared with non-enriched 
milk on cognitive performance and subjective state in 6-8 year old school children 
 
 
I DO NOT wish my son/daughter ..............................................................(Please insert 
child’s name) 
 
to take part in the above research study. 
 
 
Signed...........................................................(parent/carer) 
 
 
Date................................................................ 
 
Please only return this slip if you DO NOT wish your child to take part in this study.  
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Appendix 5. Expert panel approved Lacprodan®PL-20 as part of nutrition bars and milk-based 
nutritional beverages as safe, suitable and GRAS in July 2014 
 
 
 
EXPERT PANEL OPINION 
THE GENERALLY RECOGNIZED AS SAFE (GRAS) 
STATUS OF THE PROPOSED USES OF LACPRODAN PL-
20 
 
Introduction 
The undersigned, an independent panel of experts, qualified by their scientific training 
and national and international experience to evaluate the safety of food and food 
ingredients (the "Expert Panel"), was specially convened on behalf of Arla Foods 
Ingredients Group P/S, and asked to evaluate the safety and "generally recognized as 
safe" ("GRAS") status of the proposed use of Lacprodan PL-20 as an ingredient in 
certain specified foods. 
Lacprodan PL-20 is a milk protein concentrate rich in phospholipids.  Lacprodan PL-20 
is proposed for use in nutrition bars (e.g., high protein bars, meal replacement bars) 
at a maximum level of 6 g/serving, in ready-to-drink milk-based nutritional beverages 
(e.g., RTD meal replacements/supplements  such as Boost) at a maximum level of 16 
g/serving, in protein/high protein milk-based nutritional drinks at a maximum level of 
6 g/serving , and in other milk-based nutritional beverages (e.g., instant breakfast 
beverages, powder mixes) at a maximum of 8 g/serving. 
Exponent Inc. ("Exponent") performed a comprehensive search of the scientific 
literature in November 2013 relating to the safety of the milk-derived ingredient and 
its specific components for human consumption.  The specific milk-derived 
components that were the subject of the safety review included milk fat globular 
membrane (MFGM), phospholipids, and sphingolipids. Exponent summarized the 
results of the literature search and prepared a safety dossier, "GRAS Determination 
for the Use of Lacprodan PL-20 in Select Foods," for consideration by the Expert Panel. 
The Expert Panel critically evaluated Exponent's safety documentation (the dossier), 
and other available data and information that the members of the Expert Panel 
believed to be pertinent to the safety of Lacprodan PL-20 under the conditions of 
intended use.  In addition, the Expert Panel critically evaluated the method of 
manufacture and specifications for Lacprodan PL-20, analytical data confirming 
compliance with appropriate food-grade specifications and consistency of production, 
the conditions of its intended use as an ingredient in foods, and the estimated dietary 
exposure to Lacprodan PL-20.  After independent review, the Expert Panel convened 
via telephone conference call on April2, 2014, and independently, jointly, and 
unanimously concluded that the intended use of Lacprodan PL-20 as a food ingredient 
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in select foods, produced consistent with current good manufacturing practice (cGMP) 
and meeting appropriate food-grade specifications, is safe and suitable.  The Expert 
Panel further concluded that such intended use is GRAS based on scientific procedures.  
It is also the opinion of this Expert Panel that other qualified experts would concur 
with these conclusions. 
 
Summarized below is the Expert Panel's scientific analysis supporting our conclusions. 
 
Description 
Lacprodan PL-20 is a milk protein concentrate rich in phospholipids.  Protein is the 
primary constituent of Lacprodan PL-20, accounting for 49-55% of the product.  
Approximately 55% of the proteins in Lacprodan PL-20 are comprised of casein or 
whey, and the remaining 45% of proteins are MFGM proteins.  Lipid accounts for 24-
30% of Lacprodan PL-20 by weight, with the majority of lipid present as phospholipids 
and a small fraction present as triglycerides. Lacprodan PL-20 contains a minimum of 
16% phospholipids.  The phospholipid profile in Lacprodan PL-20 is comparable to the 
phospholipid profile found in both bovine and human milk, as the predominant 
phospholipids are phosphatidylcholine, sphingomyelin, and 
phosphatidylethanolamine, with each accounting for approximately 27%, 27%, and 
22% of total phospholipids, respectively.  The remaining constituents of Lacprodan PL-
20 include lactose (up to 10%); ash (up to 6%), predominantly as phosphorus and 
calcium; and moisture (up to 5%). 
Manufacturing Process 
Lacprodan PL-20 is made from standard cream with a lipid content of approximately 
40% using standard separation techniques commonly applied in the dairy industry.  In 
the production of Lacprodan PL-20, lipid in the form of triglycerides is removed from 
cream, leaving the serum phase (or aqueous phase) which contains proteins and 
phospholipids from the MFGM along with milk proteins, carbohydrates, and minerals.  
Lacprodan PL-20 is made under cGMP from food grade materials using only mechanical 
separation steps (homogenization, centrifugation and ultrafiltration).  No processing 
aids are used in the production process; consequently, Lacprodan PL-20 contains only 
components intrinsic to cream, or the milk from which cream is derived. Ascorbyl 
palmitate (21 CFR§182.3149) and tocopherol (21 CFR§184.1890) are added to prevent 
oxidation during storage; the concentration of each of these additives is approximately 
100 ppm as calculated on the powder. 
Intended Use and Estimated Intake 
Lacprodan PL-20 is rich in phospholipids naturally occurring in milk fat, including 
sphingomyelin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine 
and phosphatidylinositol.  The intended effect of using Lacprodan PL-20 as an 
ingredient in foods is to provide a dietary source of the milk-derived components in 
the ingredient. 
 
Lacprodan PL-20 is intended for use in nutrition bars (e.g., high protein bars, meal 
replacement bars) at a maximum level of 6 g/serving, in ready-to-drink milk-based 
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nutritional beverages (e.g., RTD meal replacements/supplements  such as Boost) at a 
maximum level of 16 g/serving, in protein/high protein milk-based nutritional drinks 
at a maximum level of 6 g/serving, and in other milk-based nutritional beverages (e.g., 
instant breakfast beverages, powder mixes) at a maximum of 8 g/serving. 
For the population aged 2 years and older, the per user mean and 90th percentile 
estimated daily intakes (EDIs) of Lacprodan PL-20 are 7.3 and 15.3 g/day, respectively.  
Adults 19 years of age and older are estimated to have the highest intake of Lacprodan 
PL-20 from the proposed uses; the per user mean and 90th percentile EDIs of Lacprodan 
PL-20 for adults are 7.5 and 15.9 g/day, respectively.  At the 90th percentile of intake 
among adults, Lacprodan PL-20 will deliver approximately 3.8g MFGM proteins and 
2.7g phospholipids. 
Safety 
Lacprodan PL-20 contains no novel dietary components in that the MFGM components 
in Lacprodan PL-20, i.e. phospholipids and proteins, are present in milk and milk-
derived products. Milk and milk-derived ingredients have a long history of use and are 
widely consumed in the U.S. diet.  Phospholipids account for no more than 
approximately 1% of total lipids in milk, and approximately 1 to 4% of total proteins in 
milk are MFGM proteins.  The concentration of MFGM phospholipids and proteins in 
standard milk and milk products therefore is lower than the concentration in 
Lacprodan PL-20.  The remaining components in Lacprodan PL-20, namely casein and 
whey, triglycerides, and minerals including calcium, phosphorus, potassium, and 
magnesium, are widely consumed in relatively large quantities in dairy products and 
other dietary sources.  As such, the exposure from the additional intake of these 
components resulting from the intended use of Lacprodan PL-20 is not considered to 
present a safety concern. 
The safety of the intended use of Lacprodan PL-20 therefore was evaluated by a 
critical evaluation of information pertinent to the safety of the key constituents in the 
ingredient, namely the phospholipids and MFGM proteins that account for the distinct 
compositional and nutritional profile of Lacprodan PL-20, and also the safety of the 
consumption of Lacprodan PL-20 and similar milk-derived substances.  All the 
information critically evaluated that formed the basis for this GRAS determination is 
available in the publicly available literature. 
Polar lipids present in the highest quantity in bovine milk are glycerophospholipids and 
sphingolipids (primarily sphingomyelin) and their composition also reflects the 
phospholipid profile in human milk.  It is reasonable to assume that the absorption of 
glycerophospholipids from this milk-derived ingredient (Lacprodan PL-20) is similar to 
that of other dietary glycerophospholipids, which is known to be rapid and nearly 
complete.  Following absorption, the fatty acids contained in dietary 
glycerophospholipids are incorporated into cellular membranes or enter the pool of 
absorbed fatty acids and share their metabolic fate. 
 
Phospholipids are ubiquitously found in the human diet as components of animal- and 
plant- derived foods, and as approved food additives, including the widely used lecithin 
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(i.e., a naturally occurring mixture of phosphatides of choline, ethanolamine and 
inositol; 21 CFR §184.1400) and serine-containing phosphatides that have also been 
determined to be GRAS.  The estimated daily intake of phospholipids from the diet 
(background) is in the range of0.9 to 8 g per day.  Adverse effects are not associated 
with these levels of phospholipid intake.  In addition to dietary sources, the biliary 
pathway delivers approximately 10 to 20 g of phospholipids to the intestinal lumen 
per day.  International regulations allow for the addition of up to 2 g phospholipids 
per Litre infant formula (Codex Stan 72-1981, rev 2007; Directive 2006/141/EC); in the 
USA, egg-phospholipids may be added to infant formula at a level up to 2 g per L.  
Assuming the maximum allowable level of phospholipids in infant formula and the 
typical formula intake of 1 L per day, the daily intake of phospholipids by infants from 
this source could be approximately 2 g with no anticipated adverse effects. 
Sphingolipids represent a structurally diverse category of lipids.  The sphingolipids of 
mammalian tissues include ceramides, sphingomyelins, cerebrosides, gangliosides, 
and sulfatides, with sphingosine as the principal sphingoid base.  Sphingomyelin is 
synthesized mainly via de novo pathways, but it is also obtained from the diet.  The 
intake of sphingolipids (as sphingomyelin) is estimated at 300 to 400 mg/day.  While 
the major dietary glycerophospholipids are rapidly digested and absorbed by 
pancreatic enzymes, dietary sphingolipids are more slowly digested by mucosal 
enzymes.  The available data indicate that humans digest and absorb most 
(approximately 81%) of the sphingomyelin in normal diets. Adverse effects from 
sphingomyelin intake have not been observed or reported in animal or human studies. 
The MFGM proteins belong to a variety of functional classes, with the most frequently 
observed classes comprised of immunity and defence, signal transduction, protein 
transport, and lipid metabolism.  While there is limited published evidence regarding 
the specific safety or of safety evaluations of key MFGM proteins, no information was 
identified to suggest untoward or adverse effects from their consumption in the diet.  
MFGM proteins account for approximately 1 to 4% of total proteins in bovine milk; 
therefore, each one-cup serving of whole milk provides in the range of 80 to 310 mg 
MFGM.  MFGM proteins account for approximately 2 to 4% of total protein in human 
milk.  Assuming an intake of 1 L human milk per day with a total protein content of 9 
g per L, the daily MFGM protein intake by breastfeeding infants is in the range of 180 
to 360 mg. 
Several published repeat-dose feeding studies of Lacprodan PL-20 and its primary 
components conducted in humans and animals were identified.  Although the human 
studies were not designed specifically to assess the safety of the MFGM-derived 
ingredients, the studies present indicators of safety including reports of tolerance of 
the test articles, blood lipid responses, and body weight; animal studies typically 
include measures of feed intake, body weight and growth. 
Findings from the clinical studies support the safe intake of Lacprodan PL-20 at the 
tested doses. The highest intake of Lacprodan PL-20 was 16.6 g daily for a period of 4 
weeks in a sample of 48 adults; this level of Lacprodan PL-20 delivered 8.4 g protein 
(approximately 3.8 g MFGM protein) and 2.8 g phospholipids.  No untoward effects 
were observed in the study or in additional studies in which adults consumed 
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approximately 13.5 or 14.7 g Lacprodan PL-20 daily.  In a small study of short duration 
(10 days), women consumed up to 16.8 g protein and 6 g phospholipid from 32.4 g of 
a butter serum-derived ingredient compositionally similar to Lacprodan PL-20.  
Children were also exposed to daily intakes of approximately 4 g protein (0.4 g MFGM 
protein) and 0.4 g phospholipids in a 6 month intervention with a milk-derived 
ingredient, and children consumed 0.5 g supplemental phospholipids in another study 
for a period of 6 months. 
Studies conducted in rats and mice examining the supplementation of their diets with 
formulations prepared using isolated milk fat globule membrane components that 
range in length from 3 weeks to 13 weeks did not reveal any untoward effects.  These 
studies demonstrated that the formulations were well-tolerated and supported 
growth and appropriate body weight gain and composition when provided 
concurrently with a suitable animal diet.  Feeding isolates of milk fat globule 
membranes also did not produce any untoward effects in pregnant dams 
supplemented during gestation, nor in pups exposed in utero, in terms of physical 
characteristics, growth, body weight, weight gain, and body composition.  Litter size 
and survival were not explicitly repmied, however, the authors stated that litter size 
was adjusted to 8, indicating typically sized litters. Findings from a 13-week rat study 
feeding of a milk fat globule isolate formulation (MFGM) support an acceptable daily 
intake of at least 85 mg/kg bw/d proteins and 6.25 mg/kg bw/d MFGM phospholipids, 
the highest doses tested in the study.  This level of protein intake is equivalent to 5.1 
g/day for a 60 kg adult, or approximately 0.6 g MFGM proteins assuming that MFGM-
specific proteins account for 12.5% of total protein.  The safety of intake of the MFGM 
isolate demonstrated in this animal study is consistent both with the lack of adverse 
effects noted in the clinical trials and the available information regarding the safety of 
phospholipids, including sphingomyelin, and the safety of MFGM specific proteins. 
Summary and Conclusion 
The 90th percentile per user EDI of Lacprodan PL-20 from the maximum proposed use 
levels in nutrition bars and milk-based nutritional beverages is 15.9 g/day among 
adults, which is below the level determined to be an acceptable daily intake.  
Therefore, it is reasonable to conclude that the proposed use of Lacprodan PL-20 in 
nutrition bars (e.g., high protein bars, meal replacement bars) at a maximum level of 
6 g/serving, in ready-to-drink milk-based nutritional beverages (e.g., RTD meal 
replacements/supplements  such as Boost) at a maximum level of 16 g/serving, in 
protein/high protein milk-based nutritional drinks at a maximum level of 6 g/serving, 
and in other milk-based nutritional beverages (e.g., instant breakfast beverages, 
powder mixes) at a maximum of 8 g/serving is safe and suitable, and GRAS. 
 
We, the undersigned expert panel members, have individually and collectively critically 
evaluated published and unpublished data and information pertinent to the safety of 
the proposed use of Lacprodan PL-20, a milk protein concentrate rich in phospholipids, 
in nutrition bars (e.g., high protein bars, meal replacement bars) at a maximum level 
of 6 g/serving, in ready-to-drink milk-based nutritional beverages (e.g., RTD meal 
replacements/supplements  such as Boost) at a maximum level of 16 g/serving, in 
protein/high protein milk-based nutritional drinks at a maximum level of6 g/serving, 
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and in other milk-based nutritional beverages (e.g., instant breakfast beverages, 
powder mixes) at a maximum of 8 g/serving, produced consistent with cGMP and 
meeting appropriate food-grade specifications, and unanimously conclude that it is 
"generally recognized as safe" (GRAS)  based on scientific procedures. 
 
It is our opinion that other qualified experts would concur with our conclusions. By: 
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Appendix 6. Pre-cognitive measures 10-point Likert scale to measure subjective evaluation of 
appetite, mood, motivation and mental alertness 
 
Participant Number: .................... 
Date: ........................................... 
Visual Analogue Scale items for measurement of subjective state 
Pre Cognitive Test VAS  
1. How hungry do you feel right now?  
  
           
2. How cheerful do you feel right now?  
 
 
 
 
3. How much energy do you have right now? 
 
 
 
4. How keen are you to try hard right now? 
 
 
 
 
 
Not at all 
hungry 
Very 
hungry 
Very 
cheerful 
Not at all 
cheerful 
A lot of 
energy 
No 
energy at 
all 
Very keen
 
 
Not at all 
keen
 
 
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
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5. Are you easily distracted right now? 
 
 
 
6. How easy are you finding it to concentrate right now? 
 
 
 
7. How awake do you feel right now? 
 
 
 
8. How bad tempered do you feel right now? 
 
 
 
 
 
  
Very easy Not at all 
easy 
Not at all Very 
easily 
Not at all 
awake 
Very awake 
Not at all 
bad 
tempered 
Very bad 
tempered 
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
1 2
 
3 4 5 6 87 109
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Appendix 7. Post-cognitive measures 10-point Likert scale for cognitive measure evaluation 
ratings 
 
Participant Number: .................... 
Date: ........................................... 
Visual Analogue Scale items for measurement of subjective state 
Post Cognitive Test VAS 
 
1. How hard did you find these tests you just completed? 
 
 
 
2. How much did you concentrate in the tests that you just completed? 
 
 
3. How well do you think you did in the tests that you just completed?  
 
 
4. How frustrating did you find the tests that you just completed? 
 
 
 
 
 
Extremely  
hard 
Not at all  
hard 
A large  
amount 
A small  
amount 
Extremely  
well 
Not at all 
well 
Extremely 
 frustrating 
Not at all  
frustrating 
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
1 2 3 4 5 6 87 109
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Appendix 8. SAS PROC mixed models for the Choice Reaction Time (CRT) 
 
 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model.  
 
  
 Number of correct trials Reaction time of correct trials Movement time of correct trials 
Main effect terms    
Condition F(1,67) = 0.61, p = .437 F(1,65) = 7.25, p = .009 F(1,65) = 0.54, p = .467 
Week F(1,63) = 2.41, p = .126 F(1,65) = 0.25, p = .617 F(1,65) = 0.05, p = .818 
Covariates    
Baseline F(1,67) = 8.05, p = .006  F(1,65) = 89.32, p <.001 F(1,65) = 82.72, p = <.001 
Age    
IQ  F(1,65) = 0.30, p = .584 F(1,65) = 2.40, p = .126 
Gender   F(1,65) = 4.00, p = .050 
Trial Not used in the model F(14,923) = 6.44, p <.001 F(14,922) = 1.70, p = .050 
Interaction terms    
Baseline*condition  F(1,65) = 5.94, p = .018  
Baseline*week F(1,63) = 1.79, p = .185   
Condition*week F(1,63) = 0.98, p = .325 F(2,64) = 4.42, p = .016 F(1,65) = 9.67, p = .003 
Trial*condition*week Not used in the model  F(42,788) = 1.07, p = .361 
Baseline*condition*week   F(3,1768) = 2.79, p = .039 
Gender*condition*week F(4,63) = 3.16, p = .020 F(4,64) = 7.08, p <.001 F(3,65) = 8.55, p <.001 
Age*condition*week   F(4,1768) = 1.46, p = .213 
IQ*condition*week  F(3,1830) = 4.12, p = .006  
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Appendix 9. SAS PROC mixed models for the Simple Reaction Time (SRT) 
 
 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
 
 
 
 
 Number of correct trials Reaction time of correct trials Movement time of correct trials 
Main effect terms    
Condition F(1,65) = 2.37, p = .129 F(1,65) = 2.20, p = .143 F(1,64) = 2.45, p = .122 
Week F(1,59) = 0.01, p = .919 F(1,65) = 5.25, p = .025 F(1,64) = 3.54, p = .064 
Covariates    
Baseline F(1,65) = 9.61, p = .003 F(1,65) = 108.03, p <.001 F(1,64) = 54.69, p <.001 
Age   F(1,64) = 3.74, p = .058 
IQ F(1,65) = 0.23, p = .632 F(1,65) = 0.95, p = .334 F(1,64) = 0.31, p = .582 
Gender F(1,65) = 3.09, p = .084 F(1,65) = 4.87, p = .031  
Trial Not used in the model F(14,900) = 2.49, p = .002  
Interaction terms    
Baseline*condition   F(1,64) = 4.83, p = .032 
Baseline*week  F(1,1775) = 5.32, p = .021  
Condition*week F(1,59) = 5.81, p = .019 F(1,65) = 1.28, p = .262 F(1,64) = 8.37, p = .005 
Trial*condition*week Not used in the model  F(56,1673) = 1.37, p = .038 
Baseline*condition*week    
Gender*condition*week F(3,59) = 5.95, p = .001 F(3,65) = 5.67, p = .002 F(4,64) = 2.98, p = .025 
Age*condition*week   F(3,1731) = 3.80, p = .010 
IQ*condition*week F(3,59) = 2.57, p = .063  F(3,1731) = 5.19, p = .001 
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Appendix 10. SAS PROC mixed models for the Rivermead Behavioural Memory Test for Children (RBMT-C) Task 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
 
 
  
 Immediate recall Delayed recall 
Main effect terms   
Condition F(1,65) = 2.06, p = .156 F(1,64) = 3.82, p = .055 
Week F(1,61) = 0.18, p = .675 F(1,61) = 0.07, p = .786 
Covariates   
Baseline F(1,65) = 47.77, p < .001  
Age F(1,65) = 3.31, p = .073 F(1,64) = 3.52, p = .065 
IQ  F(1,64) = 3.23, p = .077 
Gender F(1,65) = 4.10, p = .047 F(1,64) = 0.03, p = .859 
Interaction terms   
Baseline*condition  F(1,64) = 2.32, p = .132 
Baseline*week  F(1,61) = 0.02, p = .882 
Condition*week F(1,61) = 3.54, p = .065 F(1,61) = 1.25, p = .267 
Baseline*condition*week  F(1,61) = 1.50, p = .225 
Gender*condition*week F(3,61) = 0.51, p = .678 F(3,61) = 2.17, p = .101 
Age*condition*week F(3,61) = 1.76, p = .164  
IQ*condition*week   
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Appendix 11. SAS PROC mixed models for the Spatial Recognition Memory (SRM) 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
 
  
 Reaction time of correct trials   Number of correct trials   
Main effect terms   
Condition F(1,64) = 4.10, p = .047 F(1,66) = 0.11, p = .739 
Week F(1,63) = 3.37, p = .071 F(1,60) = 4.12, p = .047 
Covariates   
Baseline F(1,64) = 77.07, p <.001 F(1,66) = 3.31, p = .074 
Age   
IQ F(1,64) = 3.96, p = .051  
Gender   
Trial F(16,851) = 3.63, p <.001 Not used in the model 
Interaction terms   
Baseline*condition F(1,64) = 4.17, p = .045  
Baseline*week F(1,1570) = 3.49, p = .062  
Condition*week F(1,63) = 0.53, p = .468 F(1,60) = 0.15, p = .703 
Trial*condition*week  Not used in the model 
Baseline*condition*week F(1,1570) = 4.74, p = .030 F(3,60) = 0.93, p = .433 
Gender*condition*week F(4,63) = 0.80, p = .532  
Age*condition*week F(4,1570) = 0.30, p = .876  
IQ*condition*week F(3,1570) = 1.41, p = .238 F(4,60) = 1.48, p = .220 
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Appendix 12. SAS PROC mixed models for the Motor Screening Task (MOT) 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model.  
 
  
 Reaction time  Distance  
Main effect terms   
Condition F(1,66) = 0.91, p = .344 F(1,68) = 0.00, p = .995 
Week F(1,68) = 0.30, p = .583 F(1,69) = 5.57, p = .021 
Covariates   
Baseline F(1,1260) = 6.28, p = .012 F(1,1282) = 4.52, p = .034 
Age F(1,66) = 0.16, p = .692  
IQ F(1,66) = 0.11, p = .739  
Gender  F(1,68) = 9.09, p = .004 
Trial F(9,621) = 7.32, p <.001 F(9,621) = 1.67, p = .094 
Interaction terms   
Baseline*condition  F(1,1282) = 2.03, p = .155 
Baseline*week F(1,1260) = 4.21, p = .041 F(1,1282) = 0.93, p = .335 
Condition*week F(1,68) = 7.01, p = .010  
Trial*condition*week F(27,581) = 1.08, p = .362 F(29,599) = 0.75, p = .828 
Baseline*condition*week F(2,1260) = 9.64, p <.001  
Gender*condition*week   
Age*condition*week F(3,1260) = 2.47, p = .060 F(4,1282) = 1.82, p = .122 
IQ*condition*week F(3,1260) = 3.70, p = .011  
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Appendix 13. SAS PROC mixed models for the Spatial Span (SSP) 
 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model.  Sumattempts = total 
number of attempts at each span to the highest span achieved (inclusive) on each test occasion. HSpan = Highest span achieved on each test 
occasion. 
  
 Reaction time for  correct trials Number of correct trials Highest span 
Main effect terms    
Condition F(1,62) = 2.39, p = .127 F(1,61) = 3.04, p = .086 F(1,63) = 3.33, p = .073 
Week F(1,62) = 0.00, p = .963 F(1,45) = 0.02, p = .895 F(1,51) = 0.69, p = .410 
Covariates    
Baseline F(1,62) = 21.82, p <.001 F(1,61) = 1.85, p = .179 F(1,63) = 21.98, p <.001 
Age  F(1,61) = 6.42, p = .014 F(1,63) = 2.78, p = .100 
IQ F(1,62) = 0.20, p = .653 F(1,61) = 7.95, p = .007  
Gender F(1,62) = 0.75, p = .391 F(1,61) = 7.71, p = .007  
Trial F(26,983) = 240.90,  p <.001 Not used in the model Not used in the model 
Sumattempts F(10,41) = 3.31, p = .003 F(10,38) = 84.85, p <.001 F(10,41) = 36.41, p <.001 
Hspan Not used in the model F(1,45) = 14646.3, p <.001 Not used in the model 
Interaction terms 
   
Baseline*condition    
Baseline*week    
Condition*week F(1,62) = 5.87, p = .018 F(1,45) = 0.89, p = .351 F(1,51) = 0.49, p =.487 
Baseline*condition*week F(3,1727) = 4.86, p = .002   
Trial*condition*week  Not used in the model Not used in the model 
Gender*condition*week F(3,62) = 6.14, p = .001 F(3,45) = 1.32, p = .279  
Age*condition*week F(4,1727) = 4.59, p = .001   
IQ*condition*week F(3,1727) = 4.37, p = .005 F(3,45) = 1.40, p = .254 F(4,51) = 1.09, p = .372 
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Appendix 14. SAS PROC mixed models for the Subjective Evaluation of Appetite, Mood, Motivation and Mental Alertness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Hunger Cheerfulness Bad temper Energy levels 
Main effect terms     
Condition F(1,67) = 0.36, p = .550 F(1,66) = 2.73, p = .103 F(1,67) = 0.51, p = .478 F(1,67) = 1.89, p = .174 
Week F(1,67) = 1.10, p = .297 F(1,67) = 1.06, p = .306 F(1,60) = 0.07, p = .794 F(1,67) = 0.29, p = .594 
Covariates     
Baseline F(1,67) = 25.95, p <.001 F(1,66) = 9.69, p = .003 F(1,67) = 30.41, p <.001 F(1,67) = 35.78,  p <.001 
Interaction terms     
Baseline*condition  F(1,66) = 1.48, p = .228   
Baseline*week   F(1,60) = 3.01, p = .088  
Condition*week F(1,67) = 0.04, p = .843 F(1,67) = 0.35, p = .555 F(1,60) = 0.05, p = .818 F(1,67) = 0.05, p = .823 
Baseline*condition*week   F(2,60) = 9.61, p <.001  
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Appendix 14 continued. SAS PROC mixed models for the Subjective Evaluation of Appetite, Mood, Motivation and Mental Alertness 
 
 
 
 
 
 
 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
 
 
 
 
  
 Keenness to try hard Ease of distraction Ease of focussing Wakefulness 
Main effect terms     
Condition F(1,67) = 0.16, p = .692 F(1,66) = 6.27, p = .015 F(1,66) = 0.72, p = .399 F(1,67) = 0.13, p = .722 
Week F(1,63) = 3.96, p = .051 F(1,67) = 0.00, p = .966 F(1,65) = 0.11, p = .742 F(1,66) = 4.20, p = .045 
Covariates     
Baseline F(1,67) = 22.37,  p <.001 F(1,66) = 19.43, p <.001 F(1,66) = 17.13, p <.001 F(1,67) = 41.73, p <.001 
Interaction terms     
Baseline*condition  F(1,66) = 4.99, p = .029 F(1,66) = 1.94, p = .168  
Baseline*week   F(1,65) = 0.06, p = .812 F(1,66) = 2.05, p = .157 
Condition*week F(1,63) = 8.99, p = .004 F(1,67) = 0.17, p = .682 F(1,65) = 4.66, p = .035 F(1,66) = 1.12, p = .294 
Baseline*condition*week F(3,63) = 4.10, p = .010  F(1,65) = 4.80, p = .032  
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Appendix 15. SAS PROC mixed models for the Cognitive Test Evaluation Ratings 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
  
 Test battery difficulty Perceived concentration Perceived performance Frustration 
Main effect terms     
Condition F(1,67) = 0.32, p = .574 F(1,67) = 1.37, p = .247 F(1,67) = 1.73, p = .193 F(1,67) = 0.30, p = .585 
Week F(1,68) = 2.67, p = .107 F(1,66) = 0.05, p = .832 F(1,68) = 0.26, p = .611 F(1,68) = 0.08, p = .783 
Covariates     
Baseline F(1,67) = 25.61, p <.001 F(1,67) = 37.29, p <.001 F(1,67) = 20.09, p <.001 F(1,67) = 17.72, p <.001 
Interaction terms     
Baseline*condition     
Baseline*week     
Condition*week F(1,68) = 0.04, p = .840 F(1,66) = 0.32, p = .575 F(1,68) = 0.64, p = .427 F(1,68) = 2.86, p = .096 
Baseline*condition*week     
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Appendix 16. SAS PROC mixed models for the Attention Switching Task (acute supplementation) 
Notes. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. Accuracy: target 
accuracy used in target reaction time analysis / switch cost accuracy used in switch cost reaction time analysis. 
 
  
 
Target accuracy Target reaction time Switch cost accuracy Switch cost reaction time 
Main effect terms     
Condition F(1,142) = 0.96, p = .328 F(1,141) = 4.24, p = .041 F(1,92) = 0.02, p = .898 F(1,91) = 7.46, p = .008 
Trial F(2,142) = 1.11, p = .334 F(2,141) = 5.90, p = .004 F(1,92) = 5.55, p = .021 F(1,91) = 6.38, p = .013 
Covariates     
Baseline F(1,142) = 168.68, p <.001 F(1,141) = 0.92, p = .339 F(1,92) = 11.63, p = .001 F(1,91) = 0.03, p = .863 
Age   F(1,92) = 4.44, p = .038 F(1,91) = 1.27, p = .262 
IQ   F(1,92) = 0.58, p = .447  
Gender   F(1,92) = 1.62, p = .206 F(1,91) = 2.89, p = .093 
Accuracy Not used in the model, as 
this was the outcome 
F(1,141) = 605.26, p < .001 
Not used in the model, as 
this was the outcome 
F(1,91) = 324.43, p <.001 
Interaction term     
Baseline*condition  F(1,141) = 6.20, p = .014  F(1,91) = 3.86, p = .052 
Trial*condition F(2,142) = 0.06, p = .939 F(2,141) = 1.41, p = .248 F(1,92) = 0.12, p = .727 F(1,91) = 0.00, p = .989 
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Appendix 17. SAS PROC mixed models for the Rapid Visual Information Processing Task (acute supplementation) 
Notes. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. Total correct: Number 
of correct trials obtained. 
 
  
 Total hits Total false alarms Reaction time for hits 
Main effect terms    
Condition F(1,46) = 6.80, p = .012 F(1,42) = 0.44, p = .508 F(1,864) = 8.41, p = .004 
Covariates    
Baseline F(1,46) = 158.97, p <.001 F(1,42) = 91.37, p <.001 F(1,864) = 83.16, p <.001 
Age   F(1,864) = 12.54, p <.001 
IQ  F(1,42) = 10.44, p = .002  
Gender  F(1,42) = 0.55, p = .461 F(1,864) = 8.02, p = .005 
Trial Not used in the model Not used in the model  
Total correct Not used in the model Not used in the model F(1,864) = 25.49, p <.001 
Interaction term    
Baseline*condition  F(1,42) = 1.19, p = .281 F(1,864) = 10.86, p = .001 
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Appendix 18. SAS PROC mixed models for the N-back Task (acute supplementation) 
Notes. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. Total correct: Number 
of correct trials obtained. 
 
  
 
Target accuracy Total accuracy Reaction time for targets 
Reaction time for 
nontargets 
Main effect terms     
Condition F(1,44) = 7.55, p = .009 F(1,44) = 3.57, p = .066 F(1,1891) = 1.98, p = .160 F(1,4971) = 147.23, p <.001 
Covariates     
Baseline F(1,44) = 84.60, p <.001 F(1,44) = 65.56, p <.001 F(1,1891) = 252.76, p <.001 F(1,4971) = 228.61, p <.001 
Age    F(1,4971) = 3.87, p = .049 
IQ F(1,44) = 7.30, p = .010 F(1,44) = 7.21, p = .010 F(1,1891) = 1.30, p = .255 F(1,4971) = 172.29, p <.001 
Gender F(1,44) = 2.89, p = .096 F(1,44) = 2.12, p = .152 F(1,1891) = 2.79, p = .095 F(1,4971) = 19.18, p <.001 
Trial Not used in the model Not used in the model F(1,1891) = 5.25, p = .022 F(1,4971) = 4.92, p = .027 
Total correct Not used in the model Not used in the model F(1,1891) = 6.90, p = .009 F(1,4971) = 335.01, p <.001 
Interaction term     
Baseline*condition F(1,44) = 6.90, p = .012 F(1,44) = 3.82, p = .057 F(1,1891) = 1.56, p = .211 F(1,4971) = 138.37, p <.001 
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Appendix 19. SAS PROC mixed models for the Pattern Separation Task (acute supplementation) 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
 
  
 Pattern separation score Recognition score 
Main effect terms   
Condition F(1,44) = 1.04, p = .312 F(1,45) = 4.60, p = .038 
Covariates   
Baseline F(1,44) = 30.71, p <.001 F(1,45) = 36.05, p <.001 
Age   
IQ   
Gender F(1,44) = 3.05, p = .088 F(1,45) = 0.37, p = .547 
Interaction term   
Baseline*condition  F(1,45) = 8.25, p = .006 
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Appendix 20. SAS PROC mixed models for the Face-Name Associative Memory Exam (acute supplementation) 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
 
 
  
 Immediate recall Delayed recall 
Main effect terms   
Condition F(1,46) = 0.00, p = .978 F(1,46) = 3.60, p = .064 
Covariates   
Baseline F(1,46) = 10.60, p = .002 F(1,46) = 45.09, p <.001 
Age   
IQ  F(1,46) = 2.03, p = .161 
Gender F(1,46) = 1.97, p = .167  
Interaction term   
Baseline*condition   
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Appendix 21. SAS PROC mixed models for the Visual Verbal Learning Test (VVLT) (acute supplementation) 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model.  
 
  
 
Rate of learning New learning Retroactive interference Proactive interference 
Main effect terms     
Condition F(1,140) = 0.11, p = .737 F(1,44) = 0.16, p = .689 F(1,45) = 1.46, p = .233 F(1,45) = 0.09, p = .770 
Trial F(2,140) = 20.29,  p <.001 Not used in the model Not used in the model Not used in the model 
Covariates     
Baseline F(1,140) = 25.36,  p <.001 F(1,44) = 15.69, p <.001 F(1,45) = 2.43, p = .126 F(1,45) = 1.38, p = .247 
Age F(1,140) = 7.21, p = .008 F(1,44) = 4.30, p = .044  F(1,45) = 4.46, p = .040 
IQ F(1,140) = 17.22,  p <.001    
Gender  F(1,44) = 0.92, p = .343 F(1,45) = 0.54, p = .468 F(1,45) = 0.79, p = .379 
Interaction term     
Baseline*condition  F(1,44) = 0.16, p = .690 F(1,45) = 0.26, p = .609  
Trial*condition F(2,140) = 0.06, p = .941 Not used in the model Not used in the model Not used in the model 
397 
 
 
Appendix 21 continued. SAS PROC mixed models for the Visual Verbal Learning Test (VVLT) (acute supplementation) 
 
 
 
 
 
 
 
 
    
 
 
 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model.  
  
 
Delayed recall 
Main effect terms  
Condition F(1,44) = 3.94, p = .053 
Trial Not used in the model 
Covariates  
Baseline F(1,44) = 36.21, p <.001 
Age F(1,44) = 6.05, p = .018 
IQ  
Gender F(1,44) = 0.13, p = .722 
Interaction term  
Baseline*condition F(1,44) = 2.01, p = .164 
Trial*condition Not used in the model 
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Appendix 22. SAS PROC mixed models for the Attention Switching Task (chronic supplementation) 
Notes. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. Accuracy: target 
accuracy used in target reaction time analysis / switch cost accuracy used in switch cost reaction time analysis. 
  
 Target accuracy Target reaction time Switch cost accuracy Switch cost reaction time 
Main effect terms     
Condition F(1,45) = 0.65, p = .426 F(1,46) = 0.65, p = .424 F(1,45) = 2.85, p = .098 F(1,45) = 0.05, p = .833 
Week F(1,41) = 5.37, p = .026 F(1,41) = 5.83, p = .020 F(1,41) = 0.00, p = .982 F(1,42) = 2.00, p = .165 
Trial F(2,92) = 16.20, p <.001 F(2,94) = 12.99, p <.001 F(1,47) = 28.65, p <.001 F(1,47) = 11.66, p = .001 
Covariates     
Baseline F(1,218) = 85.67, p <.001  F(1,127) = 26.81, p <.001 F(1,127) = 1.25, p = .266 
Age F(1,45) = 5.70, p = .021    
IQ   F(1,45) = 3.88, p = .055  
Gender    F(1,45) = 1.11, p = .297 
Accuracy 
Not used in the model, as 
this was the outcome 
F(1,220) = 1075.44, p <.001 
Not used in the model, as 
this was the outcome 
F(1,127) = 487.83, p <.001 
Interaction terms     
Baseline*condition  F(1,220) = 5.02, p = .026 F(1,127) = 5.28, p = .023  
Baseline*week  F(1,220) = 4.73, p = .031 F(1,127) = 2.57, p = .111 F(1,127) = 4.07, p = .046 
Condition*week F(1,41) = 5.15, p = .029 F(1,41) = 0.22, p = .643 F(1,41) = 2.61, p = .114 F(1,42) = 5.36, p = .026 
Trial*condition F(2,92) = 1.27, p = .285    
Trial*condition*week   F(3,43) = 0.92, p = .439  
Baseline*condition*week  F(1,220) = 4.09, p = .045 F(1,127) = 3.97, p = .049 F(2,127) = 0.51, p = .602 
Gender*condition*week F(4,41) = 1.53, p = .212 F(4,41) = 1.59, p = .196 F(4,41) = 3.17, p = .023 F(3,42) = 1.12, p = .354 
Age*condition*week F(3,218) = 1.92, p = .128    
IQ*condition*week F(4,218) = 3.52, p = .008 F(4,220) = 1.16, p = .330  F(4,127) = 1.95, p = .106 
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Appendix 23. SAS PROC mixed models for the Rapid Visual Information Processing Task (chronic supplementation) 
Notes. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. Total correct: Number 
of correct trials obtained. 
 
  
 Total hits Total false alarms Reaction time for hits 
Main effect terms    
Condition F(1,43) = 0.46, p = .502 F(1,41) = 7.22, p = .010 F(1,42) = 1.88, p = .178 
Week F(1,35) = 0.91, p = .346 F(1,38) = 2.18, p = .148 F(1,41) = 4.66, p = .037 
Covariates    
Baseline F(1,43) = 137.44, p <.001 F(1,41) = 61.25, p <.001 F(1,42) = 29.43, p <.001 
Age F(1,43) = 4.94, p = .032 F(1,41) = 6.30, p = .016  
IQ F(1,43) = 7.82, p = .008  F(1,42) = 4.52, p = .039 
Gender   F(1,42) = 3.80, p = .058 
Trial Not used in the model Not used in the model F(1,1628) = 5.34, p = .021 
Total correct Not used in the model Not used in the model F(1,1628) = 10.07, p = .002 
Interaction term    
Baseline*condition  F(1,41) = 7.46, p = .009 F(1,42) = 2.16, p = .149 
Baseline*week  F(1,38) = 3.08, p = .087 F(1,1628) = 5.29, p = .022 
Condition*week F(1,35) = 0.31, p = .581 F(1,38) = 0.03, p = .863 F(1,41) = 0.12, p = .728 
Baseline*condition*week    
Gender*condition*week F(4,35) = 0.81, p = .527 F(4,38) = 0.21, p = .929 F(3,41) = 0.87, p = .463 
Age*condition*week F(3,35) = 2.21, p = .104   
IQ*condition*week F(3,35) = 2.45, p = .080   
400 
 
 
Appendix 24. SAS PROC mixed models for the N-back Task (chronic supplementation) 
 
Notes. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. Total correct: Number 
of correct trials obtained. 
 
  
 
Target accuracy Total accuracy Reaction time for targets 
Reaction time for 
nontargets 
Main effect terms     
Condition F(1,45) = 3.36, p = .073 F(1,45) = 4.66, p = .036 F(1,43) = 3.60, p = .064 F(1,42) = 0.02, p = .878 
Week F(1,33) = 0.13, p = .724 F(1,31) = 0.46, p = .502 F(1,44) = 0.41, p = .527 F(1,45) = 11.38, p = .002 
Covariates     
Baseline F(1,45) = 96.29, p <.001 F(1,45) = 89.13, p <.001 F(1,43) = 111.90, p <.001 F(1,42) = 18.63, p <.001 
Age     
IQ    F(1,42) = 4.61, p = .038 
Gender    F(1,42) = 2.28, p = .139 
Trial Not used in the model Not used in the model  F(1,9423) = 15.42, p <.001 
Total correct Not used in the model Not used in the model  F(1,9423) = 108.22, p <.001 
Interaction term     
Baseline*condition   F(1,43) = 1.50, p = .228 F(1,42) = 14.35, p = .001 
Baseline*week F(1,33) = 3.68, p = .064 F(1,31) = 4.94, p = .034   
Condition*week F(1,33) = 1.20, p = .282 F(1,31) = 0.51, p = .479 F(1,44) = 1.73, p = .195 F(1,45) = 4.82, p = .033 
Baseline*condition*week F(2,33) = 2.36, p = .111 F(2,31) = 2.02, p = .150   
Gender*condition*week F(4,33) = 0.92, p = .465 F(4,31) = 0.55, p = .702   
Age*condition*week F(4,33) = 1.69, p = .175 F(4,31) = 1.83, p = .148 F(4,3539) = 1.13, p = .342 F(4,9423) = 5.04, p = .001 
IQ*condition*week   F(4,3539) = 1.53, p = .191 F(3,9423) = 2.88, p = .034 
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Appendix 25. SAS PROC mixed models for the Pattern Separation Task (chronic supplementation) 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
  
 Pattern separation score Recognition score 
Main effect terms   
Condition F(1,45) = 5.08, p = .029 F(1,44) = 0.17, p = .685 
Week F(1,37) = 0.41, p = .525 F(1,38) = 0.08, p = .778 
Covariates   
Baseline F(1,45) = 47.15, p <.001 F(1,44) = 21.91, p <.001 
Age   
IQ   
Gender   
Interaction term   
Baseline*condition  F(1,44) = 0.69, p = .410 
Baseline*week  F(1,38) = 0.26, p = .612 
Condition*week F(1,37) = 0.43, p = .518 F(1,38) = 2.31, p = .137 
Baseline*condition*week  F(1,38) = 5.73, p = .022 
Gender*condition*week F(4,37) = 0.65, p = .629 F(4,38) = 4.99, p = .003 
Age*condition*week F(4,37) = 2.06, p = .106  
IQ*condition*week   
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Appendix 26. SAS PROC mixed models for the Face-Name Associative Memory Exam (chronic supplementation) 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
  
 Immediate recall Delayed recall 
Main effect terms   
Condition F(1,43) = 1.76, p = .192 F(1,42) = 0.04, p = .837 
Week F(1,39) = 1.70, p = .199 F(1,40) = 6.72, p = .013 
Covariates   
Baseline F(1,43) = 53.27, p <.001 F(1,42) = 70.94, p <.001 
Age F(1,43) = 5.37, p = .025 F(1,42) = 4.67, p = .036 
IQ  F(1,42) = 0.00, p = .957 
Gender   
Interaction term   
Baseline*condition F(1,43) = 0.68, p = .414 F(1,42) = 0.11, p = .736 
Baseline*week F(1,39) = 0.57, p = .453  
Condition*week F(1,39) = 4.83, p = .034 F(1,40) = 0.24, p = .628 
Baseline*condition*week F(1,39) = 5.39, p = .026 F(2,40) = 6.23, p = .004 
Gender*condition*week F(4,39) = 1.24, p = .309  
Age*condition*week   
IQ*condition*week  F(3,40) = 2.69, p = .059 
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Appendix 27. SAS PROC mixed models for the Visual Verbal Learning Test (VVLT) (chronic supplementation) 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model.  
  
 Rate of learning New learning Retroactive interference Proactive interference 
Main effect terms     
Condition F(1,43) = 2.25, p = .141 F(1,44) = 0.44, p = .512 F(1,40) = 2.86, p = .098 F(1,42) = 0.60, p = .442 
Week F(1,42) = 2.32, p = .136 F(1,42) = 0.44, p = .511 F(1,41) = 3.89, p = .055 F(1,38) = 0.13, p = .726 
Trial F(2,94) = 81.73, p <.001 Not used in the model Not used in the model Not used in the model 
Covariates     
Baseline F(1,225) = 14.07, p <.001 F(1,44) = 33.11, p <.001  F(1,42) = 1.15, p = .290 
Age F(1,43) = 6.13, p = .017  F(1,40) = 7.55, p = .009 F(1,42) = 0.32, p = .577 
IQ F(1,43) = 11.73, p = .001  F(1,40) = 0.31, p = .582 F(1,42) = 0.43, p = .516 
Gender F(1,43) = 5.77, p = .021 F(1,44) = 0.45, p = .505 F(1,40) = 7.48, p = .009  
Interaction term     
Baseline*condition   F(2,40) = 6.60, p = .003 F(1,42) = 3.56, p = .066 
Baseline*week    F(1,38) = 4.15, p = .049 
Condition*week F(1,42) = 13.31, p <.001 F(1,42) = 5.09, p = .029 F(1,41) = 5.53, p = .024 F(1,38) = 0.61, p = .441 
Trial*condition  Not used in the model Not used in the model Not used in the model 
Trial*condition*week  Not used in the model Not used in the model Not used in the model 
Baseline*condition*week     
Gender*condition*week F(3,42) = 0.66, p = .580 F(3,42) = 1.83, p = .156 F(3,41) = 1.42, p = .251 F(4,38) = 2.56, p = .054 
Age*condition*week F(3,225) = 5.10, p = .002    
IQ*condition*week     
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Appendix 27 continued. SAS PROC mixed models for the Visual Verbal Learning Test (VVLT) (chronic supplementation) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model.  
  
 Delayed recall 
Main effect terms  
Condition F(1,43) = 6.27, p = .016 
Week F(1,38) = 2.17, p = .149 
Trial Not used in the model 
Covariates  
Baseline F(1,43) = 39.85, p <.001 
Age  
IQ  
Gender F(1,43) = 2.38, p = .130 
Interaction term  
Baseline*condition F(1,43) = 3.68, p = .062 
Baseline*week  
Condition*week F(1,38) = 0.25, p = .621 
Trial*condition Not used in the model 
Trial*condition*week Not used in the model 
Baseline*condition*week  
Gender*condition*week F(3,38) = 0.89, p = .454 
Age*condition*week  
IQ*condition*week F(4,38) = 3.37, p = .019 
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Appendix 28. SAS PROC mixed models for the Cognitive Failures Questionnaire 
 
Note. Where no F value is presented, this main effect, covariate or interaction term was not retained in the final model. 
 
 Cognitive Failures Questionnaire 
Main effect terms  
Condition F(1,44) = 1.21, p = .277 
Week F(1,41) = 2.29, p = .138 
Covariates  
Baseline F(1,44) = 77.74, p <.001 
Age  
IQ  
Gender  
Interaction term  
Baseline*condition F(1,44) = 0.53, p = .473 
Baseline*week F(1,41) = 4.89, p = .033 
Condition*week F(1,41) = 4.89, p = .033 
Baseline*condition*week F(1,41) = 5.16, p = .028 
Gender*condition*week  
Age*condition*week  
IQ*condition*week  
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Appendix 29. Study 2 study advert 
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Appendix 30. Study 2 participant information sheet 
 
Investigating the benefits of a 12 week phospholipid intervention on 
cognitive performance in adults with a subjective memory complaint. 
You are being invited to take part in a research project. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully and discuss it with others if you wish. Ask me if 
there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part. 
Purpose of the research 
We wish to find out whether consuming a nutritional intervention, the details of which will 
follow, for 12 weeks will improve performance on a range of cognitive measures that assess 
memory and processing speed, and reduce the number of cognitive lapses e.g. entering a 
room and forgetting why you wanted to go in there, experienced day to day.  Cognitive failures 
include behaviours such as clumsiness and episodes of forgetfulness.  
What exactly are the supplements? 
The active supplement contains multiple phospholipids, which are thought to help cell function 
and brain activity. Phospholipids are available from a range of foods consumed as part of a 
regular diet and therefore, feature part of people’s every day nutritional intake.  The 
phospholipids in the active supplement have been extracted from cow’s milk.  The non-active 
or placebo supplement does not contain phospholipids but instead contains maltodextrin, a 
food additive used in many food products.  The additional ingredients that make up the rest 
of both supplements include items typically found in a regular diet.  Both supplements are 
available in strawberry and chocolate flavour and are provided as a powder, which is added 
to water to form a nutritional drink.  If you decide to attend a screening appointment, you will 
have the opportunity to sample the supplement in both flavours.  Before doing so, you will be 
shown a full list of the ingredients in case of a pre-existing food intolerance/allergy. This can 
be supplied prior to screening if necessary. 
Why have I been chosen? 
There is a need to develop the research area concerning phospholipid supplementation.  An 
increasing aged population means that greater emphasis is placed on ageing well.   This 
study will add to the findings of similar studies and explore whether phospholipids can 
promote healthy ageing. To see whether you may be eligible to take part, please refer to the 
study inclusion and exclusion criteria in Appendix 1 at the end of this document. 
What will I have to do? 
A study appointment break down and study timeline both available in Appendix 1 of this 
document accompany this section.  
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All appointments can take place at the University or at home.  
 
Screening appointment: 
You will learn more about the study, sample the supplement in both flavours, complete a 
version of the cognitive measures and be shown the self-report measures to be completed 
over the course of the study.  Further, conditional upon you signing the study consent form, 
you will undertake screening measures led by the researcher, provide sociodemographic and 
some health details and undertake a measure of anthropometry (waist-to-hip measurement).  
At the end of this appointment, provided that you have chosen to enter into the study and you 
meet the study inclusion and exclusion criteria (based on the details you have provided), you 
will be given six short forms to takeaway and complete in your own time before the next 
appointment.  All future appointments - you will be seen on three further occasions across 12 
weeks - will also be scheduled at this time.  The screening appointment is expected to take 
~120 minutes. 
Intervention study: 
You will complete a number of self-report questionnaires and computerised cognitive 
measures (that you will be shown during the screening appointment).  In order to explore 
whether there are any benefits of the active supplement after a single dose, at the first 
appointment following screening, the self-report and computerised cognitive measures will be 
conducted twiceː once before the consumption of the supplement and again 90 minutes post-
ingestion of the supplement. This appointment will take approx. 2 hours, with a break of 90 
minutes in between.  Please note: there is no requirement for the researcher to remain with 
you during the 90 minute break.  All subsequent appointments will last up to 1 hour.  Fifty 
sachets (packaged together) containing the supplement that you have been randomly 
allocated to receive (so there is an equal chance of getting either the active or the placebo 
supplement) will be provided at the first appointment following screening.  You will be required 
to take the contents of 1 sachet per day with 120ml of water.  You will also be given a 
consumption diary, which you will be asked to complete each day.  Using this, you can say 
whether or not you took the supplement on each day of the 12 week intervention period.  
Please note: all participants are strongly encouraged to take the supplement each day for the 
whole intervention period. All empty and part-empty supplement sachets should be kept with 
the remaining sachets to be collected at the next appointment.  Half way through the 12 week 
period, you will receive the next 50 sachets to be consumed over the rest of the 12 weeks, 
again having 1 per day. 
What are the possible disadvantages and risks of taking part? 
There are no known risks/disadvantages to taking part in this study. The composite of 
phospholipids found in the active supplement has been approved for use by an expert panel 
as safe, suitable, and ‘Generally Recognized As Safe’ (GRAS).  Given that the other 
ingredients in both supplements are available from / used in regular food products, it is not 
anticipated that there is any risk associated with consuming the supplements.  
 
You will receive £10.00 per appointment to cover travel costs and compensate for time lost. 
What are the possible benefits of taking part? 
For those allocated to the active supplement, the increased intake of phospholipids may 
facilitate improvements in your cognitive function.  However, bear in mind that there is mixed 
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evidence regarding the efficacy of phospholipid supplementation.  By participating in this 
study, you will play a role in extending the current knowledge base.  
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part, you will be 
given this information sheet to keep (and be asked to sign a consent form at screening).  You 
will be able to withdraw at any time up to 2 weeks (10 working days) following your 
participation.   You do not have to give a reason should you wish to withdraw and will not be 
disadvantaged if you choose to do so.  We may ask for your permission to keep the data 
collected so far to use in the final analysis.   
Will my taking part in this project be kept confidential? 
All procedures for handling, processing, storing, sharing and destroying participant data meet 
with Data Protection Act 1998.  All email communication will be stored on the University 
secure network and will be password protected. The consent form along with all paper records 
and measures will be stored in a lockable cabinet on the University campus, which can be 
accessed by staff and project students only.  The consent form will be the only form that 
records both your full name and your unique participant ID.  This will be stored separately to 
all other paperwork.  The latter will be identified using participant IDs only.   
All data obtained from the cognitive measures will be anonymised, so will not contain any of 
your personal information, stored on the University secure network, and will be password 
protected.  Following the completion of the study, a copy of the final composite data set 
(containing the data for all participants) will be deposited onto the Research Data Leeds 
repository in an anonymised format.  This will be referenced in any subsequent publication, 
where readers will be able to access the data on the repository. We may share this 
anonymised data with Arla Food Ingredients Group P/S based in Denmark, who have 
prepared the supplements, should they request this.  
Withdrawing  
Participation is voluntary and refusal to participate / withdrawal from the study up to 10 
working days following participation over the 12 weeks will not result in any consequences.   
What will happen to the results of the research project? 
The results will further the current knowledge concerning the use of phospholipids as a 
nutritional supplement.   They will also be used towards an educational qualification by the 
researcher (Claire Champ).  There may also be scope to use the results to support Level 3 
undergraduate dissertation projects.  Whether the data gets used for this purpose depends 
upon whether such a project is selected by year three undergraduate students. The results 
may further form the basis for a publication; however, participants will not be identifiable from 
any details in reports, presentations or scientific publications.  All data, apart from the 
anonymised composite data set available on the Research Data Leeds repository, obtained 
from participants whom completed the study and did not withdraw within the 10 working day 
period following participation will be retained for a maximum period of 3 years before being 
destroyed.  
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What if there is a problem? 
If you have a concern about the study, please contact the researcher (Claire Champ) using 
the details below in the first instance.  If you have a complaint about the researcher or would 
prefer to speak to someone other than Claire, please contact the main supervisor – details 
given below. 
Who is funding the research? 
This study is funded by the Economic and Social Research Council (ESRC) and the 
supplements were manufactured by Arla Food Ingredients Group P/S.  
Contact information 
If you would like any more information on the study, please contact: 
Claire Champ        memory-study@leeds.ac.uk 07480 518 960 
   
The main supervisor of this research is: 
Professor Louise Dye l.dye@leeds.ac.uk  0113 343 5707 
 
  
 
This research is subject to ethical guidelines set out by the British Psychological Society 
and has received ethical approval (ref no:PSC-289; date approved:14/02/2018 ).  
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Study inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
- Aged 50 years of age and over. - Any psychiatric or medical disorder that 
could interfere with cognitive function. 
- Experience reduced memory function 
where you feel your memory is not as good 
as it was. 
- Use of any drugs that affect the brain, 
including prescription, herbal and diet 
supplements. 
- Do not have any cognitive impairment as 
diagnosed by a health professional. 
- Evidence of delirium, confusion or other 
disturbance of consciousness. 
- Able to consent to participate in the study 
and willing to consume the supplement and 
complete a consumption diary daily for 12 
weeks. 
- Any neurological disorder including 
dementia, Parkinson's disease, stroke, 
focal brain lesions, multiple sclerosis, 
and epilepsy. 
- Willing and able to participate in screening 
and testing measures on four occasions 
(screening x 1, testing session x 4). 
- Current diagnosis or history of 
alcoholism or drug dependence. 
- Able to follow verbal and simple written 
instructions in English. 
- Have a history of any of infective or 
inflammatory brain disease. 
- Has normal vision and hearing, with 
appropriate corrective aids if required. 
- Have a history of head injury. 
- Able to understand cognitive testing 
instructions and responding requirements. 
- Have colour vision deficiency or dyslexia. 
- Comfortable with a researcher conducting 
screening and testing measures. 
- Lactose intolerant and/or suspects or 
knows they have an allergy to any 
ingredient in the active and placebo 
supplements. 
Should you have any questions about any of the above criteria, please contact Claire 
Champ using the contact details on the last page of this form. 
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Study appointment break down 
 
First 
occasion: 
screening 
appointment 
 
 
1 Study briefing: Discussion focused on what the study is 
and what you will be required to do 
Appointment 
length 
2 Supplement tasting  
 
Up to 120 minutes 
3 Completion of a practise version of the cognitive 
measures and familiarisation with the self-report 
measures. 
4 Opportunity to ask any questions followed by signing of 
the study consent form 
5 Completion of screening measures, sociodemographic 
and health form, and anthropometric measurement. 
Second 
occasion 
1 Cognitive measures x 1 Up to 1 hour either 
side of a 90 minute 
break* 
2 First supplement  - demonstration and consumption 
3 90 minutes after taking supplement, cognitive measures 
x 1  
Third 
occasion 
1 Cognitive measures x 1 Up to 1 hour 
Fourth 
occasion 
1 Cognitive measures x 1 Up to 1 hour 
*The first set of cognitive measures on the second occasion will act as baseline measures. After 
taking the supplement, the second set of cognitive measures will be ran 90 minutes later to explore 
the effects of a single dose of the supplement. 
 
 
Study timeline 
 
 
 
 
 
 
 
 
 
Occasion 2 
Week -1 Week 0 Week 6 
(day 42) 
Week 12 
(day 84) 
Occasion 3 Occasion 1 Occasion 4 
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Appendix 31. Study 2 consumption diary 
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Appendix 32. Adverse event form 
Adverse Events/Serious Adverse Events 
Participant ID: 
Date of report:                     Name of reporter: 
Source of information:      
Description of event: 
 
 
 
 
 
Dates of event:   Start:  End:      Still ongoing:  ?  Yes        ?  No 
Any medication taken for this AE?   Yes  No 
If YES, please specify:  
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Appendix 33. Study 2 consent form 
 
Study title: Investigating the benefits of a 12 week phospholipid intervention on 
cognitive performance in adults with a subjective memory complaint.  
 
1. I confirm that I have read and understand the participant information sheet 
version 3, dated 13th February 2018, explaining the above research project, 
and I have had the opportunity to ask questions about the project.  If I have 
asked any questions, I have received satisfactory answers. 
 
2. I agree for the data collected as a result of my participation to be stored on the 
University campus and systems, and deposited onto the Research Data Leeds 
repository.  I am happy for the anonymised data to be used in relevant future 
research. I am also happy for the anonymised data to be shared with Arla Food 
Ingredients Group P/S should they request it.  I understand that all data, apart 
from the anonymised composite data set available on the Research Data Leeds 
repository, will be retained for a maximum period of 3 years before being 
destroyed. 
 
3. I understand that relevant sections of the data collected during the study may 
be looked at by auditors from the University of Leeds or from regulatory 
authorities, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my records. 
 
4. I confirm that I do not have any food allergies/intolerances which would exclude 
me from taking part in this study and understand that I will be required to 
consume the study supplement for 12 weeks, 7 days per week, and be seen 
on three occasions across this period.  I agree to complete the consumption 
diary and keep all used and part-used supplement sachets. I understand that I 
may be contacted in between appointments from time to time. 
 
 
Continued … 
 
 
Please 
initial 
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5. I agree to take part in the above study. 
 
 
 
Participant’s name…………………………………Date ____ / ____ /_____   
 
Signature 
……………………......................................................................................................    
 
*Researcher’s name……………………………….Date ____ / ____ /_____   
 
*Signature 
……………………......................................................................................................    
 
 
*To be signed and dated in the presence of the participant.  
Once this has been signed by all parties, the participant should receive a copy of the signed 
and dated participant consent form, the information sheet and any other written information 
provided to the participants. A copy of the signed and dated consent form should be kept with 
the project’s main documents which must be kept in a secure location.  
This research is subject to ethical guidelines set out by the British Psychological Society and 
has received ethical approval (ref no:PSC-289; date approved:14/02/2018). The primary 
supervisor of this research is Professor Louise Dye (l.dye@leeds.ac.uk) 
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Appendix 34. Waist:hip ratio standard operating procedures 
 
 
Standard Operating Procedure: Measuring the Waist to Hip Ratio 
(WHR) 
 
 
 
The purpose of this procedure is to determine the ratio of waist circumference to the 
hip circumference. 
 
Procedure 
The researcher will perform the following in order of appearance: 
1. Explain the procedure to the participant. 
2. Ask the participant to remove any outdoor clothing, which may restrict 
accurate measurement. 
3. Use a flexible plastic tape measure to perform the measurements. 
4. Ensure both measurements are taken with the participant standing. 
 
Waist measurement: 
5. Ensure the waist measurement is taken at the narrowest waist level, or if 
this is not apparent, at the mid-point between the lowest rib and the top of 
the hip bone (iliac crest). 
6. Ensure the tape is not too tight or too loose, is lying flat on the skin, and is 
horizontal. 
7. Ensure the measurement is recorded on the participant’s 
sociodemographic and health form. 
 
Hip measurement: 
8. Ensure that the hip girth measurement is taken over minimal clothing. 
9. Ensure that the participant stands erect with their weight evenly distributed 
on both feet and legs. Request that participants do not tense the gluteal 
(buttock) muscles – these should be relaxed. 
10. Ensure that the hip girth measurement is taken at the level of the greatest 
protrusion of the gluteal (buttock) muscles. 
11. Ensure the tape is not too tight or too loose, is lying flat, and is horizontal. 
12. Ensure the measurement is recorded on the participant’s 
sociodemographic and health form. 
Post procedure 
 
  
Calculate the WHR as follows: 
Waist to Hip Ratio (WHR) = Gw / Gh, where Gw = waist girth, Gh = hip girth. 
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Appendix 35. Geriatric Depression Scale 15-item questionnaire 
 
Geriatric Depression Scale: Short Form 
DIRECTIONSː Choose the best answer for how you have felt over the past week: 
1. Are you basically satisfied with your life?       
 YES / NO 
2. Have you dropped many of your activities and interests?    
 YES / NO 
3. Do you feel that your life is empty?       
 YES / NO 
4. Do you often get bored?         
 YES / NO 
5. Are you in good spirits most of the time?       
 YES / NO 
6. Are you afraid that something bad is going to happen to you?    
 YES / NO 
7. Do you feel happy most of the time?       
 YES / NO 
8. Do you often feel helpless?        
 YES / NO 
9. Do you prefer to stay at home, rather than going out and doing new things?  
 YES / NO 
10. Do you feel you have more problems with memory than most?   
 YES / NO 
11. Do you think it is wonderful to be alive now?      
 YES / NO 
12. Do you feel pretty worthless the way you are now?     
 YES / NO 
13. Do you feel full of energy?        
 YES / NO 
14. Do you feel that your situation is hopeless?      
 YES / NO 
15. Do you think that most people are better off than you are?    
 YES / NO 
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Appendix 36. Montreal Cognitive Assessment   
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Appendix 37. Study 2 sociodemographic details 
 
Sociodemographic and health form 
 
Participant ID…………………………….. 
Date ………………………………………….. 
 
Thank you for agreeing to take part in this study. This questionnaire is designed to collect 
sociodemographic and health details.  If you have any questions as you go through the 
questionnaire, feel free to ask.  
 
Section one 
 
Full name: 
…………………………………………………………………………………………………
… 
Address: 
…………………………………………………………………………………...……………
… 
…………………………………………………………………………………...……………
… 
…………………………………………………………………………………...……………
… 
Post code: ………………………………….. 
Contact telephone number(s): …………………………………………………………. 
Email: ……………………………………………………………………………………… 
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Section Two 
 
Date of birth: 
……..../……..../…….... 
Age: 
…………………. 
Gender:   
 M       F 
 
Highest qualification achieved. Please tick: 
A Level or equivalent  
O Level or equivalent  
Trade (commercial or clerical)  
None  
Language spoken at home: …………………………………………….. 
Language spoken in country of birth: ………………………………….. 
   
Are you currently employed? Please circle: Yes No 
Are you married? Please circle: Yes No 
Do you live alone? Please circle: Yes No 
 
Section Three 
 
 
 
 
 
 
 
Anthropometric measurements 
Waist measure: ……………….. 
Hip measure: …………………… 
Body impedance: 
……………………………………………………………………………………………………………………… 
………………………………………………………………………………………………………….…………… 
 
………………………………………………………………………………………………………………………………………
…………………... 
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Please list all medications that you currently take: 
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
……… 
 
Please list all supplements that you currently take: 
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………… 
  
Do you have a hearing impairment? Please circle: Yes No 
If you answered yes, do you use a corrective aid? Please circle Yes No 
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Appendix 38. Study 2 Socioeconomic indicator 
Deprivation Indicator 
        Participant ID: 
        Date: 
 
 
Can you look at the things listed below and tell me which you have 
and which you do not have by marking the appropriate column? 
 
For all items you have said you don't have, please can you tell me 
whether this is because you do not want them or because you can't 
afford them.  To indicate that you can't afford them, please place a tick 
in the third column. 
 
  Yes No 
Can't 
afford 
1 A cooked meal every day..………………………..       
2 Meat or fish every other day …………….………..       
3 A roast meat joint or equivalent once a week …..       
4 A warm winter coat ………………………………..       
5 Two pairs of all-weather shoes …………………..       
6 
New, not second hand clothes when you need 
them ..       
7 Presents for friends or family once a year ………       
8 
Celebrations on special occasions such as 
Christmas ..       
9 
A holiday away from home each year 
……………       
10 A holiday abroad every year or so ……………….       
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Appendix 39. State Anxiety Scale (S-Anxiety) 
State-Trait Anxiety Inventory: State 
         Participant ID: 
         Date: 
 
DIRECTIONS: A number of statements which people have used to describe themselves are 
given below. Read each statement and then circle the response option to the right to 
indicate how you feel right now, that is, at this moment. There are no right or wrong 
answers. Do not spend too much time on any one statement but give the answer which 
seems to describe. our present feelings best. 
  
N
O
T
 A
T
 A
L
L
 
S
O
M
E
W
H
A
T
 
M
O
D
E
R
A
T
E
L
Y
 
V
E
R
Y
 M
U
C
H
 S
O
 
1 I feel calm …………………………………………………………….. 1 2 3 4 
2 I feel secure …………………………………………………………… 1 2 3 4 
3 I am tense …………………………………………………………….. 1 2 3 4 
4 I am regretful ………………………………………………………….. 1 2 3 4 
5 I feel at ease ………………………………………………………….. 1 2 3 4 
6 I feel upset ……………………………………………………………. 1 2 3 4 
7 I am presently worrying about possible misfortunes …………….. 1 2 3 4 
8 I feel rested …………………………………………………………… 1 2 3 4 
9 I feel anxious …………………………………………………………. 1 2 3 4 
10 I feel comfortable …………………………………………………….. 1 2 3 4 
11 I feel self-confident …………………………………………………… 1 2 3 4 
12 I feel nervous …………………………………………………………. 1 2 3 4 
13 I am jittery …………………………………………………………….. 1 2 3 4 
14 I feel "high strung" ……………………………………………………. 1 2 3 4 
15 I am relaxed …………………………………………………………… 1 2 3 4 
16 I feel content ………………………………………………………….. 1 2 3 4 
17 I am worried …………………………………………………………… 1 2 3 4 
18 I feel over-excited and rattled ……………………………………….. 1 2 3 4 
19 I feel joyful …………………………………………………………….. 1 2 3 4 
20 I feel pleasant …………………………………………………………. 1 2 3 4 
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Appendix 40. The Stress Arousal Checklist (SACL) 
 
The Stress Arousal Checklist 
         
 Participant ID: 
          Date: 
The adjectives shown below describe different feelings and moods. Please use this list to 
describe your feelings at this moment in time.  
 
If the adjective definitely describes your feelings circle the: 
 
 
 
If the adjective more or less describes your feelings circle the:  
 
If you do not understand the adjective, or you cannot decide 
whether it describes how you feel circle the:  
 
 
If the adjective does not describe the way you feel circle the:   
Your first reactions will be the most reliable; therefore, do not spend too long thinking 
about each adjective. Please be as honest and accurate as possible. 
Tense ++     +     ?     - Tired ++     +     ?     - 
Relaxed ++     +     ?     - Idle ++     +     ?     - 
Restful ++     +     ?     - Up tight ++     +     ?     - 
Active ++     +     ?     - Alert ++     +     ?     - 
Apprehensive ++     +     ?     - Lively ++     +     ?     - 
Worried ++     +     ?     - Cheerful ++     +     ?     - 
Energetic ++     +     ?     - Contented ++     +     ?     - 
Drowsy ++     +     ?     - Jittery ++     +     ?     - 
Bothered ++     +     ?     - Sluggish ++     +     ?     - 
Uneasy ++     +     ?     - Pleasant ++     +     ?     - 
Dejected ++     +     ?     - Sleepy ++     +     ?     - 
Nervous ++     +     ?     - Comfortable ++     +     ?     - 
Distressed ++     +     ?     - Calm ++     +     ?     - 
Vigorous ++     +     ?     - Stimulated ++     +     ?     - 
Peaceful ++     +     ?     - Activated ++     +     ?     - 
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Appendix 41. The Profile of Mood States – Short form (POMS-SF) 
 
The Profile of Mood States – Short form  
Participant ID: 
         Date: 
Instructions 
Please circle the number which best describes how you are feeling at this moment 
in time. The numbers correspond to the descriptions at the top of each column (0 = 
”Not at all“, 4 = "Extremely”)  
 
    N
o
t 
at
 a
ll 
A
 L
it
tl
e
 
M
o
d
er
at
el
y 
Q
u
it
e 
a 
b
it
 
Ex
tr
em
el
y 
     N
o
t 
at
 a
ll 
A
 L
it
tl
e
 
M
o
d
er
at
el
y 
Q
u
it
e 
a 
b
it
 
Ex
tr
em
el
y 
1 Tense 0 1 2 3 4  19 Vigorous 0 1 2 3 4 
2 Peeved 0 1 2 3 4  20 Grouchy 0 1 2 3 4 
3 Sad 0 1 2 3 4  21 Resentful 0 1 2 3 4 
4 Hopeless 0 1 2 3 4  22 On edge 0 1 2 3 4 
5 Restless 0 1 2 3 4  23 Bitter 0 1 2 3 4 
6 Active 0 1 2 3 4  24 Unable to concentrate 0 1 2 3 4 
7 Bewildered 0 1 2 3 4  25 Furious 0 1 2 3 4 
8 Discouraged 0 1 2 3 4  26 Full of pep 0 1 2 3 4 
9 Fatigued 0 1 2 3 4  27 Uneasy 0 1 2 3 4 
10 Anxious 0 1 2 3 4  28 Lively 0 1 2 3 4 
11 Cheerful 0 1 2 3 4  29 Nervous 0 1 2 3 4 
12 Uncertain about things 0 1 2 3 4  30 Bushed 0 1 2 3 4 
13 Exhausted 0 1 2 3 4  31 Helpless 0 1 2 3 4 
14 Blue 0 1 2 3 4  32 Confused 0 1 2 3 4 
15 Miserable 0 1 2 3 4  33 Unhappy 0 1 2 3 4 
16 Angry 0 1 2 3 4  34 Energetic 0 1 2 3 4 
17 Worthless 0 1 2 3 4  35 Forgetful 0 1 2 3 4 
18 Annoyed 0 1 2 3 4  36 Worn out 0 1 2 3 4 
        37 Weary 0 1 2 3 4 
 
  
427 
 
 
Appendix 42. Cognitive Failures Questionnaire (CFQ) 
 
Cognitive Failures Questionnaire 
 
Participant ID: 
         Date: 
 
The following questions are about minor mistakes which everyone makes from time 
to time, but some of which happen more often than others. 
We want to know how often these things have happened to you in the past 6 weeks. 
Please use the following scale: 
0 1 2 3 4 
Never Very Rarely Occasionally Quite often Very often 
  
1 
Do you read something and find you haven't been thinking about it 
and must read it again? 
Rating 
2 
Do you find you forget why you went from one part of the house to the 
other? 
 
3 Do you fail to notice signposts on the road?  
4 Do you find you confuse right and left when giving directions?  
5 Do you bump into people?  
6 
Do you find you forget whether you've turned off a light or a fire or 
locked the door? 
 
7 Do you fail to listen to people's names when you are meeting them?  
8 
Do you say something and realize afterwards that it might be taken as 
insulting? 
 
9 
Do you fail to hear people speaking to you when you are doing 
something else? 
 
10 Do you lose your temper and regret it?  
11 Do you leave important letters unanswered for days?  
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12 
Do you find you forget which way to turn on a road you know well but 
rarely use? 
 
13 
Do you fail to see what you want in a supermarket (although it's 
there)? 
 
14 
Do you find yourself suddenly wondering whether you've used a word 
correctly? 
 
15 Do you have trouble making up your mind?  
16 Do you find you forget appointments?  
17 Do you forget where you put something like a newspaper or a book?  
18 
Do you find you accidentally throw away the thing you want and keep 
what you meant to throw away -- as in the example of throwing away 
the matchbox and putting the used match in your pocket? 
 
19 Do you daydream when you ought to be listening to something?  
20 Do you find you forget people's names?  
21 
Do you start doing one thing at home and get distracted into doing 
something else (unintentionally)? 
 
22 
Do you find you can't quite remember something although it's "on the 
tip of your tongue"? 
 
23 Do you find you forget what you came to the shops to buy?  
24 Do you drop things?  
25 Do you find you can't think of anything to say?  
 
 
